Page last updated: 2024-12-04

cisplatin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cisplatin, with the chemical formula [Pt(NH3)2Cl2], is a platinum-based chemotherapy drug that has been used to treat various cancers, including testicular, ovarian, bladder, and lung cancer. Its synthesis involves reacting potassium tetrachloroplatinate(II) with ammonia in aqueous solution. Cisplatin's mechanism of action involves binding to DNA, inhibiting its replication and ultimately causing cell death. Its importance lies in its effectiveness against a broad range of cancers, and it has become a cornerstone of cancer treatment. However, it has significant side effects, including nephrotoxicity, ototoxicity, and nausea, which limit its use. Despite these limitations, cisplatin remains a valuable tool in cancer therapy, and ongoing research focuses on understanding its mechanism of action, developing novel platinum-based drugs with reduced side effects, and investigating its potential use in combination therapies.'

Cross-References

ID Source	ID
PubMed CID	2767
MeSH ID	M0004505
PubMed CID	5460033
MeSH ID	M0004505

Synonyms (83)

Synonym
nsc131558
AC-2109
HMS3268F06
AB00642613-02
CIS ,
cis-diammine-dichloroplatinum(ii)
cis-diaminedichloroplatinum
NEURO_000055
NCGC00090759-01
cis-dichlorodiamine platinum
cis-platinum(ii)
cis-platinum diamminedichloride
nsc-241517
nsc241517
26035-31-4
platinum, diamminedichloro-
replaced cas registry number(s): 14283-03-5
NCGC00090759-02
cisplatin(cis-diammenedichloroplatinum)
trans-dichlorodiammineplatinum.(transplatin)
cis-diamminedichloroplatinum(ii)(cis-ddp)
dichloroplatinumdiamine
bdbm50028111
NCGC00090759-03
cis-diamminedichlorplatine
NCGC00260049-01
tox21_113470
tox21_202500
BCP9000536
tox21_111011
cas-15663-27-1
platinum,diamminedichloro-
HY-17394
CS-1122
tox21_111011_1
NCGC00263537-01
AB00642613_03
AKOS025401526
HMS3654E14
SW222225-1
BRD-K69172251-001-01-4
SDCCGSBI-0050893.P003
BP-25382
lopac-p-4394
NCGC00015812-01
abiplatin
platosin
platinum diamminodichloride
NCGC00162292-01
NCGC00094229-01
cis platinum
dichlorodiammineplatinum
diamminodichloride, platinum
NCGC00162292-02
NCGC00094229-02
platinoxan
dtxsid4024983 ,
cis-platinum ii
tox21_500918
NCGC00261603-01
diammine(dichloro)platinum
NCGC00162292-05
BC164315
placis
cis-diammine-dichloroplatinum
cis-platinous diamine dichloride
cis-diamminedichloro platinum (ii)
platistin
platiran
plastistil
platinol-aq vha plus
cisplatina
citosin
blastolem
platiblastin-s
metaplatin
cysplatyna
cis-dichloroammine platinum (ii)
platinum, diaminedichloro-, cis-
citoplatino
l01xa01
cis-platinum ii diamine dichloride
cis-diamminedichloridoplatinum

Research Excerpts

Bioavailability

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (8)

Role	Description
mutagen	An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution.
antineoplastic agent	A substance that inhibits or prevents the proliferation of neoplasms.
photosensitizing agent	A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells.
cross-linking reagent	A reagent with two reactive groups, usually at opposite ends of the molecule, that are capable of reacting with and thereby forming bridges between macromolecules, principally side chains of amino acids in proteins, allowing the locations of naturally reactive areas within the proteins to be identified.
genotoxin	A role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells.
nephrotoxin	A poison that interferes with the function of the kidneys.
ferroptosis inducer	Any substance that induces or promotes ferroptosis (a type of programmed cell death dependent on iron and characterized by the accumulation of lipid peroxides) in organisms.
apoptosis inducer	Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

Class	Description
diamminedichloroplatinum
diamminedichloroplatinum
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (93)

Potency Measurements

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	8.6438	0.0032	45.4673	12,589.2998	AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	35.9583	0.0040	23.8416	100.0000	AID485290
Chain A, Putative fructose-1,6-bisphosphate aldolase	Giardia intestinalis	Potency	19.9054	0.1409	11.1940	39.8107	AID2451
Chain A, HADH2 protein	Homo sapiens (human)	Potency	12.6224	0.0251	20.2376	39.8107	AID886; AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	12.6224	0.0251	20.2376	39.8107	AID886; AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	12.5893	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	39.8107	0.1259	19.1169	125.8920	AID2549
acetylcholinesterase	Homo sapiens (human)	Potency	50.5019	0.0025	41.7960	15,848.9004	AID1347395; AID1347397; AID1347398; AID1347399
15-lipoxygenase, partial	Homo sapiens (human)	Potency	0.1000	0.0126	10.6917	88.5700	AID887
phosphopantetheinyl transferase	Bacillus subtilis	Potency	4.0075	0.1413	37.9142	100.0000	AID1490
RAR-related orphan receptor gamma	Mus musculus (house mouse)	Potency	10.5909	0.0060	38.0041	19,952.5996	AID1159521
USP1 protein, partial	Homo sapiens (human)	Potency	79.4328	0.0316	37.5844	354.8130	AID504865
TDP1 protein	Homo sapiens (human)	Potency	21.2748	0.0008	11.3822	44.6684	AID686978; AID686979
GLI family zinc finger 3	Homo sapiens (human)	Potency	11.8068	0.0007	14.5928	83.7951	AID1259369; AID1259392
Microtubule-associated protein tau	Homo sapiens (human)	Potency	2.6651	0.1800	13.5574	39.8107	AID1460; AID1468
AR protein	Homo sapiens (human)	Potency	36.9321	0.0002	21.2231	8,912.5098	AID588516; AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	33.9972	0.0112	12.4002	100.0000	AID1030
hypothetical protein, conserved	Trypanosoma brucei	Potency	12.5893	0.2239	11.2451	35.4813	AID624173
EWS/FLI fusion protein	Homo sapiens (human)	Potency	11.7452	0.0013	10.1577	42.8575	AID1259253; AID1259256
glucocorticoid receptor [Homo sapiens]	Homo sapiens (human)	Potency	26.8325	0.0002	14.3764	60.0339	AID720692
retinoic acid nuclear receptor alpha variant 1	Homo sapiens (human)	Potency	27.8939	0.0030	41.6115	22,387.1992	AID1159553
retinoid X nuclear receptor alpha	Homo sapiens (human)	Potency	44.6684	0.0008	17.5051	59.3239	AID588544
estrogen-related nuclear receptor alpha	Homo sapiens (human)	Potency	30.6195	0.0015	30.6073	15,848.9004	AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
estrogen nuclear receptor alpha	Homo sapiens (human)	Potency	0.0756	0.0002	29.3054	16,493.5996	AID743075
G	Vesicular stomatitis virus	Potency	19.4971	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2D6	Homo sapiens (human)	Potency	10.9640	0.0010	8.3798	61.1304	AID1645840
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	1.4125	0.0355	20.9770	89.1251	AID504332
thyroid stimulating hormone receptor	Homo sapiens (human)	Potency	33.8808	0.0016	28.0151	77.1139	AID1224843; AID1224895; AID1259385; AID1259395
activating transcription factor 6	Homo sapiens (human)	Potency	62.1354	0.1434	27.6121	59.8106	AID1159516
v-jun sarcoma virus 17 oncogene homolog (avian)	Homo sapiens (human)	Potency	14.0848	0.0578	21.1097	61.2679	AID1159526; AID1159528
Histone H2A.x	Cricetulus griseus (Chinese hamster)	Potency	44.9591	0.0391	47.5451	146.8240	AID1224845; AID1224896
Caspase-7	Cricetulus griseus (Chinese hamster)	Potency	17.4643	0.0067	23.4960	68.5896	AID1346980
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	2.2387	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	11.2202	0.3548	28.0659	89.1251	AID504847
caspase-3	Cricetulus griseus (Chinese hamster)	Potency	17.4643	0.0067	23.4960	68.5896	AID1346980
thyroid hormone receptor beta isoform 2	Rattus norvegicus (Norway rat)	Potency	36.8506	0.0003	23.4451	159.6830	AID743065; AID743067
heat shock protein beta-1	Homo sapiens (human)	Potency	37.5751	0.0420	27.3789	61.6448	AID743210
nuclear factor erythroid 2-related factor 2 isoform 1	Homo sapiens (human)	Potency	34.8122	0.0006	27.2152	1,122.0200	AID651741; AID743202; AID743219
lethal factor (plasmid)	Bacillus anthracis str. A2012	Potency	25.1189	0.0200	10.7869	31.6228	AID912
Interferon beta	Homo sapiens (human)	Potency	19.4971	0.0033	9.1582	39.8107	AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	19.4971	0.0123	8.9648	39.8107	AID1645842
Cellular tumor antigen p53	Homo sapiens (human)	Potency	10.5930	0.0023	19.5956	74.0614	AID651631
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	19.4971	0.0123	8.9648	39.8107	AID1645842
ATPase family AAA domain-containing protein 5	Homo sapiens (human)	Potency	26.6032	0.0119	17.9420	71.5630	AID651632
Ataxin-2	Homo sapiens (human)	Potency	26.6032	0.0119	12.2221	68.7989	AID651632
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	19.4971	0.0123	8.9648	39.8107	AID1645842
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	4.4668	0.0601	10.7453	37.9330	AID492961
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE	Homo sapiens (human)	Potency	28.1838	0.0032	45.4673	12,589.2998	AID1705; AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASE	Homo sapiens (human)	Potency	7.0795	0.0040	23.8416	100.0000	AID485290
Chain A, HADH2 protein	Homo sapiens (human)	Potency	12.7585	0.0251	20.2376	39.8107	AID886; AID893
Chain B, HADH2 protein	Homo sapiens (human)	Potency	12.7585	0.0251	20.2376	39.8107	AID886; AID893
Chain A, 2-oxoglutarate Oxygenase	Homo sapiens (human)	Potency	12.5893	0.1778	14.3909	39.8107	AID2147
Chain A, ATP-DEPENDENT DNA HELICASE Q1	Homo sapiens (human)	Potency	25.1189	0.1259	19.1169	125.8920	AID2549
endonuclease IV	Escherichia coli	Potency	1.4125	0.7079	12.4324	31.6228	AID1708
thioredoxin reductase	Rattus norvegicus (Norway rat)	Potency	0.5034	0.1000	20.8793	79.4328	AID488773; AID588453; AID588456
RGS12	Homo sapiens (human)	Potency	1.9953	0.7943	10.9914	25.1189	AID879
15-lipoxygenase, partial	Homo sapiens (human)	Potency	0.7943	0.0126	10.6917	88.5700	AID887
USP1 protein, partial	Homo sapiens (human)	Potency	31.6228	0.0316	37.5844	354.8130	AID504865
GLS protein	Homo sapiens (human)	Potency	35.4813	0.3548	7.9355	39.8107	AID624146
TDP1 protein	Homo sapiens (human)	Potency	18.2563	0.0008	11.3822	44.6684	AID686978; AID686979
Microtubule-associated protein tau	Homo sapiens (human)	Potency	7.9433	0.1800	13.5574	39.8107	AID1460; AID1468
Thrombopoietin	Homo sapiens (human)	Potency	12.5893	0.0251	7.3048	31.6228	AID917; AID918
DNA polymerase III, partial	Bacillus subtilis	Potency	18.8876	1.0621	14.1528	26.6795	AID485295
aldehyde dehydrogenase 1 family, member A1	Homo sapiens (human)	Potency	15.8489	0.0112	12.4002	100.0000	AID1030
hypothetical protein, conserved	Trypanosoma brucei	Potency	1.9012	0.2239	11.2451	35.4813	AID624147
regulator of G-protein signaling 4	Homo sapiens (human)	Potency	1.5003	0.5318	15.4358	37.6858	AID504845
euchromatic histone-lysine N-methyltransferase 2	Homo sapiens (human)	Potency	0.3823	0.0355	20.9770	89.1251	AID504332
Bloom syndrome protein isoform 1	Homo sapiens (human)	Potency	28.1838	0.5406	17.6392	96.1227	AID2364; AID2528
cytochrome P450 2D6 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0020	7.5337	39.8107	AID891
hexokinase-4 isoform 1	Homo sapiens (human)	Potency	31.6228	2.5119	13.8003	28.1838	AID743207
peripheral myelin protein 22 isoform 1	Homo sapiens (human)	Potency	84.9214	23.9341	23.9341	23.9341	AID1967
cytochrome P450 2C19 precursor	Homo sapiens (human)	Potency	12.5893	0.0025	5.8400	31.6228	AID899
cytochrome P450 2C9 precursor	Homo sapiens (human)	Potency	3.1623	0.0063	6.9043	39.8107	AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1	Homo sapiens (human)	Potency	10.0000	0.0018	15.6638	39.8107	AID894
vitamin D3 receptor isoform VDRA	Homo sapiens (human)	Potency	15.8489	0.3548	28.0659	89.1251	AID504847
chromobox protein homolog 1	Homo sapiens (human)	Potency	8.9125	0.0060	26.1688	89.1251	AID488953
glucokinase regulatory protein	Homo sapiens (human)	Potency	31.6228	2.5119	13.8003	28.1838	AID743207
guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1	Homo sapiens (human)	Potency	1.9953	0.7943	12.1263	25.1189	AID879
mitogen-activated protein kinase 1	Homo sapiens (human)	Potency	25.1189	0.0398	16.7842	39.8107	AID995
flap endonuclease 1	Homo sapiens (human)	Potency	36.0192	0.1337	25.4129	89.1251	AID488816; AID588795
histone-lysine N-methyltransferase 2A isoform 2 precursor	Homo sapiens (human)	Potency	50.1187	0.0103	23.8567	63.0957	AID2662
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1	Homo sapiens (human)	Potency	26.8545	0.4256	12.0591	28.1838	AID504536
DNA polymerase iota isoform a (long)	Homo sapiens (human)	Potency	57.1220	0.0501	27.0736	89.1251	AID588590
DNA polymerase kappa isoform 1	Homo sapiens (human)	Potency	63.4054	0.0316	22.3146	100.0000	AID588579
cytochrome P450 3A4 isoform 1	Homo sapiens (human)	Potency	39.8107	0.0316	10.2792	39.8107	AID884; AID885
M-phase phosphoprotein 8	Homo sapiens (human)	Potency	2.6158	0.1778	24.7352	79.4328	AID488949
histone acetyltransferase KAT2A isoform 1	Homo sapiens (human)	Potency	19.9526	0.2512	15.8432	39.8107	AID504327
muscarinic acetylcholine receptor M1	Rattus norvegicus (Norway rat)	Potency	0.1413	0.0010	6.0009	35.4813	AID943
neuropeptide S receptor isoform A	Homo sapiens (human)	Potency	25.1189	0.0158	12.3113	615.5000	AID1461
Gamma-aminobutyric acid receptor subunit pi	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit delta	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-5	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-4	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit gamma-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit alpha-6	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Histamine H2 receptor	Cavia porcellus (domestic guinea pig)	Potency	3.1623	0.0063	8.2350	39.8107	AID883
Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-3	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
GABA theta subunit	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
Gamma-aminobutyric acid receptor subunit epsilon	Rattus norvegicus (Norway rat)	Potency	39.8107	1.0000	12.2248	31.6228	AID885
phosphoglycerate kinase	Trypanosoma brucei brucei TREU927	Potency	26.8545	0.0757	8.4742	29.0628	AID504547
ATP-dependent phosphofructokinase	Trypanosoma brucei brucei TREU927	Potency	3.7933	0.0601	10.7453	37.9330	AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (258)

Process	via Protein(s)	Taxonomy
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle G2/M phase transition	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
ER overload response	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
in utero embryonic development	Cellular tumor antigen p53	Homo sapiens (human)
somitogenesis	Cellular tumor antigen p53	Homo sapiens (human)
release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic progenitor cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
T cell proliferation involved in immune response	Cellular tumor antigen p53	Homo sapiens (human)
B cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
T cell lineage commitment	Cellular tumor antigen p53	Homo sapiens (human)
response to ischemia	Cellular tumor antigen p53	Homo sapiens (human)
nucleotide-excision repair	Cellular tumor antigen p53	Homo sapiens (human)
double-strand break repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
protein import into nucleus	Cellular tumor antigen p53	Homo sapiens (human)
autophagy	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
Ras protein signal transduction	Cellular tumor antigen p53	Homo sapiens (human)
gastrulation	Cellular tumor antigen p53	Homo sapiens (human)
neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of neuroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
protein localization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA replication	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell population proliferation	Cellular tumor antigen p53	Homo sapiens (human)
determination of adult lifespan	Cellular tumor antigen p53	Homo sapiens (human)
mRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
rRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
response to salt stress	Cellular tumor antigen p53	Homo sapiens (human)
response to inorganic substance	Cellular tumor antigen p53	Homo sapiens (human)
response to X-ray	Cellular tumor antigen p53	Homo sapiens (human)
response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of gene expression	Cellular tumor antigen p53	Homo sapiens (human)
cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
viral process	Cellular tumor antigen p53	Homo sapiens (human)
glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
cerebellum development	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of cell growth	Cellular tumor antigen p53	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
mitotic G1 DNA damage checkpoint signaling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of telomere maintenance via telomerase	Cellular tumor antigen p53	Homo sapiens (human)
T cell differentiation in thymus	Cellular tumor antigen p53	Homo sapiens (human)
tumor necrosis factor-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
regulation of tissue remodeling	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV	Cellular tumor antigen p53	Homo sapiens (human)
multicellular organism growth	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of mitochondrial membrane permeability	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to glucose starvation	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
entrainment of circadian clock by photoperiod	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial DNA repair	Cellular tumor antigen p53	Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
transcription initiation-coupled chromatin remodeling	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of proteolysis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of DNA-templated transcription	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Cellular tumor antigen p53	Homo sapiens (human)
response to antibiotic	Cellular tumor antigen p53	Homo sapiens (human)
fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of fibroblast proliferation	Cellular tumor antigen p53	Homo sapiens (human)
circadian behavior	Cellular tumor antigen p53	Homo sapiens (human)
bone marrow development	Cellular tumor antigen p53	Homo sapiens (human)
embryonic organ development	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation	Cellular tumor antigen p53	Homo sapiens (human)
protein stabilization	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of helicase activity	Cellular tumor antigen p53	Homo sapiens (human)
protein tetramerization	Cellular tumor antigen p53	Homo sapiens (human)
chromosome organization	Cellular tumor antigen p53	Homo sapiens (human)
neuron apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of cell cycle	Cellular tumor antigen p53	Homo sapiens (human)
hematopoietic stem cell differentiation	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glial cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
type II interferon-mediated signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
cardiac septum morphogenesis	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of programmed necrotic cell death	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex assembly	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stress	Cellular tumor antigen p53	Homo sapiens (human)
thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of thymocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
necroptotic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to xenobiotic stimulus	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to ionizing radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to gamma radiation	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to UV-C	Cellular tumor antigen p53	Homo sapiens (human)
stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
signal transduction by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
cellular response to actinomycin D	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondria	Cellular tumor antigen p53	Homo sapiens (human)
cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
replicative senescence	Cellular tumor antigen p53	Homo sapiens (human)
oxidative stress-induced premature senescence	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
oligodendrocyte apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of execution phase of apoptosis	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of mitophagy	Cellular tumor antigen p53	Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediator	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of miRNA transcription	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of G1 to G0 transition	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of miRNA processing	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvate	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of pentose-phosphate shunt	Cellular tumor antigen p53	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxia	Cellular tumor antigen p53	Homo sapiens (human)
regulation of fibroblast apoptotic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of reactive oxygen species metabolic process	Cellular tumor antigen p53	Homo sapiens (human)
negative regulation of stem cell proliferation	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of cellular senescence	Cellular tumor antigen p53	Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathway	Cellular tumor antigen p53	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cell population proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of B cell proliferation	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nuclear DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
signal transduction in response to DNA damage	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
isotype switching	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of DNA replication	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of isotype switching to IgG isotypes	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloading	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
positive regulation of cell cycle G2/M phase transition	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
negative regulation of receptor internalization	Ataxin-2	Homo sapiens (human)
regulation of translation	Ataxin-2	Homo sapiens (human)
RNA metabolic process	Ataxin-2	Homo sapiens (human)
P-body assembly	Ataxin-2	Homo sapiens (human)
stress granule assembly	Ataxin-2	Homo sapiens (human)
RNA transport	Ataxin-2	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
cognition	Amyloid-beta precursor protein	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglial cell activation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
suckling behavior	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation involved in immune response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of translation	Amyloid-beta precursor protein	Homo sapiens (human)
protein phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
intracellular copper ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
endocytosis	Amyloid-beta precursor protein	Homo sapiens (human)
response to oxidative stress	Amyloid-beta precursor protein	Homo sapiens (human)
cell adhesion	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of epidermal growth factor-activated receptor activity	Amyloid-beta precursor protein	Homo sapiens (human)
Notch signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
axonogenesis	Amyloid-beta precursor protein	Homo sapiens (human)
learning or memory	Amyloid-beta precursor protein	Homo sapiens (human)
learning	Amyloid-beta precursor protein	Homo sapiens (human)
mating behavior	Amyloid-beta precursor protein	Homo sapiens (human)
locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
axo-dendritic transport	Amyloid-beta precursor protein	Homo sapiens (human)
cholesterol metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of cell population proliferation	Amyloid-beta precursor protein	Homo sapiens (human)
adult locomotory behavior	Amyloid-beta precursor protein	Homo sapiens (human)
visual learning	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of gene expression	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of G2/M transition of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
microglia development	Amyloid-beta precursor protein	Homo sapiens (human)
axon midline choice point recognition	Amyloid-beta precursor protein	Homo sapiens (human)
neuron remodeling	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite development	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of Wnt signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular matrix organization	Amyloid-beta precursor protein	Homo sapiens (human)
forebrain development	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection development	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of chemokine production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-1 beta production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of interleukin-6 production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
ionotropic glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of multicellular organism growth	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of neuron differentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of glycolytic process	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of mitotic cell cycle	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of JNK cascade	Amyloid-beta precursor protein	Homo sapiens (human)
astrocyte activation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of long-term neuronal synaptic plasticity	Amyloid-beta precursor protein	Homo sapiens (human)
collateral sprouting in absence of injury	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of inflammatory response	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of peptidyl-tyrosine phosphorylation	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of synapse structure or activity	Amyloid-beta precursor protein	Homo sapiens (human)
synapse organization	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of calcium-mediated signaling	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular process controlling balance	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic assembly at neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of protein metabolic process	Amyloid-beta precursor protein	Homo sapiens (human)
neuron apoptotic process	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum calcium ion homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
neuron cellular homeostasis	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Amyloid-beta precursor protein	Homo sapiens (human)
response to interleukin-1	Amyloid-beta precursor protein	Homo sapiens (human)
modulation of excitatory postsynaptic potential	Amyloid-beta precursor protein	Homo sapiens (human)
NMDA selective glutamate receptor signaling pathway	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of spontaneous synaptic transmission	Amyloid-beta precursor protein	Homo sapiens (human)
cytosolic mRNA polyadenylation	Amyloid-beta precursor protein	Homo sapiens (human)
negative regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of long-term synaptic potentiation	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transduction	Amyloid-beta precursor protein	Homo sapiens (human)
cellular response to amyloid-beta	Amyloid-beta precursor protein	Homo sapiens (human)
regulation of presynapse assembly	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
amyloid fibril formation	Amyloid-beta precursor protein	Homo sapiens (human)
neuron projection maintenance	Amyloid-beta precursor protein	Homo sapiens (human)
positive regulation of T cell migration	Amyloid-beta precursor protein	Homo sapiens (human)
central nervous system development	Amyloid-beta precursor protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (62)

Process	via Protein(s)	Taxonomy
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
transcription cis-regulatory region binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
cis-regulatory region sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
core promoter sequence-specific DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
TFIID-class transcription factor complex binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specific	Cellular tumor antigen p53	Homo sapiens (human)
protease binding	Cellular tumor antigen p53	Homo sapiens (human)
p53 binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA binding	Cellular tumor antigen p53	Homo sapiens (human)
chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
DNA-binding transcription factor activity	Cellular tumor antigen p53	Homo sapiens (human)
mRNA 3'-UTR binding	Cellular tumor antigen p53	Homo sapiens (human)
copper ion binding	Cellular tumor antigen p53	Homo sapiens (human)
protein binding	Cellular tumor antigen p53	Homo sapiens (human)
zinc ion binding	Cellular tumor antigen p53	Homo sapiens (human)
enzyme binding	Cellular tumor antigen p53	Homo sapiens (human)
receptor tyrosine kinase binding	Cellular tumor antigen p53	Homo sapiens (human)
ubiquitin protein ligase binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase regulator activity	Cellular tumor antigen p53	Homo sapiens (human)
ATP-dependent DNA/DNA annealing activity	Cellular tumor antigen p53	Homo sapiens (human)
identical protein binding	Cellular tumor antigen p53	Homo sapiens (human)
histone deacetylase binding	Cellular tumor antigen p53	Homo sapiens (human)
protein heterodimerization activity	Cellular tumor antigen p53	Homo sapiens (human)
protein-folding chaperone binding	Cellular tumor antigen p53	Homo sapiens (human)
protein phosphatase 2A binding	Cellular tumor antigen p53	Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor binding	Cellular tumor antigen p53	Homo sapiens (human)
14-3-3 protein binding	Cellular tumor antigen p53	Homo sapiens (human)
MDM2/MDM4 family protein binding	Cellular tumor antigen p53	Homo sapiens (human)
disordered domain specific binding	Cellular tumor antigen p53	Homo sapiens (human)
general transcription initiation factor binding	Cellular tumor antigen p53	Homo sapiens (human)
molecular function activator activity	Cellular tumor antigen p53	Homo sapiens (human)
promoter-specific chromatin binding	Cellular tumor antigen p53	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
ATP hydrolysis activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA clamp unloader activity	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
DNA binding	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
RNA binding	Ataxin-2	Homo sapiens (human)
epidermal growth factor receptor binding	Ataxin-2	Homo sapiens (human)
protein binding	Ataxin-2	Homo sapiens (human)
mRNA binding	Ataxin-2	Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
DNA binding	Amyloid-beta precursor protein	Homo sapiens (human)
serine-type endopeptidase inhibitor activity	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
heparin binding	Amyloid-beta precursor protein	Homo sapiens (human)
enzyme binding	Amyloid-beta precursor protein	Homo sapiens (human)
identical protein binding	Amyloid-beta precursor protein	Homo sapiens (human)
transition metal ion binding	Amyloid-beta precursor protein	Homo sapiens (human)
receptor ligand activity	Amyloid-beta precursor protein	Homo sapiens (human)
PTB domain binding	Amyloid-beta precursor protein	Homo sapiens (human)
protein serine/threonine kinase binding	Amyloid-beta precursor protein	Homo sapiens (human)
signaling receptor activator activity	Amyloid-beta precursor protein	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (71)

Process	via Protein(s)	Taxonomy
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nuclear body	Cellular tumor antigen p53	Homo sapiens (human)
nucleus	Cellular tumor antigen p53	Homo sapiens (human)
nucleoplasm	Cellular tumor antigen p53	Homo sapiens (human)
replication fork	Cellular tumor antigen p53	Homo sapiens (human)
nucleolus	Cellular tumor antigen p53	Homo sapiens (human)
cytoplasm	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrion	Cellular tumor antigen p53	Homo sapiens (human)
mitochondrial matrix	Cellular tumor antigen p53	Homo sapiens (human)
endoplasmic reticulum	Cellular tumor antigen p53	Homo sapiens (human)
centrosome	Cellular tumor antigen p53	Homo sapiens (human)
cytosol	Cellular tumor antigen p53	Homo sapiens (human)
nuclear matrix	Cellular tumor antigen p53	Homo sapiens (human)
PML body	Cellular tumor antigen p53	Homo sapiens (human)
transcription repressor complex	Cellular tumor antigen p53	Homo sapiens (human)
site of double-strand break	Cellular tumor antigen p53	Homo sapiens (human)
germ cell nucleus	Cellular tumor antigen p53	Homo sapiens (human)
chromatin	Cellular tumor antigen p53	Homo sapiens (human)
transcription regulator complex	Cellular tumor antigen p53	Homo sapiens (human)
protein-containing complex	Cellular tumor antigen p53	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
Elg1 RFC-like complex	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
nucleus	ATPase family AAA domain-containing protein 5	Homo sapiens (human)
cytoplasm	Ataxin-2	Homo sapiens (human)
Golgi apparatus	Ataxin-2	Homo sapiens (human)
trans-Golgi network	Ataxin-2	Homo sapiens (human)
cytosol	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
membrane	Ataxin-2	Homo sapiens (human)
perinuclear region of cytoplasm	Ataxin-2	Homo sapiens (human)
ribonucleoprotein complex	Ataxin-2	Homo sapiens (human)
cytoplasmic stress granule	Ataxin-2	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
dendrite	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular region	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular space	Amyloid-beta precursor protein	Homo sapiens (human)
nuclear envelope lumen	Amyloid-beta precursor protein	Homo sapiens (human)
cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
mitochondrial inner membrane	Amyloid-beta precursor protein	Homo sapiens (human)
endosome	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
endoplasmic reticulum lumen	Amyloid-beta precursor protein	Homo sapiens (human)
smooth endoplasmic reticulum	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi lumen	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi-associated vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cytosol	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
clathrin-coated pit	Amyloid-beta precursor protein	Homo sapiens (human)
cell-cell junction	Amyloid-beta precursor protein	Homo sapiens (human)
synaptic vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
membrane	Amyloid-beta precursor protein	Homo sapiens (human)
COPII-coated ER to Golgi transport vesicle	Amyloid-beta precursor protein	Homo sapiens (human)
axon	Amyloid-beta precursor protein	Homo sapiens (human)
growth cone	Amyloid-beta precursor protein	Homo sapiens (human)
platelet alpha granule lumen	Amyloid-beta precursor protein	Homo sapiens (human)
neuromuscular junction	Amyloid-beta precursor protein	Homo sapiens (human)
endosome lumen	Amyloid-beta precursor protein	Homo sapiens (human)
trans-Golgi network membrane	Amyloid-beta precursor protein	Homo sapiens (human)
ciliary rootlet	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic spine	Amyloid-beta precursor protein	Homo sapiens (human)
dendritic shaft	Amyloid-beta precursor protein	Homo sapiens (human)
perikaryon	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
apical part of cell	Amyloid-beta precursor protein	Homo sapiens (human)
synapse	Amyloid-beta precursor protein	Homo sapiens (human)
perinuclear region of cytoplasm	Amyloid-beta precursor protein	Homo sapiens (human)
presynaptic active zone	Amyloid-beta precursor protein	Homo sapiens (human)
spindle midzone	Amyloid-beta precursor protein	Homo sapiens (human)
recycling endosome	Amyloid-beta precursor protein	Homo sapiens (human)
extracellular exosome	Amyloid-beta precursor protein	Homo sapiens (human)
receptor complex	Amyloid-beta precursor protein	Homo sapiens (human)
early endosome	Amyloid-beta precursor protein	Homo sapiens (human)
membrane raft	Amyloid-beta precursor protein	Homo sapiens (human)
cell surface	Amyloid-beta precursor protein	Homo sapiens (human)
Golgi apparatus	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Amyloid-beta precursor protein	Homo sapiens (human)
plasma membrane	Gamma-aminobutyric acid receptor subunit gamma-2	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit alpha-1	Rattus norvegicus (Norway rat)
plasma membrane	Gamma-aminobutyric acid receptor subunit beta-2	Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (54)

Assay ID	Title	Year	Journal	Article
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID651635	Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504749	qHTS profiling for inhibitors of Plasmodium falciparum proliferation	2011	Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043	Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347094	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154	Primary screen GU AMC qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845	Primary qHTS for Inhibitors of ATXN expression
AID1347104	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424	RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425	Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)	2019	The Journal of biological chemistry, 11-15, Volume: 294, Issue:46	Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347098	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092	qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	2018	Oncotarget, Jan-12, Volume: 9, Issue:4	Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID686947	qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen	2013	Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15	Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID588349	qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID504812	Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347050	Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347049	Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen	2019	Science translational medicine, 07-10, Volume: 11, Issue:500	Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630	Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay	2021	Cell reports, 04-27, Volume: 35, Issue:4	A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347057	CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151	Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347410	qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library	2019	Cellular signalling, 08, Volume: 60	A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588378	qHTS for Inhibitors of ATXN expression: Validation
AID504810	Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	2010	Endocrinology, Jul, Volume: 151, Issue:7	A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347405	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347058	CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504836	Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation	2002	The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16	Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347059	CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation	2019	PloS one, , Volume: 14, Issue:7	Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083	qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen	2020	Antiviral research, 01, Volume: 173	A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (6.25)	29.6817
2010's	9 (56.25)	24.3611
2020's	6 (37.50)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 89.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

Metric	This Compound (vs All)
Research Demand Index	89.41 (24.57)
Research Supply Index	2.40 (2.92)
Research Growth Index	4.55 (4.65)
Search Engine Demand Index	153.55 (26.88)
Search Engine Supply Index	2.00 (0.95)

This Compound (89.41)

All Compounds (24.57)

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	10 (100.00%)	84.16%
Other	11 (100.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1133)

Trial Overview

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma [NCT00253370]	Phase 2	44 participants (Actual)	Interventional	2005-10-31	Completed
A Randomized Phase II Trial Evaluating an Organ-conserving Strategy With Radiotherapy + CDDP + Gemcitabine vs Radiotherapy + CDDP in Muscle-infiltrative Bladder Cancer [NCT01495676]		69 participants (Actual)	Interventional	2011-07-06	Active, not recruiting
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck [NCT01810913]	Phase 2/Phase 3	613 participants (Anticipated)	Interventional	2013-03-22	Recruiting
Open-label, Phase 2 Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metast [NCT05849246]	Phase 2	130 participants (Anticipated)	Interventional	2023-05-30	Not yet recruiting
Treatment of Peritoneal Carcinomatosis With Pressurized IntraPeritoneal Aerosol - The PIPAC-OPC2 Trial [NCT03287375]	Phase 2	143 participants (Actual)	Interventional	2016-12-01	Completed
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) [NCT04700124]	Phase 3	784 participants (Anticipated)	Interventional	2021-04-21	Active, not recruiting
Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era [NCT02289807]		0 participants (Actual)	Interventional	2015-03-31	Withdrawn
A Phase III Trial of Concurrent Radiation and Chemotherapy for Advanced Head and Neck Carcinomas [NCT00047008]	Phase 3	743 participants (Actual)	Interventional	2002-07-31	Completed
Phase II Trial of Cisplatin Combined With Oral TS-1 in Patients With Advanced Solid Tumors With Different Degrees of Liver Dysfunction [NCT03519074]	Phase 2	48 participants (Anticipated)	Interventional	2016-07-22	Recruiting
A Phase I / Pilot Study of Intra-Arterial Supradose Cisplatin With Simultaneous Intravenous Thiosulfate Neutralization in Patients With Primary Lung Cancer or Lung Metastases [NCT01114958]	Phase 1	8 participants (Actual)	Interventional	2009-09-03	Completed
A Retrospective Study of Extremity Osteosarcoma Patients Who Recieved Intra-arterial Limb Infusion of Cisplatin During Neoadjuvant Chemotherapy [NCT03909776]		99 participants (Actual)	Interventional	2019-01-01	Completed
Randomized Phase II Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer [NCT01283204]	Phase 2	180 participants (Actual)	Interventional	2010-03-09	Completed
A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy [NCT02422498]	Phase 2	49 participants (Actual)	Interventional	2015-04-14	Completed
A Phase II, Multicenter, Randomized,Two-Arm Clinical Study: An Investigational Arm Containing Nimotuzumab in Combination With Radiotion Therapy and Cisplatyn, and a Control Arm With Radiation Therapy and Cisplatin for the Definitive Treatment of Stage IB [NCT01301612]	Phase 2	0 participants (Actual)	Interventional	2011-01-31	Withdrawn(stopped due to Regulatory requirement. A phase III study is being designed.)
Treatment of Childhood Nasopharyngeal Carcinoma With Neoadjuvant Chemotherapy and Concomitant Chemoradiotherapy: A Groupwide Phase III Study [NCT00274937]	Phase 3	111 participants (Actual)	Interventional	2006-02-20	Completed
Panitumumab in Combination With Cisplatin/Gemcitabine Chemotherapy in Patients With Cholangiocarcinomas - a Randomized Clinical Phase II Study [NCT01320254]	Phase 2	93 participants (Actual)	Interventional	2011-06-30	Completed
An Open-label, Multicenter Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of LBL-024 Combined With Etoposide and Platinum in the First-line Treatment of Patients With Advanced Neuroendocrine Carcinoma (NEC) [NCT06157827]	Phase 1/Phase 2	68 participants (Anticipated)	Interventional	2023-12-05	Not yet recruiting
A Phase 2 Study Using Chemoimmunotherapy With Gemcitabine, Cisplatin and Nivolumab in Newly Diagnosed Nasopharyngeal Carcinoma (NPC) [NCT06064097]	Phase 2	50 participants (Anticipated)	Interventional	2023-12-20	Not yet recruiting
Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE) [NCT04216290]	Phase 2	95 participants (Anticipated)	Interventional	2021-03-17	Active, not recruiting
Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC [NCT04092283]	Phase 3	660 participants (Anticipated)	Interventional	2020-04-29	Active, not recruiting
Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination With Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC) [NCT03382561]	Phase 2	160 participants (Actual)	Interventional	2018-05-02	Active, not recruiting
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases [NCT02595905]	Phase 2	333 participants (Anticipated)	Interventional	2016-09-15	Active, not recruiting
Phase I Dose-Escalation Bioavailability Study of Oral Triapine in Combination With Concurrent Chemoradiation for Locally Advanced Cervical Cancer (LACC) and Vaginal Cancer [NCT02595879]	Phase 1	22 participants (Actual)	Interventional	2019-09-18	Active, not recruiting
A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) Versus Placebo in Combination With Cisplatin and Pemetrexed in Chemonaive Patients With Malignant Pleural Mesothelioma [NCT01064648]	Phase 1/Phase 2	117 participants (Actual)	Interventional	2010-03-15	Active, not recruiting
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer [NCT00588770]	Phase 3	403 participants (Actual)	Interventional	2008-08-08	Active, not recruiting
A Feasibility Study of Vorinostat (SAHA) Combined With Isotretinoin and Chemotherapy in Infants With Embryonal Tumors of the Central Nervous System [NCT00867178]	Phase 1	33 participants (Actual)	Interventional	2009-02-25	Completed
Multiinstitutional Open Label Randomized Phase II Study Comparing Cetuximab and Radiotherapy Versus Cisplatin and Radiotherapy as Firstline Treatment for Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-NHSCC) [NCT01216020]	Phase 2	70 participants (Actual)	Interventional	2010-10-31	Terminated(stopped due to insufficient recruitment)
Randomized Phase II Trial of SP vs. GP in Advanced Biliary Cancer [NCT01375972]	Phase 2	92 participants (Actual)	Interventional	2008-03-31	Completed
A Phase I/II, Multi-Center Dose Escalation Study of Simultaneous Boost Intensity-Modulated Radiotherapy for Locally Advanced Cervical Cancer [NCT01230996]	Phase 1/Phase 2	22 participants (Actual)	Interventional	2010-07-31	Completed
A Phase II Trial of Induction and Adjuvant Camrelizumab Combined With Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT05213884]	Phase 2	30 participants (Anticipated)	Interventional	2022-01-01	Recruiting
Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer [NCT01642251]	Phase 1/Phase 2	156 participants (Actual)	Interventional	2012-09-28	Completed
Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer [NCT03366766]	Phase 2	14 participants (Actual)	Interventional	2017-12-20	Completed
A Randomized, Multicenter, Phase II Trial of Cisplatin, Irinotecan and Bevacizumab (PCA) vs. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer [NCT00911820]	Phase 2	88 participants (Actual)	Interventional	2009-07-31	Completed
A Single Institutional Phase II Clinical Trial of Abraxane Combined With Cisplatin in Metastatic Breast Cancer [NCT01149798]	Phase 2	73 participants (Actual)	Interventional	2010-06-30	Completed
Induction Chemotherapy Combined With Low-dose Radiation Plus Cadonilimab in Loco-regionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Open-label, Randomized Controlled Phase III Clinical Trial [NCT05941741]	Phase 3	380 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Phase Ib Clinical Trial to Evaluate the Safety and Efficacy of TQB2618 Injection Combined Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma [NCT05834543]	Phase 1/Phase 2	75 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
Randomized Phase II Study of Induction Bevacizumab, Etoposide and Cisplatin Followed by Whole Brain Radiotherapy (WBRT) Versus WBRT Alone in Breast Cancer With Untreated Brain Metastases [NCT02185352]	Phase 2	120 participants (Actual)	Interventional	2014-04-21	Active, not recruiting
A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix [NCT01281852]	Phase 1	37 participants (Actual)	Interventional	2011-03-14	Completed
A Randomized Phase II Trial of Neoadjuvant Combination Chemotherapy of DCS (Cisplatin + Docetaxel + S-1) and DCF (Docetaxel + Cisplatin + 5-FU) in Patients With Locally Advanced Gastric Adenocarcinoma [NCT01286766]	Phase 2	6 participants (Actual)	Interventional	2009-09-30	Completed
INTRATYMPANIC STEROID TREATMENT FOR THE PREVENTION OF INNER EAR TOXICITY ASSOCIATED WITH SYSTEMIC TREATMENT WITH CISPLATIN. [NCT01285674]		20 participants (Anticipated)	Interventional	2011-01-31	Not yet recruiting
Multicenter, Randomized, Double-blind, Phase Ⅲ Clinical Study to Evaluate the Efficacy and Safety of TQB2450 Plus Chemotherapy（Cisplatin or Carboplatin+ 5-Fluorouracil (5-FU) ） Versus Placebo Plus Chemotherapy as First-Line Treatment in Patients With Recu [NCT03855384]	Phase 3	334 participants (Anticipated)	Interventional	2019-06-11	Recruiting
A Randomized Multicenter Phase II Study of Intensity-modulated Radiotherapy Combined With Chemotherapy Versus Intensity-modulated Radiotherapy Alone for Stage II Nasopharyngeal Carcinoma [NCT01187238]	Phase 2	84 participants (Actual)	Interventional	2010-05-31	Completed
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes [NCT01295502]	Phase 1	45 participants (Anticipated)	Interventional	2011-04-04	Active, not recruiting
A Phase IIB/III Randomized, Double-blind, Placebo Controlled Study Comparing First Line Therapy With or Without TG4010 Immunotherapy Product in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT01383148]	Phase 2/Phase 3	222 participants (Actual)	Interventional	2012-04-30	Terminated
A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer [NCT01198392]	Phase 3	270 participants (Anticipated)	Interventional	2008-09-30	Recruiting
A Phase I Study of Adjuvant Chemotherapy With Gemcitabine Plus Cisplatin in Patients With Biliary Tract Cancer Undergoing Curative Resection Without Major Hepatectomy [NCT01297998]	Phase 1	24 participants (Actual)	Interventional	2011-01-31	Completed
Phase II Study of Patients With Peritoneal Carcinomatosis From Gastric Cancer Treated With Preoperative Systemic Chemotherapy Followed by Peritonectomy and Intraperitoneal Chemotherapy [NCT01379482]	Phase 2	18 participants (Actual)	Interventional	2005-01-31	Completed
A Phase II Single Arm Trial of Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma [NCT03822897]	Phase 2	103 participants (Actual)	Interventional	2019-06-28	Active, not recruiting
A Randomized Phase III Trial Of Paclitaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Versus Topotecan Plus Cisplatin In Stage IVB, Recurrent Or Persistent Carcinoma of the Cervix [NCT00064077]	Phase 3	513 participants (Actual)	Interventional	2003-05-31	Completed
Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF Versus Carboplatin/Paclitaxel in Patients With Stage III &Amp; IV or Recurrent Endometrial Cancer [NCT00063999]	Phase 3	1,381 participants (Actual)	Interventional	2003-08-25	Completed
International Randomized Study of Transarterial Chemoembolization Versus CyberKnife for Recurrent Hepatocellular Carcinoma [NCT01327521]	Phase 3	0 participants (Actual)	Interventional	2011-02-28	Withdrawn(stopped due to Accrual below target levels)
Phase II Study of KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma to Evaluate Safety, Efficacy and Tolerance [NCT03927495]	Phase 2	100 participants (Anticipated)	Interventional	2019-05-22	Recruiting
Survival Analysis of A Chinese Randomized Crossover Study Comparing Erlotinib to Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations [NCT01131429]	Phase 2	60 participants (Anticipated)	Interventional	2010-06-30	Not yet recruiting
A Three-Arm Phase III Study of Concomitant Versus Sequential Chemotherapy and Thoracic Radiotherapy for Patients With Locally Advanced Inoperable Non-small Cell Lung Cancer [NCT01134861]	Phase 3	610 participants (Actual)	Interventional	1994-07-31	Completed
A Phase II Study of Induction Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A) in Patients With Locally Advanced Head and Neck Cancer (CTRC# 11-36) [NCT01588431]	Phase 2	5 participants (Actual)	Interventional	2011-12-31	Active, not recruiting
A Phase I Trial of Induction Chemotherapy and Chemoradiotherapy With TS-1 and Cisplatin (SP) as First-line Treatment in Patients With High Risk Advanced Gastric Cancer [NCT01269255]	Phase 1	6 participants (Actual)	Interventional	2009-12-31	Completed
A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0) [NCT01283217]	Phase 3	166 participants (Anticipated)	Interventional	2010-03-31	Recruiting
Randomized Controlled Trial Comparing Concurrent Chemoradiation Versus Concurrent Chemoradiation Followed by Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients [NCT02036164]	Phase 3	500 participants (Anticipated)	Interventional	2014-01-31	Recruiting
Efficacy and Safety of Tunlametinib Capsules Versus Combination Chemotherapy of Investigator's Choice in Advanced NRAS-mutant Melanoma Patients Who Had Previously Received Immunotherapy [NCT06008106]	Phase 3	165 participants (Anticipated)	Interventional	2023-09-22	Not yet recruiting
Phase II Randomized Controlled Trial of Accelerated Fractionation Radiotherapy (6 Fractions Per Week) Versus Concurrent Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT01291095]	Phase 2	80 participants (Anticipated)	Interventional	2011-02-28	Recruiting
A Phase 3 Study of Pembrolizumab in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants With Metastatic Nonsquamous Non-Sm [NCT03976323]	Phase 3	1,005 participants (Actual)	Interventional	2019-06-28	Active, not recruiting
Phase III Randomized Clinical Trial for Stage III Epithelial Ovarian Cancer Randomizing Between Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy [NCT03772028]	Phase 3	538 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Phase 1b/2 Study of PEP503 (Radioenhancer) With Radiotherapy in Combination With Concurrent Chemotherapy for Patients With Head and Neck Cancer [NCT02901483]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2016-10-11	Terminated(stopped due to bussiness reason)
Study of Pd-1 Antibody in Combination With Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer [NCT04516616]	Phase 2	82 participants (Anticipated)	Interventional	2020-12-01	Recruiting
A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes and Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma [NCT02421640]	Phase 2	116 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Induction Chemotherapy and Toripalimab Followed by Surgery or Radiotherapy for Larynx Preservation in Resectable Laryngeal/Hypopharyngeal Carcinoma [NCT04995120]	Phase 2	42 participants (Anticipated)	Interventional	2021-04-07	Recruiting
Phase Ib Trial of Multiple-ascending Doses of EMD 1201081 in Combination With 5-FU/Cisplatin and Cetuximab in First-line Subjects With Recurrent/ Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT01360827]	Phase 1	13 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Study terminated due to potential safety concerns in combination with platinum-based therapies)
Intrapleural Hypertonic Cisplatin Treatment for Malignant Pleural Effusion in Patients With Non-small-cell Lung Cancer. [NCT02407912]		50 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Neoadjuvant Low-dose Radiotherapy, Tislelizumab, Combined With Albumin-bound Paclitaxel and Cisplatin in Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma (NeoRTPC02): an Open Label, Single-arm, Phase II Clinical Trial [NCT05343325]	Phase 2	25 participants (Anticipated)	Interventional	2022-03-09	Recruiting
The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) [NCT02072148]		112 participants (Actual)	Interventional	2014-03-31	Completed
Official Title: A Phase II Multicenter, Open Label, Non-randomized Study of Neoadjuvant and Adjuvant Treatment With IPH5201 and Durvalumab in Patients With Resectable, Early-stage (II to IIIA) Non-Small Cell Lung Cancer (MATISSE) [NCT05742607]	Phase 2	70 participants (Anticipated)	Interventional	2023-06-23	Recruiting
GOG-3068: A Phase III Randomized Trial of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Cisplatin Versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery Followed by Niraparib Maintenance in Patients With Newly Diagnosed Stage III a [NCT05659381]	Phase 3	230 participants (Anticipated)	Interventional	2023-12-11	Not yet recruiting
Phase I/Ib Study of AKT Inhibitor Ipatasertib With Chemoradiation for Locally Advanced Head and Neck Cancer [NCT05172245]	Phase 1	46 participants (Anticipated)	Interventional	2022-09-19	Recruiting
Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Using Cisplatin, Mitomycin, and Adriamycin in Peritoneal Surface Malignancies Also Known as Hyperthermic Intraperitoneal Chemotherapy. [NCT02349958]	Phase 2	200 participants (Anticipated)	Interventional	2006-09-30	Recruiting
A Phase Ib Study of BKM120 With Weekly Cisplatin and Radiotherapy in High Risk Locally Advanced Squamous Cell Cancer of the Head and Neck [NCT02113878]	Phase 1	23 participants (Actual)	Interventional	2014-09-29	Completed
Phase III Randomized Non-inferiority Trial of Reduced-dose Versus Standard Dose Radiotherapy for Stage II-III Nasopharyngeal Carcinoma Which Have Favorable Response After Induction Chemotherapy [NCT05304468]	Phase 3	380 participants (Anticipated)	Interventional	2022-03-29	Recruiting
InterAACT - An International Multicentre Open Label Randomised Phase II Advanced Anal Cancer Trial Comparing Cisplatin Plus 5-Fluorouracil Versus Carboplatin Plus Weekly Paclitaxel in Patients With Inoperable Locally Recurrent or Metastatic Disease [NCT02560298]	Phase 2	91 participants (Actual)	Interventional	2016-08-23	Active, not recruiting
Endostar Combined With IP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study [NCT03797625]	Phase 2	76 participants (Anticipated)	Interventional	2017-05-04	Recruiting
A Randomized Controlled Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib as the Maintenance Therapy for Extensive-stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy [NCT03781869]	Phase 2	116 participants (Anticipated)	Interventional	2018-12-31	Not yet recruiting
Preliminary Study of Maintenance Therapy for Patients With Extensive Stage of Small-cell Lung Cancer [NCT03769935]	Phase 2	90 participants (Actual)	Interventional	2017-01-01	Completed
Randomized Trial of Comparing One Cycle With Three Cycles Induction Chemotherapy Using Docetaxel, Cisplatin and Fluorouracil in Locoregionally Advanced Nasopharyngeal Carcinoma [NCT02096380]		120 participants (Anticipated)	Observational [Patient Registry]	2014-05-31	Not yet recruiting
Phase III Randomized Trial of Pleurectomy/Decortication Plus Systemic Therapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM) [NCT04158141]	Phase 3	16 participants (Actual)	Interventional	2020-01-29	Terminated(stopped due to Permanent Administrative Closure)
Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently With Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical Cancer [NCT03738228]	Phase 1	40 participants (Actual)	Interventional	2019-01-07	Active, not recruiting
A Phase I Study of the Wee 1 Kinase (Wee 1) Inhibitor AZD1775 in Combination With Radiotherapy and Cisplatin in Cervical, Upper Vaginal and Uterine Cancers (10041848, 10008224, 10008238, 10046888, 10014735) [NCT03345784]	Phase 1	10 participants (Actual)	Interventional	2018-05-29	Active, not recruiting
Phase I/II Study of Brentuximab Vedotin and Methotrexate/ L-asparaginase/ Dexamethasone (B-MAD) Chemotherapy in Patients With Newly-diagnosed Extranodal NK/ T-cell Lymphoma [NCT03246750]	Phase 1/Phase 2	34 participants (Actual)	Interventional	2019-01-30	Active, not recruiting
A Pilot Study: Phase II Study of Histology-based Consolidation Chemotherapy Following Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer [NCT01336543]	Phase 2	0 participants (Actual)	Interventional	2011-03-31	Withdrawn(stopped due to Low accrual, small patient population at center.)
A Prospective Phase II Study of Involved Field Elective Volume De-Intensification for Oropharyngeal and Laryngeal Squamous Cell Carcinoma Treated With Intensity Modulated Radiation Therapy [NCT03067610]	Phase 2	72 participants (Actual)	Interventional	2017-01-20	Completed
A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer [NCT01348009]	Phase 1/Phase 2	63 participants (Anticipated)	Interventional	2011-05-31	Recruiting
Efficacy of Carboplatin Administered Concomitantly With Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other Than Average Risk Medulloblastoma/PNET Patients [NCT00392327]	Phase 3	379 participants (Actual)	Interventional	2007-03-26	Active, not recruiting
Chemoradiotherapy With Very Low Dose Elective Nodal IMRT for Locally Advanced Head & Neck Cancer: the CCRO11 Multi-Institutional Phase II Trial [NCT01372111]	Phase 2	76 participants (Anticipated)	Interventional	2011-03-31	Active, not recruiting
Effect of DPP4 Inhibitors on Cisplatin-induced Acute Kidney Injury [NCT02250872]	Phase 2/Phase 3	182 participants (Anticipated)	Interventional	2014-12-31	Recruiting
The Efficacy and Safety of Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer [NCT05812430]	Phase 2	20 participants (Anticipated)	Interventional	2023-04-10	Recruiting
A Phase II Study of Cytoreduction, Gastrectomy, and Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT02891447]	Phase 2	24 participants (Actual)	Interventional	2016-09-01	Completed
Recombinant Human Endostatin in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Negative Driver Gene: a Multicenter, Single-Arm Trial [NCT05574998]	Phase 2	100 participants (Anticipated)	Interventional	2021-02-01	Recruiting
Toripalimab Plus Etoposide and Platinum-based Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Genitourinary Small Cell Carcinoma：A Multicenter, Prospective, Open Label, Single-arm, Phase II Study [NCT05760053]	Phase 2	33 participants (Anticipated)	Interventional	2023-02-18	Recruiting
EGFR Tyrosine Kinase Inhibitor Combined With Concurrent or Sequential Chemotherapy for Advanced Lung Cancer Patients of Gradual Progression After First-line EGFR-TKI Therapy: a Randomized Controlled Study [NCT03544814]	Phase 2	99 participants (Actual)	Interventional	2015-01-01	Completed
LCI-LUN-NSC-SBRT-001: Phase II Prospective Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation and Adjuvant Immunotherapy for Locally-Advanced Non-Small Cell Lung Cancer [NCT03141359]	Phase 2	61 participants (Actual)	Interventional	2017-05-12	Active, not recruiting
Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer Receiving Radiotherapy With Concurren [NCT00101582]	Phase 3	188 participants (Actual)	Interventional	2005-08-31	Completed
Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer [NCT02182778]	Phase 3	246 participants (Actual)	Interventional	2014-07-09	Completed
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Can [NCT02542293]	Phase 3	953 participants (Actual)	Interventional	2015-11-03	Active, not recruiting
A Phase I Dose Escalation Study of MK1775 in Monotherapy, in Combination With 5-Fluorouracil, and in Combination With 5-Fluorouracil and Cisplatin in Patients With Advanced Solid Tumor [NCT01047007]	Phase 1	11 participants (Actual)	Interventional	2010-01-18	Terminated(stopped due to The study has been terminated due to business reasons.)
A Randomized Phase II Study of Capecitabine and Cisplatin (XP) +/- Sorafenib (Nexavar®) in Patients With Advanced Gastric Cancer [NCT01187212]	Phase 2	195 participants (Actual)	Interventional	2010-08-31	Completed
Phase II Safety and Toxicity Study of Cisplatin With or Without Cetuximab and Concomitant Radiotherapy for Locoregionally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) [NCT01301248]	Phase 2	80 participants (Anticipated)	Interventional	2008-03-31	Active, not recruiting
Cetuximab in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck [NCT00122460]	Phase 3	442 participants (Actual)	Interventional	2004-12-31	Completed
A Pilot Study of Chemoradiotherapy Plus Temsirolimus (Torisel) for Advanced Head and Neck Cancer [NCT01326468]		0 participants (Actual)	Interventional	2011-01-31	Withdrawn(stopped due to funding)
A Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva [NCT00068406]	Phase 2	61 participants (Actual)	Interventional	2005-01-31	Completed
A Phase II Trial of Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer [NCT00394433]	Phase 2	38 participants (Actual)	Interventional	2006-09-30	Completed
Phase I/II Trial of Best Supportive Care and Chemotherapy, Either Cisplatin or Paclitaxel, in Patients With Primary Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer Presenting With Inoperable Malignant Bowel Obstruction [NCT01083537]	Phase 1/Phase 2	1 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to Slow accrual)
Phase III Open Label First Line Therapy Study of Tislelizumab With Chemotherapy Versus Chemotherapy in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(NSCLC) [NCT03663205]	Phase 3	334 participants (Actual)	Interventional	2018-07-23	Completed
Camrelizumab Combined With Induction Chemotherapy and Intensity Modulated Radiotherapy for the Treatment of Locally Advanced Nasopharyngeal Carcinoma:a Randomized, Multicenter, Phase II Trial [NCT05097209]	Phase 2	200 participants (Anticipated)	Interventional	2022-04-06	Recruiting
A Phase 1, Single Arm Investigator-initiated Study to Investigate the Safety of Combining the Antibody Magrolimab With Standard First Line Platinum-based Chemotherapy (With Cisplatin / Gemcitabine) in Advanced Urothelial Carcinoma [NCT05738161]	Phase 1	26 participants (Anticipated)	Interventional	2023-06-21	Recruiting
A Randomized, Double-Blind Placebo-Controlled, Phase 3 Study of Debio 1143 in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head an [NCT04459715]	Phase 3	730 participants (Actual)	Interventional	2020-08-07	Active, not recruiting
A Phase I, Multi-Center, Open Label, Dose De-Escalation and Expansion Study of Gemcitabine and Cisplatin With AG120 or Pemigatinib for Advanced Cholangiocarcinoma [NCT04088188]	Phase 1	8 participants (Actual)	Interventional	2021-01-25	Active, not recruiting
Phase II Trial of Standard Platinum Doublet Chemotherapy + Various Proton Beam Therapy (PBT) Doses in Order to Determine the Optimal Dose of PBT for Unresectable Stage 2/3 Non-Small Cell Lung Cancer [NCT03132532]	Phase 2	18 participants (Actual)	Interventional	2017-07-31	Active, not recruiting
Phase III Randomized Study With Cisplatinum and Conventional or Adaptive High Dose Radiotherapy for Advanced Head and Neck Cancer [NCT01504815]	Phase 3	268 participants (Actual)	Interventional	2012-03-31	Active, not recruiting
Chemoembolization in Hepatocellular Carcinoma or Neuroendocrine Hepatic Metastases: A Phase II Multi-Center Trial [NCT00003907]	Phase 2	50 participants (Actual)	Interventional	1999-12-15	Completed
Randomized Trial of Concurrent Chemoradiation With Weekly Versus Three-week Cisplatin in Patients With Advanced Cervical Cancer [NCT01097252]	Phase 3	104 participants (Actual)	Interventional	2002-01-31	Completed
Tolerability of Laser-assisted Cisplatin + 5-fluorouracil- an Exploratory Proof of Concept Study of Topical Combination Chemotherapy for Basal Cell Carcinoma [NCT03541252]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2018-03-09	Completed
A PHASE II STUDY Of ADJUVANT CHEMOTHERAPY After SURGERY For STAGE I Lung ADENOCARCINOMA PATIENTS With MICROPAPILLARY COMPONENT More Than Or EQUAL To 20% [NCT03351842]	Phase 2	460 participants (Anticipated)	Interventional	2017-09-01	Recruiting
Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial [NCT05144100]	Phase 2/Phase 3	498 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
Establishing of Neuronal-like Cells From Patients With Cisplatin-Induced Peripheral Neuropathy [NCT02492360]		0 participants (Actual)	Observational	2017-12-31	Withdrawn(stopped due to Lack of funding)
Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With Intensity-modulated Radiotherapy In The Treatment Of Locally Advanced Nasopharyngeal Carcinoma PhaseⅡClinical Randomized Study [NCT02187315]	Phase 2	160 participants (Anticipated)	Interventional	2014-05-31	Recruiting
Cadonilimab Combined With Induction Chemotherapy and Definitive Radiotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma: a Phase II, Single-arm Trial (EC-CRT-006) [NCT06143748]	Phase 2	46 participants (Anticipated)	Interventional	2023-12-15	Not yet recruiting
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study [NCT05857631]		90 participants (Anticipated)	Interventional	2023-05-29	Recruiting
Neoadjuvant Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial [NCT04473716]	Phase 1	20 participants (Actual)	Interventional	2020-07-30	Completed
A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) [NCT03800134]	Phase 3	826 participants (Actual)	Interventional	2018-12-06	Active, not recruiting
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years [NCT01096368]	Phase 3	479 participants (Actual)	Interventional	2010-05-07	Active, not recruiting
A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage III Non-small Cell Lung Cancer [NCT00334815]	Phase 2	29 participants (Actual)	Interventional	2006-06-15	Active, not recruiting
Multicenter Randomized Phase III Study Comparing Fixed Doses Versus Toxicity Adjusted Dosing of Cisplatin and Etoposide for Patients With Small Cell Lung Cancer. [NCT00526396]	Phase 3	160 participants (Anticipated)	Interventional	2007-09-30	Active, not recruiting
Phase Ib/II Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma [NCT01029873]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2010-02-28	Completed
Four Cycles of Cisplatin-Based Chemotherapy in Metastatic Urothelial Carcinoma Compared to Six Cycles: Randomized Phase III Trial - FOCUS Study - [NCT03296306]	Phase 3	330 participants (Anticipated)	Interventional	2016-09-30	Recruiting
Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hodgkin Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse Who Are Eligible for High Dose Treatment Followed by Autologous [NCT02280993]	Phase 1	72 participants (Anticipated)	Interventional	2014-05-31	Active, not recruiting
A Phase 1/2 Study of Apatinib in Combination With AP(Pemetrexed/Cisplatin) or AC(Pemetrexed/Carboplatin) as First-line Chemotherapy for Advanced Epidermal Growth Factor Receptor(EGFR) Wild Type Non-squamous Non-small Cell Lung Cancer [NCT03201146]	Phase 1/Phase 2	48 participants (Anticipated)	Interventional	2017-06-27	Recruiting
Phase I /II Study of Postoperative Chemoradiation in Patients With Node-positive Esophageal Squamous Cell Carcinoma [NCT02446574]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2007-07-31	Completed
A Phase 1 Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Advanced or Recurrent Malignancies [NCT02433626]	Phase 1	51 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Phase Ⅱ Study of S-1 Combined Cisplatin Hyperthermic Intraperitoneal Chemotherapy for Palliative Operation Gastric Cancer of Stage IV Limited Peritoneal Metastasis [NCT02291211]	Phase 2	60 participants (Anticipated)	Interventional	2014-09-30	Recruiting
Recombinant Adenoviral p53 Human Gene Combined With Chemotherapy in Treatment of Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer [NCT02435186]	Phase 2	100 participants (Anticipated)	Interventional	2015-06-30	Not yet recruiting
Recombinant Adenoviral Human p53 Gene With or Without Cisplatin in Treatment of Malignant Pleural - a Phase 2, Double Blinded, Randomized, Active Controlled Study [NCT02429726]	Phase 2	90 participants (Anticipated)	Interventional	2015-06-30	Not yet recruiting
Non Randomized, Multicenter, Prospective Pediatric Hodgkin Lymphoma Treatment Trial Stratified According to Initial Risk Factors and Response to Chemotherapy, Reduced Cumulative Doses of Antineoplastic Agents and Radiotherapy. [NCT03500133]	Phase 4	500 participants (Anticipated)	Interventional	2017-10-06	Recruiting
A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas [NCT04620187]	Phase 2	55 participants (Anticipated)	Interventional	2020-12-24	Recruiting
Cisplatin Combined With Irinotecan or Etoposide for Untreated Extensive-stage Small Cell Lung Cancer: a Multicenter Randomized Control Clinical Trial [NCT02323737]	Phase 2	62 participants (Actual)	Interventional	2010-07-31	Completed
Los Tres Paso Trial: Step One - Neoadjuvant Palbociclib Monotherapy, Step Two - Concurrent Chemoradiation Therapy, and Step Three - Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative, HPV-Unrelated Head and Neck Squamous Cell Carcinoma [NCT03389477]	Phase 2	26 participants (Actual)	Interventional	2018-04-27	Active, not recruiting
Pilot Study Using Myeloablative Busulfan/Melphalan (BuMel) Consolidation Following Induction Chemotherapy for Patients With Newly Diagnosed High-Risk Neuroblastoma [NCT01798004]	Phase 1	150 participants (Actual)	Interventional	2013-04-08	Active, not recruiting
A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma [NCT01175356]	Phase 1	99 participants (Actual)	Interventional	2010-10-04	Active, not recruiting
Combination Chemotherapy With or Without Maintenance Sunitinib Malate (NSC 736511) for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study [NCT00453154]	Phase 1/Phase 2	156 participants (Actual)	Interventional	2007-03-15	Completed
Phase II Multi-Center Study of Nab-paclitaxel, Gemcitabine and Cisplatin (NGC-Triple Regimen as Preoperative Therapy in Patients With Potentially Resectable and Borderline Resectable Pancreatic Cancer [NCT03392571]	Phase 2	0 participants (Actual)	Interventional	2018-08-15	Withdrawn(stopped due to Study was stopped due to lack of funding)
A Phase I Study of INCB024360 (Epacadostat) Alone, INCB024360 in Combination With Pembrolizumab (MK-3475), and INCB024360 and Pembrolizumab in Combination With Chemotherapy in Patients With Advanced Solid Tumors (KEYNOTE-434) [NCT02862457]	Phase 1	34 participants (Actual)	Interventional	2016-08-23	Completed
Phase I/II Study to Evaluate the Safety and Tolerability of LiPlaCis (Liposomal Cisplatin Formulation) in Patients With Advanced or Refractory Tumours [NCT01861496]	Phase 1/Phase 2	50 participants (Actual)	Interventional	2013-04-30	Completed
Sequential Chemoradiotherapy With Reduced Target Delineation and Radiation Doses During Radiotherapy for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT03389295]	Phase 2	118 participants (Actual)	Interventional	2010-01-31	Completed
Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. [NCT02328716]	Phase 3	32 participants (Anticipated)	Interventional	2012-02-29	Recruiting
A Phase II Randomized Study For Patients With Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery And Concomitant Chemoradiation By Either BID Irradiation Plus 5-Fluorouracil And Cisplatin Or QD Irradiation Plus Gemcitabine Followed By Selecti [NCT00777491]	Phase 2	70 participants (Actual)	Interventional	2008-12-31	Completed
A Randomized Phase II Study: Sequencing Topoisomerase Inhibitors for Extensive Stage Small Cell Lung Cancer (SCLC): Topotecan Sequenced With Etoposide/Cisplatin, and Irinotecan/Cisplatin Sequenced With Etoposide [NCT00057837]	Phase 2	140 participants (Actual)	Interventional	2004-07-14	Completed
"Phase II Trial of Definitive Chemoradiation With Elective Nodal Irradiation Dose De-escalation for p16 Positive Squamous Cell Carcinoma of the Oropharynx ENID" [NCT04444869]	Phase 2	28 participants (Anticipated)	Interventional	2020-09-28	Recruiting
Phase II Study of Preoperative TPF Chemotherapy in Locally Advanced Resectable Oral Cavity Squamous Cell Cancer in Order to Improve the Rate of Pathological Complete Response [NCT01914900]	Phase 2	14 participants (Actual)	Interventional	2012-06-30	Completed
A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer [NCT03003962]	Phase 3	669 participants (Actual)	Interventional	2017-01-02	Active, not recruiting
A Phase II Trial Neoadjuvant Paclitaxel and Cisplatin in Patients With Locally Advanced Head and Neck Cancer [NCT00337532]	Phase 2/Phase 3	50 participants	Interventional	2005-05-31	Completed
Phase III Randomized Trial of HIPEC in Primary Stage Three & Four Ovarian Cancer After Interval Cytoreductive Surgery (FOCUS) [NCT05827523]	Phase 3	520 participants (Anticipated)	Interventional	2023-05-31	Recruiting
Randomized Phase II Trial of Radiotherapy With Concurrent Cisplatin +/- Concurrent Cetuximab for HPV-Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC) in KRAS-Variant Patients [NCT04106362]	Phase 2	1 participants (Actual)	Interventional	2020-01-14	Terminated(stopped due to low enrollment)
Implementation and Evaluation of PIPAC for the Treatment of Patients With Peritoneal Carcinomatosis - a Feasibility Study. [NCT02320448]	Phase 2	35 participants (Actual)	Interventional	2015-03-31	Completed
Cisplatin Based Regimen to Patients With Advanced Pancreatic Cancer and Homologous Recombination Deficiency [NCT06095141]	Phase 2/Phase 3	30 participants (Anticipated)	Interventional	2023-12-01	Recruiting
Phase II Trial of Xevinapant and Chemoradiotherapy in Adjuvant Treatment for Patients With Head and Neck Squamous Cell Carcinoma With High Risk Pathologic Features [NCT06084845]	Phase 2	180 participants (Anticipated)	Interventional	2024-01-10	Not yet recruiting
A Phase I Study of M6620 (VX-970, Berzosertib) in Combination With Cisplatin and XRT in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC; SDC 10060121) [NCT02567422]	Phase 1	45 participants (Anticipated)	Interventional	2017-04-17	Active, not recruiting
Neoadjuvant Three-component Chemotherapy Based on a Combination of Doxorubicin, Cisplatin and Methotrexate in Patients Aged 24-40 Years With Primary Bone Tumors to Increase the Response Rate Compared With Two-component Chemotherapy [NCT05057130]	Phase 2/Phase 3	50 participants (Anticipated)	Interventional	2022-01-10	Recruiting
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing [NCT02734537]	Phase 2	189 participants (Anticipated)	Interventional	2016-11-23	Recruiting
A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma [NCT04848753]	Phase 3	663 participants (Actual)	Interventional	2021-06-23	Active, not recruiting
A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer [NCT02215265]	Phase 3	1,100 participants (Anticipated)	Interventional	2015-10-31	Recruiting
A MULTICENTER, OPEN-LABEL, PHASE 1B/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH CHEMOTHERAPY WITH OR WITHOUT OTHER ANTI-CANCER IMMUNOTHERAPIES AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED MALIGNANCIES [NCT03317496]	Phase 1/Phase 2	67 participants (Actual)	Interventional	2017-12-21	Terminated(stopped due to The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522).)
A Randomized, Controlled, Double-blind, Multi-center Phase Ⅲ Registration Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions [NCT04914598]	Phase 3	290 participants (Anticipated)	Interventional	2021-05-31	Not yet recruiting
Phase III Clinical Trial of Intravenous Paclitaxel Plus Intraperitoneal Cisplatin for Neo-adjuvant Chemotherapy in Patients With Advanced Ovarian Cancer [NCT04885270]	Phase 3	50 participants (Anticipated)	Interventional	2021-08-04	Recruiting
A Non-comparative Randomized 2:1 Phase II Study of Docetaxel, Cisplatin, and 5-fluorouracil in Combination or Not With Atezolizumab in Patients With Metastatic or Unresectable Locally Advanced Squamous Cell Anal Carcinoma [NCT03519295]	Phase 2	99 participants (Anticipated)	Interventional	2018-07-22	Active, not recruiting
A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic [NCT02453282]	Phase 3	1,118 participants (Actual)	Interventional	2015-07-21	Active, not recruiting
A Phase Ib, Open-label Trial to Investigate the Safety and Tolerability of SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma [NCT04282070]	Phase 1	91 participants (Actual)	Interventional	2020-03-27	Active, not recruiting
Clinical Study of Adbelizumab Combined With Concurrent Chemoradiotherapy in Locally Advanced Cervical Cancer [NCT06149767]	Phase 2	26 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination With Chemotherapy for the First Line Treatment for Patients With Advanced Biliary Tract Cancers (TOURMALINE) [NCT05771480]	Phase 3	140 participants (Anticipated)	Interventional	2023-08-16	Recruiting
Combined Therapy Using D-TACE, Gemcitabine and Cisplatin Chemotherapy, and PD1 Antibody for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma: a Single-center, Single-arm Trial [NCT05738057]	Phase 2	22 participants (Anticipated)	Interventional	2023-06-30	Recruiting
A Prospective Study of Dynamic Monitoring Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy [NCT03559803]		58 participants (Actual)	Interventional	2016-10-31	Active, not recruiting
A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junctio [NCT00583674]	Phase 2	171 participants (Actual)	Interventional	2007-12-31	Completed
A Pilot, Randomized, Self-controlled Study of the Effects of Intratympanic Sodium Thiosulfate on the Degree of Hearing Loss in Patients Receiving Cisplatin Therapy [NCT01369641]		1 participants (Actual)	Interventional	2011-08-24	Terminated(stopped due to Poor accrual)
The Efficacy and Safety of Nanoparticle Albumin-bound (NAB)-Paclitaxel Plus Cisolation Versus CEP (Cisplatin, Epirubicin,Cyclophosphamide) in Induction Therapy for Thymoma: a Study for a Single-center Prospective Phase II Randomized Controlled Train. [NCT05816694]	Phase 2	50 participants (Anticipated)	Interventional	2023-04-30	Not yet recruiting
Phase I Study of Targeted Lung Chemotherapy in the Treatment of Metastatic Tumors [NCT01014598]	Phase 1	11 participants (Actual)	Interventional	2007-12-04	Completed
A Single-Arm, Single-Center Phase II Clinical Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in The Treatment of Stage IIA2 To IVA (2018 FIGO) Locally Advanced Cervical Cancer [NCT05105672]	Phase 2	20 participants (Anticipated)	Interventional	2021-03-08	Recruiting
International, Randomized, Open-Label, Phase 3 Trial of Gemcitabine/Cisplatin Plus PF-3512676 Versus Gemcitabine/Cisplatin Alone as First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer [NCT00254904]	Phase 3	839 participants (Actual)	Interventional	2005-11-30	Terminated(stopped due to See Termination Reason in Detailed Description)
Definitive Concurrent Hypofractionated Radiotherapy With Weekly Cisplatin in Locally Advanced Squamous Cell Carcinoma Head and Neck (SCCHN) [NCT03880396]		62 participants (Actual)	Observational	2019-03-10	Completed
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of th [NCT03515538]	Phase 2	48 participants (Actual)	Interventional	2018-07-12	Completed
Phase Ib/IIa Study of SLIT Cisplatin by Inhalation in the Treatment of Patients Wtih Relapsed/Progressive Osteosarcoma Metastatic to the Lung [NCT00102531]	Phase 1/Phase 2	19 participants (Actual)	Interventional	2005-01-12	Completed
Safety and Efficacy of Gemcitabine Based Neoadjuvant Chemotherapy Followed by Chemoradiation in Locally Advanced Cervical Cancer Patients and Association With Human Equilibrative Nucleoside Transporter 1 (hENT1) Expression [NCT02309658]	Phase 2	50 participants (Actual)	Interventional	2013-09-30	Completed
Nedaplatin Versus Cisplatin and Capecitabine Versus Fluorouracil in Induction Chemotherapy Plus Concurrent Chemoradiotherapy for Locoregionally Advanced NPC： a Phase 3, Multicentre, Non-inferiority, Randomised Factorial Trial [NCT03503136]	Phase 3	632 participants (Anticipated)	Interventional	2018-06-30	Not yet recruiting
A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer [NCT01111942]	Early Phase 1	4 participants (Actual)	Interventional	2010-02-28	Terminated(stopped due to lack of enrollment)
Phase I Trial Of Cisplatin And KML-001 In Advanced Non-Small Cell Lung Cancer and Other Platinum Responsive Malignancies [NCT01110226]	Phase 1	23 participants (Actual)	Interventional	2010-04-27	Terminated(stopped due to Toxicity was not felt to be acceptable for further development.)
Randomised Phase-III-trial of Simultaneous Radiochemotherapy (RCT) of Locally Advanced Head and Neck Cancer in the Stages III and IV A-B: Comparing Dose Reduced Radiotherapy (63,6 Gy) With Paclitaxel/Cisplatin to Standard Radiotherapy (70,2 Gy) With 5-Flu [NCT01126216]	Phase 3	221 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to "After an Interims analysis the Data Safety Monitoring board recommended this because no significant difference between the two arms was seen and was not expected with an reasonable recruitment of patients.~No interruptions of the trial were made.")
An Open Label Randomized Controlled Phase II Trial of Panitumumab in Combination With Epirubicin, Cisplatin and Capecitabine (ECX) Versus ECX Alone in Subjects With Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal Junction. [NCT01234324]	Phase 2	171 participants (Actual)	Interventional	2010-10-31	Completed
Phase 2 Study of Weekly Paclitaxel in Combination With Cisplatin as Neoadjuvant Therapy for Locally Advanced Breast Cancer Patients [NCT02199418]	Phase 2	132 participants (Actual)	Interventional	2013-01-31	Completed
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of TQB2618 Injection Combined With Penpulimab in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma [NCT05563480]	Phase 2	90 participants (Anticipated)	Interventional	2022-10-27	Recruiting
A Phase I Study of TS-1, Cisplatin & RAD001 (Everolimus) [NCT01096199]	Phase 1	35 participants	Interventional		Terminated
Randomized Phase II Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer Patients [NCT01096745]	Phase 2	78 participants (Anticipated)	Interventional	2010-07-31	Terminated(stopped due to Planning for randomized phase III trial for this issue.)
A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma [NCT02281708]	Phase 3	1,012 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy: a Patient Preference Multicenter Randomized Phase II Trial [NCT06084897]	Phase 2	120 participants (Anticipated)	Interventional	2023-10-16	Recruiting
A Multi-Center, Randomized Phase III Study of Neoadjuvant Anti-PD-1 Immunotherapy Plus TP Chemotherapy Versus TP Chemotherapy or Up-Front Surgery in Resectable Locally Advanced Oral Squamous Cell Carcinoma [NCT05798793]	Phase 3	309 participants (Anticipated)	Interventional	2023-11-20	Not yet recruiting
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinic [NCT05294172]	Phase 3	295 participants (Actual)	Interventional	2022-06-16	Active, not recruiting
Phase I Study of TRC102 in Combination With Cisplatin and Pemetrexed in Patients With Advanced Solid Tumors / Phase II Study of TRC102 With Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin [NCT02535312]	Phase 1/Phase 2	30 participants (Actual)	Interventional	2016-03-08	Active, not recruiting
Hyperthermic Intraoperative Intraperitoneal Chemotherapy of Recurrent Ovarian Cancer - A Feasibility Study [NCT00968799]		6 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to poor patient accrual)
A Randomized Phase I/II Study of Standard Chemotherapy (Cisplatin and Pemetrexed) With or Without Axitinib in Patients With Malignant Mesothelioma: Interim Biopsy Analysis to Determine Efficacy [NCT01211275]	Phase 1/Phase 2	32 participants (Actual)	Interventional	2009-05-22	Completed
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus [NCT00492778]	Phase 2	165 participants (Actual)	Interventional	2008-02-25	Active, not recruiting
A Phase 3 Study of Sodium Thiosulfate for Reduction of Cisplatin-Induced Ototoxicity in Children With Average-Risk Medulloblastoma and Reduced Therapy in Children With Medulloblastoma With Low-Risk Features [NCT05382338]	Phase 3	225 participants (Anticipated)	Interventional	2023-02-20	Recruiting
A Phase 3, Randomized, Double-Blind Study of Pembrolizumab Versus Placebo in Combination With Adjuvant Chemotherapy With or Without Radiotherapy for the Treatment of Newly Diagnosed High-Risk Endometrial Cancer After Surgery With Curative Intent (KEYNOTE- [NCT04634877]	Phase 3	990 participants (Anticipated)	Interventional	2021-01-10	Active, not recruiting
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers [NCT03768414]	Phase 3	452 participants (Actual)	Interventional	2019-02-07	Active, not recruiting
A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol [NCT03737994]	Phase 2	10 participants (Actual)	Interventional	2019-07-25	Active, not recruiting
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) [NCT03533582]	Phase 2/Phase 3	537 participants (Anticipated)	Interventional	2018-05-24	Recruiting
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors [NCT03067181]	Phase 3	2,059 participants (Anticipated)	Interventional	2017-05-25	Recruiting
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients [NCT02724579]	Phase 2	45 participants (Anticipated)	Interventional	2017-11-17	Recruiting
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment [NCT00980460]	Phase 3	236 participants (Actual)	Interventional	2009-09-14	Active, not recruiting
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (≥ 4 cm) - IIIA Non-small Cell Lung Cancer (NSCLC) [NCT00324805]	Phase 3	1,501 participants (Actual)	Interventional	2007-06-01	Active, not recruiting
PEI REGIMEN: A THERAPEUTIC OPTION IN SMALL CELL LUNG CANCER? A MONOINSTITUTIONAL EXPERIENCE OF 46 CONSECUTIVE CASES [NCT02324296]		46 participants (Actual)	Observational	1998-12-31	Completed
Cisplatin and Sodium Thiosulfate Otoprotection With or Without SAHA/Vorinostat Histone Deacetylase Inhibition for Relapsed/Refractory Hepatoblastoma and Other Embryonal Tumors [NCT05756660]	Early Phase 1	33 participants (Anticipated)	Interventional	2023-03-01	Recruiting
Chidamide Combined With Cisplatin in Recurrent or Metastatic Head and Neck Adenoid Cystic Carcinoma: A Prospective, Open-label, Phase II Study of a Single Center [NCT03639168]	Phase 2	22 participants (Actual)	Interventional	2018-06-06	Completed
Clinical Study of Disulfiram Combined With Cisplatin in the Treatment of Advanced Gastric Cancer [NCT05667415]		40 participants (Anticipated)	Interventional	2023-06-01	Not yet recruiting
A Phase II Study of Genomic-guided 'Standard-of-care' Chemotherapy for in Advanced Gastric Cancer Patients [NCT01100801]	Phase 2	90 participants (Anticipated)	Interventional	2010-07-31	Recruiting
A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites [NCT01327235]	Phase 2	336 participants (Actual)	Interventional	2011-03-31	Completed
A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease [NCT00025259]	Phase 3	1,734 participants (Actual)	Interventional	2002-09-30	Completed
Randomized Phase II Study of Two Different Regimens of TPF Induction Chemotherapy Regimen Followed by Radiation Therapy Plus Cetuximab (TPF-CET-HART) vs. HART and Cis-platinum, 5-FU (PF-HART) in Patients With Locally Advanced Unresectable Squamous Cell Ca [NCT01181401]	Phase 2	94 participants (Actual)	Interventional	2010-08-31	Completed
A Phase I Study of Extended Field Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients Cervical Carcinoma Metastatic to the Para-Aortic Lymph Nodes [NCT00003377]	Phase 1	29 participants (Actual)	Interventional	1999-11-30	Completed
A Study of TS-1 Plus Cisplatin in Patients With Advanced Non-small-cell Lung Cancer [NCT01874678]		45 participants (Actual)	Interventional	2011-03-31	Completed
A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) [NCT03126916]	Phase 3	724 participants (Anticipated)	Interventional	2018-05-14	Active, not recruiting
Cytoreductive Surgery Plus Hyperthermic Intraoperative Peritoneal Chemotherapy With Cisplatin to Treat Peritoneal Carcinomatosis From Upper Gastrointestinal Cancer; the HIPCUpp-trial [NCT01116791]	Phase 2	34 participants (Actual)	Interventional	2010-07-31	Terminated(stopped due to Insufficient enrollment in Pancreatic & Biliary arm)
Preoperative S-1 Plus Cisplatin-based Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma : Randomized, Phase II Trial [NCT03814759]	Phase 2	102 participants (Anticipated)	Interventional	2016-12-12	Recruiting
Perioperative Versus Preoperative Chemotherapy With Surgery in Patients With Locoregional Squamous Carcinoma of Esophagus [NCT01225523]	Phase 1	350 participants (Actual)	Interventional	1997-01-31	Completed
Efficacy and Safety of Anlotinib Combined With Platinum Plus Pemetrexed in T790M Mutation Negative Metastastic Non-squamous Non-small-cell Lung Cancer After Progression on First-line EGFR TKI: a Phase II, Muti-center, Single Arm Study [NCT03706287]	Phase 1/Phase 2	62 participants (Anticipated)	Interventional	2018-12-06	Recruiting
Phase II Open-label Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Systemic Therapy for Locally Advanced or Metastatic Nasopharyngeal Carcinoma (NPC) [NCT01309633]	Phase 2	80 participants (Actual)	Interventional	2011-09-02	Completed
Adjuvant Chemotherapy Versus Observation After Radiation With Concurrent Cisplatin of Cervical Cancer (With Pelvic or Para-aortic Node Involvement) :A Phase 3 Prospective Multi-institutional Randomised Controlled Trial [NCT03468010]	Phase 3	432 participants (Anticipated)	Interventional	2018-03-01	Recruiting
Prospective Randomized Trial Comparing Induction Chemotherapy Plus Concurrent Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01245959]	Phase 3	476 participants (Anticipated)	Interventional	2011-01-31	Active, not recruiting
A Multicenter Randomized Phase II Study to Evaluate the Benefit of Chemotherapy Plus Best Supportive Care (BSC) Versus BSC in Patients With Metastatic Oesophageal Cancer of Squamous Cell-type Who Have Not Experienced a Disease Progression or Unacceptable [NCT01248299]	Phase 2	105 participants (Actual)	Interventional	2011-01-31	Terminated
Immune Reconstitution and Biomarker Identification in Patients With Newly Diagnosed Low and Intermediate Risk Hodgkins Lymphoma Receiving Chemotherapy With or Without Radiation Therapy: TXCH-HD-12A [NCT01858922]	Phase 2	40 participants (Actual)	Interventional	2012-12-19	Active, not recruiting
Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer [NCT02402920]	Phase 1	83 participants (Actual)	Interventional	2015-07-22	Active, not recruiting
Phase II Randomized Trial Comparating Two Concomitant Administration of Radiotherapy With Cisplatin in Patients With Not Operated or Inoperable HNSCC or With Recurrence High Risk in Adjuvant Postoperative Treatment [NCT03330249]	Phase 2	124 participants (Actual)	Interventional	2015-12-03	Completed
An Open Label Dose Escalation and Pharmacokinetic Phase I Study With Pazopanib in Combination With Cisplatin (CDDP) Every Three Weeks in Patients With Advanced Solid Tumors [NCT01165385]	Phase 1	35 participants (Actual)	Interventional	2010-06-30	Completed
JS001 Combined With Nab-paclitaxel and Cisplatin or Carboplatin as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma : a Prospective, Single Arm, Single Center, Phase II Clinical Trial [NCT05173246]	Phase 2	43 participants (Anticipated)	Interventional	2020-11-17	Recruiting
A Randomized Phase III Study of TaxoteRe Plus Cisplatin Versus AlImta Plus Cisplatin in 1st Line Non-squamous Cell Type Lung Cancer [NCT01282151]	Phase 3	148 participants (Actual)	Interventional	2011-07-31	Terminated(stopped due to Difficulty in recruitment due to approval of maintenance pemetrexed treatment)
A Randomized Phase II Study of Concurrent Chemoradiation With Every 3 Week of Cisplatin vs With Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma [NCT01171781]	Phase 2	110 participants (Anticipated)	Interventional	2009-11-30	Recruiting
Phase I/II Study of Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer [NCT01284413]	Phase 1/Phase 2	68 participants (Actual)	Interventional	2010-12-31	Completed
"An Open-label, Multi-center, Non-randomized Phase Ib Study to Investigate the Safety, Efficacy, and Pharmacokinetics of BAY 73-4506 Regorafenib, Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Nonsquamous Non-Small Cel [NCT01187615]	Phase 1	9 participants (Actual)	Interventional	2010-08-31	Terminated
A Phase III Study to Investigate the Differential Influence of Prior Chemotherapy on the Efficacy of Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (IIIB, IV) With or Without EGFR Gene Mutation [NCT01204307]	Phase 2	101 participants (Actual)	Interventional	2010-01-31	Completed
A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer [NCT02501278]	Phase 2	0 participants (Actual)	Interventional	2016-05-31	Withdrawn(stopped due to company (Inovio) is no longer able to support the study)
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Single-center, Phase II Clinical Study [NCT05588219]	Phase 2	30 participants (Anticipated)	Interventional	2022-12-01	Recruiting
PIONEER-Panc: Phase II Investigations of New and Emerging Therapies for Pancreatic Cancer [NCT04481204]	Phase 2	105 participants (Actual)	Interventional	2023-04-18	Active, not recruiting
A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN) [NCT00627835]	Phase 1	0 participants (Actual)	Interventional		Withdrawn(stopped due to Site decided not to open this study)
NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer [NCT04989283]	Phase 2	0 participants (Actual)	Interventional	2021-09-09	Withdrawn(stopped due to Due to no accrual)
A Feasibility Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and in Maintenance for Resectable Malignant Pleural Mesothelioma [NCT03228537]	Phase 1	29 participants (Actual)	Interventional	2018-07-16	Active, not recruiting
A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination With Intravenous Triapine in Women With Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer [NCT02466971]	Phase 3	437 participants (Actual)	Interventional	2016-05-10	Active, not recruiting
A Randomized Phase II Non-inferiority Study of Two Cycles Versus Three Cycles of Cisplatin Based Concurrent Chemoradiotherapy for Low Risk Locoregionally Advanced Nasopharyngeal Carcinoma Based on Pretreatment Plasma EBV DNA Level [NCT02871518]	Phase 2	236 participants (Anticipated)	Interventional	2016-08-31	Recruiting
Phase I/II Trial of Combination Chemotherapy With Docetaxel, Cisplatin and 5-FU for Unresectable Advanced Esophageal Cancer. [NCT00915850]	Phase 1/Phase 2	32 participants (Anticipated)	Interventional	2007-08-31	Recruiting
CPT-SIOP-2009: Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Patients With Choroid Plexus Tumors [NCT01014767]	Phase 3	27 participants (Actual)	Interventional	2009-11-30	Terminated(stopped due to PI departure from coordinating institution)
Phase I Trial of BYL719 in Combination With Concurrent Cisplatin-based Chemoradiotherapy in Patients With Locoregionally Advanced Squamous Cell Carcinoma of Head and Neck (LA-SCCHN) [NCT02537223]	Phase 1	9 participants (Actual)	Interventional	2015-09-30	Completed
A Phase II/III Trial of Durvalumab and Chemotherapy for Patients With High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy [NCT04628767]	Phase 2/Phase 3	249 participants (Anticipated)	Interventional	2021-11-12	Recruiting
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT02270814]	Phase 2	74 participants (Actual)	Interventional	2015-02-02	Active, not recruiting
Feasibility and Dose Discovery Analysis of Zoledronic Acid With Concurrent Chemotherapy in the Treatment of Newly Diagnosed Metastatic Osteosarcoma [NCT00742924]	Phase 1	24 participants (Actual)	Interventional	2008-08-31	Completed
A Phase II Study of Postoperative Intensity Modulated Radiation Therapy (IMRT) With Concurrent Cisplatin and Bevacizumab Followed by Carboplatin and Paclitaxel for Patients With Endometrial Cancer [NCT01005329]	Phase 2	34 participants (Actual)	Interventional	2009-11-06	Completed
A Multicenter, Phase II/III Study to Assess Radiation Induced Mucositis in Subjects With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Administered Cisplatin and Radiation With or Without P276-00 [NCT01903018]	Phase 2	73 participants (Actual)	Interventional	2012-07-31	Completed
The Sinai Robotic Surgery Trial in HPV-related Oropharyngeal Squamous Cell Carcinoma (SIRS 2.0 Trial) [NCT05419089]	Phase 2	199 participants (Anticipated)	Interventional	2022-07-12	Recruiting
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance [NCT00572169]	Phase 3	177 participants (Actual)	Interventional	2006-11-30	Active, not recruiting
A Prospective,Randomized,Controlled,Multicenter,Phase III Study of Stage Ⅲ Study of Gemcitabine Plus Cisplatin With or Without Endostatin to the Metastatic Nasopharyngeal Carcinoma [NCT01915134]	Phase 3	362 participants (Anticipated)	Interventional	2013-08-31	Recruiting
A Randomised Study of TPF as Neoadjuvant Chemotherapy Followed by Concomitant Chemoradiotherapy (CRT) With Conventional Radiotherapy (RT) Versus Concomitant CRT With Accelerated RT in Patients With Locally Advanced Head and Neck Squamous Cell Cancer (HNSC [NCT00774319]	Phase 2	70 participants (Anticipated)	Interventional	2008-12-31	Recruiting
A Phase I Study of the PI3-Kinase Inhibitor BKM120 in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors [NCT01971489]	Phase 1	0 participants (Actual)	Interventional	2015-09-30	Withdrawn
A Phase 2, Randomized, Open Label Study Of Figitumumab (CP-751,871) Plus Cisplatin (Or Carboplatin) And Etoposide, Versus Cisplatin (Or Carboplatin) And Etoposide Alone, As First Line Treatment In Patients With Extensive Stage Disease Small Cell Lung Canc [NCT00977561]	Phase 2	9 participants (Actual)	Interventional	2010-04-30	Terminated(stopped due to See termination reason in detailed description.)
A Phase Ib, Open-label Study of Alpelisib (BYL719) in Combination With Cisplatin in Patients With HPV+ Solid Tumor Malignancies [NCT02620839]	Phase 1	28 participants (Actual)	Interventional	2016-12-01	Terminated(stopped due to Funding)
A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients. [NCT00659269]	Phase 3	319 participants (Actual)	Interventional	2006-07-31	Completed
Randomized Trial of Concurrent Cisplatin Chemoradiotherapy Plus Capecitabine Adjuvant Chemotherapy vs Concurrent Cisplatin Chemoradiotherapy Alone for Patients With Local Advanced Nasopharyngeal Carcinoma at High Risk of Distant Metastasis [NCT02973386]	Phase 3	278 participants (Anticipated)	Interventional	2017-01-31	Recruiting
A Prospective Study of Heated Intra-Peritoneal Chemotherapy (H.I.P.E.C.) With Doxorubicin and Cisplatin in Pediatric Patients With Pelvic and Abdominal Tumors. The TOAST IT Trial (Trial Of Adjuvant Surgical Treatment With Intraperitoneal Chemotherapy) [NCT04213794]	Early Phase 1	43 participants (Anticipated)	Interventional	2019-11-08	Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer [NCT04005716]	Phase 3	457 participants (Actual)	Interventional	2019-07-22	Active, not recruiting
Phase II Study of RADPLAT and Tarceva in Locally Advanced Head and Neck Squamous Cell Carcinoma (SCCA) [NCT00304278]	Phase 2	21 participants (Actual)	Interventional	2006-03-31	Completed
Role of Neoadjuvant Chemotherapy in the Conservative Management of Non-muscle Invasive Bladder Cancer (NMIBC) T1b [NCT04245618]		50 participants (Anticipated)	Observational	2020-07-31	Not yet recruiting
Feasibility and Efficacy of Molecular Analysis-Directed Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer [NCT00705549]	Phase 2	88 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Due to poor accrual)
A Phase II Study of Endostar (Recombinant Human Endostatin ®) With Cisplatin and Capecitabine (Xeloda) as 1st Line Treatment in the Advanced Gastric Cancer [NCT00842491]	Phase 2	45 participants (Actual)	Interventional	2008-11-30	Completed
Phase II, Prospective, Randomized, Non-comparative Study of Treatment With Induction Chemotherapy With Cisplatin and Gemcitabine Followed by Chemoradiation or Definitive Chemoradiation in Invasive Locally Advanced Carcinomas of Uterine Cervix. [NCT01973101]	Phase 2	120 participants (Anticipated)	Interventional	2012-06-30	Recruiting
Concurrent Chemoradiotherapy Alone Versus Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Low-risk Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial [NCT05979961]	Phase 3	424 participants (Anticipated)	Interventional	2023-08-31	Not yet recruiting
AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB - LR and PNET 5 MB - WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (PNET 5 MB -SR), OR TP53 MUTATION, AND REGISTRY FOR MB OCCU [NCT02066220]	Phase 2/Phase 3	360 participants (Anticipated)	Interventional	2014-06-30	Active, not recruiting
A Phase II Study of Extended Field IMRT External Beam Irradiation and Intracavitary Brachytherapy With Concurrent Weekly Cisplatin in Patients With Stage I-IVA Cervical Cancer Who Have FDG PET Positive Pelvic or Para-Aortic Lymph Nodes [NCT00590967]	Phase 2	69 participants (Actual)	Interventional	2003-05-31	Terminated(stopped due to Due to low accrual)
A Randomized, Double-blind, Multi-center Phase III Study of Penpulimab (AK105) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [NCT04974398]	Phase 3	298 participants (Anticipated)	Interventional	2021-08-16	Recruiting
GP vs PF as Induction Chemotherapy Combined With CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma：a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial [NCT03840421]	Phase 3	468 participants (Anticipated)	Interventional	2019-04-03	Active, not recruiting
An Exploratory Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of HLX07 (Recombinant Anti-EGFR Humanized Monoclonal Antibody) Combined With Chemotherapy in Patients With Advanced Solid Tumors. [NCT03577704]	Phase 1/Phase 2	56 participants (Actual)	Interventional	2018-08-08	Completed
An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors [NCT02937116]	Phase 1	233 participants (Actual)	Interventional	2016-10-19	Completed
Exploratory Study of Molecular Phenotype Changes and Personalized Treatment for Patients With Castration Resistant Prostate Cancer [NCT02208583]		150 participants (Anticipated)	Interventional	2014-06-30	Recruiting
Randomized, Double-Blind, Phase 2/3 Study in Subjects With Malignant Pleural Mesotheliomato Assess ADI-PEG 20 With Pemetrexed and Cisplatin (ATOMIC-Meso Phase 2/3 Study) [NCT02709512]	Phase 2/Phase 3	249 participants (Actual)	Interventional	2017-08-01	Completed
Immunochemotherapy: Do Platin-based Chemotherapeutics Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients? [NCT02285413]	Phase 2	54 participants (Actual)	Interventional	2011-02-28	Completed
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients [NCT01755897]		337 participants (Actual)	Interventional	2012-11-30	Completed
A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent With Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061) [NCT01595061]	Phase 2	57 participants (Actual)	Interventional	2012-07-02	Active, not recruiting
[NCT02513355]	Phase 4	400 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Randomized Non-inferiority Trial of Radiotherapy Plus Nimotuzumab or Cisplatin in Patients With Favorable Response to Induction Chemotherapy for Low-risk Locoregionally Advanced-Staged Nasopharyngeal Carcinoma [NCT04456322]	Phase 3	326 participants (Anticipated)	Interventional	2020-07-06	Recruiting
Phase II Study Comparing Gemcitabine Plus Cisplatin to Docetaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma [NCT02016417]	Phase 2	120 participants (Anticipated)	Interventional	2014-05-31	Not yet recruiting
A Single Arm, Open Label, Phase 1b Study of Xevinapant in Combination With Weekly Cisplatin and Intensity-modulated Radiotherapy to Assess Safety and Tolerability in Participants With LA SCCHN, Suitable for Definitive Chemoradiotherapy (HyperlynX) [NCT06056310]	Phase 1	40 participants (Anticipated)	Interventional	2024-01-09	Not yet recruiting
Comparison of Efficacy and Tolerance Between Combination Therapy and Monotherapy as a First Line Chemotherapy in Elderly Patient With Advanced Gastric Cancer; Multicenter Randomized Phase 3 Study [NCT02114359]	Phase 3	111 participants (Actual)	Interventional	2014-02-28	Completed
Phase II Study Comparing Intensity Modulated Radiotherapy (IMRT) in Combination With Concurrent Chemotherapy and IMRT Alone for Stage II Nasopharyngeal Carcinoma [NCT02116231]	Phase 2	80 participants (Anticipated)	Interventional	2014-04-30	Not yet recruiting
Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer [NCT02128243]	Phase 2	242 participants (Actual)	Interventional	2014-09-30	Completed
Multimodal Therapy of Advanced Cervical Cancer With Radiotherapy or Chemoradiation, Interstitial Brachytherapy in Combination With Hyperthermia [NCT03249519]		999 participants (Anticipated)	Interventional	2017-08-01	Recruiting
Intensity Modulated Radiotherapy Plus Cisplatin Versus Intensity Modulated Radiotherapy in Patients With Stage 2 Nasopharyngeal Carcinoma: A Phase 3 Multicenter, Open-label, Randomized, Non-inferior Clinical Trial [NCT03068936]	Phase 3	716 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
Erlotinib Treatment Beyond Progression in EGFR Mutant or Patients Who Have Responded EGFR TKI in Stage IIIB/IV NSCLC [NCT02064491]	Phase 2	18 participants (Actual)	Interventional	2014-02-28	Completed
Induction Versus Adjuvant Gemcitabine/Cisplatin in Locally Advanced Non-metastatic Nasopharyngeal Carcinoma: A Randomized Phase III Trial [NCT04898374]	Phase 3	120 participants (Anticipated)	Interventional	2021-05-01	Recruiting
Phase II Clinical Randomized Study of the Effect of Chronomodulated Chemotherapy Followed by Concurrent IMRT Chemo-radiotherapy on the Dendritic Cells Subsets and Immunity in the Treatment of Advanced Nasopharyngeal Cancer [NCT03196869]	Phase 2	128 participants (Anticipated)	Interventional	2017-04-07	Recruiting
[NCT02444949]	Phase 2	75 participants (Actual)	Interventional	2014-06-30	Completed
Hypofractionated Radiotherapy and Concurrent Cisplatin for Locally Advanced Head and Neck Cancer: A Feasibility Trial [NCT03194061]		20 participants (Actual)	Interventional	2015-01-01	Active, not recruiting
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) [NCT04846634]	Phase 2	90 participants (Anticipated)	Interventional	2021-08-31	Not yet recruiting
Recombinant Adenoviral Human p53 Gene Combined With Radio- and Chemo-therapy in Treatment of Unresectable, Locally Advanced Head and Neck Cancer - a Open-labeled Randomized Phase 2 Study [NCT02429037]	Phase 2	60 participants (Anticipated)	Interventional	2015-05-31	Not yet recruiting
A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma [NCT06172296]	Phase 3	478 participants (Anticipated)	Interventional	2024-02-14	Not yet recruiting
Reduced-dose Radiotherapy With/Without Concurrent Chemotherapy Versus Standard Chemoradiotherapy for High-risk Locoregionally Advanced Nasopharyngeal Carcinoma Who Achieved Complete Response After Induction Chemotherapy Plus Immunotherapy: a Randomized, O [NCT06092957]	Phase 3	504 participants (Anticipated)	Interventional	2023-10-09	Recruiting
Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician's Choice Systemic Therapy in Subjects With BreAst Cancer [NCT04711824]	Phase 1/Phase 2	41 participants (Anticipated)	Interventional	2022-03-09	Recruiting
A Phase II Pilot Trial Of Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and the Addition Of Paricalcitol Upon Disease Progression in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (NABPLAGEMD) [NCT03415854]	Phase 2	11 participants (Actual)	Interventional	2018-01-31	Completed
A Phase I Study of Ceritinib (LDK378), a Novel ALK Inhibitor, in Combination With Gemcitabine-Based Chemotherapy in Patients With Advanced Solid Tumors [NCT02227940]	Phase 1	38 participants (Anticipated)	Interventional	2015-01-08	Completed
A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC [NCT05543330]	Phase 1/Phase 2	96 participants (Anticipated)	Interventional	2022-09-30	Not yet recruiting
A Treatment Strategy of the Use of 1st Line Chemotherapy in Patients With Poor-Prognosis Disseminated Non-Seminomatous Germ Cell Tumors Based on Tumor Marker Decline: A Phase II Trial of Paclitaxel, Ifosfamid and Cisplatin Regimen. [NCT02414685]	Phase 2	19 participants (Actual)	Interventional	2015-04-30	Completed
A Phase Ib Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers (PANTHEoN) [NCT04892875]	Phase 1	0 participants (Actual)	Interventional	2023-12-31	Withdrawn(stopped due to Funding)
IMMUNOCERV: Evaluating the Safety of Chemoradiation Combined With PDS0101 Immunotherapy in Treating Locally Advanced Cervical Cancer [NCT04580771]	Phase 2	35 participants (Anticipated)	Interventional	2020-10-14	Recruiting
A Phase I Trial of AT13387 in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN) Receiving Concurrent Radiation and Cisplatin [NCT02381535]	Phase 1	2 participants (Actual)	Interventional	2015-09-21	Active, not recruiting
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA) [NCT02135042]	Phase 2/Phase 3	685 participants (Actual)	Interventional	2014-04-21	Active, not recruiting
Phase II Trial of 5-FU, Leucovorin, Gemcitabine, and Cisplatin for Adenocarcinomas of the Urothelial Tract and Urachal Remnant [NCT00082706]	Phase 2	46 participants (Actual)	Interventional	2003-04-23	Active, not recruiting
A Phase I Study of Nelfinavir and Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Vulvar Cancer Not Amenable to Surgical Resection [NCT04169763]	Phase 1	18 participants (Anticipated)	Interventional	2020-08-07	Recruiting
Immuno-Chemotherapy as Single Treatment Modality for Larynx Preservation (ICoLP) [NCT04030455]	Phase 2	25 participants (Anticipated)	Interventional	2019-08-07	Recruiting
A Multicenter, Phase II Clinical Study of AK104 (Anti-PD-1/CTLA-4 Bispecific Antibody) Alone or in Combination With Chemotherapy in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma [NCT05522894]	Phase 2	80 participants (Anticipated)	Interventional	2022-10-01	Not yet recruiting
DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy [NCT05541016]	Phase 2	320 participants (Anticipated)	Interventional	2023-02-21	Recruiting
CASPIAN-RT Trial: Hypofractionated Consolidative Radiation Therapy After Durvalumab (MEDI4736) Plus Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer [NCT05161533]	Phase 2	0 participants (Actual)	Interventional	2023-10-19	Withdrawn(stopped due to Closed per SRC Low Accrual Policy. Study closed prior to any participants enrolled.)
A Phase II, Single-Arm Trial Assessing Local Control of Near Total Endoscopic Resection Followed by Concurrent Chemotherapy and Proton Radiation in the Treatment of Unresectable Sinonasal Tumors [NCT03274414]	Phase 2	3 participants (Actual)	Interventional	2017-09-01	Completed
A Randomized, Placebo-Controlled, Phase 2 Study of Docetaxel and Cisplatin/Carboplatin With or Without Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck [NCT01064479]	Phase 2	123 participants (Actual)	Interventional	2010-02-05	Completed
An Open Label, Dose Escalation, Safety and Pharmacokinetics Phase 1 Study With Ombrabulin Administered as a 30-minute Intravenous Infusion in Combination With Cisplatin Administered as an Intravenous Infusion Every 3 Weeks in Patients With Advanced Solid [NCT01021150]	Phase 1	12 participants (Anticipated)	Interventional	2010-03-31	Completed
De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma [NCT02281955]	Phase 2	115 participants (Actual)	Interventional	2014-08-31	Active, not recruiting
Pilot Study of Adjuvant Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Colorectal Cancer at High Risk for the Development of Metachronous Peritoneal Metastases [NCT02575859]	Phase 1/Phase 2	20 participants (Actual)	Interventional	2006-01-31	Completed
The Prospective Study of Sintilimab Combination With Chemotherapy Sequential Radiotherapy for Advanced Esophageal Squamous Cell Carcinoma [NCT06138028]	Phase 2/Phase 3	90 participants (Anticipated)	Interventional	2023-09-20	Recruiting
A Prospective, Single-arm, Exploratory Study on the Efficacy and Safety of Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Patients With Neuroendocrine Bladder Carcinoma [NCT06091124]	Phase 2	22 participants (Anticipated)	Interventional	2023-11-16	Recruiting
A Randomized, Double-blind, Multicenter Study of Lenvatinib, Temalizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma [NCT05823311]	Phase 3	80 participants (Anticipated)	Interventional	2023-10-31	Recruiting
Neoadjuvant Chemotherapy Plus Cystectomy vs Cystectomy Alone for cT0 Muscle-invasive Bladder Cancer After Maximal TURBt: Multicentre Prospective Randomized Controlled Trial [NCT05776758]	Phase 3	236 participants (Anticipated)	Interventional	2023-11-30	Recruiting
A Single Arm Phase 2 Study of Y-90 SIRT in Combination With Durvalumab (MEDI 4736) and Gemcitabine/Cisplatin in Locally Advanced, Unresectable or Metastatic Intrahepatic Cholangiocarcinoma [NCT05655949]	Phase 2	30 participants (Anticipated)	Interventional	2023-12-31	Recruiting
A Phase Ⅱ, Open Label, Single-center Study of Lenvatinib and Tirelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma [NCT05532059]	Phase 2	100 participants (Anticipated)	Interventional	2022-01-31	Recruiting
Phase II Study of Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer [NCT05521997]	Phase 2	42 participants (Anticipated)	Interventional	2024-01-31	Not yet recruiting
Randomized Phase I Study Assessing the Safety and Tolerability Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at Completion of Interval Cytoreductive Surgery Compared to Surgery and Chemotherapy Prior to Surgery for Patients With Stage III/IV Ovarian C [NCT05415709]	Early Phase 1	45 participants (Anticipated)	Interventional	2022-06-13	Recruiting
Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers [NCT00939848]	Phase 2/Phase 3	124 participants (Actual)	Interventional	2011-04-30	Completed
Open Label, Phase II Study of Capecitabine (Xeloda®) as Fluoropyrimidine of Choice in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer Suitable for Treatment With a Fluoropyrimidine-Based Regimen [NCT00454636]	Phase 2	158 participants (Actual)	Interventional	2007-03-31	Completed
A Phase II Study of Efficacy and Safety of Paclitaxel and Cisplatin Every 2 Weeks as the First-line Treatment of Patients With Ovarian Cancer Stage Ic-IV. [NCT00964626]	Phase 2	60 participants (Anticipated)	Interventional	2009-04-30	Recruiting
Paclitaxel In Combination With Cisplatin and 5-fluorouracil(TPF) Induction Chemotherapy for Locally Advanced Borderline-resectable Esophageal Squamous Cell Carcinoma: A Phase II Clinical Trial [NCT02976909]	Phase 2	46 participants (Actual)	Interventional	2016-10-31	Completed
Atezolizumab With Platinum and Etoposide Chemotherapy Followed by Cystectomy for Patients With Localized Small Cell Neuroendocrine Bladder Cancer [NCT05312671]	Phase 2	63 participants (Anticipated)	Interventional	2022-06-27	Recruiting
A Randomized Phase II Study of Gemcitabine/Cisplatin With or Without Sorafenib to Evaluate the Efficacy and Safety in Patients With Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial [NCT00758381]	Phase 2	114 participants (Anticipated)	Interventional	2007-08-31	Recruiting
Phase II Prospective Study Evaluating the Role of Directed Cisplatin Based Chemo With Either Vinorelbine or Pemetrexed for the Adj Tx of Early Stage NSCLC in Patients Using Genomic Expression Profiles of Chemo Sensitivity to Guide Therapy [NCT00545948]	Phase 2	31 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Study terminated due to reproducibility issues with genomics prediction model.)
Phase II Trial of Etoposide Plus Cisplatin Compared With Irinotecan Plus Cisplatin for First-line Treatment of Non-primary Pancreatic Metastatic and/or Unresectable Gastrointestinal Neuroendocrine Tumor G3 Type [NCT03963193]	Phase 2	112 participants (Anticipated)	Interventional	2019-06-01	Not yet recruiting
Phase 2 Study of Adjuvant Chemotherapy With Docetaxel, Capecitabine and Cisplatin in Patients With Advanced Gastric Cancer [NCT00976976]	Phase 2	46 participants (Actual)	Interventional	2007-05-31	Completed
Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cispla [NCT00771563]	Phase 3	104 participants (Actual)	Interventional	2008-06-30	Completed
Phase 1/2, Open-Label, Single-Arm Safety and Efficacy Dose-Finding, Systemic Exposure, and Device Technical Effects of PRV111 (Cisplatin Transmucosal System) in Subjects With Oral Squamous Cell Carcinoma [NCT03502148]	Phase 1/Phase 2	10 participants (Actual)	Interventional	2018-06-19	Completed
A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer [NCT00408694]	Phase 2	46 participants (Actual)	Interventional	2006-12-13	Completed
A Phase II Study of Sorafenib With Gemcitabine/Cisplatin in Advanced Hepatocellular Carcinoma [NCT00808145]	Phase 2	0 participants (Actual)	Interventional	2009-02-28	Withdrawn(stopped due to Lack of enrollment, many screen failures and non eligible study participants)
Clinical Randomized Control Trial of Intraoperative Implanting Chemotherapeutic Drugs Sustained Release Following Resection of Hepatocellular Carcinoma Against Postoperative Short-term Recurrence [NCT00817895]		150 participants (Actual)	Interventional	2008-12-31	Completed
Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer [NCT00381706]	Phase 2	245 participants (Actual)	Interventional	2006-09-15	Completed
A Randomized, Open-Label, Controlled, Phase II Trial of Combination Chemotherapy With or Without Panitumumab as First-line Treatment of Subjects With Metastatic or Recurrent Head and Neck Cancer, and Cross-over Second-line Panitumumab Monotherapy of Subje [NCT00454779]	Phase 2	113 participants (Actual)	Interventional	2007-01-01	Completed
A Phase 1/2 Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Weekly Doses of Palifermin (rHuKGF) for the Reduction of Oral Mucositis in Subjects With Locally Advanced Head and Neck Cancer (HNC) Receiving Postoperati [NCT00626639]	Phase 1/Phase 2	5 participants (Actual)	Interventional	2005-07-31	Completed
A Phase III, Randomized, Double-Blind, Placebo Controlled, Multi-Center, International Study of Durvalumab Given Concurrently With Definitive Chemoradiation Therapy in Patients With Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma (KUNLUN [NCT04550260]	Phase 3	640 participants (Actual)	Interventional	2020-10-19	Active, not recruiting
A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer [NCT04486833]	Phase 1/Phase 2	158 participants (Anticipated)	Interventional	2021-09-03	Recruiting
A Phase 1 Dose-Finding Study Of The Anti-Angiogenesis Agent, AG-013736, In Combinations Of Paclitaxel/Carboplatin, Weekly Paclitaxel, Docetaxel, Capecitabine, Gemcitabine/Cisplatin and Pemetrexed/Cisplatin In Patients With Advanced Solid Tumors [NCT00454649]	Phase 1	102 participants (Actual)	Interventional	2005-12-31	Completed
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer [NCT00003298]	Phase 2	39 participants (Actual)	Interventional	1999-06-01	Completed
Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and Optional Postoperative Normothermic Intraperitoneal (IP) Chemotherapy to Treat Primary or Recurrent Carcinoma of Ovarian, Fallopian Tube, Uterine, or Peritoneal Origin [NCT01970722]	Phase 1	40 participants (Anticipated)	Interventional	2014-05-19	Active, not recruiting
Multicenter Phase II Study Evaluating Docetaxel and CDDP as Induction Regimen Prior to Surgery or Radiochemotherapy With Docetaxel, Followed by Adjuvant Docetaxel Therapy in Chemonaive Patients With NSCLC Stage II, IIIa and IIIb [NCT00432315]	Phase 2	80 participants (Actual)	Interventional	2001-05-31	Completed
Phase II Randomized Controlled Trial on the Safety and Efficacy of 4 Versus 6 Courses of Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients Previously Treated With Neoadjuvant Chemotherapy Plus Radical Surgery [NCT02365935]		215 participants (Actual)	Interventional	2007-02-28	Completed
A Phase 1/2, Open-label, Dose-exploration and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NTX-301 Monotherapy in Advanced Solid Tumours, and in Combination With Platinum-based Chemotherapy in Advanced Ova [NCT04851834]	Phase 1/Phase 2	12 participants (Actual)	Interventional	2021-08-25	Terminated(stopped due to Study was terminated by IP Holder (collaborator), PinotBio Inc.)
Randomized, Controlled Study of the Safety and Efficacy of DC-CTL Immune Cell for Non-Small Cell Lung Cancer [NCT02766348]	Phase 2	60 participants (Anticipated)	Interventional	2016-05-31	Not yet recruiting
Randomized Phase III Trial Evaluating the Role of Autologous Stem Cell Transplantation in Previously Untreated Patients With Stage B and C Chronic Lymphocytic Leukemia [NCT00931645]	Phase 3	241 participants (Actual)	Interventional	2001-04-30	Completed
Combination of Cisplatin Plus Gemcitabine Induction Chemotherapy and Intensity-modulated Radiotherapy With or Without Concurrent Cisplatin for Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01854203]	Phase 2/Phase 3	300 participants (Anticipated)	Interventional	2013-07-31	Recruiting
A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin [NCT04541355]	Phase 2	16 participants (Actual)	Interventional	2020-10-14	Completed
A Phase III, Multicenter, Randomized Study of ABX Plus Cisplatin (AP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer [NCT02546934]	Phase 3	254 participants (Anticipated)	Interventional	2016-03-31	Completed
Phase II Clinical Trial With Metronomic Oral Vinorelbine and Tri-weekly Cisplatin as Induction Therapy and Subsequent Concomitantly With Radiotherapy (RT) in Patients With Lung Cancer (NSCLC) Locally Advanced Unresectable [NCT02709720]	Phase 2	67 participants (Actual)	Interventional	2016-04-15	Completed
A Phase II, Prospective, Open-label Clinical Trial of Pre-Operative PD-1 Antibody (Toripalimab) + Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer [NCT04177875]	Phase 2	44 participants (Anticipated)	Interventional	2019-05-01	Recruiting
Sequential High Dose MVAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin), Followed by Gemcitabine Plus Cisplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer [NCT00635726]	Phase 2	41 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to Due to poor accrual)
A Phase I/II Randomized Study to Determine the Maximum Tolerated Dose, Safety, Pharmacokinetics and Antitumor Activity of Debio 1143 Combined With Concurrent Chemo-Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and [NCT02022098]		144 participants (Actual)	Interventional	2013-10-31	Completed
Phase II Clinical Study of Patients Randomized, Open, Controlled Evaluation of Autologous Tumor Tissue Antigen Sensitized DC-CIK Cells Combined With Chemotherapy in the Treatment of Patients With Esophageal Resection [NCT02644863]	Phase 2	60 participants (Anticipated)	Interventional	2015-12-31	Recruiting
Study of Endostar Combined With Docetaxel and Cisplatin on the Angiogenesis of Advanced Non-small Cell Lung Cancer [NCT00657423]	Phase 3	80 participants (Anticipated)	Interventional	2008-04-30	Recruiting
Nedaplatin Versus Cisplatin in Induction Chemotherapy Combined With Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma：a Prospective, Parallel, Randomized, Open Labeled, Phase III Non-Inferiority Clinical Study [NCT04437329]	Phase 3	352 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Clinical Trial of Tumor Cell-derived Microparticles Packaging Chemotherapeutic Drugs to Treat Malignant Pleural Effusion [NCT02657460]	Phase 2	90 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase II Study to Evaluate the Efficacy and Safety of Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Unresectable Locally Advanced or Metastatic Urothelial Carcinoma [NCT04211012]	Phase 2	30 participants (Anticipated)	Interventional	2020-11-30	Not yet recruiting
Prospective Randomized Trial Comparing Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa Nasopharyngeal Carcinoma [NCT06095167]	Phase 3	476 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
A Phase II Randomised Controlled Study Assessing the Role of Dose Escalation Using [18F] FMISO PET CT in Head and Neck Cancer: The DE-HyART (Dose Escalation Using Hypoxia-adjusted Radiotherapy) Protocol [NCT06087614]	Phase 2	124 participants (Anticipated)	Interventional	2023-10-31	Recruiting
Phase II Study: Induction Chemotherapy Followed by Transoral Robotic Surgery and Neck Dissection for Definitive Management of Oropharyngeal Squamous Cell Carcinoma. (NECTORS Trial) [NCT04277858]	Phase 2	60 participants (Anticipated)	Interventional	2018-08-14	Recruiting
A Randomized Phase II Trial of Docetaxel, Cisplatin, and Hypofractionated Radiotherapy Versus Docetaxel and Cisplatin for Limited Volume Stage IV Non-small Cell Lung Cancer: The Synergistic Metastases Annihilation With Radiotherapy and Docetaxel (Taxotere [NCT00887315]	Phase 2	11 participants (Actual)	Interventional	2009-04-30	Terminated(stopped due to Slow accrual and loss of sponsor)
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer [NCT00887159]	Phase 2	168 participants (Actual)	Interventional	2009-07-16	Completed
Randomized phase2 Study of IP vs. GP as the First-line Therapy Followed by Two Different Sequences as the 2nd or 3rd-line Therapy for Patients With Advanced NSCLC; [NCT01003964]	Phase 2	289 participants (Actual)	Interventional	2009-02-28	Completed
A Phase I, Open-label, Non-randomized Study, to Assess the Safety and Tolerability of Cediranib (AZD2171) in Combination With Cisplatin Plus a Fluoropyrimidine (Capecitabine or S-1) in Japanese Patients With Previously Untreated Locally Advanced or Metast [NCT00960349]	Phase 1	14 participants (Actual)	Interventional	2009-08-31	Completed
Prospective Non-inferior Clinical Trial Comparing Concurrent Chemoradiotherapy or Radiotherapy Alone in Patients With Intermediate Risk Nasopharyngeal Carcinoma in Intensity-modulated Radiotherapy Era [NCT02633202]	Phase 3	338 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A Randomized Phase II Clinical Trial of an Adenovirus-mediated Endostatin Gene (E10A) Combined With Cisplatin and Paclitaxel in Patients With Head and Neck Cancer [NCT00634595]	Phase 2	116 participants (Anticipated)	Interventional	2008-03-31	Recruiting
Pembrolizumab + Platinum Doublets Without Radiation for Patients With PD-L1 ≥50% Locally Advanced Non-small Cell Lung Cancer: a Multicenter Prospective Single Arm Phase II Study [NCT04153734]	Phase 2	21 participants (Anticipated)	Interventional	2019-12-01	Not yet recruiting
A Phase I Dose Escalation Study of Edotecarin (PHA-782615) and Cisplatin in Adult Patients With Advanced/Metastatic Solid Tumors [NCT00072332]	Phase 1	0 participants	Interventional	2003-08-31	Completed
Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer. [NCT00680940]	Phase 2	221 participants (Actual)	Interventional	2008-06-30	Completed
A Multicenter Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy Plus Adjuvant Chemotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT00677118]	Phase 3	506 participants (Anticipated)	Interventional	2006-06-30	Active, not recruiting
Oral Vinorelbine And Cisplatin With Concomitant Radiotherapy Followed By Either Consolidation Therapy With Oral Vinorelbine And Cisplatin Plus Best Supportive Care Or Best Supportive Care Alone In Stage III Non Small Cell Lung Cancer (NSCLC), A Randomized [NCT00683514]	Phase 3	201 participants (Actual)	Interventional	2005-04-30	Completed
Phase IV Study of Concurrent Chemoradiotherapy With Paclitaxel and Cisplatin in Previously Untreated, Inoperable (Stage IIIa or IIIb) Non-small-cell Lung Cancer [NCT00686322]	Phase 4	6 participants (Actual)	Interventional	2008-04-30	Completed
Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer [NCT00718354]	Phase 3	740 participants (Actual)	Interventional	2008-07-31	Completed
Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer [NCT05880082]	Phase 2	62 participants (Anticipated)	Interventional	2023-05-31	Not yet recruiting
A Controlled Clinical Study of Envafolimab (PD-L1 Antibody) Subcutaneous Injection Combined With Endostar and Concurrent Chemoradiotherapy in Treatment of Locally Advanced Primary Cervical Cancer [NCT05879796]		30 participants (Anticipated)	Observational	2023-05-16	Not yet recruiting
An Open-label, Multi-center Phase Ib/III Study Evaluating the Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation [NCT05504278]	Phase 1	144 participants (Anticipated)	Interventional	2022-09-20	Recruiting
QUILT 2.023: A Phase 3, Open-Label, 3-Cohort Randomized Study of N-803, in Combination With Current Standard of Care VS Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic NSCLC. [NCT03520686]	Phase 3	1,538 participants (Anticipated)	Interventional	2018-05-18	Active, not recruiting
A Phase I/II Study of Concurrent Pemetrexed/Cisplatin/Radiation in Stage IIIA/B Non-Small Cell Lung Cancer [NCT00529100]	Phase 1/Phase 2	49 participants (Actual)	Interventional	2005-12-31	Completed
Comparison Between Two Regimens of Chemotherapy Concurrent With Radiotherapy in Locally Advanced Head and Neck Cancer [NCT03998696]	Phase 4	60 participants (Actual)	Interventional	2017-07-01	Completed
A Randomized Study of the Efficacy and Safety of OncoGel™ Treatment as an Adjunctive Therapy to Systemic Chemotherapy and Concurrent External Beam Radiation Prior to Surgery in Subjects With Localized or Loco-regional Esophageal Cancer [NCT00573131]	Phase 2	137 participants (Actual)	Interventional	2008-01-31	Terminated(stopped due to OncoGel did not show any impact on overall tumor response)
A Phase I/II Trial of Intraperitoneal (IP) Cisplatin Combined With IV Paclitaxel in Patients With Epithelial Ovarian Cancer Optimally Debulked at Their Initial Surgery Performed Following Neoadjuvant Intravenous Chemotherapy [NCT00889733]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2007-02-28	Terminated(stopped due to Poor recruitment)
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma [NCT04003636]	Phase 3	1,069 participants (Actual)	Interventional	2019-09-24	Active, not recruiting
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC [NCT03811015]	Phase 3	636 participants (Anticipated)	Interventional	2019-08-16	Recruiting
A Phase II Clinical Study of Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable Head and Neck Squamous Cell Carcinoma [NCT06081673]	Phase 2	72 participants (Anticipated)	Interventional	2023-10-30	Recruiting
Toripalimab in Combination With Cetuximab，Cisplatin and 5-FU for Conversion Therapy of Locally Nonresectable Oral Cavity Squamous Cell Carcinoma （OCSCC） [NCT06081582]	Phase 2	33 participants (Anticipated)	Interventional	2023-07-06	Recruiting
Neoadjuvant Chemotherapy With Docetaxel, Cisplatin Followed by Maintenance Therapy With the EGFR Inhibitor Erlotinib (Tarceva) in Patients With Stage I, II and III Non-Small Cell Lung Cancer Following Definitive Surgical Resection [NCT00254384]	Phase 1	50 participants (Actual)	Interventional	2005-10-05	Active, not recruiting
A Randomized Phase II Trial for Patients With p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer [NCT02254278]	Phase 2	316 participants (Actual)	Interventional	2014-10-31	Active, not recruiting
A Phase II Study of (Neoadjuvant Chemotherapy Trial Prior to Extirpative Surgery) for Clinical Stage TanyN2-3M0 Squamous Cell Carcinoma of the Penis [NCT00512096]	Phase 2	30 participants (Actual)	Interventional	1999-08-31	Completed
A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion [NCT01004978]	Phase 3	235 participants (Actual)	Interventional	2009-10-28	Completed
Study of Radiation Therapy With Concomitant Nab-paclitaxel and Cisplatin Chemotherapy in Patients With Locally Advanced Cervical Cancer [NCT04017377]		15 participants (Anticipated)	Interventional	2019-09-01	Recruiting
Safety and Efficacy of Anlotinib Hydrochloride Combined With Pemetrexed Plus Cisplatin/Carboplatin (AP) as First Line Treatment for Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer [NCT04012619]	Phase 1	8 participants (Actual)	Interventional	2019-04-30	Completed
Phase II Prospective Study Evaluating the Role of Personalized Chemotherapy Regimens for Chemo-Naive Select Stage IIIB and IV Non-Small Cell Lung Cancer (NSCLC) in Patients Using a Genomic Predictor of Platinum Resistance to Guide Therapy [NCT00509366]	Phase 2	101 participants (Actual)	Interventional	2007-05-31	Terminated(stopped due to Study terminated due to reproducibility issues with genomics prediction model.)
An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease [NCT00400179]	Phase 3	1,053 participants (Actual)	Interventional	2005-05-31	Completed
Phase II Clinical Trial for Adjuvant Concurrent Chemoradiation Therapy in Post-operative Cervical Cancer Patients [NCT00950261]	Phase 2	0 participants (Actual)	Interventional	2009-01-31	Withdrawn(stopped due to A competing trial has been initiated.)
"Randomized Phase II Trial With Cetuximab and Cisplatin in the Treatment of ER-negative, PgR-negative, HER2-negative Metastatic Breast Carcinoma (Basal Like)" [NCT00463788]	Phase 2	181 participants (Actual)	Interventional	2007-06-30	Completed
Induction Chemotherapy (IC) With Paclitaxel and Cisplatin (PC) Followed by Concomitant Chemoradiotherapy (CCRT) in Patient With Advanced Squamous Carcinoma of the Head and Neck (SSCHN). [NCT00959387]	Phase 2	60 participants (Actual)	Interventional	2009-08-31	Completed
A Phase 2 Randomized Trial of Radiotherapy Plus Panitumumab Compared to Chemoradiotherapy With Unresected, Locally Advanced Squamous Cell Carcinoma of the Head and Neck [NCT00547157]	Phase 2	152 participants (Actual)	Interventional	2007-11-30	Completed
A Phase I Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology [NCT03330028]	Phase 1	29 participants (Actual)	Interventional	2017-10-27	Completed
A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent /CTEP-Supplied Agent ABT-888 (NSC #737664) and CTEP-Supplied Agent Bevacizumab (NSC #704865) in Ne [NCT00989651]	Phase 1	431 participants (Actual)	Interventional	2009-10-28	Completed
Phase Ib/II Study of the Gamma-Secretase Inhibitor (GSI) RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma [NCT01196416]	Phase 1/Phase 2	14 participants (Actual)	Interventional	2010-08-31	Completed
[NCT02142010]		67 participants (Anticipated)	Interventional	2014-08-31	Recruiting
Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma [NCT04804696]	Phase 2	53 participants (Anticipated)	Interventional	2021-02-10	Recruiting
A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Sma [NCT03164616]	Phase 3	1,186 participants (Actual)	Interventional	2017-06-01	Active, not recruiting
Effects of Exercise in Combination With Epoetin Alfa During High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma [NCT00577096]		120 participants (Actual)	Interventional	2001-10-31	Completed
Randomized Phase 3 Trial of Triple Combination of Induction, Concurrent and Adjuvant Chemotherapy Versus Concurrent Chemotherapy Alone in High Risk Nasopharyngeal Carcinoma Patients Treated With Intensity-modulated Radiotherapy [NCT02621970]	Phase 3	534 participants (Anticipated)	Interventional	2016-01-31	Not yet recruiting
A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer [NCT00622349]	Phase 3	707 participants (Actual)	Interventional	2004-02-29	Completed
A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination With Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer [NCT05198830]	Phase 2	78 participants (Anticipated)	Interventional	2022-12-15	Recruiting
A Phase I Adaptive Design Trial of Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors [NCT02537561]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to The pharmaceutical company did not want to follow through with support for the study.)
An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer [NCT05500092]	Phase 2	52 participants (Anticipated)	Interventional	2023-01-25	Recruiting
A Phase II Trial of Concurrent Chemoradiation With Cisplatin Every 3 Week in Advanced Cervical Cancer Patients [NCT00916500]	Phase 2	71 participants (Actual)	Interventional	2006-03-31	Completed
A Randomized Phase II Study Comparing Pemetrexed Plus Cisplatin With Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Non-squamous Non-small Cell Lung Cancer [NCT01401192]	Phase 2	304 participants (Anticipated)	Interventional	2011-07-31	Recruiting
A Phase Ib, Multi-centre, Open-label Study of a First-in-class Nucleotide Analogue Acelarin (NUC-1031) in Combination With Cisplatin in Patients With Locally Advanced/Metastatic Biliary Tract Cancers [NCT02351765]	Phase 1	21 participants (Actual)	Interventional	2016-01-31	Completed
Prospective Non-inferiority Randomized Trial Comparing Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation and Traditional Clinical Target Volume in Radiotherapy for Nasopharyngeal Carcinoma [NCT02627807]		386 participants (Actual)	Interventional	2015-12-31	Active, not recruiting
Open-label, Randomized, Controlled, Multicenter Phase II Trial Investigating 2 Cilengitide Regimens in Combination With Cetuximab and Platinum-based Chemotherapy (Cisplatin/Vinorelbine or Cisplatin/Gemcitabine) Compared to Cetuximab and Platinum-based Che [NCT00842712]	Phase 2	232 participants (Actual)	Interventional	2009-02-28	Completed
An Open Label Phase 1 Study to Assess the Maximum Tolerated Dose of ZACTIMA™ Given Concomitantly With Weekly Cisplatin Chemotherapy and Radiation Therapy in Patients With Previously Untreated, Unresected Stage III-IV Head and Neck Squamous Cell Carcinoma [NCT00450138]	Phase 1	48 participants (Actual)	Interventional	2006-12-31	Completed
An Open Labeled Phase 2 Study of Gemcitabine in Combination With Cisplatin, 5-FU (24h CI) and Folinic Acid in Patients With Inoperable Esophageal Cancer [NCT00759226]	Phase 2	92 participants (Actual)	Interventional	2002-07-31	Completed
A Pilot Study of Heated Intraperitoneal Chemotherapy (HIPEC) After Interval Cytoreductive Surgery (CRS) in Patients Who Have Received Neoadjuvant Chemotherapy (NACT) for Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancers [NCT03540017]	Phase 1	15 participants (Anticipated)	Interventional	2019-03-12	Recruiting
Trial to Determine the CR Rate at the Primary Tumor Site After 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head & Neck Carcinoma Treated With Definitive Concurrent Cisplatin & Radiation Therapy [NCT00736944]	Phase 2	30 participants (Actual)	Interventional	2008-12-19	Completed
Prospective Study of Fertility-sparing Treatment Strategy in Patients With Early Cervical Cancer(SYSUGO-005/CSEM009) [NCT02624531]		60 participants (Anticipated)	Interventional	2015-11-30	Recruiting
An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) [NCT02624999]	Phase 2	0 participants (Actual)	Interventional	2016-12-31	Withdrawn(stopped due to PI changed institution)
Phase Ib Trial of Dose-escalating AZD1775 in Combination With Concurrent Radiation and Cisplatin for Intermediate and High Risk Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT02585973]	Phase 1	12 participants (Actual)	Interventional	2015-10-26	Completed
MK-0646 IMPACT Study: MK-0646, Insulin Growth Factor 1 Receptor Antibody in Stage IIIB or IV Metastatic Non-Squamous Lung Cancer, Combined With Pemetrexed (Alimta) and Cisplatin, a Randomized Phase II Trial. [NCT00799240]	Phase 2	27 participants (Actual)	Interventional	2009-06-30	Completed
A Multicentre, Randomised, Phase III Trial of Platinum-based Chemotherapy Versus Non-platinum Chemotherapy, After ERCC1 Stratification, in Patients With Advanced/Metastatic Non-small Cell Lung Cancer [NCT00801736]	Phase 3	648 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to The antibody used did not appear prognostic/predictive based on interim results.)
An Prospective, Multicenter, Double-blind, Randomized, Controlled Clinical Study of Nimotuzumab Combined With Paclitaxel and Cisplatin as First-line Treatment of Metastatic Esophageal Squamous Cell Carcinomas [NCT02611700]	Phase 3	504 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer [NCT02607540]	Phase 3	210 participants (Anticipated)	Interventional	2014-10-31	Recruiting
Neoadjuvant Chemotherapy and Radical Surgery Versus Concurrent Chemoirradiation in FIGO Stage IIB Cervical Cancer [NCT02595554]	Phase 3	220 participants (Anticipated)	Interventional	2015-11-30	Recruiting
A Phase 1/2 Study of the Bromodomain Inhibitor Molibresib in Combination With Etoposide/Platinum in Patients With NUT Carcinoma [NCT04116359]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2020-09-18	Withdrawn(stopped due to Other - Protocol moved to Disapproved)
Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma: a Single Arm, Multicentre Trial. [NCT04063683]	Phase 2	47 participants (Actual)	Interventional	2019-10-07	Active, not recruiting
Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin in Second or Later-Line Treatment in Advanced Biliary Tract Cancers: a Prospective, Open Label, Single-arm Phase II Trial [NCT04111380]	Phase 2	30 participants (Anticipated)	Interventional	2019-09-24	Recruiting
A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation [NCT01683175]	Phase 2	94 participants (Actual)	Interventional	2012-08-31	Active, not recruiting
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC) [NCT00746655]		0 participants (Actual)	Interventional	2009-07-31	Withdrawn(stopped due to Unable to recruit)
Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer: A Randomized, Controlled, Multicenter Phase II Clinical [NCT04300959]	Phase 2	80 participants (Anticipated)	Interventional	2020-01-01	Recruiting
A Prospective, Randomized Trial Of Simultaneous Pancreatic Cancer Treatment With Enoxaparin and ChemoTherapy (PROSPECT) [NCT00785421]	Phase 2/Phase 3	312 participants (Actual)	Interventional	2004-04-30	Completed
An Open, Multicenter, Randomized Phase III Clinical Study on Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma [NCT02677597]	Phase 3	268 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Intensity-modulated Radiation Therapy Combined With Cisplatin-based or Carboplatin-based Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma：: A Phase 3 Trial [NCT03919552]	Phase 3	482 participants (Anticipated)	Interventional	2018-01-31	Recruiting
Phase II Single-Arm Trial Comparing the Use of FLT PET to Standard Computed Tomography to Assess the Treatment Response of Neoadjuvant Docetaxel and Cisplatin in Stage IB-IIIA Resectable Non-small Cell Lung Cancer [NCT00963807]	Phase 2	26 participants (Actual)	Interventional	2009-09-30	Completed
Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine [NCT02648425]	Phase 1	31 participants (Actual)	Interventional	2014-08-05	Completed
Phase Ib Trial of Pembrolizumab (MK-3475) With Platinum-Based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate [NCT03582475]	Phase 1	15 participants (Actual)	Interventional	2018-12-20	Completed
A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma [NCT00554788]	Phase 3	60 participants (Actual)	Interventional	2008-02-04	Active, not recruiting
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepat [NCT02807181]	Phase 2/Phase 3	89 participants (Actual)	Interventional	2017-01-31	Completed
A Phase I/II Study Evaluating the Combination of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Patients With Advanced Gastric Cancer [NCT00845884]	Phase 1/Phase 2	49 participants (Anticipated)	Interventional	2009-02-28	Not yet recruiting
A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of CS1001 in Combination With Fluorouracil and Cisplatin (FP) Compared to Placebo in Combination With FP as First-Line Therapy in Subjects With Unresectable L [NCT04187352]	Phase 3	540 participants (Actual)	Interventional	2019-12-19	Completed
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial [NCT02567253]	Phase 2	56 participants (Actual)	Interventional	2016-03-31	Completed
A Phase I Study of Dasatinib, Cetuximab and Radiation With or Without Cisplatin in Locally Advanced Squamous Cell Carcinoma of Head and Neck (HNSCC) [NCT00882583]	Phase 1	22 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Low accrual)
Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck [NCT00639769]	Phase 2	41 participants (Actual)	Interventional	2002-02-28	Completed
Randomized Phase III Study Of Neoadjuvant Chemotherapy Followed By Surgery Vs. Concomitant Radiotherapy And Chemotherapy In FIGO Ib2, IIa>4 cm or IIb Cervical Cancer [NCT00039338]	Phase 3	686 participants (Anticipated)	Interventional	2002-03-31	Active, not recruiting
A Phase III Randomised Study Comparing Concomitant Radiochemotherapy With Cisplatin and Docetaxel as Induction Versus Consolidation Treatment in Patients With Locally Advanced Unresectable Non-small Cell Lung Cancer. [NCT00633568]	Phase 3	125 participants (Actual)	Interventional	2007-01-31	Terminated(stopped due to Slow recruitment)
[NCT02795884]	Phase 3	0 participants (Actual)	Interventional	2016-06-30	Withdrawn(stopped due to Because of reconsideration of using erlotinib(EGFR Tyrosine kinase inhibitor) as adjuvant aim)
Phase II Trial of Brostallicin and Cisplatin in Patients With Metastatic Triple Negative Breast Cancer [NCT01091454]	Phase 2	48 participants (Actual)	Interventional	2010-06-30	Completed
Advanced Non-small Cell Lung Cancer With Chinese Medicine Comprehensive Treatment Plan [NCT02777788]	Phase 2/Phase 3	120 participants (Anticipated)	Interventional	2014-09-30	Active, not recruiting
Randomized, Open Label, Phase 3 Clinical Study To Evaluate The Effect Of The Addition Of CP-751,871 To Gemcitabine And Cisplatin In Patients With Advanced Non-Small Cell Lung Cancer [NCT00907504]	Phase 3	0 participants (Actual)	Interventional	2010-07-31	Withdrawn
A Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel vs. Carboplatin and Paclitaxel for Optimally Debulked, Advanced Endometrial Carcinoma [NCT00942357]	Phase 3	813 participants (Actual)	Interventional	2009-06-29	Active, not recruiting
A Phase Ib Trial of Intraperitoneal Cisplatin and Nab-paclitaxel Administered by Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in the Treatment of Advanced Malignancies Confined to the Peritoneal Cavity [NCT04000906]	Phase 1	36 participants (Anticipated)	Interventional	2020-11-11	Recruiting
AN OPEN-LABEL, PHASE 1 STUDY OF R-CVP OR R-GDP IN COMBINATION WITH INOTUZUMAB OZOGAMICIN IN SUBJECTS WITH CD22-POSTIVE NON-HODGKIN'S LYMPHOMA [NCT01055496]	Phase 1	103 participants (Actual)	Interventional	2010-03-31	Completed
A Randomised Phase II Study of Two Regimens of Palliative Chemoradiation Therapy in the Management of Locally Advanced Non Small Cell Lung Cancer [NCT00193921]	Phase 2	82 participants (Actual)	Interventional	2003-02-28	Completed
Phase 1 Study of Ixabepilone in Combination With Cisplatin in Subjects With Advanced Solid Tumors [NCT00832117]	Phase 1	30 participants (Actual)	Interventional	2009-05-31	Completed
Pilot Study of the Feasibility of Intrapleural Photodynamic Therapy in a Multimodal Treatment Combining Extended Pleurectomy/Decortication, Adjuvant Chemotherapy and Prophylactic Radiotherapy in Patients With Malignant Pleural Mesothelioma [NCT02662504]	Phase 2	6 participants (Actual)	Interventional	2016-01-16	Completed
Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the Treatment of Small Volume Recurrent Ovarian Carcinoma Limited to the Peritoneal Cavity: A Phase I Trial [NCT00942838]	Phase 1	0 participants (Actual)	Interventional	2009-07-31	Withdrawn(stopped due to PI decision due to under accrual.)
Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) Chemotherapy Plus Cisplatin (or Carboplatin) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type [NCT02906150]	Phase 2	140 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
Induction Chemotherapy Followed by Chemoradiation With Cetuximab and Cisplatin for Inoperable Squamous Cell Carcinoma of the Head and Neck [NCT00868491]	Phase 2	30 participants (Anticipated)	Interventional	2008-03-31	Completed
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Rilotumumab (AMG102) With Epirubicin, Cisplatin, and Capecitabine (ECX) as First-line Therapy in Advanced MET-Positive Gastric or Gastroesophageal Junction Adenocarcinoma [NCT01697072]	Phase 3	609 participants (Actual)	Interventional	2012-10-31	Terminated(stopped due to All Amgen sponsored AMG102 clinical studies were terminated following a pre-planned Data Monitoring Committee safety review of study 20070622.)
A Pilot Induction Regimen Incorporating Chimeric 14.18 Antibody (ch14.18, Dinutuximab) (NSC# 764038) and Sargramostim (GM-CSF) for the Treatment of Newly Diagnosed High-Risk Neuroblastoma [NCT03786783]	Phase 2	42 participants (Actual)	Interventional	2019-01-14	Active, not recruiting
A Phase I Dose Escalation Study to Investigate the Safety and Pharmacokinetics of Intravenous CUDC-101 With Concurrent Cisplatin and Radiation Therapy in Subjects With Locally Advanced Head and Neck Cancer [NCT01384799]	Phase 1	12 participants (Actual)	Interventional	2011-11-30	Completed
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) [NCT04329494]	Phase 1	49 participants (Anticipated)	Interventional	2020-08-21	Recruiting
The Study of Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for Patient With the Advanced Non-small Cell Lung Cancer( NSCLC) [NCT01393080]		160 participants (Anticipated)	Interventional	2011-03-31	Recruiting
A Multicenter Trial Evaluating the Efficacy and Safety of Nedaplatin Plus Docetaxel in Neoadjuvant Chemotherapy Followed by Nedaplatin in Concurrent Chemoradiation for Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01479504]	Phase 3	2 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer (KEYNOTE-A18/ENGOT-cx11/GOG-3047) [NCT04221945]	Phase 3	980 participants (Anticipated)	Interventional	2020-05-12	Active, not recruiting
Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells. [NCT05137067]	Phase 2	90 participants (Actual)	Interventional	2021-01-20	Completed
IPI-Biochemotherapy for Chemonaive Patients With Metastatic Melanoma [NCT01409174]	Phase 1	19 participants (Actual)	Interventional	2013-02-28	Terminated(stopped due to Slow accrual, closed in Phase I.)
A Phase II Trial of Erlotinib Versus Combination of Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage IIIA Non-small-cell Lung Cancer After Complete Resection With Sensitizing EGFR Mutation in Exon 19 or 21 and Wild-type K-ras [NCT01410214]	Phase 2	80 participants (Anticipated)	Interventional	2011-05-31	Recruiting
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer [NCT04311762]	Phase 1	9 participants (Anticipated)	Interventional	2020-02-26	Recruiting
Phase II Study Evaluating Combination Chemotherapy + Radiotherapy (RT) With Avelumab in Muscle Invasive Bladder Cancer [NCT03617913]	Phase 2	2 participants (Actual)	Interventional	2018-09-19	Completed
Phase I Biochemotherapy With Cisplatin, Temozolomide, With Increasing Doses of Abraxane, Combined With Interleukin-2 and Interferon in Patients With Metastatic Melanoma [NCT00970996]	Phase 1	10 participants (Actual)	Interventional	2009-09-30	Completed
A Feasibility and Phase II Study of Proton Beam Radiotherapy for Patients With Cervical Cancer and FDG-PET Positive Para-aortic Lymph Nodes [NCT01019278]	Phase 2	0 participants (Actual)	Interventional	2009-07-31	Withdrawn
Open Label, Randomised Multicentre Phase III Study Of Irinotecan Hydrochloride (Campto (Registered)) And Cisplatin Versus Etoposide And Cisplatin In Chemotherapy Naive Patients With Extensive Disease - Small Cell Lung Cancer [NCT00143455]	Phase 3	485 participants (Actual)	Interventional	2002-06-30	Completed
A Phase I/II Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan (GAX-CI) in Combination in Metastatic Pancreatic Cancer [NCT03535727]	Phase 1/Phase 2	86 participants (Anticipated)	Interventional	2018-06-21	Recruiting
A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy [NCT04430036]	Phase 2	4 participants (Actual)	Interventional	2020-10-14	Active, not recruiting
Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma [NCT00567567]	Phase 3	665 participants (Actual)	Interventional	2007-11-05	Completed
Chemoembolization for Hepatocellular Carcinoma [NCT02821533]	Phase 2	24 participants (Actual)	Interventional	2012-02-29	Terminated(stopped due to Poor case accrual)
A Randomized Trial of Adding Bevacizumab to Neoadjuvant Platinum-Fluorouracil Concurrent Chemoradiation in Locally Advanced Esophageal Squamous Cell Carcinoma [NCT02812641]	Phase 2	50 participants (Anticipated)	Interventional	2016-06-30	Recruiting
A Phase II Investigation of Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx Cancer Patients Managed With Primary (Chemo) Radiation [NCT05800574]	Phase 2	22 participants (Anticipated)	Interventional	2023-03-14	Recruiting
Phase I/II Trial Evaluating Carbon Ion Radiotherapy With Concurrent Chemotherapy for Salvaging Treatment of Locally Recurrent Nasopharyngeal Carcinoma [NCT02801487]	Phase 1/Phase 2	6 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to Slow accrual of patients.)
Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO) [NCT02845050]	Phase 1/Phase 2	0 participants (Actual)	Interventional	2016-07-31	Withdrawn(stopped due to No participants found)
Liver Resection Versus Transarterial Chemoembolization for the Treatment of Intermediate-stage Hepatocellular Carcinoma: a Prospective Non-randomized Trial [NCT02755311]	Phase 3	198 participants (Anticipated)	Interventional	2014-03-31	Recruiting
Concurrent Docetaxel Plus Cisplatin or Cisplatin Alone With Intensity-modulated Radiotherapy in High Risk Locregionally Advanced Nasopharyngeal Carcinoma: a Phase 2 Randomized Controlled Trial [NCT02610556]	Phase 2	130 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase I Feasibility Trial IP Cisplatin and IV Paclitaxel on Day 1 Followed by IP Paclitaxel on Day 8 Every 21 Days as Front-Line Treatment of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma [NCT00814086]	Phase 1	23 participants (Actual)	Interventional	2009-02-28	Completed
A Pilot/ Feasibility Study Comparing Response Rates of Intra-arterial and Intravenous Cisplatin Chemotherapy, Combined With Radiation, in Patients With Locally Advanced Carcinoma of the Oral Cavity and Oropharynx [NCT01587820]	Early Phase 1	1 participants (Actual)	Interventional	2012-06-30	Terminated(stopped due to lack of enrollment)
Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma [NCT00779714]	Phase 3	360 participants (Anticipated)	Interventional	2008-10-31	Recruiting
Intensity-modulated Radiotherapy With or Without Concurrent Chemotherapy for Stage II Nasopharyngeal Carcinoma: a Phase 3 Non-inferior Multicenter Randomized Controlled Trial [NCT02610010]	Phase 3	462 participants (Anticipated)	Interventional	2015-11-30	Recruiting
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin [NCT00999700]	Phase 3	282 participants (Anticipated)	Interventional	2009-09-30	Active, not recruiting
A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin as First-Line Therapy in Participants With Advanced and/or Unresectable Biliary Tract Carcinoma [NCT04924062]	Phase 3	158 participants (Actual)	Interventional	2020-07-10	Active, not recruiting
Phase I Study of Induction Cisplatin, Docetaxel, and Nintedanib for Stage IB-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection [NCT02225405]	Phase 1	26 participants (Actual)	Interventional	2015-04-03	Active, not recruiting
PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study [NCT04115410]		4,724 participants (Anticipated)	Observational	2020-07-01	Not yet recruiting
Feasibility, Efficacy and Safety of Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC) With Oxaliplatin, Cisplatin and Doxorubicin in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancers and Primary Tumors of the Perito [NCT02604784]	Phase 1/Phase 2	105 participants (Actual)	Interventional	2015-10-31	Completed
A Phase II-III Randomized Trial Pemetrexed-Cisplatin Chemotherapy With or Without Bevacizumab (Avastin), 15 mg/kg, for Malignant Pleural Mesothelioma (MPM) [NCT00651456]	Phase 2/Phase 3	448 participants (Actual)	Interventional	2008-02-29	Completed
Efficacy and Safety of Rh-endostatin（Endostar）Combined With Platinum-based Doublet Chemotherapy and Pembrolizumab as First Line Therapy in Patients With Advanced or Metastatic Non-small-cell Lung Cancer [NCT04094909]	Phase 2	186 participants (Anticipated)	Interventional	2020-02-06	Not yet recruiting
Disitamab Vedotin Plus Penpulimab and Cisplatin in Advanced Gastric Cancer [NCT05313906]	Phase 2	40 participants (Anticipated)	Interventional	2022-05-07	Not yet recruiting
Combined Stereotactic Radiotherapy and Conventional Fractionation in Stage II and III Non Small Cell Lung Cancer (NSCLC) With Peripheral Tumors Smaller Than 5 cm [NCT01933568]	Phase 1	15 participants (Actual)	Interventional	2013-02-28	Completed
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC [NCT01993810]	Phase 3	330 participants (Actual)	Interventional	2014-02-03	Active, not recruiting
Phase II Study of Docetaxel and Cisplatin Chemotherapy Versus Docetaxel and Cisplatin Chemotherapy Combined With High Dose Proton Pump Inhibitor in Metastatic Breast Cancer [NCT01069081]	Phase 2	94 participants (Actual)	Interventional	2009-08-31	Completed
Role of Early 18F-FDG-PET/CT Scan in Predicting Mediastinal Downstaging With Neoadjuvant Chemotherapy in Resectable Stage III A NSCLC [NCT02607423]	Phase 2	0 participants (Actual)	Interventional	2015-11-19	Withdrawn(stopped due to The study failed to meet its accrual targets.)
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III, a Prospective Phase II Treatment Trial [NCT05076942]	Phase 2	157 participants (Anticipated)	Interventional	2021-01-01	Recruiting
UARK 2006-15: A Phase III Randomized Study of Tandem Transplants With or Without Bortezomib (Velcade) and Thalidomide (Thalomid) to Evaluate Its Effect on Response Rate and Durability of Response in Multiple Myeloma Patients [NCT00574080]	Phase 3	20 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to low accrual)
A Phase III Study of Adjuvant Postoperative Irradiation With or Without Cisplatin/Taxol Chemotherapy Following TAH/BSO for Patients With Endometrial Cancer [NCT00006027]	Phase 3	0 participants	Interventional	2000-08-31	Completed
A Randomized Study of Adjuvant Radiation Treatment Versus Radiation and Chemotherapy in Patients With Vulvar Cancer and Involved Nodes [NCT00006096]	Phase 3	0 participants	Interventional	2001-03-31	Terminated
A Randomized，Double-blind，Controlled，Multi-center Phase III Clinical Study Evaluating SHR-1701 or Placebo Plus Chemotherapy With or Without BP102 (Bevacizumab) as First-Line Treatment in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer [NCT05179239]	Phase 3	572 participants (Anticipated)	Interventional	2022-02-26	Recruiting
A Phase II Pilot Study of Multi-Agent Neo-Adjuvant Chemoradiation in Patients With Locally Advanced Pancreatic Adenocarcinoma [NCT00262951]	Phase 2	23 participants (Actual)	Interventional	2005-01-31	Terminated(stopped due to Closed at a planned interim analysis by meeting a predefined toxicity endpoint)
Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis [NCT00001332]	Phase 1	50 participants	Interventional	1992-12-31	Completed
Phase I Study of TTC (Taxotere/Temodar/Cisplatin) in Metastatic Melanoma Patients [NCT00527761]	Phase 1	23 participants (Actual)	Interventional	2004-08-31	Completed
Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy [NCT02944357]		0 participants (Actual)	Interventional	2016-11-30	Withdrawn
A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer [NCT00123318]	Phase 3	52 participants (Actual)	Interventional	2003-02-28	Completed
A Phase II Trial of Cisplatin in Early Stage ER-, PR-, HER-2 Negative Breast Cancer [NCT00148694]	Phase 2	27 participants (Actual)	Interventional	2004-07-31	Completed
A Phase II Study of Paclitaxel and Cisplatin in Previously Untreated, Unresectable Invasive Thymoma or Thymic Carcinoma [NCT00818090]	Phase 2	39 participants (Actual)	Interventional	2008-09-30	Terminated(stopped due to marginal statistical significance)
The Safety and Efficacy of Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC，A Single-arm Study [NCT05469061]	Phase 2	17 participants (Anticipated)	Interventional	2022-01-01	Recruiting
A Randomized Phase II Trial of Strontium-89 With or Without Cisplatin for the Palliation of Bone Pain Secondary to Hormone Refractory Prostate Cancer [NCT00156884]	Phase 2	58 participants (Anticipated)	Interventional	2003-08-31	Completed
Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma [NCT00158678]	Phase 3	310 participants (Anticipated)	Interventional	2005-09-27	Completed
A Phase II Trial of Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma [NCT04006041]	Phase 2	44 participants (Anticipated)	Interventional	2019-06-25	Recruiting
An Open-Label, Multicentre, Randomised, Phase III Study Comparing Topotecan/Cisplatin and Topotecan/Etoposide Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer [NCT00320359]	Phase 3	700 participants (Actual)	Interventional	2002-08-31	Completed
The Efficacy and Safety of Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil, Concurrent Chemotherapy of Cisplatin and IMRT in Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective, Multi-centeric, Open, Non-controlled, Phas [NCT04004871]	Phase 2	60 participants (Anticipated)	Interventional	2019-07-05	Not yet recruiting
A Randomized Phase II Trial of Chemoradiotherapy Versus Chemoradiotherapy and Vandetanib for High-Risk Postoperative Advanced Squamous Cell Carcinoma of the Head and Neck [NCT00720083]	Phase 2	34 participants (Actual)	Interventional	2008-11-30	Terminated(stopped due to Withdrawal of drug supply.)
A Randomized Controlled Trial of Chemotherapy With 5FU and Cisplatin Before and After Surgery for Stage II,III Squamous Cell Carcinoma of the Thoracic Esophagus:JCOG9907 [NCT00190554]	Phase 3	330 participants	Interventional	2000-05-31	Terminated
Comparing Standard Concurrent Chemo-radiation to Neoadjuvant Chemotherapy Then Surgery or Radiation in Patients Stage Ib2-early IIb Cervical Carcinoma [NCT01000415]	Phase 3	824 participants (Anticipated)	Interventional	2009-06-30	Recruiting
A Prospective Observational Study of the Efficacy and Safety of CPT-11 Plus Platinum Analogues Regimens for UGT1A1 Genotype Guided Patients With Several Solid Tumors [NCT01040312]		321 participants (Actual)	Observational	2009-10-15	Completed
A Phase II Study of Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer [NCT00388154]	Phase 2	21 participants (Actual)	Interventional	2004-08-31	Completed
A PHASE II STUDY OF BEVACIZUMAB IN COMBINATION WITH DEFINITIVE RADIOTHERAPY AND CISPLATIN CHEMOTHERAPY IN UNTREATED PATIENTS WITH LOCALLY ADVANCED CERVICAL CARCINOMA [NCT00369122]	Phase 2	60 participants (Actual)	Interventional	2006-08-11	Completed
PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146 [NCT01074970]	Phase 2	135 participants (Actual)	Interventional	2010-02-28	Completed
Phase II Study of Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib [NCT05948462]	Phase 2	0 participants (Actual)	Interventional	2023-11-30	Withdrawn(stopped due to Study withdrawn by pharmaceutical funding partner)
An Open-label Window of Opportunity Trial to Evaluate the Activity of Durvalumab (MEDI4736) and Tremelimumab With Platinum-based Chemotherapy (Gemcitabine and Cisplatin) in Intrahepatic Cholangiocarcinoma (ICC) [NCT04989218]	Phase 1/Phase 2	20 participants (Anticipated)	Interventional	2023-01-30	Recruiting
Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel (Taxol®, Bristol-Myers Squibb), Cisplatin (Platinol®, Abbott Laboratories), ZD1839 (IRESSA®) and Radiotherapy Fol [NCT00493025]	Phase 2	19 participants (Actual)	Interventional	2005-04-30	Terminated(stopped due to Closed due to early stopping rule-Low accrual)
A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) to the Pelvis ± Chemotherapy for Post-Operative Patients With Either Endometrial or Cervical Carcinoma [NCT00331760]	Phase 2	106 participants (Actual)	Interventional	2006-03-31	Completed
A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer [NCT01058408]	Phase 1	3 participants (Actual)	Interventional	2010-02-28	Terminated
DAHANCA 37 A Phase II Study of Intensity Modulated Proton Therapy (IMPT) for Re-irradiation With Curative Intent for Recurrent or New Primary Head and Neck Cancer [NCT03981068]		20 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell Lymphoma [NCT02532192]	Phase 1	0 participants (Actual)	Interventional	2015-12-31	Withdrawn(stopped due to Withdrawal of study support.)
Phase III Study of S-1 + Cisplatin Compared With Single-agent Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix [NCT00770874]	Phase 3	375 participants (Actual)	Interventional	2008-09-30	Completed
Neoadjuvant Docetaxel+Cisplatin and 5-fluorouracil (TPF) Followed by Radiotherapy+Concomitant Chemo or Cetuximab Versus Radiotherapy+Concomitant Chemo or Cetuximab in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. A Randomize [NCT01086826]	Phase 3	320 participants (Actual)	Interventional	2008-03-31	Completed
An Evaluation of Preoperative Chemotherapy With Irinotecan and Cisplatin for Advanced, But Resectable Gastric Cancer: A Coordinated Multidisciplinary, Multicenter Study Linking Functional Imaging, Genomic Expression Profiles and Histopathology [NCT00062374]	Phase 2	55 participants (Actual)	Interventional	2003-06-30	Completed
Phase Ib Study of Pembrolizumab in Combination With Chemo Radiotherapy (CRT) for Locally-advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) [NCT02586207]	Phase 1	59 participants (Actual)	Interventional	2015-11-30	Active, not recruiting
Immunotherapy With MK-3475 in Locoregionally Advanced, Surgically Resectable Head and Neck Squamous Cell Carcinoma [NCT02296684]	Phase 2	67 participants (Actual)	Interventional	2015-03-25	Active, not recruiting
Pilot Trial of Sirolimus, Gemcitabine and Cisplatin for Patients With High Risk for Cholangiocarcinoma Recurrence [NCT01888302]	Phase 1	1 participants (Actual)	Interventional	2013-09-30	Completed
A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas [NCT01900158]	Phase 1	24 participants (Actual)	Interventional	2013-05-31	Completed
Preconditioning Chemotherapy Combined With Cytokine Induced Killer Cell Immunotherapy in Advanced Non Small Cell Lung Cancer [NCT01902875]		100 participants (Anticipated)	Observational	2013-06-30	Recruiting
The Feasibility Study of Oral Rehydration Therapy for Short Hydration in Chemotherapy With Cisplatin Plus Gemcitabine for Biliary Tract Cancer [NCT01917617]	Phase 2	50 participants (Actual)	Interventional	2013-05-22	Completed
A Phase II Clinical Trial of Adjuvant Postoperative Irradiation Combined With Paclitaxel/Carboplatin(TP) or Cisplatin/Doxorubicin/Cyclophosphamide (CAP) Chemotherapy for Patients With High-risk Endometrial Cancer [NCT01918124]	Phase 2	80 participants (Anticipated)	Interventional	2008-01-31	Completed
Efficacy of 6x R-CHOP Followed by Myeloablative Radiochemotherapy and Autologous Stem Cell Transplantation vs. 3 x (R-CHOP/R-DHAP) Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation [NCT00209222]	Phase 3	360 participants (Anticipated)	Interventional	2004-07-31	Recruiting
Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as 1st-line Chemotherapy in Patients With Metastatic Esophageal Cancer. [NCT00209690]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2003-10-31	Completed
Evaluation of the Benefits of Oral Metronomic Cyclophosphamide in Combination With Standard Cisplatin-etoposide Based Chemotherapy for Squamous Cell Lung Carcinoma [NCT01947062]	Phase 3	60 participants (Anticipated)	Interventional	2013-10-31	Not yet recruiting
Multicenter Phase II Study of Pemetrexed/Cisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type [NCT01951482]	Phase 2	108 participants (Anticipated)	Interventional	2013-06-30	Recruiting
Randomized Phase II Trial of Transoral Endoscopic Head And Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin Versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer [NCT01953952]	Phase 2	0 participants (Actual)	Interventional	2013-12-31	Withdrawn(stopped due to Slow accrual)
A Randomized Registry Trial of Adjuvant Mitotane vs. Mitotane With Cisplatin/Etoposide After Primary Surgical Resection of Localized Adrenocortical Carcinoma With High Risk of Recurrence (ADIUVO-2 Trial) [NCT03583710]	Phase 3	240 participants (Anticipated)	Interventional	2018-08-20	Recruiting
Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of Lurbinectedin (PM01183) in Combination With Cisplatin in Patients With Advanced Solid Tumors [NCT01980667]	Phase 1	41 participants (Actual)	Interventional	2014-07-30	Completed
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or [NCT02875314]	Phase 4	250 participants (Anticipated)	Interventional	2015-09-30	Recruiting
A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer [NCT01993979]	Phase 3	261 participants (Actual)	Interventional	2012-05-31	Active, not recruiting
Apatinib Mesylate Combined With Albumin Binds Paclitaxel and Carboplatin or Cisplatinum as First-line Treatment for Stage II-IV Epithelial Ovarian Cancer Followed by Apatinib Maintenance Therapy:a Single-arm,Exploratory Clinical Study [NCT04590625]	Phase 2	58 participants (Anticipated)	Interventional	2020-10-31	Recruiting
A Prospective Randomized Controlled Study of Radiotherapy and the Concurrent Three-week and Single-week TP Chemotherapy for Advanced Cervical Squamous Cell Carcinoma and the Correlation Between HPV Classification and Sensitivity. [NCT04588090]		200 participants (Anticipated)	Interventional	2016-01-01	Active, not recruiting
Clinical Study on Docetaxel Plus Cisplatin(TP) Regimen Combined With Postoperative Radiotherapy for Stage Ia2- IIb Cervical Cancer [NCT01999933]	Phase 2/Phase 3	600 participants (Anticipated)	Interventional	2013-11-30	Recruiting
Comparison of Postoperative Adjuvant Chemotherapy With/Without Rh-endostatin: a Randomized, PhaseⅢ and Open Clinical Study of Non-small Cell Lung Cancer in PhaseⅠB [NCT02001168]	Phase 3	392 participants (Anticipated)	Interventional	2013-10-31	Active, not recruiting
A Single-arm Prospective Clinical Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin for the Neoadjuvant Treatment of Biliary Tract Malignancies [NCT06181032]	Phase 1	35 participants (Anticipated)	Interventional	2023-12-23	Not yet recruiting
Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma [NCT03925090]	Phase 2	150 participants (Anticipated)	Interventional	2019-12-08	Active, not recruiting
Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma Based on HPV Subtype and Plasma Circulating Free HPV DNA Level and Clearance Rate [NCT05268614]	Phase 2	250 participants (Anticipated)	Interventional	2022-05-05	Recruiting
A Single-Arm Phase 2 Study to Investigate Bintrafusp Alfa With Platinum-Pemetrexed for TKI-Resistant EGFR-Mutant NSCLC [NCT04971187]	Phase 2	3 participants (Actual)	Interventional	2021-06-30	Terminated(stopped due to PI Request)
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy [NCT02445391]	Phase 3	415 participants (Actual)	Interventional	2015-10-20	Active, not recruiting
Sequential Paclitaxel Plus Cisplatin Chemotherapy and Radiotherapy as First Line Treatment for Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial [NCT02016274]	Phase 2	70 participants (Anticipated)	Interventional	2013-12-31	Recruiting
A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients With High Grade Upper Tract Urothelial Carcinoma [NCT02412670]	Phase 2	36 participants (Actual)	Interventional	2015-08-27	Completed
Feasibility Study of the Combination of Radiotherapy, Chemotherapy and Hyperthermia for the Treatment of Stage IIB-III-IVA Cervical Cancer [NCT00008112]	Phase 2	0 participants	Interventional	2000-06-30	Active, not recruiting
Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Node-positive Thoracic Esophageal Squamous Cell Carcinoma: a One-arm, Phase II Clinical Study [NCT05637268]	Phase 2	23 participants (Anticipated)	Interventional	2020-11-26	Recruiting
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors [NCT01220583]	Phase 2	252 participants (Actual)	Interventional	2011-01-31	Active, not recruiting
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features [NCT04671667]	Phase 2	188 participants (Anticipated)	Interventional	2021-04-27	Recruiting
Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO) [NCT04267848]	Phase 3	1,210 participants (Anticipated)	Interventional	2020-06-16	Recruiting
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST) [NCT02194738]		8,300 participants (Anticipated)	Interventional	2014-09-26	Recruiting
A Phase 1 Study of RAD001 in Combination w/ Cetuximab and Cisplatin as First-line Therapy in Recurrent & Metastatic Squamous Cell Cancer of the Head & Neck [NCT01009346]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2009-10-31	Terminated(stopped due to Toxicity)
Neoadjuvant Immunotherapy Combined With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Cancer: an Open Label, Randomized Control, Phase II Trial [NCT04625543]	Phase 2	0 participants (Actual)	Interventional	2020-12-31	Withdrawn(stopped due to insufficient money)
A Phase II Single-arm Study of Tazemetostat With Docetaxel, Cisplatin, and 5-fluorouracil as Preoperative Treatment for Locally Advanced Potentially Resectable SMARCB1 (INI-1)- Deficient Sinonasal Carcinoma [NCT05151588]	Phase 2	30 participants (Anticipated)	Interventional	2023-09-01	Not yet recruiting
A Randomized Study of Gemcitabine Plus Docetaxel After Cisplatin, Etoposide and Radiation Therapy in Stage III Unresectable NSCLC [NCT00191139]	Phase 2	64 participants (Actual)	Interventional	2003-03-31	Completed
Study of the Isotopic Distribution of Intraperitoneal Postoperative Locoregional Chemotherapy for Peritoneal Carcinomatosis of Ovarian Origin [NCT02667925]		0 participants (Actual)	Interventional	2016-03-31	Withdrawn(stopped due to Because of the obsolescence of the study)
Detecting Chemosensitivity and Predicting Treatmemt Efficacy With Circulating Tumour Cells From Peripheral Blood in Metastatic Nasopharyngeal Carcinoma Patients [NCT04544969]		50 participants (Anticipated)	Observational [Patient Registry]	2020-04-01	Recruiting
A Randomized, Double-blind, Parallel-controlled, Multicenter Phase III Clinical Study [NCT06048926]		30 participants (Anticipated)	Interventional	2022-07-30	Enrolling by invitation
A Phase II Study of Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Gastric Cancer and Limited Peritoneal Metastasis: ROBO-CHIP Trial [NCT05753306]	Phase 2	20 participants (Anticipated)	Interventional	2023-03-16	Recruiting
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer [NCT05624996]	Phase 3	474 participants (Anticipated)	Interventional	2023-05-10	Recruiting
A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies [NCT05516914]	Phase 1/Phase 2	490 participants (Anticipated)	Interventional	2022-09-01	Recruiting
A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation [NCT05118854]	Phase 2	27 participants (Anticipated)	Interventional	2022-03-30	Recruiting
Randomized Phase II/III Trial of Radiation With High-Dose Cisplatin (100 mg/m2) Every Three Weeks Versus Radiation With Low-Dose Weekly Cisplatin (40 mg/m2) for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN) [NCT05050162]	Phase 2/Phase 3	464 participants (Anticipated)	Interventional	2021-10-27	Recruiting
A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Given Concurrently With Platinum-based Chemoradiation Therapy in Patients With Locally Advanced, Unresectable NSCLC (Stage III) (PACIFIC2) [NCT03519971]	Phase 3	328 participants (Actual)	Interventional	2018-03-29	Active, not recruiting
Phase III Randomized Trial of Immunotherapy With or Without Consolidative Radiotherapy for Oligometastatic Head and Neck Squamous Cell Carcinoma [NCT05721755]	Phase 3	290 participants (Anticipated)	Interventional	2023-06-08	Recruiting
A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer [NCT04648033]	Phase 1	21 participants (Actual)	Interventional	2020-12-07	Completed
An Open Label, Randomized, Two Arm Phase III Study of Nivolumab in Combination With Ipilimumab Versus Extreme Study Regimen (Cetuximab + Cisplatin/Carboplatin + Fluorouracil) as First Line Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the [NCT02741570]	Phase 3	947 participants (Actual)	Interventional	2016-10-05	Completed
Phase II Trial of Induction Therapy With Docetaxel, Cisplatin and Fluorouracil in Previously Untreated Patients With Locally Advanced Squamous Cell Carcinoma and/or Poorly Differentiated Carcinoma of the Nasal Cavity and/or Paranasal Sinuses [NCT00707473]	Phase 2	31 participants (Actual)	Interventional	2008-06-16	Active, not recruiting
Multicenter Phase II Study of Weekly Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Squamous Cell Cancer of the Head and Neck [NCT01645748]	Phase 2	35 participants (Actual)	Interventional	2008-10-31	Completed
Effect of Oral Nutritional Supplements From the Beginning of Radiotherapy on Body Weight Loss of Patients With Nasopharyngeal Carcinoma and Its Cost-effectiveness Analysis: A Prospective Multicenter Randomized Controlled Trial [NCT04823468]		214 participants (Anticipated)	Interventional	2021-07-19	Recruiting
A Trial Comparing Pre-operative Chemo-radiotherapy With Cisplatin and Fluorouracil Versus Chemotherapy With Docetaxel and Irinotecan in PET Non Responders Resectable Cancer Esophagus: a Multicenter Study [NCT01608464]	Phase 2	170 participants (Actual)	Interventional	2012-05-31	Terminated(stopped due to poor accrual)
A Prospective Open Label Phase II Study to Optimize the Dose in 3D Pulsed Dose Rate Brachytherapy in Patients With Locally Advanced Cervical Cancer [NCT02880007]	Phase 2	48 participants (Actual)	Interventional	2011-06-06	Completed
Phase II of Radiochemotherapy in Elderly Patients With Oesophagus Cancer [NCT02879227]	Phase 2	23 participants (Actual)	Interventional	2010-01-31	Completed
A Phase II Study to Compare Paclitaxel or S1 Plus Cisplatin in Concurrent Chemoradiotherapy for Squamous Cell Carcinoma of Esophagus [NCT02586753]	Phase 2	2 participants (Anticipated)	Interventional	2015-12-31	Not yet recruiting
Safety of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Biliary Tract Cancer Patients With Peritoneal Metastases [NCT05285358]	Phase 1	12 participants (Anticipated)	Interventional	2022-09-19	Recruiting
Open Label Randomized, Multi-centre Phase III Trial of TPF Plus Concomitant Treatment With Cisplatin and Radiotherapy Versus Concomitant Cetuximab and Radiotherapy in Locally Advanced, Unresectable Head and Neck Cancer. [NCT00716391]	Phase 3	519 participants (Actual)	Interventional	2008-07-07	Completed
TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma, a Prospective,Parallel, Randomized, Open Labeled, Multicenter Phase III Clinical Trial [NCT02940925]	Phase 3	241 participants (Actual)	Interventional	2016-10-20	Completed
A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer [NCT00717938]	Phase 3	390 participants (Actual)	Interventional	2008-06-30	Completed
A Phase II Trial of Xevinapant in Combination With Post-Operative Cisplatin and Radiotherapy for High Risk Head and Neck Cancer [NCT06145412]	Phase 2	54 participants (Anticipated)	Interventional	2023-11-16	Recruiting
Phase II Study of Induction Checkpoint Blockade for Untreated Stage I-IIIA Non-Small Cell Lung Cancers Amenable for Surgical Resection [NCT03158129]	Phase 2	101 participants (Actual)	Interventional	2017-06-09	Active, not recruiting
Late-Course Accelerated Hyperfractionated IMRT Versus Conventionally Fractionated IMRT in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: A Prospective Randomized Clinical Trial [NCT00778908]	Phase 2/Phase 3	120 participants (Actual)	Interventional	2008-01-31	Completed
Randomized Trial Comparing Low-Dose Weekly to High-Dose Cisplatin Concurrent With Radiation for Locally Advanced Head and Neck Cancer. [NCT03649048]		100 participants (Anticipated)	Interventional	2018-11-05	Recruiting
A Single-arm Phase II Study of Chemoradiotherapy Plus Pembrolizumab as Adjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma Patients at High Risk of Recurrence Following Preoperative Chemoradiotherapy Plus Surgery [NCT03322267]	Phase 2	26 participants (Anticipated)	Interventional	2018-10-27	Recruiting
a Prospective Random Study on the Efficacy and Safety of Bevacizumab in Untreated Patients With Locally Advanced Cervical Cancer [NCT04138992]	Phase 2/Phase 3	150 participants (Anticipated)	Interventional	2020-08-01	Recruiting
Intensity-modulated Radiotherapy Plus Concurrent Chemotherapy Versus Intensity-modulated Radiotherapy Alone In Patients With rT3/T4 Locally Advanced Recurrent Nasopharyngeal Carcinoma: A Phase 3 Multicenter Prospective Randomised Controlled Trial (IMRT) [NCT04136886]	Phase 3	346 participants (Anticipated)	Interventional	2020-01-01	Recruiting
Phase Ⅱ Study of Concurrent Chemotherapy and Radiotherapy for Stage II Nasopharyngeal Carcinoma [NCT00817258]	Phase 2	37 participants (Anticipated)	Interventional	2007-01-31	Recruiting
A Phase III Clinical Trial of Bevacizumab With IV Versus IP Chemotherapy in Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma [NCT00951496]	Phase 3	1,560 participants (Actual)	Interventional	2009-08-11	Completed
Phase II Study of Cisplatinum and Everolimus in Patients With Metastatic or Unresectable Neuroendocrine Carcinomas (NEC) of Extrapulmonary Origin [NCT02695459]	Phase 2	39 participants (Actual)	Interventional	2016-03-30	Active, not recruiting
Multicenter Study on Efficacy and Safety of Concurrent and Adjuvant Chemotherapy With Cisplatin and Docetaxel Combined With Radiotherapy for Local Advanced Cervical Cancer [NCT02703961]	Phase 3	598 participants (Anticipated)	Interventional	2016-02-29	Recruiting
Sequential Cisplatin/Vinorelbine/Bevacizumab Followed by Docetaxel/Gemcitabine/Bevacizumab Versus Cisplatin/Docetaxel/Bevacizumab in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer [NCT00620971]	Phase 2	77 participants (Actual)	Interventional	2008-01-31	Completed
Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer [NCT01194869]	Phase 2	25 participants (Actual)	Interventional	2010-06-30	Terminated(stopped due to Slow accrual, availability of other clinical options)
Clinical Study of Hydrochloride Anlotinib Combined With Concurrent Radiochemotherapy for Locally Advanced (Stage IB3 and IIA2-IVA) Cervical Cancer [NCT04772001]		53 participants (Anticipated)	Interventional	2021-03-12	Recruiting
Multicenter Phase III, Randomized Study to Evaluate Treatment Customized According to RAP80 and BRCA1 Assessment in Patients With Advanced Non-small-cell Lung Cancer [NCT00617656]	Phase 3	400 participants (Actual)	Interventional	2008-02-29	Terminated(stopped due to No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm over the control arm- would not be confirmed.)
A Multi-Center Randomized Phase IB/II Study of Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) [NCT04203160]	Phase 1/Phase 2	78 participants (Anticipated)	Interventional	2020-06-23	Recruiting
Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas of the Prospective, Single Arm Phase II Clinical Study [NCT02665702]	Phase 2	76 participants (Anticipated)	Interventional	2016-01-31	Recruiting
Selection of Chemoradiotherapy Based on Response to Induction Chemotherapy - a Phase II Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck [NCT01133678]	Phase 2	50 participants (Actual)	Interventional	2010-05-04	Terminated(stopped due to Primary endpoint reached futility boundary)
Toripalimab Combined With Induction Chemotherapy Followed by Radiotherapy Alone or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multi-center, Randomized Controlled Trial [NCT04907370]	Phase 3	540 participants (Actual)	Interventional	2021-08-01	Active, not recruiting
PD-1 Antibody SHR-1210 Combined With Paclitaxel and Cisplatin Versus Placebo Combined With Paclitaxel and Cisplatin as First-line Therapy for Advanced Esophageal Cancer: a Randomized, Double-blinded, Controlled, Multi-center Phase III Trial [NCT03691090]	Phase 3	596 participants (Actual)	Interventional	2018-12-03	Completed
Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer [NCT04192903]	Phase 2	55 participants (Anticipated)	Interventional	2019-12-25	Recruiting
To Investigate the Efficacy and Safety of Nimotuzumab Combined With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Local Advanced Cervical Squamous Cell Carcinoma [NCT04678791]		286 participants (Anticipated)	Interventional	2020-12-31	Not yet recruiting
A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma [NCT02856568]	Phase 1	0 participants (Actual)	Interventional	2017-05-01	Withdrawn(stopped due to Site dropped study)
Induction Chemotherapy of Docetaxel, Cisplatin and Xeloda in Nomogram-predicted High Risk Locoregionally Advanced Nasopharyngeal Carcinoma [NCT02786641]	Phase 3	235 participants (Anticipated)	Interventional	2016-08-31	Not yet recruiting
Phase I Study of Intraoperative Hyperthermic Intraperitoneal Chemoperfusion With Cisplatin in Patients With Recurrent Ovarian Cancer [NCT01387399]	Phase 1	9 participants (Anticipated)	Interventional	2011-06-30	Active, not recruiting
A National, Multi Center, Randomized, Open-label, Phase II Trial of Erlotinib Versus Combination of GC as (Neo)Adjuvant Treatment in Stage IIIA-N2 NSCLC With Sensitizing EGFR Mutation in Exon 19 or 21(EMERGING) [NCT01407822]	Phase 2/Phase 3	72 participants (Actual)	Interventional	2011-12-05	Active, not recruiting
[NCT01488838]	Phase 2	120 participants (Actual)	Interventional	2011-11-30	Completed
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial [NCT01414608]	Phase 3	926 participants (Actual)	Interventional	2012-01-09	Completed
Phase I Study of High Linear Energy Transfer (Neutron) Therapy Followed by Concurrent Chemotherapy and Standard Photon Thoracic RT (TRT) in Stage III NSCLC (Non-Small Cell Lung Cancer) Patients [NCT01416961]	Phase 1	0 participants (Actual)	Interventional	2011-08-31	Withdrawn(stopped due to Neutron therapy has become unavailable)
Randomized Phase Ⅱ Trial of Induction Chemotherapy Using Gemcitabine and Cisplatin in Concurrence With Intensity-modulated Radiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01417390]	Phase 2	80 participants (Anticipated)	Interventional	2011-11-30	Recruiting
Individualized 1st Line Chemotherapy Based on BRCA1 and RRM1 mRNA Expression Levels for Advanced Non-small Cell Lung Cancer [NCT01424709]	Phase 2	120 participants (Anticipated)	Interventional	2010-12-31	Active, not recruiting
SIOP CNS GCT II: Prospective Trial for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Intracranial Germ Cell Tumors [NCT01424839]	Phase 4	400 participants (Anticipated)	Interventional	2011-10-31	Recruiting
Phase 2 Study of Nimotuzumab in Combination With TPF for Head and Neck Squamous Cell Carcinoma [NCT01425736]	Phase 2	91 participants (Actual)	Interventional	2009-01-31	Completed
A Phase 1 Trial of Intratumoral Cisplatin for Early Stage, Resectable, Non-Small Cell Lung Cancer [NCT04809103]	Phase 1	10 participants (Anticipated)	Interventional	2021-03-08	Recruiting
Randomized Multicenter Phase II Trial of S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy After Curative Resection of Stage II-IV(M0) Gastric Cancer [NCT01426646]	Phase 2	218 participants (Anticipated)	Interventional	2011-09-30	Recruiting
Phase III Randomized Trial of Comparing CCRT vs. RT Alone for Cervical Cancer Patients Primarily Treated by Radiotherapy and With Clinically Defined Good-prognosis [NCT00846508]	Phase 3	208 participants (Anticipated)	Interventional	2009-02-28	Enrolling by invitation
Randomized Controlled Trial of the Efficacy of Adjuvant Chemotherapy in Patients With Residual Lesions After Concurrent Radiochemotherapy for Locally Advanced Cervical Cancer [NCT04409860]		120 participants (Anticipated)	Interventional	2020-05-26	Recruiting
A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery as Treatment for Relapsed and Refractory Non-Small Cell Lung Cancer [NCT02889666]	Phase 1	500 participants (Anticipated)	Interventional	2008-01-31	Recruiting
A Phase III, Multicenter Randomized Controlled Study of Neo-adjuvant Chemotherapy Paclitaxel + Cisplatin Versus Surgery Alone for Stage IIA-IIIB Esophageal Squamous Cell Carcinoma [NCT02395705]	Phase 3	528 participants (Anticipated)	Interventional	2015-06-30	Completed
A Phase 1b Study of Ficlatuzumab, Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Intermediate or High Risk, Previously Untreated, Locally Advanced Head and Neck Squamous Cell Carcinoma With Biomarker Correlatives [NCT02277184]	Phase 1	1 participants (Actual)	Interventional	2015-09-30	Terminated(stopped due to the investigator left the institution)
Phase III Randomized Trial of High Dose Chemoradiation and Systemic Chemotherapy vs Systemic Chemotherapy Alone in Patients With Unresectable Nonmetastatic Cholangiocarcinoma [NCT02773485]	Phase 3	155 participants (Anticipated)	Interventional	2015-05-31	Recruiting
A Randomized Phase II Study of Weekly Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Weekly Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer [NCT00173888]	Phase 2	15 participants (Actual)	Interventional	2003-07-31	Completed
A Phase II Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer [NCT00798655]	Phase 2	46 participants (Actual)	Interventional	2007-11-30	Completed
Intensified Methotrexate, Vinblastine, Doxorubicin and Cisplatin +/-Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma in Patients Without Harvey Nor Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations. Phase II Study [NCT02818725]	Phase 3	133 participants (Actual)	Interventional	2010-06-30	Completed
Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer [NCT00150670]	Phase 3	300 participants	Interventional	2002-03-31	Completed
Clinical Study of Ganoderma Lucidum Spore Combined With Chemotherapy [NCT02844114]	Phase 2	60 participants (Anticipated)	Interventional	2016-01-31	Recruiting
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab for Participants With Advanced Solid Tumors [NCT03564691]	Phase 1	442 participants (Anticipated)	Interventional	2018-07-11	Active, not recruiting
Phase III Trial of 3-weekly vs. 5-weekly Schedule of S-1 Plus Cisplatin Combination Chemotherapy for First Line Treatment of Advanced Gastric Cancer. [NCT00915382]	Phase 3	625 participants (Actual)	Interventional	2009-01-31	Completed
A Randomized Controlled Study of Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide and Cisplatin Chemotherapy [NCT02875457]	Phase 3	100 participants (Anticipated)	Interventional	2016-09-30	Not yet recruiting
Phase II Clinical Trial of Cisplatin + Gemcitabine in Combination With Mild, Fever-Range Whole-Body Hyperthermia to Treat Patients With Advanced, Inoperable Pancreatic Cancer [NCT00178763]	Phase 2	36 participants (Anticipated)	Interventional	2003-09-30	Recruiting
A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination With Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma [NCT05691478]	Phase 2/Phase 3	1,122 participants (Anticipated)	Interventional	2023-03-03	Suspended(stopped due to Scheduled Interim Monitoring)
A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers [NCT05063552]	Phase 2/Phase 3	430 participants (Anticipated)	Interventional	2023-03-13	Recruiting
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab [NCT03811002]	Phase 3	545 participants (Anticipated)	Interventional	2019-07-26	Recruiting
Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer [NCT03775265]	Phase 3	475 participants (Anticipated)	Interventional	2019-06-03	Recruiting
A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers [NCT01825603]	Phase 1	17 participants (Actual)	Interventional	2013-04-09	Completed
Phase I Study of Intravenous Triapine® (IND #68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies. [NCT00335998]	Phase 1	24 participants (Actual)	Interventional	2006-03-31	Completed
Swallowing Outcomes and Circulating Tumor DNA in Patients With HPV Related Oropharyngeal Cancer Treated With Transoral Surgery and Reduced Intensity Adjuvant Therapy [NCT04920344]	Phase 2	15 participants (Actual)	Interventional	2021-07-19	Active, not recruiting
Pembrolizumab and aMVAC Chemotherapy as Neoadjuvant Therapy in Non-Urothelial Histology Muscle-Invasive Bladder Cancer: A Pilot Trial [NCT04383743]	Phase 2	17 participants (Anticipated)	Interventional	2020-11-24	Recruiting
S1 Combined With Cisplatin in Treatment of Recurrence/Metastasis of ESCC Open-label Single Center Phase II Clinical Study [NCT01854749]	Phase 2	57 participants (Actual)	Interventional	2011-11-30	Completed
Comparison of Every 3 Week Versus Weekly Cisplatin Concurrent With Radiation in Squamous Cell Carcinoma of the Head and Neck (SCCHN) and Correlation With Oxidative Stress Markers [NCT02994069]	Phase 2	80 participants (Anticipated)	Interventional	2017-04-11	Recruiting
GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer [NCT01859728]	Phase 2	48 participants (Anticipated)	Interventional	2013-01-31	Recruiting
Prospective Randomized Trial Comparing Concurrent Chemoradiotherapy With or Without Induction Gemcitabine and Cisplatin in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT01872962]	Phase 3	480 participants (Actual)	Interventional	2013-11-30	Active, not recruiting
A Multicenter, Randomized, Open Label, Phase II Study Evaluating the Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer [NCT03838263]	Phase 2	62 participants (Actual)	Interventional	2019-07-25	Active, not recruiting
A Randomized, Phase III, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Palifermin (NSC# 740548; IND # 6370) for the Reduction of Oral Mucositis in Patients With Locally Advanced Head and Neck Cancer Receiving Radiation Ther [NCT00360971]	Phase 3	21 participants (Actual)	Interventional	2006-07-31	Terminated(stopped due to Due to positive preliminary results from other palifermin studies.)
"Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: The Minimalist Trial (MINT)" [NCT03621696]	Phase 2	63 participants (Actual)	Interventional	2018-10-23	Active, not recruiting
PROTECT: On-line Adaptive Proton Therapy for Cervical Cancer to Reduce the Impact on Morbidity and the Immune System [NCT05406856]		30 participants (Anticipated)	Interventional	2022-05-02	Recruiting
Phase II Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-Fluorouracil for Peritoneal Carcinomatosis [NCT00004547]	Phase 2	188 participants (Actual)	Interventional	2000-01-31	Completed
A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma [NCT00942331]	Phase 3	506 participants (Actual)	Interventional	2009-07-15	Completed
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer [NCT01683864]	Phase 2/Phase 3	3 participants (Actual)	Interventional	2012-09-30	Terminated(stopped due to Recruitment problems)
A PHASE III RANDOMIZED STUDY OF CISPLATIN (NSC #119875) AND TAXOL (PACLITAXEL) (NSC #125973) WITH INTERVAL SECONDARY CYTOREDUCTION VERSUS CISPLATIN AND PACLITAXEL IN PATIENTS WITH SUBOPTIMAL STAGE III & IV EPITHELIAL OVARIAN CARCINOMA [NCT00002568]	Phase 3	470 participants (Anticipated)	Interventional	1994-06-30	Completed
A Randomized Study of Purged Versus Unpurged Peripheral Blood Stem Cell Transplant Following Dose Intensive Induction Therapy for High Risk Neuroblastoma [NCT00004188]	Phase 3	495 participants (Actual)	Interventional	2001-02-28	Completed
A Phase II Study of Irinotecan and Cisplatin for Metastatic or Unresectable High Grade Neuroendocrine Carcinoma of the Gastrointestinal Tract [NCT00353015]	Phase 2	21 participants (Actual)	Interventional	2003-03-31	Completed
Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer [NCT00995761]	Phase 2	48 participants (Actual)	Interventional	2009-10-31	Completed
A Phase II, Single-center, Randomized Study of Eribulin Plus Cisplatin (EP) Versus Gemcitabine Plus Cisplatin (GP) as First-Line Treatment in Patients With Advanced Triple-Negative Breast Cancer [NCT04517292]	Phase 2	160 participants (Anticipated)	Interventional	2020-10-08	Not yet recruiting
A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC) [NCT01240590]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2011-01-26	Completed
Multi-center Phase II Clinical Randomized Study of Chronomodulated Chemotherapy Followed by Concurrent Chemo-radiotherapy With IMRT in the Treatment of Advanced Nasopharyngeal Cancer [NCT02937519]	Phase 2	160 participants (Anticipated)	Interventional	2015-06-30	Recruiting
A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma [NCT00524498]	Phase 2	60 participants (Actual)	Interventional	2007-09-30	Completed
p53-Adjusted Neoadjuvant Chemotherapy for Potentially Resectable Esophageal Cancer: A Multicenter, Randomized Controlled, Predictive Marker Clinical Trial [NCT00525200]	Phase 3	170 participants (Actual)	Interventional	2007-06-30	Completed
Open-label, Multicenter, Randomized Phase II Trial of Treatment With Cisplatin and Pemetrexed or Cisplatin and Oral Vinorelbine in Chemotherapy Naïve Patients Affected by Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase [NCT02919462]	Phase 2	2 participants (Actual)	Interventional	2016-03-31	Terminated(stopped due to low recruitement rate)
Prospective, Randomized, Multicenter, Phase II Noninferiority Study of S-1 Concurrent Intensity-modulated Radiation Therapy (IMRT) Versus S-1 and Cisplatin Concurrent IMRT in Inoperable Esophageal Squamous Cell Carcinoma [NCT02913066]	Phase 2	88 participants (Anticipated)	Interventional	2016-09-30	Recruiting
Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel ± Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer [NCT00535509]		285 participants (Actual)	Interventional	2007-06-30	Completed
Pilot Study Targeting Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer As Part of Adjuvant Therapy and Preventive Strategy [NCT01209520]		6 participants (Actual)	Interventional	2009-07-31	Completed
An International Randomized Phase III Study of First-line Erlotinib Followed by Second-line Cisplatin + Gemcitabine Versus First-line Cisplatin + Gemcitabine Followed by Second-line Erlotinib in Advanced Non Small Cell Lung Cancer [NCT00349219]	Phase 3	760 participants (Actual)	Interventional	2006-12-31	Completed
A Phase II Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab Plus Olaparib Combination Therapy Compared With Durvalumab Monotherapy as Maintenance Therapy in Patients Whose Disease Has Not Progressed F [NCT03775486]	Phase 2	401 participants (Actual)	Interventional	2018-12-21	Active, not recruiting
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer [NCT02899728]	Phase 2	9 participants (Actual)	Interventional	2018-03-30	Terminated(stopped due to Inadequate accrual rate)
A Phase I Study Using Abdominal Radiotherapy as a Cisplatin Chemosensitizer for Optimally Debulked Stage III/IV Carcinoma of the Endometrium [NCT00448643]	Phase 1	12 participants (Actual)	Interventional	2002-05-31	Completed
A Phase II Trial of Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer [NCT04224740]	Phase 2	37 participants (Actual)	Interventional	2020-06-15	Active, not recruiting
A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC) [NCT03765918]	Phase 3	704 participants (Anticipated)	Interventional	2018-12-17	Active, not recruiting
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC [NCT04585490]	Phase 3	48 participants (Anticipated)	Interventional	2021-08-25	Recruiting
Neoadjuvant Nivolumab Plus Paclitaxel/ Cisplatin- Chemo- Radiotherapy (Neo-NTP-CRT) Followed by Esophagectomy for Locally Advanced Esophageal Squamous Cell Carcinoma (ESCC) [NCT05130684]	Phase 2	43 participants (Anticipated)	Interventional	2021-02-22	Recruiting
Phase I Study of AGuIX Gadolinium-based Nanoparticles in Combination With Chemoradiation and Brachytherapy in Locally Advanced Cervical Cancer [NCT03308604]	Phase 1	18 participants (Anticipated)	Interventional	2018-05-17	Recruiting
A Phase II Study of Induction Chemotherapy Followed by Surgical Treatment in Locally Advanced Oropharyngeal And Supraglotic Cell Carcinoma [NCT02760667]	Phase 2	20 participants (Actual)	Interventional	2015-06-30	Active, not recruiting
A Prospective Clinical Study of Ruxolitinib Phosphate Tablets and Etoposide Combined With DDGP Regimen (RUE-DDGP) in Induction Therapy of T/NK Cell Lymphoma-associated Hemophagocytic Syndrome. [NCT04999878]	Phase 4	30 participants (Anticipated)	Interventional	2021-05-30	Recruiting
Phase II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin as First Line Treatment in Patients With Stage IV Non-squamous Non Small Cell Lung Cancer (NSCLC) [NCT00942825]	Phase 2	195 participants (Actual)	Interventional	2009-04-30	Completed
A Phase Ib, Open-label, Dose Escalation Trial Investigating Different Doses and Schedules of Sym004 in Combination With Platinum-doublets in Subjects With Stage IV Non-small Cell Lung Cancer [NCT02083679]	Phase 1	15 participants (Actual)	Interventional	2014-07-31	Terminated(stopped due to Sponsor the return rights of the compound to the collaboration partner for further clinical development)
A Phase II Study of OSI-774 in Combination With Cisplatin and Docetaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer [NCT00076310]	Phase 2	50 participants (Actual)	Interventional	2004-01-28	Active, not recruiting
A Phase II Trial of Concomitant Boost Radiation and Concurrent Cisplatin for Advanced Head and Neck Carcinomas [NCT00005088]	Phase 2	0 participants	Interventional	2000-04-30	Completed
A Phase I Study of CBLB502 in the Treatment of Patients With Poor Prognosis Advanced Squamous Cell Carcinomas of the Head and Neck Receiving Chemoradiotherapy [NCT01728480]	Phase 1	0 participants (Actual)	Interventional	2014-01-31	Withdrawn(stopped due to Financial Sponsor requested termination)
[NCT01483300]	Phase 2	80 participants (Anticipated)	Interventional	2011-11-30	Recruiting
A Phase II Trial of Adjuvant Chemotherapy in Patients With Lymph Node Metastasis After Radical Surgery in FIGO Stage IA2-IIA Cervical Cancer [NCT01487226]	Phase 2	69 participants (Anticipated)	Interventional	2008-01-31	Recruiting
Pilot Study of Cisplatin, Etoposide, Bleomycin and Escalating Dose Cyclophosphamide Therapy for Children With High Risk Malignant Germ Cell Tumors [NCT00066482]		19 participants (Actual)	Interventional	2004-07-31	Completed
Phase II Trial of Imatinib Mesylate Maintenance Therapy in Patients With C-Kit (+) Extensive-Stage Small Cell Lung Cancer [NCT00248482]	Phase 2	6 participants (Actual)	Interventional	2002-02-28	Completed
A Phase 1 Study of Halichondrin B Analog (E7389) in Combination With Cisplatin in Advanced Solid Tumors [NCT00415324]	Phase 1	36 participants (Actual)	Interventional	2006-12-31	Completed
Randomized Phase III Trial Comparing Induction Chemotherapy With Cisplatin/5-fluorouracil (PF) or Docetaxel/Cisplatin/5-fluorouracil (TPF) Plus Chemoradiotherapy (CRT) Versus CRT Alone as First-line Treatment or Unresectable Locally Advanced Head and Neck [NCT00261703]	Phase 2/Phase 3	439 participants (Actual)	Interventional	2002-12-31	Completed
Phase II Trial of Dose-dense Paclitaxel and Cisplatin as Neo-adjuvant Chemotherapy for Operable Stage II and IIA Non-Small Cell Lung Cancer [NCT00291850]	Phase 2	50 participants (Actual)	Interventional	2005-06-30	Terminated(stopped due to no patient recruitment)
[NCT00083252]	Phase 2	0 participants	Interventional		Completed
A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx [NCT05966194]	Phase 2	216 participants (Anticipated)	Interventional	2023-12-01	Not yet recruiting
Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples. [NCT01703910]	Phase 2	29 participants (Actual)	Interventional	2012-11-30	Completed
CRP on Radiobiological and Clinical Studies on Viral-induced Cancer's Response to Radiotherapy With Comprehensive Morbidity Assessment [NCT00122772]	Phase 3	601 participants (Actual)	Interventional	2005-11-30	Completed
Multi-Center, Phase Ib/IIa Safety and Preliminary Efficacy Study of Phenoxodiol (Intravenous) as a Chemo-Sensitizing Agent for Cisplatin and Paclitaxel in Epithelial Ovarian Cancer or Primary Peritoneal Cancer, Platinum- and/or Taxane-Refractory or Resist [NCT00091377]	Phase 1/Phase 2	65 participants (Actual)	Interventional	2004-08-31	Completed
A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder [NCT00330499]	Phase 3	67 participants (Actual)	Interventional	2002-10-31	Completed
"Phase II Non-Randomized Three Arm Trial of Induction Chemotherapy With Nab-Paclitaxel and Cisplatin (AP: Arms 1 and 3) or Single Agent Nab-paclitaxel (A: Arm 2) as Induction Therapy Followed by Definitive Concurrent Chemoradiation for Locally Advanced Sq [NCT02573493]	Phase 2	96 participants (Actual)	Interventional	2016-04-13	Active, not recruiting
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer [NCT05819892]	Phase 1	21 participants (Anticipated)	Interventional	2023-07-17	Recruiting
A Phase I Study of Concurrent CPT-11/Cisplatin and Celecoxib With Radiation Therapy for Patients With Unresectable Non-Small Cell Lung Cancer (NSCLC) [NCT00346801]	Phase 1	20 participants (Actual)	Interventional	2003-09-30	Completed
A Phase 1 Study of Oral MRX-1024 in Combination With Standard Fractionation Radiation Therapy and High-Dose Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck Following Surgical Resection [NCT00427102]	Phase 1	0 participants	Interventional	2007-01-31	Terminated(stopped due to No subjects enrolled and PI went to another facility)
A Phase I Trial of Sequential Ipilimumab After Chemoradiation for the Primary Treatment of Patients With Locally Advanced Cervical Cancer Stages IB2/IIA With Positive Para-Aortic Lymph Nodes Only and Stage IIB/IIIB/IVA With Positive Lymph Nodes [NCT01711515]	Phase 1	34 participants (Actual)	Interventional	2012-10-01	Completed
Randomized Phase II Study Evaluating The Tolerability Of Adjuvant Docetaxel-based Chemotherapy For Completely Resected Stage IB-II Non-Small Cell Lung Cancer (NSCLC): Toledo Trial [NCT00434668]	Phase 2	99 participants (Anticipated)	Interventional	2005-12-31	Completed
A Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Doses of Cisplatin for Children With Peritoneal Carcinomatosis or Advanced Peritoneal and Retroperitoneal Disease [NCT00436657]	Phase 1	10 participants (Actual)	Interventional	2007-02-28	Completed
Randomized, Phase III Trial Comparing Etoposide/Cisplatin (EP) With Irinotecan/Cisplatin (IP) in Patients With Previously Untreated, Extensive Disease (ED) Small Cell Lung Cancer (SCLC) [NCT00349492]	Phase 3	372 participants (Anticipated)	Interventional	2006-06-30	Completed
Phase III, Open, Multicenter and Randomized Study of Customized Adjuvant Chemotherapy Based on BRCA1 mRNA Levels in Completely Resected Stages II-IIIA Non-Small-Cell Lung Cancer Patients [NCT00478699]	Phase 3	500 participants (Actual)	Interventional	2007-06-30	Completed
A Phase I Study of the Combination of Chemoradiotherapy With Biologic Therapy for Advanced Head and Neck Cancer [NCT00405405]	Phase 1	13 participants (Actual)	Interventional	2006-12-31	Completed
A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma [NCT05211323]	Phase 2	88 participants (Anticipated)	Interventional	2022-12-07	Recruiting
A Phase II Study of Adjuvant Postoperative Radiation With Cisplatin Followed by Carboplatin/Paclitaxel Chemotherapy Following Total Abdominal Hysterectomy/Bilateral Salpino-Oophorectomy (TAH/BSO) for Patients With Stage I, II and IIIa Malignant Mixed Meso [NCT00505492]	Phase 2	4 participants (Actual)	Interventional	2002-02-28	Terminated(stopped due to Slow accrual.)
Optimal Preoperative Therapy for Intrahepatic Cholangiocarcinoma (OPTIC) [NCT05514912]	Phase 2	0 participants (Actual)	Interventional	2024-03-01	Withdrawn(stopped due to PI has decided to terminate this study due to study supporter pulling support on this study.)
A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer [NCT03952585]	Phase 2/Phase 3	590 participants (Anticipated)	Interventional	2019-10-09	Suspended(stopped due to End of Initial Phase of Multi-phase protocol)
Adjuvant Therapy for Melanoma Patients With Regional Lymph Node Metastases With Interferon Alfa-2B vs. Biochemotherapy Using Cisplatin + Vinblastine + DTIC + Interferon Plus IL-2 [NCT00002882]	Phase 3	140 participants (Actual)	Interventional	1995-11-30	Completed
Phase II Study of Paclitaxel (TAXOL), Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer [NCT00511992]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
Phase 2 Study of Inductive Plus Concurrent Chemoradiation Versus Concurrent Plus Adjuvant Chemoradiation for High-risk Locally Advanced Nasopharyngeal Carcinoma in the Era of IMRT [NCT01797900]	Phase 2	130 participants (Actual)	Interventional	2013-03-31	Completed
A Phase II Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission (AS-CR) by Applying Non-Host-Exhausting and Timely Dose-Reduced Mel-80-CFZ-TD-Pace Transplant(s) With Interspersed Mel-20-CFZ-TD-Pace With CFZ-RD and CFZ-D Ma [NCT02128230]	Phase 2	20 participants (Actual)	Interventional	2014-06-10	Terminated(stopped due to Low enrollment and Futility as determined by Amgen's Carfilzomib NASCR program.)
Penpulimab Plus Chemotherapy With or Without Anlotinib as First-line Therapy for Patients With Advanced Esophageal Squamous Cell Carcinoma (Answer): A Randomized Two-arm Clinical Study [NCT05214222]	Phase 2	100 participants (Anticipated)	Interventional	2022-09-02	Recruiting
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies [NCT02983045]	Phase 1/Phase 2	557 participants (Actual)	Interventional	2016-12-19	Completed
A Prospective Phase II Clinical Trial of Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Locally Advanced Nasopharyngeal Carcinoma [NCT04769076]	Phase 2	40 participants (Anticipated)	Interventional	2021-03-01	Not yet recruiting
Effect of Neoadjuvant Cisplatin Based Chemoradiation Therapy for Locally Advanced Triple Negative Breast Cancer: Clinical Outcome and Correlation to Biological Parameters [NCT00603408]	Phase 2	5 participants (Actual)	Interventional	2007-12-31	Terminated(stopped due to Study was discontinued due to lack of accrual.)
Autologous Dendritic Cell-cytokine Induced Killer Cell Immunotherapy Combined With S-1 Based Chemotherapy in Patients With Advanced Gastric Cancer [NCT01783951]	Phase 1/Phase 2	63 participants (Actual)	Interventional	2013-02-01	Completed
Sun Yat-sen Memorial Hospital, Sun Yat-sen University [NCT05444673]	Phase 4	30 participants (Anticipated)	Interventional	2022-06-01	Recruiting
Phase I Study Evaluating a Stereotactic Boost/Treatment for Recurrent or Metastatic Cancer of the Head and Neck [NCT02474368]	Phase 1	21 participants (Actual)	Interventional	2015-11-30	Active, not recruiting
Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation [NCT00653068]	Phase 3	70 participants (Actual)	Interventional	2008-12-08	Active, not recruiting
A Phase I Dose-Escalation Study of Cisplatin and Radiation Therapy for Patients With Triple Negative Breast Cancer [NCT01674842]	Phase 1	55 participants (Actual)	Interventional	2012-10-31	Completed
Phase I Trial of the Treatment of Advanced Endometrial Cancer With Concurrent Weekly Paclitaxel and Cisplatin and Whole Abdominal Radiation Therapy [NCT00005840]	Phase 1	35 participants (Actual)	Interventional	2000-07-31	Completed
Phase II Trial Of Surgery With Perioperative RPR/INGN 201 (Ad5CMV-p53) Gene Therapy Followed By Chemoradiotherapy For Advanced, Resectable Squamous Cell Carcinoma Of The Oral Cavity, Oropharynx, Larynx, and Pharynx [NCT00017173]	Phase 2	13 participants (Actual)	Interventional	2003-02-28	Terminated(stopped due to Terminated for poor accrual.)
A Phase 1/2, Open-label, Study to Investigate the Safety, Tolerability, and Efficacy of SC-43 Administered in Combination With Cisplatin in Subjects With Advanced or Refractory Non-small Cell Lung Cancer or Biliary Tract Carcinoma [NCT04733521]	Phase 1/Phase 2	100 participants (Anticipated)	Interventional	2021-05-01	Not yet recruiting
A Phase III Study Comparing Etoposide and Cisplatin (EP) With Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Irradiation (EP/TRT) for Limited-Stage Small-Cell Lung Cancer : JCOG0202-MF [NCT00144989]	Phase 3	281 participants (Actual)	Interventional	2002-09-30	Completed
Feasibility Study for Multicenter Randomized Controlled Phase III Clinical Trial of Cisplatin + Irinotecan Therapy and Cisplatin + Irinotecan + Krestin Therapy for Extensive-Stage Disease (ED) Small Cell Lung Cancer [NCT00546130]	Phase 2	45 participants (Anticipated)	Interventional	2007-11-30	Recruiting
A Phase III Randomized Trial Between 5 Day 3 Weekly and Weekly Cisplatin Based Chemotherapy for Patients With Locally Advanced Cervical Cancer [NCT00548821]	Phase 3	0 participants	Interventional		Not yet recruiting
Phase I Clinical and Pharmacokinetic Study of CBP501 and Cisplatin Every 3 Weeks in Patients With Advanced Refractory Solid Tumors [NCT00551512]	Phase 1	48 participants (Actual)	Interventional	2006-11-30	Completed
A Multicenter Randomized Phase III Trial of Neo-adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer (CRITICS Study) [NCT00407186]	Phase 3	788 participants (Actual)	Interventional	2007-01-11	Active, not recruiting
Phase II Study to Evaluate the Efficacy of Upfront Obinutuzumab in Mantle Cell Lymphoma Patients Treated by DHAP Followed by Autologous Transplantation Plus Obinutuzumab Maintenance Then MRD Driven Maintenance [NCT02896582]	Phase 2	86 participants (Actual)	Interventional	2016-10-31	Active, not recruiting
A Phase Ⅰb/II Study of Surufatinib Combined With Chemotherapy Plus Toripalimab or Not in Patients With Small Cell Lung Cancer [NCT04996771]	Phase 1/Phase 2	88 participants (Anticipated)	Interventional	2021-11-09	Recruiting
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study [NCT04900623]	Phase 2	75 participants (Anticipated)	Interventional	2021-07-02	Recruiting
A Prospective Randomized Controlled Trial for Postoperative Adjuvant Chemotherapy for pTanyN0M0 Upper Urinary Urothelial Carcinoma With Lymphovascular Invasion [NCT04255771]	Phase 3	200 participants (Anticipated)	Interventional	2020-03-01	Not yet recruiting
A Phase I, Open Label Study to Assess the Safety and Tolerability of ZD6474 (ZACTIMA) in Combination With Vinorelbine (Navelbine) or Gemcitabine (Gemzar) Plus Cisplatin as First Line Therapy in Patients With Locally Advanced or Metastatic (Stage IIIB-IV) [NCT00496275]	Phase 1	17 participants (Actual)	Interventional	2006-08-31	Completed
DREAM3R: DuRvalumab (MEDI4736) With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial [NCT04334759]	Phase 3	214 participants (Actual)	Interventional	2021-02-18	Active, not recruiting
Multi-center Prospective Randomized Controlled Clinical Trial of Postoperative Adjuvant Chemotherapy, Adjuvant Radiotherapy, or Surgery Alone for High-risk Histological Node Negative Patients With Thoracic Esophageal Squamous Cell Carcinoma [NCT02891083]	Phase 3	486 participants (Anticipated)	Interventional	2016-01-31	Recruiting
NGR004:A Phase IB Study of NGR-hTNF in Combination With Cisplatin in Patient Affected by Advanced or Metastatic Solid Tumor [NCT00483093]	Phase 1	22 participants (Actual)	Interventional	2007-07-31	Completed
A Phase I Study Dose Escalation Clinical Study Of Hepatic Intraarterial Cisplatin, In Combination With Systemic Intravenous Liposomal Doxorubicin Administered Every Four Weeks to Patients With Advanced Cancer And Dominant Liver Involvement [NCT00507962]	Phase 1	51 participants (Actual)	Interventional	2005-03-31	Completed
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer [NCT04692051]	Phase 2	100 participants (Anticipated)	Interventional	2019-09-01	Recruiting
A Phase III Randomized Study of Chemo-radiotherapy Versus Radiotherapy Alone in the Adjuvant Treatment of Salivary Glands and Nasal Tumors (IMRT or Protontherapy) [NCT02998385]	Phase 3	342 participants (Anticipated)	Interventional	2017-01-20	Recruiting
A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexate Followed by Consolidation With Stem Cell Rescue vs. [NCT00336024]	Phase 3	91 participants (Actual)	Interventional	2007-08-06	Active, not recruiting
A Phase I-II Study of Systemic Capecitabine, Cisplatin and Intraperitoneal Docetaxel (XPID) in Patients With Advanced Stomach Cancer With Peritoneal Seeding [NCT01525771]	Phase 1/Phase 2	37 participants (Actual)	Interventional	2011-02-28	Completed
A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC) [NCT01528618]	Phase 3	362 participants (Actual)	Interventional	2012-02-21	Completed
Cisplatin and 5-fluorouracil(PF) or Docetaxel,Cisplatin and 5-fluorouracil (TPF) Neoadjuvant Chemotherapy With Chemoradiation Therapy for Locally Advanced Nasopharyngeal Carcinoma--A Randomised Prospective Multicenter Phase 3 Study [NCT01536223]	Phase 3	400 participants (Anticipated)	Interventional	2012-04-30	Recruiting
Phase II Trial of Neoadjuvant Chemotherapy for HPV-Associated Squamous Cell Carcinoma of the Oropharynx Followed by Reduced Dose Radiotherapy/Chemoradiotherapy for Responders or Standard Dose Chemoradiotherapy for Non-Responders [NCT01525927]	Phase 2	2 participants (Actual)	Interventional	2010-08-31	Terminated(stopped due to Principal Investigator left institution. IRB approval lapsed.)
Phase II/III Clinical Trial of Intensity Modulated Radiation Therapy With Concurrent Cisplatin for Stage I-IVA Cervical Carcinoma [NCT01554397]	Phase 2/Phase 3	70 participants (Actual)	Interventional	2011-10-13	Active, not recruiting
Phase I/II Study of Gemzar and Platinol Followed by Alimta and Gemzar in Patients With Advanced or Metastatic Bladder Cancer [NCT00101842]	Phase 1/Phase 2	61 participants	Interventional	2004-12-31	Completed
A Prospectively Randomized Controlled Clinical Trial Comparing TheraSphere With Cisplatin-Based TACE (Trans Arterial Chemo Embolization) in the Management of Advanced Stage, Unresectable Hepatocellular Carcinoma (HCC) [NCT00109954]	Phase 3	120 participants (Anticipated)	Interventional	2005-02-28	Completed
Phase I Study of OSI-7904L in Combination With Cisplatin in Patients With Advanced Solid Tumors [NCT00116896]	Phase 1	25 participants	Interventional	2003-06-30	Completed
An Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin as Treatment for Chemotherapy-naive Patients With Extensive Disease-Small Cell Lung Cancer. [NCT00043927]	Phase 3	760 participants	Interventional	2001-04-30	Completed
Management Of Anemia Under RadioChemotherapy (MARCH): An Open, Randomized Multicenter Study Of The Effect Of NeoRecormon On Treatment Outcome In Patients With Advanced Cervical Cancer Stage IIB -IVA Treated With Primary Simultaneous Radiochemotherapy (Rad [NCT00046969]	Phase 4	450 participants (Anticipated)	Interventional	2002-07-31	Completed
Treatment of Patients With Stage IB2 Carcinoma of the Cervix: A Randomized Comparison of Radical Hysterectomy and Tailored Chemo-Radiation Versus Primary Chemo-Radiation [NCT00054067]	Phase 3	0 participants	Interventional	2003-02-28	Terminated
Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck [NCT00057850]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2002-01-31	Completed
Definitive Concurrent Chemoradiotherapy With Docetaxel Plus Cisplatin Versus 5-fluorouracil Plus Cisplatin in Patients With Esophageal Squamous Cell Carcinoma: a Phase II Randomized Controlled Trial [NCT02969473]	Phase 2	120 participants (Anticipated)	Interventional	2010-10-31	Active, not recruiting
A Phase I/II, Open-Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic, and Efficacy Study of Orally Administered S-1 in Combination With Cisplatin in Patients With Advanced Gastric Cancer [NCT00072787]	Phase 1/Phase 2	41 participants	Interventional	2003-10-31	Completed
A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma [NCT00077545]	Phase 2	39 participants (Anticipated)	Interventional	2004-01-31	Completed
Randomized Phase 2 Study of Capecitabine vs Gemcistabine Plus Cisplatin in Patients With Resected Extrahepatic Cholangiocarcinoma With Regional Lymph Node Metastasis [NCT03079427]	Phase 2	101 participants (Actual)	Interventional	2017-05-15	Completed
A Randomized Phase II Comparison Of Two Cisplatin-Paclitaxel Containing Chemoradiation Regimens In Resected Gastric Cancers [NCT00011960]	Phase 2	0 participants	Interventional	2001-05-31	Completed
Phase II Early Postoperative Paclitaxel Followed By Paclitaxel And Cisplatin Concurrent With Radiation Therapy For Resected, High Risk Squamous Carcinoma Of The Head And Neck [NCT00011999]	Phase 2	70 participants (Actual)	Interventional	2001-03-31	Completed
Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (St [NCT00016367]	Phase 2	22 participants (Actual)	Interventional	1999-05-13	Completed
A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer [NCT00016874]	Phase 1	0 participants	Interventional	2000-12-31	Completed
An Open Label, Sequential Multi-Center Multi Dose Study Of G17T Immunogen In Combination With Cisplatin (CDDP) And 5-Fluorouracil (5-FU) In Subjects With Metastatic Or Locally Recurrent Gastric Or Gastroesophageal Cancer Previously Untreated With Chemothe [NCT00020787]	Phase 3	8 participants (Actual)	Interventional	2001-07-31	Completed
Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lun [NCT00021333]	Phase 2	29 participants (Actual)	Interventional	1999-09-30	Completed
A Two-blinded, Multicentre, Phase II/III RCT of Concurrent Chemo-radiotherapy Combined or Not Combined With TNF as the Therapy for Local-advancedNPC [NCT05433597]	Phase 2/Phase 3	172 participants (Anticipated)	Interventional	2022-07-01	Not yet recruiting
A Phase I Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer. [NCT00846443]	Phase 1	12 participants (Anticipated)	Interventional	2009-01-31	Recruiting
A Phase 1 / Phase 2 Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer [NCT02990468]	Phase 1/Phase 2	29 participants (Actual)	Interventional	2017-04-19	Completed
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [NCT02855944]	Phase 3	349 participants (Actual)	Interventional	2017-03-01	Completed
An Exploratory Phase II Clinical Trial of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer [NCT05772377]	Phase 2	36 participants (Anticipated)	Interventional	2023-07-01	Not yet recruiting
A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin [NCT00024323]	Phase 1	0 participants	Interventional	2001-03-31	Completed
A Phase I, Open-Label Study Evaluating The Pharmacokinetics of Components of S-1 Patients With Impaired Hepatic Function [NCT00398424]	Phase 1	24 participants (Anticipated)	Interventional	2006-02-28	Completed
Phase III Study Evaluating Two Strategies of Maintenance, One With Pemetrexed in Continuous Strategy and One According to the Response of Induction Chemotherapy, in Non Squamous Non Small Cell Lung Cancer of Advanced Stage [NCT01631136]	Phase 3	932 participants (Actual)	Interventional	2012-07-31	Completed
Promune™ (CPG 7909 Injection) In Combination With Chemotherapy In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer, A Randomized, Multi-Center, Controlled, Phase 2 Study [NCT00070629]	Phase 2	116 participants (Actual)	Interventional	2003-05-31	Completed
An Open-label, Multicenter, Randomized, 3 Arm Study of S-1 Compared With S-1/CDDP, or S-1/CDDP Compared With 5-FU/CDDP in Patients With Advanced Gastric Cancer Previously Untreated With Chemotherapy for Advanced Disease [NCT00202969]	Phase 3	180 participants (Anticipated)	Interventional	2005-07-31	Completed
Phase I/II Study of Docetaxel, Cisplatin and 5-fluorouracil(TPF) as Chemotherapy in Pre-treated Patients With Metastatic Esophageal Cancer. [NCT00209716]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2003-12-31	Completed
A Phase II Study of Cisplatin and Irinotecan Induction Chemotherapy, Followed by ZD 1839 (IRESSA) in Adult Patients With Surgically Unresectable and/or Metastatic Esophageal or Gastric Carcinomas [NCT00215995]	Phase 2	21 participants (Actual)	Interventional	2003-07-31	Completed
Doctoral CRP on Clinical and Experimental Studies to Improve Radiotherapy Outcome in AIDS Cancer Patients [NCT00122746]	Phase 3	322 participants (Anticipated)	Interventional	2004-12-31	Recruiting
Phase 1-2a Dose-Ranging Study of TLK286 in Combination With Cisplatin as First-Line Therapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer [NCT00077883]	Phase 1/Phase 2	50 participants (Anticipated)	Interventional	2004-02-29	Completed
Phase I Trial of Cisplatin, Pemetrexed, and Imatinib Mesylate in Unresectable or Metastatic Malignant Mesothelioma [NCT00402766]	Phase 1	19 participants (Actual)	Interventional	2006-08-31	Completed
A Phase II Evaluation Of Triapine (NCI-Supplied Agent: NSC #663249, IND #68338) In Combination With Cisplatin (Commercially Available: NSC # 119875) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma [NCT00081276]	Phase 2	48 participants (Actual)	Interventional	2005-07-31	Completed
Phase II Study of the Combination of Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents at Diagnosis or in Relapse [NCT00147160]	Phase 2	87 participants (Anticipated)	Interventional	2003-10-31	Completed
A Phase II Study of Concurrent Chemoradiotherapy With Twice Weekly Paclitaxel and Cisplatin (Twice Weekly TP) Followed by Surgery for Locally Advanced Esophageal Cancer [NCT00154804]	Phase 2	40 participants (Actual)	Interventional	2001-08-31	Completed
Weekly Low-dose Paclitaxel (Phyxol) Plus 24-Hour Infusion of Cisplatin as First-line Chemotherapy for Metastatic Breast Cancer [NCT00154882]	Phase 2	43 participants (Anticipated)	Interventional	2003-09-30	Recruiting
UARK 2000-46, A Phase II Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally in Multiple Myeloma Patients [NCT00083538]	Phase 2	40 participants (Actual)	Interventional	2001-02-28	Completed
Phase II Study Comparing Radiochemotherapy With the Folfox 4 Regimen Versus Radiochemotherapy With 5FU-Cisplatin (Herskovic Regimen) in First Line Treatment of Patients With Inoperable Esophageal Cancer [NCT00160030]	Phase 2	97 participants (Actual)	Interventional	2004-09-30	Completed
Clinical Study of Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer [NCT04731909]		80 participants (Anticipated)	Interventional	2018-10-01	Recruiting
A Two Arm Phase II Study Comparing Docetaxel/Cisplatin Induction Therapy Followed By Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Followed By Consolidation Docetaxel/Cisplatin in Patients With Locally Advanced Unresectable NSCLC (Stage [NCT00174772]	Phase 2	72 participants (Actual)	Interventional	2004-03-31	Completed
Prospective Phase I/II Study of Adjuvant Radiochemotherapy for Gastric Cancer [NCT00188266]	Phase 1/Phase 2	65 participants (Anticipated)	Interventional	2002-08-31	Completed
Lipiodol-based Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Randomized Controlled Trial of Aqueous Cisplatin Emulsion Versus Cisplatin Particle Suspension [NCT03268499]	Phase 2	77 participants (Actual)	Interventional	2016-09-09	Completed
A Randomised Phase III Study in Advanced Oesophageal Cancer to Compare Quality of Life and Palliation of Dysphagia in Patients Treated With Radiotherapy vs ChemoRadiotherapy. [NCT00193882]	Phase 3	220 participants (Actual)	Interventional	2003-07-07	Completed
Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) NSCLC. Randomized Phase II Study [NCT00198367]	Phase 2	120 participants (Actual)	Interventional	2003-01-31	Completed
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults (NOA-07) [NCT01614132]	Phase 1/Phase 2	33 participants (Actual)	Interventional	2009-01-31	Completed
Phase II Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy [NCT02432365]	Phase 2	64 participants (Anticipated)	Interventional	2015-02-28	Recruiting
A Pilot Study of MR Imaging Based Intracavitary Brachytherapy for Cervical Cancer [NCT01016561]		12 participants (Actual)	Interventional	2009-07-31	Terminated(stopped due to Poor accrual/enrollments)
A Randomized, Open, Multicenter Phase 1/Phase 2 Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squ [NCT05783921]	Phase 1/Phase 2	60 participants (Anticipated)	Interventional	2023-05-23	Recruiting
Adaptive-Dose to Mediastinum With Immunotherapy (Durvalumab MEDI4736) and Radiation in Locally-Advanced Non-Small Cell Lung Cancer [NCT04372927]	Phase 2	1 participants (Actual)	Interventional	2021-12-10	Terminated(stopped due to Terminated due to slow accrual)
A Phase II Clinical Trial of Neoadjuvant Chemotherapy With M-VAC Plus Avastin in Patients With Locally Advanced Urothelial Cancer [NCT00506155]	Phase 2	60 participants (Actual)	Interventional	2007-06-30	Completed
A Phase II Trial of Combination of Toripalimab and Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma [NCT04005170]	Phase 2	42 participants (Actual)	Interventional	2019-06-25	Completed
A Randomized Phase II Study of Neoadjuvant PD-1 Blockade Alone or Plus TPF Induction Chemotherapy for Resectable Local Advanced Oral Squamous Cell Carcinoma [NCT04649476]	Phase 2	68 participants (Actual)	Interventional	2021-03-22	Active, not recruiting
Durvalumab and Standard Chemotherapy for the Treatment of Lymph Node Positive Bladder Cancer [NCT05137262]	Phase 2	60 participants (Anticipated)	Interventional	2021-10-13	Recruiting
Phase II Trial of Durvalumab (MEDI4736) Maintenance Therapy After Concurrent Chemoradiation Therapy With Durvalumab (MEDI4736) for Limited Disease-small Cell Lung Cancer [NCT03585998]	Phase 2	51 participants (Actual)	Interventional	2018-06-19	Active, not recruiting
Feasibility Trial of Intraperitoneal Chemotherapy in Stage IA, IB, IC, II, III, IV and Recurrent Platinum Sensitive Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma and Stage III and IV Uterine Cancer [NCT00582205]	Phase 2	21 participants (Actual)	Interventional	2006-01-31	Terminated(stopped due to Study completed per investigator.)
A Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (mDCF) in Patients With Unresectable or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma [NCT00515411]	Phase 2	111 participants (Actual)	Interventional	2006-10-23	Completed
A Phase II Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced, Unresectable Head and Neck Squamous Cell Carcinoma [NCT04405154]	Phase 2	32 participants (Anticipated)	Interventional	2020-06-01	Not yet recruiting
A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma [NCT01585805]	Phase 2	107 participants (Anticipated)	Interventional	2012-05-15	Active, not recruiting
Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial [NCT04559139]	Phase 2/Phase 3	186 participants (Anticipated)	Interventional	2021-02-24	Recruiting
A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) [NCT01893801]	Phase 1/Phase 2	25 participants (Actual)	Interventional	2013-05-31	Completed
Phase I Open Label Trial of Alimta® Plus Cisplatin and Paclitaxel Given Intraperitoneally (IP) as First Line Treatment for Women With Stage III Ovarian Cancer [NCT00702299]	Phase 1	15 participants (Actual)	Interventional	2007-09-30	Completed
Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts [NCT02918955]	Phase 3	65 participants (Anticipated)	Interventional	2016-10-31	Recruiting
A European Treatment Protocol for Bone-sarcoma in Patients Older Than 40 Years [NCT02986503]		100 participants (Actual)	Observational	2002-01-31	Completed
Randomised Phase II Study of Postoperative Hepatic Arterial Infusion Chemotherapy (Interferon/Fluorouracil Versus Low-dose Cisplatin/Fluorouracil) for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus. [NCT01834963]	Phase 2	66 participants (Anticipated)	Interventional	2013-03-31	Recruiting
Nivolumab in Combination With Cisplatin and 5-Fluorouracil as Induction Therapy in Children and Adults With EBV-positive Nasopharyngeal Carcinoma [NCT06019130]	Phase 2	57 participants (Anticipated)	Interventional	2023-01-10	Recruiting
Treatment of Adrenocortical Tumors With Surgery Plus Lymph Node Dissection and Multiagent Chemotherapy: A Groupwide Phase III Study [NCT00304070]	Phase 3	78 participants (Actual)	Interventional	2007-05-03	Completed
Multicenter Phase III Study of Intensity-modulated Radiotherapy Alone Compared to Intensity-modulated Radiotherapy Combined Chemotherapy for Lower Risk Locally Advanced Nasopharyngeal Carcinoma [NCT01817023]	Phase 3	590 participants (Anticipated)	Interventional	2013-04-30	Recruiting
A Randomized Phase II Trial of Cisplatin With or Without Wee1 Kinase Inhibitor AZD1775 (MK-1775) for First-line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (RM-SCCHN) [NCT02196168]	Phase 2	6 participants (Actual)	Interventional	2014-03-31	Terminated(stopped due to Inadequate accrual rate)
A Phase I, Single-arm, Open-label, Three Step Dose Escalation Study With Intraperitoneal Pressurized Cisplatin and Doxorubicin in Recurrent Ovarian Cancer and Peritoneal Carcinomatosis [NCT02475772]	Phase 1	15 participants (Actual)	Interventional	2016-11-30	Completed
Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer [NCT01487499]	Phase 3	4 participants (Actual)	Interventional	2011-12-31	Terminated(stopped due to Unable to enroll adequate number of participants)
An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Using the Combination Treatment of SHR-1210, Gemcitabine and Cis-platinum by Recurrent and Metastatic NPC [NCT03121716]	Phase 1	23 participants (Actual)	Interventional	2017-04-26	Completed
Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features: the p53abn-RED Trial, the MMRd-GREEN Trial, the NSMP-ORANGE Trial and the POLEmut-BLUE Trial [NCT05255653]	Phase 2/Phase 3	1,615 participants (Anticipated)	Interventional	2021-11-11	Recruiting
Phase III Study Of Post-Operative Adjuvant Concurrent Chemoradiotherapy For High Risk Oral Cavity Squamous Cell Carcinoma Patients [NCT00201383]	Phase 3	161 participants	Interventional	1999-10-31	Completed
A Randomized Phase 2 Trial of Cisplatin/Gemcitabine With or Without M6620 (VX-970) in Metastatic Urothelial Carcinoma [NCT02567409]	Phase 2	87 participants (Actual)	Interventional	2016-08-19	Active, not recruiting
Phase I Dose-Escalation /Phase II Monocentric Open Trial for Evaluation of Safety and Efficacy of Intracavitary Cisplatin-Fibrin Localized Chemotherapy After Pleurectomy/Decortication or Extrapleural Pneumonectomy for the Treatment of Patients With Malign [NCT01644994]	Phase 1/Phase 2	47 participants (Actual)	Interventional	2012-11-30	Completed
A Phase 2 Study of Neoadjuvant Pembrolizumab-Based Combination Immunotherapy in the Treatment of Early Stage Non-Small Cell Lung Cancer [NCT04061590]	Phase 2	0 participants (Actual)	Interventional	2020-05-29	Withdrawn(stopped due to Low Accrual)
An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma [NCT02265770]	Phase 2/Phase 3	536 participants (Anticipated)	Interventional	2015-06-02	Recruiting
Randomized Phase II Trial of Two Sequential Schedules of Docetaxel and Cisplatin Followed by Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer. [NCT00424853]	Phase 2	88 participants (Actual)	Interventional	2005-05-31	Completed
Gemcitabine, Alone or in Combination With Cisplatin, in Patients With Advanced or Metastatic Cholangiocarcinomas and Other Biliary Tract Tumors: A Multicentre, Randomized Phase III Study [NCT00262769]	Phase 3	324 participants (Actual)	Interventional	2005-05-31	Completed
A Phase II Study of Weekly Low-Dose Paclitaxel Plus 24-Hour Infusion of Cisplatin as First-Line Chemotherapy for Metastatic Breast Cancer [NCT00270569]	Phase 2	43 participants (Anticipated)	Interventional	2005-10-31	Recruiting
A Prospective Phase II Controlled Study to Evaluate the Impact of Thymosin Alpha 1 on the Completion Rate of Consolidation Immunotherapy After Radical Radiochemotherapy for Locally Advanced Non-Small Cell Lung Cancer [NCT06139419]	Phase 2	114 participants (Anticipated)	Interventional	2023-07-25	Recruiting
A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER) [NCT03509012]	Phase 1	105 participants (Actual)	Interventional	2018-05-02	Active, not recruiting
Biochemotherapy With Temozolomide, Velban, Cisplatin, Interleukin-2, Interferon-alpha and Thalidomide for Metastatic Melanoma With Optional Intrathecal Interleukin-2 Treatment [NCT00505635]	Phase 2	5 participants (Actual)	Interventional	2007-03-31	Terminated(stopped due to Slow accrual)
[NCT00301301]		39 participants	Observational		Completed
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial [NCT01854255]	Phase 2	35 participants (Actual)	Interventional	2013-11-30	Completed
A Phase II Study of Concurrent Chemoradiation Followed by VIPD (Etoposide/Ifosfamide/Cisplatin/Dexamethasone) in Stage I, II Nasal NK/T-cell Lymphoma [NCT00418535]	Phase 2	0 participants	Interventional	2006-04-30	Completed
A Phase II Trial of Durvalumab With Gemcitabine and Cisplatin as Neoadjuvant Therapy for High-Risk Resectable Intrahepatic Cholangiocarcinoma [NCT06050252]	Phase 2	27 participants (Anticipated)	Interventional	2024-02-16	Not yet recruiting
A Randomized Phase II Study of Nivolumab Versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment After First-Line Treatment With Platinum-Gemcitabine-Nivolumab for Patients With Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharynge [NCT06029270]	Phase 2	156 participants (Anticipated)	Interventional	2024-02-16	Not yet recruiting
A Randomized Controlled Multi-center Clinical Trial on Treatment of Stage I/II NK/T Cell Lymphoma With DDGP Regiment (Gemcitabine,Pegaspargase,Cisplatin,Dexamethasone) [NCT01501136]	Phase 4	200 participants (Anticipated)	Interventional	2011-01-31	Recruiting
An Open-label Randomized Phase II Trial of Gemcitabine and Cisplatin With or Without Bevacizumab in EGFR Wild-type Non-squamous Non-small-cell Lung Cancer Patients [NCT01623102]	Phase 2	40 participants (Anticipated)	Interventional	2013-02-28	Recruiting
A Phase II Double Blind Randomized Trial Comparing Standard Dosing Based on Body Surface Area Versus Dosing Based on Personalized Lean Body Mass in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer Receiving First Line Cisplatin Based Chemotherapy [NCT01624051]	Phase 2	144 participants (Anticipated)	Interventional	2014-07-31	Recruiting
Cisplatin-monotherapy in the Treatment of BRCA1 Positive Breast Cancer Patients in Poland [NCT01630226]	Phase 2	100 participants (Anticipated)	Interventional	2007-06-30	Recruiting
Phase II/III Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy in Stage IIIb-IV Squamous Non-Small-Cell Lung Cancer [NCT01631357]	Phase 2/Phase 3	96 participants (Actual)	Interventional	2014-12-31	Completed
Phase 1/2, Open-Label, Safety and Efficacy, Tolerability, Anti-Tumor Effects, Systemic Exposure, and Device Technical Effects of PRV211 in Subjects With T2-T3 Oral Squamous Cell Carcinoma Amenable to Surgery [NCT05893888]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	2023-10-31	Not yet recruiting
Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma [NCT01650090]	Phase 2	28 participants (Actual)	Interventional	2012-08-31	Completed
Autologous Cytokine-Induced Killer Cell Transfusion in Combination With Gemcitabine Plus Cisplatin Regimen Chemotherapy for Metastatic Nasopharyngeal Carcinoma [NCT01655628]	Phase 2	40 participants (Anticipated)	Interventional	2012-07-31	Recruiting
Combination Treatment of S-1 With Paclitaxel Versus Paclitaxel+Cisplatin and 5-Fu+Cisplatin as First-line Treatment in Advanced Esophageal Cancer [NCT01704690]	Phase 2/Phase 3	4 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to The enrollment of the study is much slower than expected.)
A Multicenter, Randomized, Open-label, Phase II Study to Evaluate the Efficacy and Safety of Erlotinib Versus Etoposide Plus Cisplatin With Concurrent Radiotherapy in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) With Activating Mutation of Ep [NCT01714908]	Phase 2	100 participants (Anticipated)	Interventional	2012-12-14	Active, not recruiting
Multicenter Phase I/II Clinical Trial of Recombinant Human Endostatin Continued Pumping Into Vein Combining With Concurrent Chemo-Radiotherapy in the Patients With Unresectable Stage III Non-small-Cell Lung Cancer [NCT01733589]	Phase 1/Phase 2	73 participants (Actual)	Interventional	2012-11-30	Completed
Phase I Trial of Dacomitinib Concomitant With Radiotherapy With and Without Cisplatin in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck [NCT01737008]	Phase 1	12 participants (Actual)	Interventional	2013-01-31	Completed
Randomized Phase II Trial of Three-weekly Cisplatinum and Pemetrexed Versus Split-dose d1 and d8 Cisplatinum and Pemetrexed In Advanced and Inoperable Non-squamous Non-small-cell Lung Cancer (NSCLC) [NCT01742767]	Phase 2	0 participants	Interventional	2012-11-30	Recruiting
Ensure Extension Study to Assess the PFS of First-Line Erlotinib (Tarceva®) and Erlotinib After the Time of Disease Progression in Chinese Population Enrolled in the Ensure Trial [NCT02000531]	Phase 4	45 participants (Actual)	Interventional	2014-01-31	Completed
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC) [NCT05058651]	Phase 2/Phase 3	189 participants (Anticipated)	Interventional	2022-06-28	Recruiting
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B [NCT04924101]	Phase 2	120 participants (Anticipated)	Interventional	2021-07-15	Active, not recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients With EGFRm, Locally Advanced or Metastatic NSCLC Who Have Progr [NCT04765059]	Phase 3	80 participants (Anticipated)	Interventional	2021-09-12	Recruiting
Phase II Randomized Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation Versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC) [NCT03493425]	Phase 2	82 participants (Anticipated)	Interventional	2019-03-12	Recruiting
Phase III Randomized Study of Concurrent Paclitaxel/Cisplatin Chemotherapy and Radiotherapy With or Without Consolidation Chemotherapy in High-Risk Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy [NCT01755845]	Phase 3	300 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Phase III Randomized Trial of Comparing Chemoradiotherapy vs. Radiotherapy Alone in Lymph Node Negative Patients With Early-Stage Cervical Cancer Following Radical Hysterectomy [NCT01756170]	Phase 3	200 participants (Anticipated)	Interventional	2011-01-31	Recruiting
Neoadjuvant Gemcitabine and Cisplatin in Locally Advanced Bladder Cancer [NCT01801644]		60 participants (Actual)	Interventional	2007-04-30	Completed
ABX Combined With Cisplatin Compared With Gemcitabine Combined With Cisplatin in First Line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer Stage II Randomized Controlled Trials [NCT01810367]	Phase 2	84 participants (Actual)	Interventional	2011-12-31	Completed
A Randomized, Open-Label, Multicenter Phase 2 Study of Envafolimab in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin as the First-line Treatment in Patients With Locally Advanced or Metastatic Biliary Tract Cancers [NCT04910386]	Phase 2	126 participants (Anticipated)	Interventional	2024-06-01	Not yet recruiting
A Pilot Study of Neoadjuvant Therapy With Gemcitabine and Cisplatin in Patients With Resectable or Unresectable Intrahepatic Cholangiocarcinoma [NCT02256982]		3 participants (Actual)	Interventional	2014-10-31	Terminated(stopped due to Slow accrual.)
Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy [NCT01687413]	Phase 3	42 participants (Actual)	Interventional	2013-01-10	Terminated(stopped due to Slow accrual and funding issues)
A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) [NCT01821248]	Phase 2	25 participants (Anticipated)	Interventional	2013-07-23	Active, not recruiting
IIT2019-20-Zumsteg-HPVOPC: Phase II Trial of De-Intensified Post-operative Chemoradiation Following Robotic Surgery for HPV-positive Oropharyngeal Cancer [NCT04502407]	Phase 2	40 participants (Anticipated)	Interventional	2021-02-16	Active, not recruiting
A Phase 1 / 2 Study of CAN04, a Fully Humanized Monoclonal Antibody Against IL1RAP, in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumours [NCT05116891]	Phase 1/Phase 2	40 participants (Actual)	Interventional	2021-09-22	Completed
Multicenter Randomized Phase 2 Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression [NCT01828736]	Phase 2	61 participants (Actual)	Interventional	2004-02-09	Completed
Phase 2-3 Study of Silymarin on Cisplatin Induced Nephrotoxicity [NCT01829178]	Phase 2/Phase 3	30 participants (Actual)	Interventional	2013-08-31	Completed
Randomized, Controlled, Multicenter Study of Neoadjuvant Therapy With Icotinib in IIIA NSCLC Patients With Epidermal Growth Factor Receptor Mutation [NCT01843647]	Phase 2	100 participants (Anticipated)	Interventional	2013-04-30	Recruiting
Neoadjuvant Chemotherapy Plus Tislelizumab Followed by Concurrent Chemoradiotherapy and Maintenance Therapy With Tislelizumab in Patients With Stage IVA Nasopharyngeal Carcinoma: A Single-arm, Phase II Trial [NCT05448885]	Phase 2	50 participants (Anticipated)	Interventional	2021-09-01	Recruiting
RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC [NCT04849377]	Phase 2	0 participants (Actual)	Interventional	2022-06-14	Withdrawn(stopped due to lack of eligible participants due to change in study criterias)
Induction Immunochemotherapy in Stage III-IVa Cancer of Oropharynx, Hypopharynx and Larynx [NCT05551767]	Phase 2	120 participants (Anticipated)	Interventional	2022-08-30	Recruiting
Using PERS(PErsonalized Regimen Selection) Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer Multicentric, Prospective, Randomized Controlled Phase III Clinical Study [NCT03006614]	Phase 3	320 participants (Anticipated)	Interventional	2016-04-30	Recruiting
Induction Chemotherapy Plus Radiotherapy Alone Versus Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Phase 3, Multicentre, Randomised Controlled Trial [NCT04414566]	Phase 3	562 participants (Anticipated)	Interventional	2020-06-01	Not yet recruiting
Randomized Phase II Trial of Neoadjuvant Docetaxel Plus Cisplatin and 5-fluorouracil Followed by Concomitant Chemoradiotherapy and Chemoradiotherapy Alone in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck. [NCT00357149]	Phase 2	101 participants (Actual)	Interventional	2003-01-31	Completed
Effect of Genetic and Epigenetic Factors on the Clinical Response and Toxicity to Cisplatin Among Egyptian Non-small Cell Lung Cancer Patients [NCT05746598]		178 participants (Anticipated)	Observational	2020-07-01	Recruiting
A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer [NCT02300610]	Phase 1	10 participants (Actual)	Interventional	2015-02-11	Completed
Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy [NCT00379665]	Phase 2	25 participants (Actual)	Interventional	2005-10-31	Completed
Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis [NCT00001569]	Phase 1	74 participants	Interventional	1997-01-31	Completed
Phase II Study to Evaluate the Role of Postoperative Radiotherapy for Low Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer [NCT02977169]	Phase 2	300 participants (Anticipated)	Interventional	2016-11-30	Recruiting
Efficacy and Safety of Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-001) [NCT04389177]	Phase 2	50 participants (Anticipated)	Interventional	2020-07-08	Active, not recruiting
Randomized Study Assessing Two Strategies of First Line: a Strategy With Intraperitoneal Chemotherapy and a Strategy With Total Intravenous Strategy, in Patients With Epithelial Advanced Ovarian Cancer [NCT03025477]	Phase 2	84 participants (Anticipated)	Interventional	2016-10-31	Recruiting
HEADLIGHT: Hypofractionated Proton Therapy for Head and Neck Cancers [NCT05075980]	Phase 2	117 participants (Anticipated)	Interventional	2022-02-16	Recruiting
A Phase II Study of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Patients With Pancreatic Cancer and Peritoneal Metastasis [NCT04858009]	Phase 2	40 participants (Anticipated)	Interventional	2023-12-31	Not yet recruiting
Multimodality Risk Adapted Therapy Including Carboplatin/Paclitaxel/Lapatinib as Induction for Squamous Cell Carcinoma of the Head and Neck Amenable to Transoral Surgical Approaches [NCT01612351]	Phase 2	40 participants (Actual)	Interventional	2012-06-30	Active, not recruiting
A Phase II Trial of Docetaxel / Cisplatin in Patients With Recurrent or Stage IVb Endometrial Cancer [NCT01461759]	Phase 2	59 participants (Anticipated)	Interventional	2011-10-31	Recruiting
Phase I Study of Concurrent Chemoradiotherapy With Famitinib for Patients With Locally Advanced Nasopharyngeal Carcinoma [NCT01462474]	Phase 1	20 participants (Actual)	Interventional	2011-10-31	Completed
A Phase 1/2 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy of KRC-01 Intratumoral Injection Combined With Radiotherapy in Patients With Locally Advanced Cervical Cancer [NCT05570422]	Phase 1	70 participants (Anticipated)	Interventional	2024-01-01	Not yet recruiting
Phase II Study of TPF Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Young Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT03020329]	Phase 2	37 participants (Anticipated)	Interventional	2016-11-14	Recruiting
A Randomised Phase II/III Trial of Preoperative Chemoradiotherapy Versus Preoperative Chemotherapy for Resectable Gastric Cancer [NCT01924819]	Phase 2/Phase 3	574 participants (Actual)	Interventional	2009-09-30	Active, not recruiting
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Randomized, Controlled Clinical Trial (HCHTOG1903) [NCT04138212]	Phase 3	456 participants (Anticipated)	Interventional	2019-10-22	Recruiting
Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Single-arm, Phase II Clinical Study [NCT05476380]	Phase 2	39 participants (Anticipated)	Interventional	2021-02-19	Recruiting
Concurrent Cisplatin Chemoradiation With or Without Capecitabine as Adjuvant Chemotherapy in Local Advanced High Risk Nasopharyngeal Carcinoma: Randomized Control Clinical Trial [NCT02143388]	Phase 3	180 participants (Actual)	Interventional	2014-03-31	Completed
Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation [NCT01151761]	Phase 2	2 participants (Actual)	Interventional	2011-01-31	Terminated(stopped due to Poor accrual)
Phase II Trial of a 96-Hour Continuous Infusion of Paclitaxel Followed by Cisplatin for Patients With Stage III/IV and Relapsed NSCLC [NCT00001450]	Phase 2	58 participants	Interventional	1995-09-30	Completed
Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma :a Phase 2,Prospective, Open-label,Unicentral,Randomised Controlled Trial [NCT05749042]	Phase 2	70 participants (Anticipated)	Interventional	2023-01-18	Recruiting
Phase II Multi-Institutional Trial of Targeted Supradose Cisplatin Chemoradiation for Stage IV Squamous Cell Carcinoma of the Head and Neck [NCT00002932]	Phase 2	60 participants (Anticipated)	Interventional	1997-05-31	Completed
A PHASE 1-2 NEOADJUVANT DOSE FINDING, SAFETY, AND IMMUNOLOGIC EFFICACY TRIAL OF INTENSIVE LOCOREGIONAL CHEMOIMMUNOTHERAPY FOR RECURRENT OVARIAN CANCER AND TUMOR-SPECIFIC INTRANODAL AUTOLOGOUS ALPHA-DC1 VACCINES [NCT02432378]	Phase 1/Phase 2	25 participants (Anticipated)	Interventional	2015-09-04	Suspended
Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours [NCT02582697]	Phase 3	500 participants (Anticipated)	Interventional	2014-02-28	Recruiting
A Phase III Randomized Comparison of High Dose Chemotherapy G-CSF To G-CSF For Mobilization of Peripheral Blood Stem Cells For Autologous Transplantation For Patients With Responsive Metastatic Breast Cancer Or High Risk Stage II-III Patients [NCT00002836]	Phase 3	184 participants (Actual)	Interventional	1995-09-26	Completed
A Phase III Randomized Trial of Intravenous Paclitaxel and Cisplatin Versus Intravenous Paclitaxel, Intraperitoneal Cisplatin and Intraperitoneal Paclitaxel in Patients With Optimal Stage III Epithelial Ovarian Carcinoma or Primary Peritoneal Carcinoma [NCT00003322]	Phase 3	384 participants (Anticipated)	Interventional	1998-03-31	Completed
Camrelizumab Plus Cisplatin in Advanced Cutaneous Squamous Cell Carcinoma: a Single-arm, Open, Single-center Phase II Study [NCT05490485]	Phase 2	20 participants (Anticipated)	Interventional	2022-08-05	Recruiting
A Phase II Study of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) for Gastric Carcinomatosis or Positive Cytology [NCT02092298]	Phase 2	21 participants (Actual)	Interventional	2014-05-08	Completed
Paclitaxel (Albumin-bound) Combined With Radiotherapy Compared With Cisplatin Combined With Radiotherapy for the Treatment of Early Stage Nasopharyngeal Carcinoma: a Prospective, Parallel-controlled, Multicenter Phase III Clinical Study [NCT04766359]	Phase 3	364 participants (Anticipated)	Interventional	2021-03-01	Not yet recruiting
Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy [NCT04019548]	Phase 3	110 participants (Anticipated)	Interventional	2019-12-16	Recruiting
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma [NCT00602667]	Phase 2	293 participants (Actual)	Interventional	2007-12-17	Active, not recruiting
A Phase 2,Open-label Study of First Line Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin for Advanced and Metastatic Non Small Cell Lung Cancer and Biomarker Study [NCT01194453]	Phase 2	288 participants (Actual)	Interventional	2009-11-30	Completed
An International Multi Center Phase III Study of Chemoradiotherapy Versus Chemoradiotherapy Plus Hyperthermia for Locally Advanced Cervical Cancer [NCT00085631]	Phase 3	101 participants (Actual)	Interventional	2003-03-31	Terminated(stopped due to Study was closed because of slow accrual)
A Multicenter, Randomized Controlled Clinical Trial Comparing Endostar With Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Carcinoma [NCT03086681]	Phase 3	120 participants (Anticipated)	Interventional	2017-03-31	Not yet recruiting
University of Arkansas (UARK 2001-12), A Phase III Study of DTPACE Followed by Tandem Transplant With MEL 200 Versus MEL/DTPACE Hybrid and DTPACE Consolidation in Patients With Active Multiple Myeloma [NCT00083915]	Phase 3	97 participants (Actual)	Interventional	2001-06-30	Completed
An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 ( Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) Combination Therapy or Monotherapy in Patients With Locally Advanced, Unresectable or Metast [NCT05221658]	Phase 2	60 participants (Anticipated)	Interventional	2022-08-25	Recruiting
Electrochemotherapy of Gynecological Cancers [NCT04760327]	Phase 2	30 participants (Anticipated)	Interventional	2020-07-01	Recruiting
A Phase II Study of Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers [NCT02392637]	Phase 2	62 participants (Actual)	Interventional	2015-04-02	Completed
Adaptive Treatment De-escalation in Favorable Risk HPV-Positive Oropharyngeal Carcinoma [NCT03215719]	Phase 2	144 participants (Anticipated)	Interventional	2017-07-10	Recruiting
A Single-arm, Single-center, Open, Prospective Phase II Clinical Study of Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer [NCT04884906]	Phase 2	40 participants (Anticipated)	Interventional	2020-11-01	Recruiting
Adjuvant Toripalimab Versus Placebo Combined With Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) Non-small-cell Lung Cancer (LungMate-008): a Randomised, Double-blind, Controlled, Phase 3 Trial [NCT04772287]	Phase 3	341 participants (Anticipated)	Interventional	2021-03-31	Not yet recruiting
A Phase II Trial of Pancreaticoduodenectomy Plus Postoperative Cisplatin, Interferon Alfa-2b, and 5-FU Combined With Radiation Treatment for Patients With Resected Pancreatic Adenocarcinoma [NCT00068575]	Phase 2	29 participants (Actual)	Interventional	2002-05-31	Completed
UARK 98-026, Total Therapy II - A Phase III Study for Newly Diagnosed Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy [NCT00083551]	Phase 3	668 participants (Actual)	Interventional	1998-08-31	Completed
Efficacy and Safety of Pembrolizumab Plus Neoadjuvant Chemotherapy With Cisplatin and 5-Fluorouracill Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of Esophagogastric Junction [NCT04813523]	Phase 2	30 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Feasibility Study of Safety, Toxicity, and Compliance of Concomitant Chemoradiotherapy for HIV-Associated Locally-Advanced Cervical Cancer [NCT01590017]	Phase 2	41 participants (Actual)	Interventional	2014-04-01	Completed
Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma [NCT03377400]	Phase 2	40 participants (Anticipated)	Interventional	2017-12-14	Active, not recruiting
A Randomized, Controlled, Double-blind Study to Evaluate Efficacy and Survival of Combining Nimotuzumab Plus Concurrent Chemo-radiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma [NCT02409186]	Phase 3	200 participants (Anticipated)	Interventional	2015-03-31	Recruiting
Non-inferiority Prospective Randomized Trial Comparing Sequential Chemoradiotherapy With Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT03366415]	Phase 3	420 participants (Anticipated)	Interventional	2018-01-01	Recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Camrelizumab (SHR-1210) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma [NCT04426955]	Phase 3	396 participants (Actual)	Interventional	2020-06-30	Active, not recruiting
A Single Arm, Multicenter Phase II Clinical Study of Chemoradiationtherapy Combined With QL1706 (Anti-CTLA-4 and PD-1 Antibody) in Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma [NCT05490719]	Phase 2	50 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
A Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors [NCT05478785]	Phase 1/Phase 2	126 participants (Anticipated)	Interventional	2022-08-31	Not yet recruiting
Efficacy and Safety of First-line Etoposide/Platinum-based Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in Extensive Small Cell Lung Cancer: A Single-arm, Multicentral Phase II Study [NCT04363255]	Phase 2	20 participants (Anticipated)	Interventional	2020-05-01	Not yet recruiting
A Pilot Study of Cisplatin in Castration Resistant Prostate Cancer That is Becoming Refractory to Enzalutamide [NCT03275857]	Early Phase 1	37 participants (Anticipated)	Interventional	2018-09-21	Recruiting
A Randomized Phase III Prospective Study of Induction Chemotherapy Combined With Concurrent Chemoradiotherapy Versus Induction Chemotherapy Combined With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma [NCT05527470]	Phase 3	440 participants (Anticipated)	Interventional	2022-11-11	Recruiting
Chemo-embolization for Head and Neck Cancer [NCT04595981]	Phase 2	48 participants (Anticipated)	Interventional	2021-03-10	Active, not recruiting
Randomized Phase III Clinical Trial of Weekly Versus Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer [NCT01561586]	Phase 3	374 participants (Anticipated)	Interventional	2012-03-31	Recruiting
[NCT01593306]	Phase 3	80 participants (Anticipated)	Interventional	2011-07-31	Recruiting
Weekly Cisplatin or Weekly Liposome Paclitaxel Concurrent Radiation Therapy in Treating Elderly People With Cervical Cancer [NCT01594099]	Phase 2	45 participants (Anticipated)	Interventional	2012-04-30	Active, not recruiting
Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy [NCT01362127]	Phase 2	181 participants (Actual)	Interventional	2006-10-31	Completed
A Randomized, Phase II Trial Comparing Induction Chemotherapy Gemcitabine Plus Cisplatin With Docetaxel Plus Cisplatin Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma in Northwest China [NCT01596868]	Phase 2	60 participants (Anticipated)	Interventional	2012-05-31	Completed
A Phase I Dose Escalation Trial of Stereotactic Body Radiotherapy and Concurrent Cisplatin for Re-Irradiation of Unresectable, Recurrent Squamous Cell Carcinomas of the Head and Neck [NCT02158234]	Phase 1	20 participants (Actual)	Interventional	2014-07-16	Completed
Phase II Open-Label, Non-Randomized Trial of Cisplatin Chemotherapy in Patients With BRCA1-Positive Metastatic Breast Cancer [NCT01611727]	Phase 2	20 participants (Actual)	Interventional	2007-07-31	Completed
Linear Energy Transfer (LET)-Optimized Intensity Modulated Proton Therapy (IMPT) as a Component of Definitive Chemoradiation for Newly Diagnosed Squamous Cell Carcinoma of the Anal Canal: a Feasibility Trial [NCT03690921]	Phase 2	8 participants (Actual)	Interventional	2018-11-08	Completed
Phase II Trial of Docetaxel-Cisplatin Neoadjuvant Chemotherapy Followed by Concurrent Radiotherapy With Cetuximab or Weekly Cisplatin in Locally Advanced Nasopharyngeal Carcinoma [NCT01614938]	Phase 2	46 participants (Actual)	Interventional	2010-08-31	Active, not recruiting
A Phase II Trial of Combination Cabazitaxel and Cisplatin Chemotherapy in the Neo-adjuvant Treatment of Transitional Cell Carcinoma of the Urinary Bladder [NCT01616875]	Phase 2	28 participants (Actual)	Interventional	2012-05-31	Active, not recruiting
Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary: A Prospective, Open-label, Single-arm Clinical Study [NCT05241132]	Phase 2	27 participants (Anticipated)	Interventional	2021-11-12	Recruiting
A Phase III Clinical Trial of Docetaxel Plus Cisplatin Versus Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT02465736]	Phase 3	610 participants (Anticipated)	Interventional	2015-07-31	Recruiting
A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent [NCT02104986]	Phase 2	117 participants (Actual)	Interventional	2014-05-12	Completed
Preoperative Radiotherapy and Concomitant Chemotherapy Followed by Surgery for Advanced Paranasal Sinus Carcinoma [NCT00347256]		60 participants (Anticipated)	Interventional		Withdrawn
Pilot Study of Standard Therapy for Prevention of Nausea and Emesis Associated With First Line Post-Operative Intraperitoneal Chemotherapy [NCT01275664]		4 participants (Actual)	Interventional	2011-06-30	Terminated(stopped due to Study terminated due to no patient population available)
Multicenter Comparative of Toxicity and Effectiveness of Lobaplation or Cisplatin Based Adjuvant Chemotherapy in Esophageal Carcinoma [NCT03413436]	Phase 4	733 participants (Actual)	Interventional	2018-01-31	Completed
Randomized Phase 2 Trial of Tirapazamine and the Role of Tumor Hypoxia in Advanced Squamous Head and Neck Cancer [NCT00002774]	Phase 2	63 participants (Actual)	Interventional	1996-06-30	Completed
Concurrent Helical Tomotherapy With Chemotherapy in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC): a Phase I/II Trial of Radiation Dose Escalation and Fixed Dose Chemotherapy. [NCT00379717]	Phase 1/Phase 2	30 participants (Anticipated)	Interventional	2006-11-30	Recruiting
A Two-Stage Phase II Safety and Efficacy Study of IntraDose (Cisplatin/Epinephrine) Injectable Gel (MPI 5010) Administered to Patients With Unresectable Primary Hepatocellular Carcinoma [NCT00003044]	Phase 2	55 participants (Anticipated)	Interventional	1996-09-30	Active, not recruiting
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFECT OF CISPLATIN/EPINEPHRINE INJECTABLE GEL (PRODUCT MPI 5010) WHEN ADMINISTERED INTRATUMORALLY FOR ACHIEVEMENT OF TREATMENT GOALS IN RECURRENT OR REFRACTORY SQUAMOUS CELL CARCINOMA O [NCT00002659]	Phase 3	120 participants (Anticipated)	Interventional	1995-05-31	Active, not recruiting
Phase III Prospective Randomized Study of Craniospinal RT Followed by One of Two Adjuvant Chemotherapy Regimens (CCNU, CDDP, VCR OR CPM, CDDP, VCR) for Newly-Diagnosed Average Risk MedulloblastomaMEDULLOBLASTOMA [NCT00002875]	Phase 3	421 participants (Actual)	Interventional	1996-12-31	Completed
Protocol for Patients With Newly-Diagnosed Non-Metastatic Osteosarcoma - A POG/CCG Pilot Intergroup Study [NCT00003937]	Phase 3	253 participants (Actual)	Interventional	1999-09-30	Completed
A Phase I and Pharmacokinetic Study of Sequences of NSC 655649 (Rebeccamycin Analogue) and Cisplatin Without and With Granulocyte Colony-Stimulating Factor Support Every 21 Days [NCT00004189]	Phase 1	40 participants (Actual)	Interventional	1999-10-31	Completed
A Phase I/II Study Of Whole Pelvic Radiation Therapy With Concomitant Paclitaxel and Cisplatin Chemotherapy in Patients With Cervical Carcinoma (Stages I-IV) Limited to the Pelvis [NCT00003379]	Phase 1/Phase 2	40 participants (Anticipated)	Interventional	1999-11-30	Completed
A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer [NCT02127372]	Phase 1/Phase 2	43 participants (Actual)	Interventional	2004-11-30	Terminated(stopped due to The study was closed due to poor accrual)
Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma [NCT02082522]	Phase 3	28 participants (Actual)	Interventional	2014-11-12	Terminated(stopped due to Accrual rate remaining too low)
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer [NCT00001499]	Phase 2	50 participants	Interventional	1996-03-31	Completed
A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL [NCT00002711]	Phase 1	24 participants (Anticipated)	Interventional	1995-10-31	Completed
A Phase III Randomized Trial of Cisplatin (NSC #119875) With Paclitaxel (NSC #125973) Administered by Either 24 Hour Infusion or 96 Hour Infusion in Patients With Selected Stage III and Stage IV Epithelial Ovarian Cancer and Primary Peritoneal Carcinoma [NCT00002717]	Phase 3	324 participants (Anticipated)	Interventional	1996-03-31	Completed
Induction Chemotherapy Followed By Chemoradiation For Organ Preservation In Patients With Advanced Resectable Cancer Of The Hypopharynx And Base Of Tongue, Phase II [NCT00002735]	Phase 2	68 participants (Actual)	Interventional	1996-04-30	Terminated(stopped due to Terminated due to poor accrual.)
A Phase II Trial of Induction and Maintenance Pembrolizumab and Olaparib in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT05366166]	Phase 2	45 participants (Anticipated)	Interventional	2022-09-02	Recruiting
A Phase II, Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients With Resectable, Early-stage (II to IIIB) Non-small Cell Lung Cancer (NeoCOAST-2) [NCT05061550]	Phase 2	350 participants (Anticipated)	Interventional	2022-04-14	Recruiting
Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel [NCT00003087]	Phase 2	25 participants (Anticipated)	Interventional	1997-08-31	Completed
A Pilot Study of Intensive Chemotherapy With Peripheral Stem Cell Support for Infants With Malignant Brain Tumors [NCT00003141]	Phase 1	94 participants (Actual)	Interventional	1998-03-31	Completed
A Phase 1-2 Study of Rapamycin and Cisplatin/Gemcitabine for Treatment of Patients With Bladder Cancer [NCT01938573]	Phase 1/Phase 2	21 participants (Actual)	Interventional	2013-10-31	Completed
A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial [NCT00085735]	Phase 3	549 participants (Actual)	Interventional	2004-04-30	Active, not recruiting
A Phase 1 Study of d Limonene With Concurrent Radiation and Platinum Based Chemotherapy for Xerostomia Prevention in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) [NCT04392622]	Phase 1	30 participants (Anticipated)	Interventional	2021-02-15	Recruiting
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas [NCT01726582]	Phase 2	229 participants (Actual)	Interventional	2011-11-30	Completed
A Randomized Phase II Trial of Concurrent Chemotherapy and Pelvic Radiation Therapy With or Without Paclitaxel and Carboplatin in HIV-positive Women With Locally Advanced Cervical Cancer (LACC) [NCT03834571]	Phase 2	0 participants (Actual)	Interventional	2022-05-31	Withdrawn(stopped due to Not approved by CTEP)
Phase II Study to Evaluate the Efficacy of 12-month Neoadjuvant Chemotherapy in Terms of Disease-free Survival in Patients With Localized Digestive Neuroendocrine Carcinomas [NCT04268121]	Phase 2	78 participants (Anticipated)	Interventional	2021-01-05	Recruiting
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Clinical Study on Toripalimab Combined With Platinum-Based Doublet Drug Chemotherapy for Resectable, Stage II-III, Non-Small Cell Lung Cancer [NCT04158440]	Phase 3	501 participants (Actual)	Interventional	2020-04-07	Active, not recruiting
Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer [NCT01898494]	Phase 2	519 participants (Actual)	Interventional	2014-01-22	Active, not recruiting
Phase II Trial of Cetuximab Plus Cisplatin, 5- Fluorouracil and Radiation in Immunocompetent Patients With Anal Carcinoma [NCT00316888]	Phase 2	63 participants (Actual)	Interventional	2007-02-28	Completed
Phase II Study of C225 (Erbitux or Cetuximab) in Combination With Cisplatin and Definitive Radiation in Unresectable Stage IV Squamous Cell Carcinoma of the Head and Neck [NCT00096174]	Phase 2	69 participants (Actual)	Interventional	2005-04-08	Completed
Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus [NCT00033657]	Phase 2	97 participants (Actual)	Interventional	2002-08-15	Completed
QUantitative Assessment of Swallowing After Radiation (QUASAR): A Longitudinal Comparison of Swallowing Function by Systemic Therapy in Head and Neck Cancer Patients [NCT04359199]		42 participants (Anticipated)	Observational	2020-09-01	Recruiting
A Randomized Prospective Study of Early Intensification Versus Alternating Triple Therapy for Patients With Poor Prognosis Lymphoma [NCT00002835]	Phase 3	116 participants (Actual)	Interventional	1995-10-30	Completed
A Phase I/II Feasibility Study of Oral Etoposide Given Concurrently With Radiotherapy Followed With Dose Intensive Adjuvant Chemotherapy for Children With Newly Diagnosed High Stage Medulloblastoma [NCT00003573]	Phase 2	53 participants (Actual)	Interventional	1998-11-30	Completed
A Phase II Pilot Study of SPI-77 (Stealth Liposomal Cisplatin) in Patients With Recurrent Platinum-Sensitive Ovarian Cancer [NCT00004083]	Phase 2	0 participants	Interventional	1999-02-28	Completed
A Prospective, Single-arm, Open-Label, Phase II Study of Nab-paclitaxel Plus Cisplatin Plus Carilizumab as First-line Treatment in Patients With Metastatic Triple-negative Breast Cancer [NCT04537286]	Phase 2	90 participants (Anticipated)	Interventional	2020-08-25	Recruiting
Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Women With Recurrent Ovarian Cancer: an Open-label, Single-arm Phase II Clinical Trial [NCT01809379]	Phase 2	69 participants (Actual)	Interventional	2013-02-28	Completed
Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin [NCT00966914]	Phase 3	540 participants (Actual)	Interventional	2010-04-30	Completed
Efficacy and Safety of Postoperative Adjuvant Chemotherapy Combined With Camrelizumab for Patients With ⅡA -ⅢA Non-small Cell Lung Cancer：a Phase II , Single-arm Clinical Study [NCT05825443]	Phase 2	57 participants (Anticipated)	Interventional	2023-04-10	Recruiting
Phase I/ II Study of Pulmonary Suffusion to Control Minimal Residual Disease in Resectable or Ablatable Sarcoma or Colorectal Pulmonary Metastases [NCT03965234]	Phase 1/Phase 2	99 participants (Anticipated)	Interventional	2020-07-16	Recruiting
Body Surface Area-based vs Concentration-based Dosing of Cisplatin for Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Women With Advanced Ovarian Cancer [NCT05406674]	Phase 2	40 participants (Anticipated)	Interventional	2022-06-15	Recruiting
A Single-arm Exploratory Clinical Study of Envafolimab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer [NCT05799469]	Phase 2	36 participants (Anticipated)	Interventional	2023-05-01	Not yet recruiting
A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) [NCT02659059]	Phase 2	324 participants (Actual)	Interventional	2016-02-15	Completed
Phase III Randomized Trial of Immediate Adjuvant Chemotherapy or Delayed Salvage Chemotherapy in Nasopharyngeal Carcinoma Patients With Post-radiation Detectable Plasma EBV DNA [NCT02363400]	Phase 3	147 participants (Anticipated)	Interventional	2014-11-30	Enrolling by invitation
A Phase III Randomised Trial Investigating the Benefits of the Addition of Modulated Electro-hyperthermia to Chemo-radiation for Cervical Cancer in HIV Positive and Negative Women in South Africa [NCT03332069]	Phase 3	236 participants (Anticipated)	Interventional	2014-01-09	Recruiting
Observation Versus Radiation on Pelvic Lymphocysts After Radical Hysterectomy of Cervical Cancer: A Phase 3 Prospective Multi-institutional Randomised Controlled Trial [NCT03071289]	Phase 3	540 participants (Anticipated)	Interventional	2017-06-01	Recruiting
Adjuvant Chemotherapy With Paclitaxel and Cisplatin in Lymph Node-Positive Thoracic Esophageal Squamous Cell Carcinoma: A Randomized Phase 3 Trial [NCT02461043]	Phase 3	386 participants (Anticipated)	Interventional	2015-04-30	Recruiting
Camrelizumab Combined With Chemotherapy for Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma：A Phase II Clinical Study to Explore the Relationship Between Biomarkers and Efficacy [NCT04937673]	Phase 2	40 participants (Anticipated)	Interventional	2021-07-01	Not yet recruiting
Phase II Randomized Trial Comparing Paclitaxel Combined With DDP Plus Concurrent Chemoradiotherapy With DDP Plus Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT03047265]	Phase 2	164 participants (Anticipated)	Interventional	2017-02-04	Active, not recruiting
Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-risk Neuroblastoma [NCT03042429]	Phase 3	360 participants (Actual)	Interventional	2007-01-01	Completed
Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer After Concurrent Chemotherapy and Radiotherapy. A Single-arm, Single-center, Phase II Clinical Study [NCT04828395]	Phase 2	65 participants (Anticipated)	Interventional	2021-03-01	Recruiting
An Open Label, Single Arm Phase II Study of Camrelizumab in Combination With Cisplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for Resectable HNSCC [NCT04826679]	Phase 2	53 participants (Anticipated)	Interventional	2021-04-01	Recruiting
Phase II Trial To Evaluate The Efficiency And Safety Of Neoadjuvant Chemotherapy In Locally Advanced Cancer Cervix [NCT04789941]	Phase 2	50 participants (Anticipated)	Interventional	2021-04-01	Not yet recruiting
A Multicenter, Randomized, Non-inferior Phase III Study of Radiotherapy Alone Versus Concurrent Chemo-radiotherapy in Locally Advanced Nasopharyngeal Carcinoma Patients With Complete Remission of EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy [NCT05674305]	Phase 3	366 participants (Anticipated)	Interventional	2022-01-01	Recruiting
A Prospective Phase II Randomized Clinical Trial: Docetaxel and Loplatin Induction Chemotherapy Followed by Concurrent Lobaplatin Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT03117257]	Phase 2	144 participants (Anticipated)	Interventional	2016-08-19	Recruiting
Randomized, Controlled, Open Label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of CetuGEX™ Plus CT in Comparison to Cetuximab Plus CT in Patients With Stage III/IV Recurrent and/or Metastatic SCCHN [NCT02052960]	Phase 2	240 participants (Actual)	Interventional	2014-02-28	Completed
Open-label, Uncontrolled, Multicenter Phase I/Ib Trial to Investigate Safety and Efficacy of BIBW 2992 and Standard Gemcitabine/Cisplatin in Chemo-naïve Patients With Advanced Biliary Tract Adenocarcinoma [NCT01679405]	Phase 1	9 participants (Actual)	Interventional	2012-08-31	Terminated(stopped due to No sufficient clinical or molecular signals for efficacy were observed.)
The Phase Three Trials of Pemetrexed/Cisplatin Intercalating Gefitinib vs Pemetrexed/Cisplatin Treating EGFR Wild NSCLC(Non Squamous Cell Carcinoma) [NCT03374280]	Phase 2	178 participants (Anticipated)	Interventional	2016-12-01	Recruiting
Effect of Refnot on Immunity in Cancer Patients [NCT05898451]	Phase 2	55 participants (Actual)	Interventional	2009-06-04	Completed
A Study of Standard Treatment +/- Apatinib in Extensive Stage Small Cell Lung Cancer [NCT03100955]	Phase 3	120 participants (Anticipated)	Interventional	2017-03-01	Recruiting
A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer [NCT01918306]	Phase 1/Phase 2	11 participants (Actual)	Interventional	2013-09-30	Terminated(stopped due to company stopped production of study drug due to excessive toxicities, lack of efficacy)
Phase Ib/II Clinical Study of IAH0968 in Combination With Gemcitabine and Cisplatin for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors and Cholangiocarcinoma [NCT05991518]	Phase 1/Phase 2	136 participants (Anticipated)	Interventional	2023-04-25	Recruiting
A Pilot Multi-arm Study of sEphB4-HSA in Combination With Different Chemotherapy Regimens in Patients With Specific Advanced or Metastatic Solid Tumors [NCT02495896]	Phase 1	61 participants (Actual)	Interventional	2015-09-03	Terminated(stopped due to Lack of funding)
Prospective, Phase II Study to Evaluate the Efficacy of Addition of Progesterone to Standard Chemotherapy According to Etoposide-Doxorubicin-Cisplatin Scheme Plus Mitotane (EDP-M) in Patients With Advanced Adrenocortical Carcinoma (ACC) [NCT05913427]	Phase 2	80 participants (Anticipated)	Interventional	2022-06-08	Recruiting
Retrospective Observational Study of Resectable Stage IIIA Non-small Cell Lung Cancer Patients: Pathological Response After Neoadjuvant Treatment and Patient Outcomes [NCT05167487]		150 participants (Anticipated)	Observational	2021-12-13	Recruiting
Nivolumab Plus Ipilimumab Plus Two Cycles of Platinum-based Chemotherapy as First Line Treatment for Stage IV/Recurrent Non-small Cell Lung Cancer (NSCLC) Patients With Synchronous Brain Metastases [NCT05012254]	Phase 2	71 participants (Anticipated)	Interventional	2021-11-18	Recruiting
Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab (MEDI4736) for Stage III Non-small Cell Lung Cancer [NCT04364048]	Phase 2	10 participants (Actual)	Interventional	2020-06-18	Active, not recruiting
Twice-daily Radiotherapy by Simultaneous Integrated Boosting Technique Versus Twice-daily Standard Radiotherapy for Patients With Limited-stage Small Cell Lung Cancer: a Multicenter, Randomized, Controlled, Phase III Study [NCT03214003]		235 participants (Actual)	Interventional	2017-06-30	Completed
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker [NCT01982448]	Phase 2	147 participants (Actual)	Interventional	2014-04-30	Completed
Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia [NCT00003237]	Phase 2	55 participants (Anticipated)	Interventional	1998-06-22	Completed
Randomized Phase II Study to Evaluate Induction Nivolumab-Ipilimumab, Followed by Nivolumab With Chemoradiotherapy Versus Chemoradiotherapy for Advanced Cervical Cancer [NCT05492123]	Phase 2	112 participants (Anticipated)	Interventional	2022-08-30	Recruiting
BrUOG-E-215-Neoadjuvant Paclitaxel Poliglumex (PPX; CT-2103), Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial. (CTI#X64001 [NCT00522795]	Phase 2	40 participants (Actual)	Interventional	2007-08-31	Completed
A Phase I, Open-Label Study Evaluating the Pharmacokinetics of Components of S-1 in Patients With Varying Degrees of Renal Function [NCT00398307]	Phase 1	24 participants (Anticipated)	Interventional	2006-02-28	Completed
Phase II Multicenter Randomized Trial Evaluating the Association of PIPAC and Systemic Chemotherapy Versus Systemic Chemotherapy Alone as 1st-line Treatment of Malignant Peritoneal Mesothelioma [NCT03875144]	Phase 2	66 participants (Anticipated)	Interventional	2020-08-14	Recruiting
Assessment Study to Evaluate Specific Immune Response in Locally Advanced Cervix Cancer After Radio-chemotherapy (IMMUVIX) [NCT03255252]	Phase 2	29 participants (Actual)	Interventional	2017-07-15	Active, not recruiting
Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase 1/Randomized Phase 2 Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck [NCT01711541]	Phase 1/Phase 2	24 participants (Actual)	Interventional	2012-10-22	Completed
A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-operative Chemotherapy [NCT00134030]	Phase 3	1,334 participants (Actual)	Interventional	2005-11-14	Completed
A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-small Cell Lung Cancer (NSCLC) [NCT01822496]	Phase 2	59 participants (Actual)	Interventional	2013-11-04	Terminated
Efficacy and Safety of Salvage Treatment With Dose-dense TMZ Plus CDDP in the Patients With Recurrent Malignant Gliomas: a Multicentre,Prospective Clinical Study [NCT01670890]	Phase 2	120 participants (Anticipated)	Interventional	2012-08-31	Recruiting
A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations [NCT01670500]	Phase 2	118 participants (Actual)	Interventional	2012-10-31	Active, not recruiting
A Phase II Study of Intrathecal and Systemic Chemotherapy With Radiation Therapy for Children With Central Nervous System Atypical Teratoid/Rhabdoid Tumor (AT/RT) Tumor [NCT00084838]	Phase 2	25 participants (Actual)	Interventional	2003-02-28	Completed
Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Exploratory Clinical Trial [NCT04413734]	Phase 2	120 participants (Anticipated)	Interventional	2020-04-22	Recruiting
Phase II Trial of Flavopiridol and Cisplatin in Advanced Epithelial Ovarian and Primary Peritoneal Carcinomas [NCT00083122]	Phase 2	45 participants (Actual)	Interventional	2004-04-30	Completed
A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO® (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC) [NCT03790111]	Phase 2	53 participants (Actual)	Interventional	2019-03-13	Terminated(stopped due to Did not meet pre-specified Progression-Free Survival at Month 6 for Stage 2 Analysis)
Phase IB/II Trial of High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have No Prior Therapy for Their Metastatic Pancreatic Cancer [NCT03410030]	Phase 1/Phase 2	27 participants (Actual)	Interventional	2017-12-15	Completed
A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas [NCT03138720]	Phase 2	24 participants (Actual)	Interventional	2017-05-23	Active, not recruiting
A Phase 3 Multi-institutional Study for Treatment of Children With Newly Diagnosed Hepatoblastoma Using a Modified PHITT Strategy Incorporating a Randomized Assessment of Sodium Thiosulfate as Otoprotection for Children With Localized Disease, and Respons [NCT04478292]	Phase 3	330 participants (Anticipated)	Interventional	2021-03-01	Recruiting
A Phase I Study of Methoxyamine Combined With Chemo-Radiation for Locally Advanced Non-Squamous Non-Small Cell Lung Cancer [NCT02535325]	Phase 1	17 participants (Actual)	Interventional	2015-09-30	Completed
A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy Followed By Standard Chemoradiation In HPV-Negative or High-risk HPV-Positive Locally Advanced Stage III/IVa/IVb HNSCC [NCT01732640]	Phase 1/Phase 2	9 participants (Actual)	Interventional	2012-12-31	Terminated(stopped due to Slow accrual and high levels of toxicity lead to early termination.)
Open, Randomized, Controlled, Multicenter Phase III Study Comparing Cisplatin/Vinorelbine Plus Cetuximab Versus Cisplatin/Vinorelbine as First-line Treatment for Patients With Epidermal Growth Factor Receptor Expressing (EGFR-expressing) Advanced NSCLC. [NCT00148798]	Phase 3	1,861 participants (Actual)	Interventional	2004-10-31	Completed
A Prospective, Single Arm, Single Center, Phase II Clinical Trial of Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell [NCT04520035]	Phase 2	60 participants (Anticipated)	Interventional	2020-08-01	Recruiting
LS1781: Phase 2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed / Refractory Lymphoma and Patients With Clonal Cytopenia of Undetermined Significance [NCT03418038]	Phase 2	55 participants (Anticipated)	Interventional	2018-03-23	Recruiting
A Phase I Trial for the Use of Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment of BCG-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder Cancer [NCT02202772]	Phase 1/Phase 2	51 participants (Anticipated)	Interventional	2014-12-01	Recruiting
Phase I/II Study of a Triplet Combination of CBP501, Pemetrexed and Cisplatin in Patients With Advanced Solid Tumors and in Chemotherapy-naïve Patients With Malignant Pleural Mesothelioma [NCT00700336]	Phase 1/Phase 2	69 participants (Actual)	Interventional	2008-05-31	Completed
A Phase 3, Prospective，Multicenter, Randomized Open-Label Trial to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Chemotherapy Followed By Surgery Versus Up-Front Surgery as Treatment for Resectable Head And Ne [NCT05582265]	Phase 3	588 participants (Anticipated)	Interventional	2022-10-28	Recruiting
Comparative Study of Different Doses of Magnesium as a Protective Agent in Cisplatin Induced Nephrotoxicity in Patients With Head and Neck Cancer [NCT05586009]	Phase 2	75 participants (Anticipated)	Interventional	2022-10-31	Enrolling by invitation
A Phase Ib/II Trial of Neoadjuvant Tiragolumab, Atezolizumab, Paclitaxel, Cisplatin and Radiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT05743504]	Phase 1/Phase 2	32 participants (Anticipated)	Interventional	2023-03-01	Not yet recruiting
A Randomized Phase III Trial of Cisplatin Plus Paclitaxel With and Without NCI-Supplied Bevacizumab (NSC #704865) Versus the Non-platinum Doublet, Topotecan Plus Paclitaxel, With and Without NCI-Supplied Bevacizumab, in Stage IVB, Recurrent or Persistent [NCT00803062]	Phase 3	452 participants (Actual)	Interventional	2009-04-30	Completed
A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary [NCT01042522]	Phase 2	63 participants (Actual)	Interventional	2010-02-08	Active, not recruiting
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins [NCT03604653]		10 participants (Actual)	Observational	2018-05-15	Completed
A Phase I Dose-finding Trial of Hyperthermic Intraperitoneal Paclitaxel Combined With Cisplatin in Patients With Advanced-stage Ovarian Cancer [NCT05620654]	Phase 1	30 participants (Anticipated)	Interventional	2022-12-01	Recruiting
A Phase II Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy in Patients With Esophageal Squamous Cell Carcinoma [NCT01670409]	Phase 2	85 participants (Actual)	Interventional	2012-08-31	Completed
De-Escalation Protocol Of HPV Mediated Oropharyngeal Squamous Cell Carcinoma Based On The AJCC 8th Edition Staging Manual [NCT04638465]		150 participants (Anticipated)	Observational	2018-08-06	Active, not recruiting
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma FRONTiER Trial [NCT03914443]	Phase 1	36 participants (Anticipated)	Interventional	2019-05-07	Active, not recruiting
Radiotherapy Alone Versus Chemotherapy Followed By Response-Based Radiotherapy For Newly Diagnosed Primary CNS Germinoma [NCT00085098]	Phase 3	24 participants (Actual)	Interventional	2007-01-31	Completed
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451) [NCT01101451]	Phase 3	341 participants (Actual)	Interventional	2010-04-12	Active, not recruiting
A Randomized Phase II Study of SUBATM-itraconazole With Cisplatin/Gemcitabine in Patients With Previously Untreated Metastatic Squamous Non-Small Cell Lung Cancer. [NCT01752023]	Phase 2	3 participants (Actual)	Interventional	2013-03-31	Terminated(stopped due to Low Accrual)
A Phase 1B Study to Evaluate the Safety and Induction of Immune Response of CRS-207 in Combination With Pemetrexed and Cisplatin as Front-line Therapy in Adults With Malignant Pleural Mesothelioma [NCT01675765]	Phase 1	60 participants (Actual)	Interventional	2014-09-03	Completed
A Phase II Randomized Window of Opportunity Trial Evaluating Clinical and Biological Effects of Intratumoral INT230-6 in Early Stage Breast Cancer: The INVINCIBLE Trial [NCT04781725]	Phase 2	90 participants (Anticipated)	Interventional	2021-03-25	Recruiting
A Phase 3, Randomized Double-blind, Placebo-controlled, Multicenter Study of SHR-1701 in Combination With Bevacizumab and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs [NCT05132413]	Phase 3	561 participants (Anticipated)	Interventional	2021-12-30	Not yet recruiting
Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer ,a Single-arm, Phase Ⅱ Clinical Trial [NCT04865705]	Phase 2	33 participants (Anticipated)	Interventional	2020-11-10	Active, not recruiting
Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer: A Single-arm Phase II Trial. [NCT05034133]	Phase 2	20 participants (Anticipated)	Interventional	2021-09-01	Recruiting
A Multicenter Exploratory Study of Paclitaxel+Cisplatin+TQB2450 Injection Combined With or Without Anlotinib in the First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma [NCT05013697]	Phase 2	48 participants (Anticipated)	Interventional	2021-09-30	Not yet recruiting
A Phase 1/2 Study of the Bromodomain Inhibitor ZEN003694 in Combination With Etoposide/Platinum in Patients With NUT Carcinoma [NCT05019716]	Phase 1/Phase 2	55 participants (Anticipated)	Interventional	2022-07-13	Recruiting
Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol [NCT00003569]		2 participants (Actual)	Observational	1998-03-31	Completed
An Intergroup Pilot Study of Concurrent Carboplatin, Vincristine and Radiotherapy Followed by Adjuvant Chemotherapy in Patients With Newly Diagnosed High-Risk Central Nervous System Embryonal Tumors [NCT00003203]	Phase 2	168 participants (Actual)	Interventional	1998-03-31	Completed
Phase II Study of Paclitaxel and Cisplatin in Combination With Split Course Concomitant Hyperfractionated Re-Irradiation in Patients With Recurrent Squamous Cell Cancer of the Head and Neck [NCT00005087]	Phase 2	105 participants (Actual)	Interventional	2000-03-31	Completed
A Randomized Phase III Study of Pembrolizumab Given Concomitantly With Chemoradiation and as Maintenance Therapy Versus Chemoradiation Alone in Subjects With Locally Advanced Head and Neck Squamous Cell Carcinoma (KEYNOTE-412) [NCT03040999]	Phase 3	804 participants (Actual)	Interventional	2017-04-05	Active, not recruiting
LUME-Meso: Double Blind, Randomised, Multicentre, Phase II/III Study of Nintedanib in Combination With Pemetrexed / Cisplatin Followed by Continuing Nintedanib Monotherapy Versus Placebo in Combination With Pemetrexed / Cisplatin Followed by Continuing Pl [NCT01907100]	Phase 2/Phase 3	545 participants (Actual)	Interventional	2013-09-19	Terminated
A Phase 1 Trial of the ATR Inhibitor BAY 1895344 in Combination With Cisplatin and With Cisplatin Plus Gemcitabine in Advanced Solid Tumors With an Emphasis on Urothelial Carcinoma [NCT04491942]	Phase 1	74 participants (Anticipated)	Interventional	2021-08-25	Active, not recruiting
A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer [NCT02662634]	Phase 2	0 participants (Actual)	Interventional	2016-03-31	Withdrawn
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate AK104 Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer [NCT05235516]	Phase 3	636 participants (Anticipated)	Interventional	2022-06-21	Recruiting
Intensification Regimen for Previously Untreated, Resectable, Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, and Hypopharynx: Incorporation of Intensity Modulated Radiotherapy and Submandibular Gland Transfer to Minimize Treatment Morbid [NCT00566540]	Phase 2	11 participants (Actual)	Interventional	2007-12-11	Terminated(stopped due to Recruitment problems with study)
A Phase II Study of Hyperthermic Peritoneal Perfusion (HIPEC) for Adolescent and Young Adults With Desmoplastic Small Round Cell Tumor and Other Non-Carcinomas [NCT01277744]	Phase 2	22 participants (Actual)	Interventional	2011-05-09	Completed
A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations. [NCT03381066]	Phase 3	225 participants (Anticipated)	Interventional	2018-04-10	Recruiting
Efficacy and Safety of Nimotuzumab Combined With Radiotherapy and Concurrently Cisplatin in Patients With Stage IIB-IVA Cervical Squamous Cell Carcinoma [NCT03469531]	Phase 2	100 participants (Anticipated)	Interventional	2018-03-20	Recruiting
A Phase I Clinical Trial of AZD1775 in Combination With Neoadjuvant Weekly Docetaxel and Cisplatin Prior to Surgery in Squamous Cell Carcinoma of the Head and Neck (HNSCC) [NCT02508246]	Phase 1	12 participants (Actual)	Interventional	2015-07-22	Completed
Radiotherapy Combined With Immune Checkpoint Inhibitors (ICIs) as Treatment for Locally Advanced Non-small-cell Lung Cancer After Failing Induction Immuno-chemotherapy: a Prospective, Real-world Cohort Study. [NCT06031597]	Phase 3	105 participants (Anticipated)	Interventional	2023-09-15	Not yet recruiting
LCCC 1612: P53 Mutational Status and Circulating Free HPV DNA for the Management of HPV-associated Oropharyngeal Squamous Cell Cancers [NCT03077243]	Phase 2	215 participants (Actual)	Interventional	2016-12-31	Active, not recruiting
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Chemotherapy in the Treatment of EGFR WT and ALK WT Recurrent and Metastatic Non-small Cell Lung Cancer [NCT05020457]	Phase 2	60 participants (Anticipated)	Interventional	2021-12-07	Recruiting
PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer [NCT03774732]	Phase 3	327 participants (Anticipated)	Interventional	2019-03-21	Recruiting
A Randomized Phase II Trial of Transarterial Radioembolisation With Yttrium-90 (SIRT) in Comparison to Transarterial Chemoembolisation With Cisplatin (TACE) in Patients With Liver Metastases From Uveal Melanoma [NCT02936388]	Phase 2	108 participants (Anticipated)	Interventional	2016-01-31	Recruiting
"Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma: A Feasibility Phase II Randomized Clinical Trial (URANUS)" [NCT02969083]	Phase 2	200 participants (Anticipated)	Interventional	2018-05-28	Recruiting
Phase ⅡTrial of S1 Capsule Plus Cisplatin Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment in Stage Ⅱ-ⅢA Non-small Cell Lung Cancer (NSCLC) After Complete Resection [NCT02223611]	Phase 2	100 participants (Anticipated)	Interventional	2014-12-31	Not yet recruiting
A Randomized Phase 1 Trial Evaluating the Safety of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma [NCT02344095]	Phase 1	12 participants (Anticipated)	Interventional	2014-12-31	Recruiting
A Phase II Combined Modality Protocol of Debulking Surgery With Heated Intraoperative Chemotherapy (HIPEC) Followed by Intraperitoneal Chemotherapy for the Treatment of Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancers [NCT01659554]	Phase 2	4 participants (Actual)	Interventional	2012-03-31	Terminated(stopped due to Principal Investigator left institution)
Phase II Multicenter Trial of Neoadjuvant Cisplatin and Nab-paclitaxel for (N2) Defined Stage IIIA Non-Small Cell Lung Cancer (NSCLC) [NCT02276560]	Phase 2	1 participants (Actual)	Interventional	2015-01-31	Terminated(stopped due to This study was terminated due to lack of funding.)
Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma [NCT05984342]	Phase 1	50 participants (Anticipated)	Interventional	2023-08-02	Recruiting
UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma Ages 65 and Under: A Trial Enrolling Subjects to Standard Total Therapy 3 (S-TT3) [NCT00734877]	Phase 3	382 participants (Actual)	Interventional	2008-07-31	Active, not recruiting
Phase II Study of De-intensification of Radiation and Chemotherapy for Low-Risk HPV-related Oropharyngeal Squamous Cell Carcinoma [NCT01530997]	Phase 2	45 participants (Actual)	Interventional	2012-02-07	Completed
A Phase I Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy [NCT01998529]	Phase 1	7 participants (Actual)	Interventional	2014-08-20	Completed
Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study) [NCT05103501]	Phase 2	54 participants (Anticipated)	Interventional	2021-12-01	Not yet recruiting
A Phase 2 Study of Combined Chemo-immunotherapy With Cisplatin-pembrolizumab and Radiation for Unresectable Vulvar Squamous Cell Carcinoma [NCT04430699]	Phase 2	24 participants (Anticipated)	Interventional	2020-07-29	Recruiting
A Prospective, Multicenter, Open Label Phase Ⅱ Clinical Trial of Doxorubicin Hydrochloride Liposome Injection Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma [NCT03387943]	Phase 2	30 participants (Anticipated)	Interventional	2017-03-06	Recruiting
Effect of Standard Nutrition Therapy on Nutritional Status and Prognosis in Locoregionally Advanced Nasopharyngeal Carcinoma Patients With Malnutrition: A Prospective, Multicenter, Phase III Randomized Control Clinical Trial [NCT04436965]	Phase 3	266 participants (Anticipated)	Interventional	2021-08-16	Recruiting
A Phase III Trial Comparing Paclitaxel, Cisplatin Plus 5-FU (TCF) Versus Radiotherapy With Paclitaxel Plus Cisplatin (TC-RT) as Preoperative Therapy for Locally Advanced Esophageal Squamous Cancer [NCT03366883]	Phase 3	420 participants (Anticipated)	Interventional	2018-02-01	Not yet recruiting
Phase II Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer [NCT05305131]	Phase 2	50 participants (Anticipated)	Interventional	2022-03-28	Not yet recruiting
An Open-Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma [NCT04458909]	Phase 3	15 participants (Actual)	Interventional	2020-12-09	Terminated(stopped due to External information)
A Pilot Study Measuring Acute Changes in Endothelial Function in Germ Cell Tumor Patients Treated With Cisplatin and Untreated Germ Cell Tumor Controls [NCT01453660]		44 participants (Anticipated)	Observational	2011-10-11	Active, not recruiting
Randomized Phase II Trial Contrasting Weekly Paclitaxel, Carboplatin and Cetuximab (PCC) With Cetuximab, Docetaxel, Cisplatin and Fluorouracil (C-TPF) in Previously Untreated Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT01154920]	Phase 2	128 participants (Anticipated)	Interventional	2010-07-09	Active, not recruiting
A Pilot Study of Raltegravir and Cisplatin in Squamous Cell Carcinoma of the Head and Neck [NCT01275183]	Early Phase 1	5 participants (Actual)	Interventional	2010-12-31	Completed
4 Cycles Of Neoadjuvant Chemotherapy Plus Concurrent Chemoradiation Versus Concurrent Chemoradiation Alone In Patients With Stage N2-3 Nasopharyngeal Carcinoma: A Phase 3 Multicenter Randomised Controlled Trial [NCT02512315]	Phase 3	192 participants (Anticipated)	Interventional	2015-08-31	Recruiting
A Randomized Trial Comparing Induction Gemcitabine and Cisplatin Plus Intensity-modulated Radiotherapy With Concurrent Cisplatin Plus Intensity-modulated Radiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma [NCT02460887]	Phase 3	236 participants (Anticipated)	Interventional	2015-06-30	Active, not recruiting
An Open-Label, Multicenter, Randomized, Phase 3 Study of S-1 and Cisplatin Compared With 5-FU and Cisplatin in Patients With Metastatic Diffuse Gastric Cancer Previously Untreated With Chemotherapy [NCT01285557]	Phase 3	361 participants (Actual)	Interventional	2011-04-14	Terminated(stopped due to Due to significant changes in investigational and clinical practice landscape of frontline advanced gastric cancer, which challenged viability of trial and increased use of modified chemotherapeutic triplets led to slow participant accrual in study.)
A Prospective Phase II Study of Radiation Therapy and Concurrent Cisplatin Chemotherapy in the Treatment of Locally Advanced or Metastatic Malignant Melanoma [NCT00707161]	Phase 2	6 participants (Actual)	Interventional	2005-09-30	Terminated(stopped due to discontinued due to low enrollment)
PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer [NCT02299999]	Phase 2	1,460 participants (Actual)	Interventional	2014-04-07	Active, not recruiting
Safety and Efficacy of Combination of Sintilimab and Platinum-based Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal Cancer: An Open-lable, Single-arm, Exploratory Clinical Study [NCT03946969]	Phase 2	30 participants (Actual)	Interventional	2019-05-09	Active, not recruiting
A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-Reactivity in Subjects With Asthma [NCT01993329]	Phase 2	20 participants (Actual)	Interventional	2013-12-16	Completed
A Pilot Study of Molecular Profile-Directed Chemotherapy for Metastatic HER2(-) Esophagogastric Adenocarcinoma [NCT02358863]		13 participants (Actual)	Interventional	2015-02-28	Terminated(stopped due to Issues with recruitment.)
ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma - Prospective Study (ISG/OS-2) [NCT01459484]	Phase 2	225 participants (Anticipated)	Interventional	2011-06-23	Active, not recruiting
The Effectiveness and Safety of Neoadjuvant Therapy With Nab-paclitaxel and Cisplatin Followed by Surgery Versus Surgery Alone for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT03964753]	Phase 2	202 participants (Anticipated)	Interventional	2019-04-24	Recruiting
A Randomized Phase III Non-inferiority Study of Induction Chemotherapy Followed by IMRT Alone Versus Induction Chemotherapy Followed by IMRT Plus Concurrent Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma [NCT02434614]	Phase 3	440 participants (Actual)	Interventional	2015-03-31	Active, not recruiting
Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer [NCT02974426]	Phase 3	1,094 participants (Anticipated)	Interventional	2016-11-30	Recruiting
A Randomized, Controlled Phase II Study to Compare Irinotecan Combined With Cisplatin (IP) Versus Etoposide Combined With Cisplatin (EP) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Carcinoma [NCT03168594]	Phase 2	66 participants (Actual)	Interventional	2017-04-29	Terminated(stopped due to The enrollment was terminated early because the premature analysis found similar response in the two arms.)
A Phase I Dose-finding Study of Metformin in Combination With Concurrent Cisplatin and Radiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma [NCT02325401]	Phase 1	20 participants (Actual)	Interventional	2015-05-11	Completed
Phase III Multicenter Randomized Controlled Trial of PD-1 Inhibitor Combined With Preoperative Concurrent Chemoradiotherapy and Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma [NCT05357846]	Phase 3	422 participants (Anticipated)	Interventional	2022-11-01	Recruiting
Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer [NCT02985658]		0 participants	Expanded Access		No longer available
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Trial	Outcome
NCT00003298 (4) [back to overview]	Best Confirmed Response to Neoadjuvant Therapy
NCT00003298 (4) [back to overview]	Progression Free Survival
NCT00003298 (4) [back to overview]	Grade 3 or Higher Toxicity Incidence on Step 1
NCT00003298 (4) [back to overview]	Overall Survival
NCT00003377 (3) [back to overview]	Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment
NCT00003377 (3) [back to overview]	Overall Survival at 2 Years
NCT00003377 (3) [back to overview]	Disease-free Survival at 2 Years
NCT00003907 (3) [back to overview]	Time to Progression
NCT00003907 (3) [back to overview]	Overall Survival
NCT00003907 (3) [back to overview]	Tumor Response
NCT00004547 (2) [back to overview]	Number of Participants With Adverse Events
NCT00004547 (2) [back to overview]	Number of Participants With a Response
NCT00025259 (4) [back to overview]	Disease Response Assessed by Modified RECIST Criteria
NCT00025259 (4) [back to overview]	Grade 3 or 4 Non-hematologic Toxicity
NCT00025259 (4) [back to overview]	Event-free Survival
NCT00025259 (4) [back to overview]	Overall Survival
NCT00033657 (3) [back to overview]	Overall Survival Time
NCT00033657 (3) [back to overview]	Pathologic Complete Response Rate
NCT00033657 (3) [back to overview]	Recurrence-free Survival Time
NCT00047008 (10) [back to overview]	Disease-free Survival (Percentage of Participants Alive Without Disease)
NCT00047008 (10) [back to overview]	Head and Neck Radiotherapy Questionnaire (HNRQ) - AUC at One Year
NCT00047008 (10) [back to overview]	Local-regional Failure (Alternate Definition) [Percentage of Participants With Local-regional Failure]
NCT00047008 (10) [back to overview]	Local-regional Failure (Percentage of Participants With Local-regional Failure)
NCT00047008 (10) [back to overview]	Overall Survival (Percentage of Participants Alive)
NCT00047008 (10) [back to overview]	Percentage of Participants With Toxicity Grade 3 or Higher
NCT00047008 (10) [back to overview]	PSS-HN Understandability of Speech Score - AUC at One Year
NCT00047008 (10) [back to overview]	PSS-HN Public Eating Score - AUC at One Year
NCT00047008 (10) [back to overview]	Progression-free Survival (Alternate Definition of Disease-free Survival) [Percentage of Participants Alive Without Progression]
NCT00047008 (10) [back to overview]	Performance Status Scale for Head and Neck Cancer (PSS-HN) Normalcy of Diet Score - Area Under the Curve (AUC) at One Year
NCT00057837 (3) [back to overview]	Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)
NCT00057837 (3) [back to overview]	Duration of Response
NCT00057837 (3) [back to overview]	Overall Survival
NCT00062374 (2) [back to overview]	Disease Free Survival (DFS)
NCT00062374 (2) [back to overview]	Histological Response Determined by FDG Uptake Correlates
NCT00063999 (3) [back to overview]	Number of Participants With Indicated Severity of CTCAE v2 Graded Neurotoxicity and Infection
NCT00063999 (3) [back to overview]	Patient Reported Quality of Life as Measured With the Combination of Physical Well-being (PWB) Subscale and Functional Well-being (FWB) Subscale From the FACT-G
NCT00063999 (3) [back to overview]	Patient-reported Neurotoxicity (Ntx) as Measured by the FACT/GOG-Ntx Subscale (Short)
NCT00064077 (5) [back to overview]	Pain, Assessed by Brief Pain Inventory
NCT00064077 (5) [back to overview]	Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).
NCT00064077 (5) [back to overview]	Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)
NCT00064077 (5) [back to overview]	Duration of Overall Survival (OS)
NCT00064077 (5) [back to overview]	Duration of Progression-free Survival (PFS)
NCT00068406 (2) [back to overview]	Complete Clinical and Pathologic Response
NCT00068406 (2) [back to overview]	Treatment-Related Adverse Effects (Grade 3 or Higher) During Study Treatment Period
NCT00068575 (1) [back to overview]	Median Overall Survival (OS)
NCT00083122 (3) [back to overview]	Overall Survival
NCT00083122 (3) [back to overview]	Time to Progression
NCT00083122 (3) [back to overview]	Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR)
NCT00083551 (1) [back to overview]	Overall Survival
NCT00084838 (19) [back to overview]	Pre-Radiation Therapy Chemotherapeutic Response
NCT00084838 (19) [back to overview]	Grade 3-4 Hepatic Events
NCT00084838 (19) [back to overview]	Grade 3-4 Hemorrhage Events
NCT00084838 (19) [back to overview]	Grade 3-4 Dermatology Events
NCT00084838 (19) [back to overview]	Grade 3-4 Gastrointestinal Events
NCT00084838 (19) [back to overview]	Grade 3-4 Constitutional Events
NCT00084838 (19) [back to overview]	Grade 3-4 Cardiovascular Events
NCT00084838 (19) [back to overview]	Grade 3-4 Blood/Bone Marrow Events
NCT00084838 (19) [back to overview]	Grade 3-4 Auditory/Hearing Events
NCT00084838 (19) [back to overview]	Grade 3-4 Allergy/Immunology
NCT00084838 (19) [back to overview]	2-yr Overall Survival
NCT00084838 (19) [back to overview]	Grade 3/4 Events
NCT00084838 (19) [back to overview]	Grade 3-4 Renal/Genitourinary Events
NCT00084838 (19) [back to overview]	Grade 3-4 Pulmonary Events
NCT00084838 (19) [back to overview]	Grade 3-4 Pain Events
NCT00084838 (19) [back to overview]	Grade 3-4 Neurology Events
NCT00084838 (19) [back to overview]	Grade 3-4 Muscloskeletal Events
NCT00084838 (19) [back to overview]	Grade 3-4 Metabolic/Laboratory Events
NCT00084838 (19) [back to overview]	Grade 3-4 Infection/Febrile Neutropenia Events
NCT00085098 (4) [back to overview]	Toxicity and Safety as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT00085098 (4) [back to overview]	Quality of Life (QOL) and Neurocognitive Assessment (NP)
NCT00085098 (4) [back to overview]	Event-free Survival
NCT00085098 (4) [back to overview]	Number of Participants With a Response to Regimen B
NCT00085735 (22) [back to overview]	Event-free Survival (EFS)
NCT00085735 (22) [back to overview]	Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 2 (27 - 48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Post-treatment Neurocognitive Function as Measured by the Estimated Full-scale IQ (FSIQ) by CSI Group Within Time Window 1 (4 - 15 Months Post Diagnosis).
NCT00085735 (22) [back to overview]	Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Post-treatment Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) by CSI Group Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Post-treatment Grade 3+ Hearing Loss as Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)4
NCT00085735 (22) [back to overview]	Progression-free Survival (PFS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]	Overall Survival (OS)
NCT00085735 (22) [back to overview]	Overall Survival (OS)
NCT00085735 (22) [back to overview]	Event-free Survival (EFS)
NCT00085735 (22) [back to overview]	Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 2 (27-48 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 3 (49 - 72 Months Post Diagnosis)
NCT00085735 (22) [back to overview]	Incidence of Endocrine Dysfunction as Measured by Growth Hormone Stimulation Tests at the Time of Completion of Therapy by Radiotherapy (RT) Group
NCT00085735 (22) [back to overview]	Incidence of Grade 3+ Hearing Loss at 1-year Post Treatment as Assessed by CTCAE v4
NCT00085735 (22) [back to overview]	Local Posterior Fossa (LPF) Failure Rate
NCT00085735 (22) [back to overview]	Non-local Posterior Fossa (NLPF) Failure Rate
NCT00085735 (22) [back to overview]	Non-posterior Fossa (NPF) Failure Rate
NCT00085735 (22) [back to overview]	Overall Survival (OS) by Molecular Subgroup Based on Methylation Arrays
NCT00085735 (22) [back to overview]	Post-treatment Endocrine Function by CSI Group
NCT00085735 (22) [back to overview]	Compliance Rates for All Eligible and Evaluable Patients Enrolled Within Time Window 1 (4-15 Months Post Diagnosis)
NCT00096174 (3) [back to overview]	2-year Progression-free Survival Rate
NCT00096174 (3) [back to overview]	2-year Overall Survival Rate
NCT00096174 (3) [back to overview]	Overall Response Rate
NCT00101582 (8) [back to overview]	Number of Participants With Unplanned Breaks in Cisplatin Chemotherapy Treatment
NCT00101582 (8) [back to overview]	Number of Participants With Unplanned Breaks in Radiotherapy
NCT00101582 (8) [back to overview]	Patient-Reported Mouth and Throat Soreness Score
NCT00101582 (8) [back to overview]	Time to Onset of Severe (WHO Grade 3 or 4) Oral Mucositis
NCT00101582 (8) [back to overview]	Total Dose of Opioid Analgesics Used for Mucositis Within 15 Weeks
NCT00101582 (8) [back to overview]	Number of Participants With Severe (Grade 3 or 4) Oral Mucositis
NCT00101582 (8) [back to overview]	Number of Participants With Xerostomia at Month 4 (Grade 2 or Higher)
NCT00101582 (8) [back to overview]	Duration of Severe (WHO Grade 3 or 4) Oral Mucositis
NCT00102531 (1) [back to overview]	The Study Medication Was to be Considered Effective if the Population Response Rate Was Found to be Greater Than 20% and Individuals Who Demonstrated a CR or PR or Whose Tumours Demonstrated a Grade 3 or 4 Histologic Response at the Time of Surgery.
NCT00122460 (9) [back to overview]	Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
NCT00122460 (9) [back to overview]	Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
NCT00122460 (9) [back to overview]	Best Overall Response
NCT00122460 (9) [back to overview]	Disease Control
NCT00122460 (9) [back to overview]	Duration of Response
NCT00122460 (9) [back to overview]	Overall Survival Time (OS)
NCT00122460 (9) [back to overview]	Progression-free Survival Time (PFS)
NCT00122460 (9) [back to overview]	Safety - Number of Patients Experiencing Any Adverse Event
NCT00122460 (9) [back to overview]	Time to Treatment Failure
NCT00134030 (3) [back to overview]	Percentage of Patients With Overall Survival
NCT00134030 (3) [back to overview]	Toxicity as Measured by Common Terminology Criteria for Adverse Events (CTCAE) v3.0
NCT00134030 (3) [back to overview]	Event-free Survival (EFS)
NCT00143455 (5) [back to overview]	Duration of Response (DR)
NCT00143455 (5) [back to overview]	Number of Subjects With Overall Confirmed Response
NCT00143455 (5) [back to overview]	Overall Survival (OS) for the Full Analysis Population (FAP)
NCT00143455 (5) [back to overview]	Overall Survival for the Per Protocol (PP) Population
NCT00143455 (5) [back to overview]	Time to Tumor Progression (TTP)
NCT00148798 (8) [back to overview]	Disease Control Rate
NCT00148798 (8) [back to overview]	Best Overall Response Rate
NCT00148798 (8) [back to overview]	A Population Pharmacokinetic (PK) Analysis for Cetuximab in Non-Small Cell Lung Cancer (NSCLC) - Serum Cetuximab Concentrations
NCT00148798 (8) [back to overview]	Quality of Life Assessment (EORTC QLQ-C30) Social Functioning
NCT00148798 (8) [back to overview]	Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status
NCT00148798 (8) [back to overview]	Safety - Number of Patients Experiencing Any Adverse Event
NCT00148798 (8) [back to overview]	Progression-free Survival Time
NCT00148798 (8) [back to overview]	Overall Survival Time (OS)
NCT00191139 (5) [back to overview]	2-Year Survival
NCT00191139 (5) [back to overview]	Number of Patients With Overall Tumor Response
NCT00191139 (5) [back to overview]	Lung Cancer Symptom Scale (LCSS) Assessment Post-randomization
NCT00191139 (5) [back to overview]	Progression-Free Survival
NCT00191139 (5) [back to overview]	Overall Survival
NCT00253370 (3) [back to overview]	Progression-free Survival (PFS)
NCT00253370 (3) [back to overview]	The Proportion of Patients With Objective Response (Complete Response or Partial Response)
NCT00253370 (3) [back to overview]	Overall Survival (OS)
NCT00262951 (2) [back to overview]	Number of Patients in Whom Tumor Was Resectable
NCT00262951 (2) [back to overview]	Overall Survival
NCT00274937 (3) [back to overview]	Two Year Event-free Survival (EFS)
NCT00274937 (3) [back to overview]	Protective Effects of Amifostine Assessed Primarily by Sialometry
NCT00274937 (3) [back to overview]	Protective Effects of Amifostine Assessed Primarily by Sialometry: Weight of Unstimulated Saliva Production in Grams.
NCT00304070 (7) [back to overview]	Complications Associated With Radical Adrenalectomy and RLND
NCT00304070 (7) [back to overview]	Five Year Event-free Survival (EFS)
NCT00304070 (7) [back to overview]	Frequency of Lymph Node Involvement by Imaging.
NCT00304070 (7) [back to overview]	Frequency of Tumor Spillage at the Time of Tumor Resection
NCT00304070 (7) [back to overview]	Incidence and Type of Germline TP53 Mutations in Non-Brazilian Children and Children From Southern Brazil by Deoxyribonucleic Acid (DNA) Sequencing and Affymetrix Gene Chip Analysis.
NCT00304070 (7) [back to overview]	Molecular Alterations and Embryonal Markers in Children With ACT - A43 del33bp Mutation of (Beta)-Catenin.
NCT00304070 (7) [back to overview]	Toxicity Associated With Chemotherapy Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00304278 (1) [back to overview]	Survival Post Treatment
NCT00316888 (5) [back to overview]	3-year Colostomy-free Survival Rate
NCT00316888 (5) [back to overview]	3-year Overall Survival Rate
NCT00316888 (5) [back to overview]	Local Failure Rate at 3 Years
NCT00316888 (5) [back to overview]	Objective Response Rate
NCT00316888 (5) [back to overview]	3-year Progression-free Survival Rate
NCT00324805 (2) [back to overview]	Disease-free Survival
NCT00324805 (2) [back to overview]	Overall Survival
NCT00331760 (9) [back to overview]	Rate of Overall Survival at Five Years
NCT00331760 (9) [back to overview]	Rate of Local-regional Failure at Five Years
NCT00331760 (9) [back to overview]	Reproducibility of Radiation Technique (Number of Unacceptable Deviations in Central IMRT Quality Assurance Review)
NCT00331760 (9) [back to overview]	Percentage of Patients With Grade 2+ Bowel Adverse Events
NCT00331760 (9) [back to overview]	Percentage of Patients With Any Grade 3+ Treatment-related Adverse Events
NCT00331760 (9) [back to overview]	Percentage of Patients With Any Late Grade 3+ Treatment-related Adverse Events
NCT00331760 (9) [back to overview]	Rate of Distant Metastases at Five Years
NCT00331760 (9) [back to overview]	Rate of Disease-free Survival at Five Years
NCT00331760 (9) [back to overview]	Percentage of Cervical Carcinoma Patients That Were Chemotherapy Compliant
NCT00334815 (4) [back to overview]	Overall Survival
NCT00334815 (4) [back to overview]	Progression-free Survival
NCT00334815 (4) [back to overview]	Adverse Events
NCT00334815 (4) [back to overview]	Response Rate (Confirmed or Unconfirmed Partial Response)
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Central Hypothyroidism
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Diabetes Insipidus
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Low Somatomedin C
NCT00336024 (10) [back to overview]	Rates of Nutritional Toxicities
NCT00336024 (10) [back to overview]	Rates of Gastrointestinal Toxicities
NCT00336024 (10) [back to overview]	Median/Range of Patients for Total Quality of Life (QOL) Score, Intelligence Quotient (IQ) and Processing Speed Index (PSI).
NCT00336024 (10) [back to overview]	Percentage of Participants With Event Free Survival (EFS)
NCT00336024 (10) [back to overview]	Percentage of Participants With Any Acute Adverse Events
NCT00336024 (10) [back to overview]	Number of Participants With Secondary Malignancies
NCT00336024 (10) [back to overview]	Number of Participants With Chronic Primary Hypothyroidism/Subclinical Compensatory HypothyroidismHypothyroidism/Subclinical Compensatory Hypothyroidism
NCT00360971 (6) [back to overview]	Duration of Oral Mucositis as Measured in Terms of Days
NCT00360971 (6) [back to overview]	Time to Second Primary Tumor
NCT00360971 (6) [back to overview]	Number of Patients With Grade 3 or 4 Mucositis as Measured by the World Heath Organization (WHO) Scale
NCT00360971 (6) [back to overview]	Time to Onset of Grade 3 or 4 Oral Mucositis as Measured by the World Heath Organization (WHO) Scale
NCT00360971 (6) [back to overview]	Progression-free Survival
NCT00360971 (6) [back to overview]	Overall Survival
NCT00369122 (4) [back to overview]	Overall Survival (Three-year Rate Reported)
NCT00369122 (4) [back to overview]	Disease-free Survival (Three-year Rate Reported)
NCT00369122 (4) [back to overview]	Number of Subjects With Treatment-related SAEs and AEs as Assessed by CTCAE v. 3.0 Criteria at Any Time.
NCT00369122 (4) [back to overview]	Number of Subjects With Treatment-related Serious Adverse Events (SAEs) and Adverse Events (AEs) as Assessed by CTCAE v. 3.0 Criteria Within the First 90 Days From Treatment Start.
NCT00381706 (5) [back to overview]	Overall Survival in Patients With Adenocarcinoma
NCT00381706 (5) [back to overview]	Progression-free Survival in Patients With Adenocarcinoma
NCT00381706 (5) [back to overview]	Response Rate (Complete and Partial) in Patients With Measurable Esophageal or GE Junction Adenocarcinoma
NCT00381706 (5) [back to overview]	Time to Treatment Failure in Patients With Adenocarcinoma
NCT00381706 (5) [back to overview]	Tumor Response Rate (Complete and Partial) in Patients With Squamous Cell Carcinoma
NCT00388154 (2) [back to overview]	Overall Objective Response Rate (CR + PR)
NCT00388154 (2) [back to overview]	Participant Responses
NCT00392327 (14) [back to overview]	The Estimated Full-scale IQ (FSIQ) at 60+/-12 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]	The Estimated Full-scale IQ (FSIQ) at 30+/-6 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]	Percent Probability of Overall Survival (OS) for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]	Percent Probability of Event-free Survival (EFS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]	Percent Probability of Event-free Survival (EFS) for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]	Tumor Response to Radiation Therapy for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]	Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
NCT00392327 (14) [back to overview]	The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]	Percent Probability of Overall Survival (OS) for Patients With Supratentorial Primitive Neuroectodermal Tumor (SPNET)
NCT00392327 (14) [back to overview]	Tumor Response to Radiation Therapy for Patients With Medulloblastoma
NCT00392327 (14) [back to overview]	Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 60+/-12 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]	Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 30+/-6 Months Post Diagnosis for SPNET Patients
NCT00392327 (14) [back to overview]	The Estimated Full-scale IQ (FSIQ) at 9+/-3 Months Post Diagnosis for Medulloblastoma Patients
NCT00392327 (14) [back to overview]	Metacognition Index (MI) on the Behavior Rating Inventory of Executive Function (BRIEF) at 9+/-3 Months Post Diagnosis for SPNET Patients
NCT00394433 (4) [back to overview]	10-month Progression-Free Survival Rate
NCT00394433 (4) [back to overview]	Overall Survival
NCT00394433 (4) [back to overview]	Best Response
NCT00394433 (4) [back to overview]	Progression-Free Survival
NCT00400179 (5) [back to overview]	Time to Treatment Failure (TTF)
NCT00400179 (5) [back to overview]	Progression-free Survival (PFS)
NCT00400179 (5) [back to overview]	Overall Response Rate (ORR)
NCT00400179 (5) [back to overview]	Median Survival
NCT00400179 (5) [back to overview]	Duration of Response (DR)
NCT00408694 (9) [back to overview]	Percentage of Patients With Other Grade 3-5 Adverse Events Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment
NCT00408694 (9) [back to overview]	One- and Two-year Distant Metastases-free Rates
NCT00408694 (9) [back to overview]	One- and Two-year Loco-regional Progression-free Rates
NCT00408694 (9) [back to overview]	Patient Tolerability to Each Component (Concurrent and Adjuvant) of the Protocol Treatment Regimen
NCT00408694 (9) [back to overview]	Death During or Within 30 Days of Discontinuation of Protocol Treatment.
NCT00408694 (9) [back to overview]	One- and Two-year Progression-free Survival Rates
NCT00408694 (9) [back to overview]	Percentage of Patients With a Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment During the First Year.
NCT00408694 (9) [back to overview]	Percentage of Patients With Grade 4 Hemorrhage or Any Grade 5 Adverse Event Assessed to be Definitely, Probably, or Possibly Related to Protocol Treatment After the First Year.
NCT00408694 (9) [back to overview]	One- and Two-year Overall Survival Rates
NCT00453154 (4) [back to overview]	Number of Participants With Overall Tumor Response
NCT00453154 (4) [back to overview]	Progression-free Survival (Phase II)
NCT00453154 (4) [back to overview]	Overall Survival
NCT00453154 (4) [back to overview]	Maximum Tolerated of Sunitinib Combined With Cisplatin and Etoposide (Phase I)
NCT00454636 (6) [back to overview]	Time to Response
NCT00454636 (6) [back to overview]	Progression-Free Survival (PFS)
NCT00454636 (6) [back to overview]	Percentage of Participants With Grade 3 Hand-Foot Syndrome (HFS)
NCT00454636 (6) [back to overview]	Overall Survival (OS)
NCT00454636 (6) [back to overview]	Duration of Response
NCT00454636 (6) [back to overview]	Overall Response Rate (ORR)
NCT00454649 (34) [back to overview]	Apparent Oral Clearance (CL/F) for Capecitabine
NCT00454649 (34) [back to overview]	Apparent Oral Clearance (CL/F) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Carboplatin
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Pemetrexed
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Paclitaxel
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Gemcitabine
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Docetaxel
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Cisplatin
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Carboplatin
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Capecitabine
NCT00454649 (34) [back to overview]	Plasma Decay Half Life (t1/2) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Pemetrexed
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Paclitaxel
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Gemcitabine
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Docetaxel
NCT00454649 (34) [back to overview]	Plasma Clearance (CL) for Cisplatin
NCT00454649 (34) [back to overview]	Percentage of Participants With Objective Response
NCT00454649 (34) [back to overview]	Maximum Tolerated Dose (MTD) of Axitinib (AG-013736) in Combination With Chemotherapy
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Pemetrexed
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Paclitaxel
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Gemcitabine
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Docetaxel
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Cisplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Carboplatin
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Capecitabine
NCT00454649 (34) [back to overview]	Maximum Observed Plasma Concentration (Cmax) for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 8 Hours [AUC (0-8)] for Cisplatin
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Capecitabine
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Time 24 Hours [AUC (0-24)] for Axitinib (AG-013736)
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Pemetrexed
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Paclitaxel
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Gemcitabine
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Docetaxel
NCT00454649 (34) [back to overview]	Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-∞)] for Carboplatin
NCT00454779 (12) [back to overview]	Duration of Response (DOR) During the Second-line Treatment Phase
NCT00454779 (12) [back to overview]	Overall Survival (OS) for the Second-line Treatment
NCT00454779 (12) [back to overview]	Progression Free Survival (PFS) During the First-line Treatment Phase
NCT00454779 (12) [back to overview]	Progression Free Survival (PFS) During the Second-line Treatment Phase
NCT00454779 (12) [back to overview]	Overall Response Rate (ORR) During the Second-line Treatment Phase
NCT00454779 (12) [back to overview]	Rate of Disease Control (RDC) During the First-line Treatment Phase
NCT00454779 (12) [back to overview]	Rate of Disease Control (RDC) During the Second-line Treatment Phase
NCT00454779 (12) [back to overview]	Time to Response (TTR) During the First-line Treatment Phase
NCT00454779 (12) [back to overview]	Duration of Response (DOR) During the First-line Treatment Phase
NCT00454779 (12) [back to overview]	Time to Response (TTR) During the Second-line Treatment Phase
NCT00454779 (12) [back to overview]	Overall Survival (OS) for the First-line Treatment
NCT00454779 (12) [back to overview]	Overall Response Rate (ORR) During the First-line Treatment Phase
NCT00463788 (5) [back to overview]	Best Overall Response (BOR)
NCT00463788 (5) [back to overview]	Overall Survival (OS) Time
NCT00463788 (5) [back to overview]	Progression-Free Survival (PFS) Time
NCT00463788 (5) [back to overview]	Safety- Number of Participants Experiencing Any Adverse Event (AE)
NCT00463788 (5) [back to overview]	Time to Response (TTR)
NCT00492778 (4) [back to overview]	Number of Participants That Experienced Adverse Effects Grade 3 or Higher
NCT00492778 (4) [back to overview]	Number of Participants That Experienced Death on Study
NCT00492778 (4) [back to overview]	Number of Participants With Disease Progression or Death.
NCT00492778 (4) [back to overview]	Number of Participants in Select Prognostic Groups Who Experienced Progression or Death on Study.
NCT00505635 (1) [back to overview]	Time to Progression (TTP)
NCT00506155 (2) [back to overview]	Percentage of Participants With Response Defined as the Absence of Residual Muscle Invasive Cancer in Resected Specimen
NCT00506155 (2) [back to overview]	5-year Overall Survival (OS)
NCT00509366 (3) [back to overview]	Mean Change From Baseline to Follow-up Cycle in Quality of Life - Functional Assessment of Cancer Therapy-Lung (FACT-L)
NCT00509366 (3) [back to overview]	1-year Progression Free Survival Rate in Chemo-naive Select Stage IIIB or Stage IV NSCLC Patients
NCT00509366 (3) [back to overview]	Median Time to Progressive Disease
NCT00511992 (2) [back to overview]	Number of Patients Who Experienced Toxicities Associated With Intraperitoneal Cisplatin With Intravenous Paclitaxel and Avastin.
NCT00511992 (2) [back to overview]	Number of Patients Able to Complete 6 Cycles of Treatment.
NCT00512096 (1) [back to overview]	Number of Participants With Pathologic Complete Remission (pCR)
NCT00515411 (2) [back to overview]	6 Month Progression Free Survival (PFS)
NCT00515411 (2) [back to overview]	Overall Survival
NCT00522795 (1) [back to overview]	Complete Pathologic Response
NCT00529100 (9) [back to overview]	Phase 2: Time to Progressive Disease (PD)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Overall Survival (OS) at 1 Year
NCT00529100 (9) [back to overview]	Phase 1: Maximum Tolerated Dose (MTD) of Pemetrexed in Combination With Cisplatin and Radiation Therapy
NCT00529100 (9) [back to overview]	Phase 2: Site of Progressive Disease (PD)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Progression Free Survival (PFS)
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Overall Survival (OS) at 2 Years and 3 Years
NCT00529100 (9) [back to overview]	Phase 2: Percentage of Participants With Objective Tumor Response (Response Rate)
NCT00529100 (9) [back to overview]	Phase 1: Number of Participants With Adverse Events (AE; Toxicity)
NCT00529100 (9) [back to overview]	Progression Free Survival (PFS)
NCT00545948 (3) [back to overview]	Percentage of Patients With Completely Resected NSCLC Tumors That Can Be Analyzed and Used to Direct Adjuvant Chemotherapy
NCT00545948 (3) [back to overview]	2-Year Progression-Free Survival Rate in Patients With Completely Resected Stage IB, II, or IIIA NSCLC
NCT00545948 (3) [back to overview]	2-Year Overall Survival in Patients Treated for NSCLC
NCT00547157 (6) [back to overview]	ORR by 6 Months - Central
NCT00547157 (6) [back to overview]	Overall Survival
NCT00547157 (6) [back to overview]	Local Regional Control Rate at 2 Years
NCT00547157 (6) [back to overview]	Progression-free Survival
NCT00547157 (6) [back to overview]	Duration of Local Regional Control
NCT00547157 (6) [back to overview]	CRR by 6 Months - Central
NCT00554788 (3) [back to overview]	Percentage of Participants With Adverse Events as Assessed by the Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0
NCT00554788 (3) [back to overview]	Response Rate to the Induction Phase of the Regimen
NCT00554788 (3) [back to overview]	Event-free Survival (EFS)
NCT00566540 (2) [back to overview]	Percentage of Participants With Serious Adverse Events
NCT00566540 (2) [back to overview]	Treatment Completion
NCT00567567 (14) [back to overview]	Incidence Rate of Local Recurrence
NCT00567567 (14) [back to overview]	Intraspinal Extension
NCT00567567 (14) [back to overview]	OS in Patients 12-18 Months, Stage 4, MYCN Nonamplified Tumor/Unfavorable Histopathology/Diploid DNA Content/Indeterminant Histology/Ploidy and Patients > 547 Days, Stage 3, MYCN Nonamplified Tumor AND Unfavorable Histopathology/Indeterminant Histology
NCT00567567 (14) [back to overview]	Peak Serum Concentration of Isotretinoin in Patients Enrolled on Either A3973, ANBL0032, ANBL0931, ANBL0532 and Future High Risk Studies
NCT00567567 (14) [back to overview]	Event-free Survival Rate
NCT00567567 (14) [back to overview]	Proportion of Patients With a Polymorphism
NCT00567567 (14) [back to overview]	Response After Induction Therapy
NCT00567567 (14) [back to overview]	Surgical Response
NCT00567567 (14) [back to overview]	Topotecan Systemic Clearance
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Neutropenia
NCT00567567 (14) [back to overview]	Enumeration of Peripheral Blood Cluster of Differentiation (CD)3, CD4, and CD8 Cells
NCT00567567 (14) [back to overview]	EFS Pts Non-randomly Assigned to Single CEM (12-18 Mths, Stg. 4, MYCN Nonamplified Tumor/Unfavorable or Indeterminant Histopathology/Diploid DNA Content & Pts>547 Days, Stg.3, MYCN Nonamplified Tumor AND Unfavorable or Indeterminant Histopathology).
NCT00567567 (14) [back to overview]	Type of Surgical or Radiotherapy Complication
NCT00567567 (14) [back to overview]	Duration of Greater Than or Equal to Grade 3 Thrombocytopenia
NCT00573131 (1) [back to overview]	Overall Tumor Response at the Primary Tumor Site Based on Measurement of Primary Tumor Volume (Excluding Involved Lymph Nodes) by Spiral CT
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Short Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Long Term)
NCT00577096 (10) [back to overview]	Total Number of Days of Stem Cell Collection (Long Term)
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets.(Short Term)
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Long Term)
NCT00577096 (10) [back to overview]	Number of Red Blood Cell Transfusions Needed to Maintain Hemoglobin Levels (Short Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Long Term)
NCT00577096 (10) [back to overview]	Number of Platelet Transfusions Needed to Maintain Adequate Number of Platelets. (Long Term)
NCT00577096 (10) [back to overview]	Number of Stem Cell Collection Attempts (Short Term)
NCT00577096 (10) [back to overview]	Hemoglobin Levels Before Chemotherapy and During Transplantation Period (Short Term)
NCT00582205 (2) [back to overview]	Number of Patients With Dose Reductions or Dose Delays Due to Neuropathy or Toxicity
NCT00582205 (2) [back to overview]	Number of Patients Who Are Able to Receive 6 Cycles of Intraperitoneal Cisplatin Chemotherapy.
NCT00588770 (3) [back to overview]	Progression-free Survival (PFS)
NCT00588770 (3) [back to overview]	Overall Survival (OS)
NCT00588770 (3) [back to overview]	Overall Response Rate
NCT00590967 (3) [back to overview]	Tolerance of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured the Number of Participants With by Grade 4 or Higher Toxicity
NCT00590967 (3) [back to overview]	Number of Participants With Acute Toxicity of IMRT Extended-field External Radiotherapy to Pelvis and Para-aortic Region, Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy (Grade 3 or Higher)
NCT00590967 (3) [back to overview]	Efficacy of IMRT Extended-field Radiation Combined With Intracavitary Irradiation, and Cisplatin Chemotherapy as Measured by PET Scan Disease Status
NCT00602667 (62) [back to overview]	Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]	Cyclophosphamide Apparent Oral Clearance in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]	CEPM AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]	CEPM AUC0-24h in Induction Chemotherapy
NCT00602667 (62) [back to overview]	CEPM AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]	CEPM AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]	4-OH Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]	4-OH Cyclophosphamide AUC0-24h in Induction Chemotherapy
NCT00602667 (62) [back to overview]	4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]	4-OH Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]	Methotrexate Volume of Central Compartment in Induction Cycle 4
NCT00602667 (62) [back to overview]	Pharmacogenetic Variation on Central Nervous System Transmitters
NCT00602667 (62) [back to overview]	Numbers of Patients With Molecular Abnormalities by Tumor Type
NCT00602667 (62) [back to overview]	Numbers of Patients With Gene Alterations
NCT00602667 (62) [back to overview]	Number of Successful Collections for Frozen and Fixed Tumor Samples
NCT00602667 (62) [back to overview]	Number of Participants With Chromosomal Abnormalities
NCT00602667 (62) [back to overview]	Number and Type of Genetic Polymorphisms
NCT00602667 (62) [back to overview]	Concentration of Cerebrospinal Fluid Neurotransmitters
NCT00602667 (62) [back to overview]	Topotecan Clearance in Consolidation Chemotherapy
NCT00602667 (62) [back to overview]	Topotecan AUC0-24h in Maintenance Chemotherapy
NCT00602667 (62) [back to overview]	Topotecan AUC0-24h in Consolidation Chemotherapy
NCT00602667 (62) [back to overview]	Topotecan Apparent Oral Clearance in Maintenance Chemotherapy
NCT00602667 (62) [back to overview]	Rate of Local Disease Progression
NCT00602667 (62) [back to overview]	Rate of Distant Disease Progression
NCT00602667 (62) [back to overview]	Percentage of Patients With Objective Responses Rate to Induction Chemotherapy
NCT00602667 (62) [back to overview]	Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients by DNA Methylation Subgroup
NCT00602667 (62) [back to overview]	Percent Probability of Progression-free Survival (PFS) for Medulloblastoma Patients
NCT00602667 (62) [back to overview]	Percent Probability of Event-free Survival (EFS) for Medulloblastoma Patients
NCT00602667 (62) [back to overview]	Percent of PET Scans With Loss of Signal Intensity
NCT00602667 (62) [back to overview]	Percent of Patients With Sustained Objective Responses Rate After Consolidation
NCT00602667 (62) [back to overview]	Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan
NCT00602667 (62) [back to overview]	Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan
NCT00602667 (62) [back to overview]	Overall Survival (OS) Compared to Historical Controls
NCT00602667 (62) [back to overview]	OSI-420 AUC0-24h
NCT00602667 (62) [back to overview]	Methotrexate Volume of Central Compartment in Induction Cycle 3
NCT00602667 (62) [back to overview]	Methotrexate Volume of Central Compartment in Induction Cycle 2
NCT00602667 (62) [back to overview]	Methotrexate Volume of Central Compartment in Induction Cycle 1
NCT00602667 (62) [back to overview]	Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 4
NCT00602667 (62) [back to overview]	Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 3
NCT00602667 (62) [back to overview]	Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 2
NCT00602667 (62) [back to overview]	Methotrexate Concentration at 42 Hours Post-dose in Induction Cycle 1
NCT00602667 (62) [back to overview]	Methotrexate Clearance in Induction Cycle 4
NCT00602667 (62) [back to overview]	Methotrexate Clearance in Induction Cycle 3
NCT00602667 (62) [back to overview]	Methotrexate Clearance in Induction Cycle 2
NCT00602667 (62) [back to overview]	Methotrexate Clearance in Induction Cycle 1
NCT00602667 (62) [back to overview]	Methotrexate AUC0-66h in Induction Cycle 4
NCT00602667 (62) [back to overview]	Methotrexate AUC0-66h in Induction Cycle 3
NCT00602667 (62) [back to overview]	Methotrexate AUC0-66h in Induction Cycle 2
NCT00602667 (62) [back to overview]	Methotrexate AUC0-66h in Induction Cycle 1
NCT00602667 (62) [back to overview]	Feasibility and Toxicity of Administering Vinblastine With Induction Chemotherapy for Patients With Metastatic Disease as Measured by the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity
NCT00602667 (62) [back to overview]	Feasibility and Toxicity of Administering Oral Maintenance Therapy in Children <3 Years of Age as Measured by the Percentage of Total Scheduled Maintenance Doses Received
NCT00602667 (62) [back to overview]	Feasibility and Toxicity of Administering Consolidation Therapy Including Cyclophosphamide and Pharmacokinetically Targeted Topotecan to Patients With Metastatic Disease Based on the Percentage of Courses Delayed for More Than 7 Days Due to Toxicity
NCT00602667 (62) [back to overview]	Event-free Survival (EFS) Compared to Historical Controls
NCT00602667 (62) [back to overview]	Erlotinib AUC0-24h
NCT00602667 (62) [back to overview]	Erlotinib Apparent Volume of Central Compartment
NCT00602667 (62) [back to overview]	Erlotinib Apparent Oral Clearance
NCT00602667 (62) [back to overview]	Cyclophosphamide Clearance in Induction Chemotherapy
NCT00602667 (62) [back to overview]	Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 2
NCT00602667 (62) [back to overview]	Cyclophosphamide Clearance in Consolidation Chemotherapy Cycle 1
NCT00602667 (62) [back to overview]	Cyclophosphamide AUC0-24h in Maintenance Chemotherapy Cycle A1
NCT00602667 (62) [back to overview]	Cyclophosphamide AUC0-24h in Induction Chemotherapy
NCT00602667 (62) [back to overview]	Cyclophosphamide AUC0-24h in Consolidation Chemotherapy Cycle 2
NCT00603408 (4) [back to overview]	Overall Response
NCT00603408 (4) [back to overview]	Number of Participants With Medical Toxicities
NCT00603408 (4) [back to overview]	Number of Participants With Surgical Complications
NCT00603408 (4) [back to overview]	Overall Survival Rate (OS)
NCT00626639 (3) [back to overview]	Number of Participants With Disease Progression by Week 12
NCT00626639 (3) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT00626639 (3) [back to overview]	Overall Survival
NCT00639769 (2) [back to overview]	Number of Patients With Each Worst-grade Toxicity
NCT00639769 (2) [back to overview]	Patient Response
NCT00653068 (4) [back to overview]	Event-free Survival
NCT00653068 (4) [back to overview]	Overall Survival (OS)
NCT00653068 (4) [back to overview]	Toxic Death
NCT00653068 (4) [back to overview]	Non-hematological Toxicity Associated With Chemotherapy: Grade 3 or Higher During Protocol Therapy
NCT00659269 (4) [back to overview]	Neurotoxicity Assessment at Cycle 2
NCT00659269 (4) [back to overview]	Change in Neurotoxicity Assessment Between Cycle 4 and Baseline
NCT00659269 (4) [back to overview]	Neurotoxicity Assessment at Baseline
NCT00659269 (4) [back to overview]	Neurotoxicity Assessment at Cycle 4
NCT00700336 (1) [back to overview]	4M PFS Rate of Patients With Previously Untreated, Unresectable Malignant Pleural Mesothelioma (MPM) Treated With CBP501, Pemetrexed and Cisplatin
NCT00702299 (6) [back to overview]	Maximum-tolerated Dose of Pemetrexed With a Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)
NCT00702299 (6) [back to overview]	Patients That Completed at Least 6 Courses of Therapy of Pemetrexed Along With Day 2 i.p. Cisplatin (75 mg/m2) and Day 8 i.p. Paclitaxel (60 mg/m2)at the Determined Maximum Tolerated Dose
NCT00702299 (6) [back to overview]	Pharmacokinetics (Mean Cmax, ug/mL)for Different Dosages of Pemetrexed
NCT00702299 (6) [back to overview]	Progression-free Survival at 18 Months as Assessed by Cancer Antigen 125
NCT00702299 (6) [back to overview]	Overall Survival
NCT00702299 (6) [back to overview]	Patients Experienced Grade >=3 Toxicity at Dose Level 5 (1,000 mg/m2 IP Pemetrexed)
NCT00736944 (21) [back to overview]	Complete and Partial Response Rates of Primary Tumor by FDG Uptake on PET Scan
NCT00736944 (21) [back to overview]	Correlate Nodal Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
NCT00736944 (21) [back to overview]	Correlate Overall Tumor Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
NCT00736944 (21) [back to overview]	Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy
NCT00736944 (21) [back to overview]	Disease Free Survival
NCT00736944 (21) [back to overview]	Correlate Primary Tumor Site Response Rates Based on Visual Categorical Criteria of Assessment With That Based on CT Scan and FDG-PET/CT
NCT00736944 (21) [back to overview]	Radiographic Complete and Partial Response Rates of Primary Tumor as Assessed by Conventional CT Scan Using RECIST Criteria
NCT00736944 (21) [back to overview]	Correlate SPARC Expression (Intensity of Staining) by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy
NCT00736944 (21) [back to overview]	Clinical Partial Response Rate at the Primary Tumor
NCT00736944 (21) [back to overview]	Radiographic Overall Complete and Partial Response Rates as Assessed by Conventional CT Scan Using RECIST Criteria
NCT00736944 (21) [back to overview]	Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Complete Response Rate to Induction Chemotherapy
NCT00736944 (21) [back to overview]	Radiographic Complete and Partial Response Rates of Involved Lymph Nodes as Assessed by Conventional CT Scan Using RECIST Criteria
NCT00736944 (21) [back to overview]	Correlate SPARC Expression by Immunohistochemistry (IHC) in Baseline Primary Tumor Tissue With Primary Tumor Site Partial Response Rate to Induction Chemotherapy
NCT00736944 (21) [back to overview]	Clinical Complete Response Rate at the Primary Tumor
NCT00736944 (21) [back to overview]	Overall Complete and Partial Response Rates by FDG Uptake on PET Scan
NCT00736944 (21) [back to overview]	Complete and Partial Response Rates of Involved Lymph Nodes by FDG Uptake on PET Scan
NCT00736944 (21) [back to overview]	Clinical Overall Complete and Partial Response Rates
NCT00736944 (21) [back to overview]	Clinical Complete and Partial Response Rates to the Involved Regional Nodes
NCT00736944 (21) [back to overview]	Adverse Events Experienced During Induction Chemotherapy in the First Ten Patients for a Pre-planned Safety Analysis
NCT00736944 (21) [back to overview]	Time to Progression
NCT00736944 (21) [back to overview]	Overall Survival
NCT00742924 (1) [back to overview]	Limiting Toxicity
NCT00770874 (2) [back to overview]	Overall Survival
NCT00770874 (2) [back to overview]	Progression Free Survival, Safety
NCT00777491 (6) [back to overview]	Percentage of Patients With Grade 3 or Higher Genitourinary, Gastrointestinal, or Hematologic Adverse Events
NCT00777491 (6) [back to overview]	Number of Patients Experiencing Complete Response of the Primary Tumor After Induction Therapy
NCT00777491 (6) [back to overview]	Number of Participants With Progression or Removal of Bladder Five Years After Therapy
NCT00777491 (6) [back to overview]	Percentage of Patients Without Distant Metastases by Three Years
NCT00777491 (6) [back to overview]	Change in American Urological Association Symptom Index (AUASI) Score at 3 Years
NCT00777491 (6) [back to overview]	Percentage of Patients Who Completed Treatment Per Protocol
NCT00798655 (2) [back to overview]	Probability of 2-year Overall Survival
NCT00798655 (2) [back to overview]	Probability of Progression-free Survival (PFS) at 2 Years
NCT00803062 (4) [back to overview]	To Determine and Compare the Frequency and Severity of Adverse Events as Assessed by CTCAE Version 3.0 for the Regimens Administered on This Study.
NCT00803062 (4) [back to overview]	Progression-free Survival
NCT00803062 (4) [back to overview]	Overall Survival
NCT00803062 (4) [back to overview]	Tumor Response
NCT00832117 (5) [back to overview]	Number of Participants With Best Response As Assessed With Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00832117 (5) [back to overview]	Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations Per National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE)Version 3 Criteria
NCT00832117 (5) [back to overview]	Participants Experiencing Dose Limiting Toxicity (DLT)
NCT00832117 (5) [back to overview]	Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Cisplatin in Combination With Ixabepilone, 32 mg/m^2
NCT00832117 (5) [back to overview]	Number of Participants With Laboratory Abnormalities Per National Cancer Institute (NCI) Common Terminology Criteria Adverse Events (CTCAE)Version 3 Criteria
NCT00842712 (6) [back to overview]	Randomized Part: Progression Free Survival (PFS) Time - Independent Read
NCT00842712 (6) [back to overview]	Randomized Part: Overall Survival (OS) Time
NCT00842712 (6) [back to overview]	Randomized Part: Best Overall Response (BOR) Rate
NCT00842712 (6) [back to overview]	Safety run-in Part: Number of Participants With Dose Limiting Toxicities (DLTs)
NCT00842712 (6) [back to overview]	Randomized Part: Time to Treatment Failure
NCT00842712 (6) [back to overview]	Randomized Part: Progression Free Survival (PFS) Time - Investigator Read
NCT00882583 (1) [back to overview]	MTD of Daily Oral Dasatinib in Combination With Cetuximab/RT in Cohort A and Daily Oral Dasatinib in Combination With Cetuximab/Cis or Carboplatin/RT in Cohort B 2. MTD of Daily Oral Dasatinib in Combination With Cisplatin/Cetuximab/RT in Cohort B
NCT00887159 (4) [back to overview]	Progression-free Survival (PFS)
NCT00887159 (4) [back to overview]	PFS
NCT00887159 (4) [back to overview]	Response Rate
NCT00887159 (4) [back to overview]	Overall Survival (OS)
NCT00911820 (5) [back to overview]	Overall Response (OR) Rate
NCT00911820 (5) [back to overview]	Progression-Free Survival
NCT00911820 (5) [back to overview]	Best Response
NCT00911820 (5) [back to overview]	Overall Survival
NCT00911820 (5) [back to overview]	7-month Progression-Free Survival
NCT00942331 (4) [back to overview]	Overall Survival (OS)
NCT00942331 (4) [back to overview]	Number of Patients Experiencing Grade 3+ Toxicity
NCT00942331 (4) [back to overview]	Objective Response
NCT00942331 (4) [back to overview]	Progression-free Survival (PFS)
NCT00942357 (5) [back to overview]	Patient-reported Peripheral Neuropathy Symptoms
NCT00942357 (5) [back to overview]	Patient-reported Quality of Life (QOL)
NCT00942357 (5) [back to overview]	Number of Participants With Acute Adverse Effects as Graded by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events Version (CTCAE) Version 3.0
NCT00942357 (5) [back to overview]	Number of Participants With Late Adverse Events as Graded by the NCI CTCAE Version 3.0
NCT00942357 (5) [back to overview]	Number of Participants With Recurrence, Progression or Death
NCT00942825 (1) [back to overview]	The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per RECIST Criteria, or Until Death Due to Any Reason.
NCT00951496 (7) [back to overview]	Patient Reported Neurotoxicity (Ntx)
NCT00951496 (7) [back to overview]	Median Progression-free Survival
NCT00951496 (7) [back to overview]	Patients With Adverse Events by Treatment Group, as Defined by NCI CTCAE (Common Terminology Criteria for Adverse Events Version 3.0) Version 3.0
NCT00951496 (7) [back to overview]	Patient Reported Quality of Life (QOL)
NCT00951496 (7) [back to overview]	Overall Survival
NCT00951496 (7) [back to overview]	Patient Reported Fatigue
NCT00951496 (7) [back to overview]	Patient Reported Nausea
NCT00963807 (5) [back to overview]	Overall Response Rate Reported as a Proportion of the Total Number of Patients Who Received at Least One Cycle of Therapy Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)
NCT00963807 (5) [back to overview]	Change in FLT Uptake in Responders and Non-responders
NCT00963807 (5) [back to overview]	Change in FLT Uptake
NCT00963807 (5) [back to overview]	Change in 18F-Fluorothymidine (FLT) Uptake
NCT00963807 (5) [back to overview]	Change in 18F-Fluorodeoxyglucose (FDG) Uptake
NCT00968799 (4) [back to overview]	Overall Survival
NCT00968799 (4) [back to overview]	Fitness for Systemic Chemotherapy
NCT00968799 (4) [back to overview]	Nephrotoxicity
NCT00968799 (4) [back to overview]	Surgical Complications
NCT00977561 (1) [back to overview]	Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
NCT00980460 (5) [back to overview]	Event-free Survival
NCT00980460 (5) [back to overview]	Number of Cycles on Which Grade 3 or Higher Adverse Events Coded According to CTC AE Version 5 Were Observed
NCT00980460 (5) [back to overview]	Disease Status at the End of 2 Courses of Therapy
NCT00980460 (5) [back to overview]	Number of Deaths
NCT00980460 (5) [back to overview]	Feasibility of Referral for Liver Transplantation
NCT00995761 (1) [back to overview]	Response Rates Confirmed With CT or MRI
NCT01004978 (4) [back to overview]	Overall Survival (OS)
NCT01004978 (4) [back to overview]	Progression-free Survival (PFS)
NCT01004978 (4) [back to overview]	Progression-free Survival (PFS) Among Patients With Extra-hepatic Progression
NCT01004978 (4) [back to overview]	Progression-free Survival (PFS) Among Patients With Intra-hepatic Progression
NCT01005329 (6) [back to overview]	Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 1 Year After Treatment Start
NCT01005329 (6) [back to overview]	Pelvic Failure Rate (Two-year Rate Reported)
NCT01005329 (6) [back to overview]	Overall Survival (Two-year Rate Reported)
NCT01005329 (6) [back to overview]	Distant Failure (Two-year Rate Reported)
NCT01005329 (6) [back to overview]	Disease-free Survival (Two-year Rate Reported)
NCT01005329 (6) [back to overview]	Percentage of Participants With Treatment-related, Grade 3+, Non-hematologic Adverse Events Occuring Within 90 Days After Treatment Start
NCT01009346 (2) [back to overview]	Maximum Tolerated Dose (MTD) of RAD001 in Combination With Cetuximab and Cisplatin.
NCT01009346 (2) [back to overview]	Progression Free Survival (PFS) of RAD001 in Combination With Weekly Cetuximab and Cisplatin.
NCT01042522 (3) [back to overview]	Overall Survival (OS)
NCT01042522 (3) [back to overview]	Progression-free Survival (PFS)
NCT01042522 (3) [back to overview]	Tumor Response Rate
NCT01047007 (1) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs)
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimate of the OS in the MTD Confirmation/EE Cohorts
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimate of the PFS in the MTD Confirmation/EE Cohorts
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimate of the Progression-Free Survival (PFS) in the DE Cohorts
NCT01055496 (17) [back to overview]	Participants Reporting DLT AEs for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 2
NCT01055496 (17) [back to overview]	Participants Reporting Dose Limiting Toxicity (DLT) Adverse Events (AEs) for Participants in the DE Cohort and the MTD Confirmation Cohort for Arm 1
NCT01055496 (17) [back to overview]	Percentage of Participants With a Best OR of CR or PR According to International Response Criteria for NHLs in the DE Cohorts
NCT01055496 (17) [back to overview]	Percentage of Participants With Any Grade 3/4 Chemistry Abnormality During Therapy
NCT01055496 (17) [back to overview]	Percentage of Participants With Any Grade 3/4 Hematology Abnormality During Therapy
NCT01055496 (17) [back to overview]	Percentage of Participants With Best Overall Response (OR) of Complete Response (CR) or Partial Response (PR) According to International Response Criteria for NHLs in the MTD and EE Cohorts
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the DE Cohorts
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimates of the Probability of Being Alive and Free From PD or New Anticancer Therapy at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts.
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the DE Cohorts
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimate of the Overall Survival (OS) in the DE Cohorts
NCT01055496 (17) [back to overview]	Percentage of Participants With a Treatment Emergent AE
NCT01055496 (17) [back to overview]	Mean Inotuzumab Ozogamicin Serum Concentrations
NCT01055496 (17) [back to overview]	Mean Inotuzumab Ozogamicin Serum Concentrations
NCT01055496 (17) [back to overview]	Kaplan-Meier Estimates of the Probability of Being Alive at 6, 12, and 24 Months in the MTD Confirmation/EE Cohorts
NCT01064479 (5) [back to overview]	Disease Control (CR + PR + Stable Disease [SD])
NCT01064479 (5) [back to overview]	Overall Survival (OS)
NCT01064479 (5) [back to overview]	Progression Free Survival (PFS)
NCT01064479 (5) [back to overview]	Rash Rates
NCT01064479 (5) [back to overview]	Number of Participants With Tumor Response (Complete Response [CR] + Partial Response [PR])
NCT01064648 (9) [back to overview]	Disease Control Rate by Modified RECIST (Phase II)
NCT01064648 (9) [back to overview]	Disease Control Rate by RECIST 1.1 (Phase II)
NCT01064648 (9) [back to overview]	Maximum Tolerated Dose of Cediranib in Combination With Cisplatin and Pemetrexed (Phase I)
NCT01064648 (9) [back to overview]	Progression-free Survival (Phase II)
NCT01064648 (9) [back to overview]	Response Rate by Modified RECIST (Phase II)
NCT01064648 (9) [back to overview]	Response Rate by RECIST1.1 (Phase II)
NCT01064648 (9) [back to overview]	(Phase I) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01064648 (9) [back to overview]	(Phase II) Number of Patients With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT01064648 (9) [back to overview]	Overall Survival (Phase II)
NCT01091454 (6) [back to overview]	6-month Progression-free Survival (6-mo PFS) Rate
NCT01091454 (6) [back to overview]	3-month Progression-free Survival (3-mo PFS) Rate
NCT01091454 (6) [back to overview]	Confirmed Response Rate
NCT01091454 (6) [back to overview]	Duration of Response
NCT01091454 (6) [back to overview]	Time to Disease Progression
NCT01091454 (6) [back to overview]	Survival Time
NCT01096368 (10) [back to overview]	OS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]	OS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only.
NCT01096368 (10) [back to overview]	EFS of Children With Supratentorial Classic Ependymoma Who Achieve Complete Resection at First or Second Surgery or Children Who Achieve Complete Response (CR) After Induction Chemo and Who Are Non-randomly Assigned to Observation
NCT01096368 (10) [back to overview]	EFS in Children Who Have Completely Resected Ependymoma at Initial Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	EFS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01096368 (10) [back to overview]	EFS With Incomplete Resection After Initial Surgery, Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	Overall Survival (OS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	OS in Children With Incomplete Resection After Initial Surgery Who Then Achieved CR After Induction Chemotherapy or GTR/NTR After Second Surgery and Are Treated With Post-radiation Maintenance Chemotherapy or Post-radiation Observation Only
NCT01096368 (10) [back to overview]	OS of Children With Incompletely Resected Ependymoma Who Are Unable to Achieve a Complete Response (CR) by Post-operative Induction Chemotherapy or by Second Surgery and Who Are Non-randomly Assigned to Receive Maintenance Chemotherapy
NCT01133678 (1) [back to overview]	Tumor Responses
NCT01151761 (8) [back to overview]	Freedom From Local Progression at 12 Months
NCT01151761 (8) [back to overview]	Liver Transplant Conversion Rate
NCT01151761 (8) [back to overview]	Liver Transplant Rate
NCT01151761 (8) [back to overview]	Median Time to Overall Survival
NCT01151761 (8) [back to overview]	Overall Survival at 12 Months
NCT01151761 (8) [back to overview]	Pathologic Complete Response Rate
NCT01151761 (8) [back to overview]	Progression-free Survival at 12 Months
NCT01151761 (8) [back to overview]	Serum CA 19-9 Levels
NCT01175356 (3) [back to overview]	Percentage of MIBG Avid Patients Treated With MIBG Labeled With Iodine-131 and Bu/Mel Chemotherapy
NCT01175356 (3) [back to overview]	Incidence of Unacceptable Toxicity and Sinusoidal Obstruction Syndrome (SOS), Assessed by Common Terminology Criteria (CTV)v.4.0 for Toxicity Assessment and Grading for I-MIBG
NCT01175356 (3) [back to overview]	Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131
NCT01194453 (2) [back to overview]	Progression Free Survival (PFS)
NCT01194453 (2) [back to overview]	Response Rate
NCT01194869 (3) [back to overview]	Pathologic Complete Response (pCR) at the Time of Surgery After Preoperative Treatment
NCT01194869 (3) [back to overview]	Clinical Response Rate (Complete Pathologic Response Rate After Surgery)
NCT01194869 (3) [back to overview]	Clinical Response Rate During Follow-up (Disease Recurrence)
NCT01196416 (9) [back to overview]	Progression-free Survival (Phase II)
NCT01196416 (9) [back to overview]	Participants Evaluated for Toxicity
NCT01196416 (9) [back to overview]	Maximum Tolerated Dose for RO4929097
NCT01196416 (9) [back to overview]	Cycle 1 Mean Day 2 Trough/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB)
NCT01196416 (9) [back to overview]	Cycle 1 C Max/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB)
NCT01196416 (9) [back to overview]	Cycle 1 AUC/Pharmacokinetics of Gamma-secretase Inhibitor RO4929097 in Combination With Temozolomide (Phase IB)
NCT01196416 (9) [back to overview]	Overall Survival (Phase II)
NCT01196416 (9) [back to overview]	Number of Participants With Presence or Absence of Markers of Notch Signalling Pathway Inhibition in Patient Tumors (Phase Ib)
NCT01196416 (9) [back to overview]	Maximum-tolerated Dose for Cisplatin, Vinblastine and TMZ
NCT01240590 (3) [back to overview]	Number of Participants With Serious and Non-Serious Adverse Events (Phase I & II)
NCT01240590 (3) [back to overview]	Maximum Tolerated Dose (MTD) of Cisplatin (Phase I)
NCT01240590 (3) [back to overview]	Maximum Tolerated Dose (MTD) of Crolibulin (Phase I)
NCT01275664 (2) [back to overview]	Frequency of Adverse Effects as Assessed by the NCI CTCAE v 4.0
NCT01275664 (2) [back to overview]	Number of Participants With Complete Control Defined as no Vomiting and no Use of Rescue Medications (for Nausea or Emesis)
NCT01277744 (2) [back to overview]	Recurrence Free Survival
NCT01277744 (2) [back to overview]	Overall Survival
NCT01285557 (8) [back to overview]	Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE)
NCT01285557 (8) [back to overview]	Duration of Response (DR)
NCT01285557 (8) [back to overview]	Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3
NCT01285557 (8) [back to overview]	Overall Response Rate (ORR): Percentage of Participants With Overall Response
NCT01285557 (8) [back to overview]	Overall Survival (OS)
NCT01285557 (8) [back to overview]	Progression-free Survival (PFS)
NCT01285557 (8) [back to overview]	Time to Treatment Failure (TTF)
NCT01285557 (8) [back to overview]	Time to Tumor Response (TTR)
NCT01362127 (3) [back to overview]	HRQOL and Swallowing Function
NCT01362127 (3) [back to overview]	Pathological Complete Histological Response (pCR) After Resection Than Chemotherapy Alone in Patients With Resectable Carcinoma of the Esophagus and Cardia.
NCT01362127 (3) [back to overview]	Safety of Respective Neoadjuvant Therapies.
NCT01414608 (6) [back to overview]	Progression-free Survival Rate at 5 Years
NCT01414608 (6) [back to overview]	Overall Survival Rate at 5 Years
NCT01414608 (6) [back to overview]	Quality of Life for Global Health Status
NCT01414608 (6) [back to overview]	Number of Participants With Adverse Events (Grade 3 or Higher) in First Year
NCT01414608 (6) [back to overview]	Patterns of Disease Recurrence
NCT01414608 (6) [back to overview]	Radiation Protocol Compliance
NCT01530997 (10) [back to overview]	Overall Survival Rate
NCT01530997 (10) [back to overview]	Cause-Specific Survival
NCT01530997 (10) [back to overview]	Distant Metastases Free Survival
NCT01530997 (10) [back to overview]	Pathologic Complete Response Rate After De-escalated CRT in HPV-positive and/or p16 Positive Oropharyngeal Squamous Cell Carcinoma (OPSCC).
NCT01530997 (10) [back to overview]	European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-H&N-35
NCT01530997 (10) [back to overview]	Regional Control
NCT01530997 (10) [back to overview]	The Eating Assessment Tool (EAT-10) Composite Score
NCT01530997 (10) [back to overview]	Two-Year Local Control
NCT01530997 (10) [back to overview]	European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status/QoL
NCT01530997 (10) [back to overview]	The Rosenbek Penetration Aspiration Scale
NCT01590017 (2) [back to overview]	Patients With Adverse Events
NCT01590017 (2) [back to overview]	Treatment Completion Rate
NCT01595061 (4) [back to overview]	Progression-free Survival (PFS)
NCT01595061 (4) [back to overview]	Adverse Events (Grade 3 or Higher) During Treatment Period
NCT01595061 (4) [back to overview]	Complete Pathologic Response
NCT01595061 (4) [back to overview]	Complete Clinical Response
NCT01612351 (9) [back to overview]	Number of Patients Who Decreased in Risk Level Post Induction Chemotherapy.
NCT01612351 (9) [back to overview]	Overall Response Rate
NCT01612351 (9) [back to overview]	Voice and Swallowing Function - Voice-Related Quality of Life Assessment (VRQOL)
NCT01612351 (9) [back to overview]	Estimate the Pathologic Complete Response Rate at the Primary Site and in the Neck Following Induction Chemotherapy
NCT01612351 (9) [back to overview]	Voice and Swallowing Function- MD Anderson Dysphagia Inventory (MDADI)
NCT01612351 (9) [back to overview]	Feasibility of 3 Part Therapy
NCT01612351 (9) [back to overview]	Number of Subjects Who Experience Grade 3/4 Adverse Events According to CTCAE 4.0
NCT01612351 (9) [back to overview]	Response Rates at the Neck.
NCT01612351 (9) [back to overview]	Response Rates at the Primary Site
NCT01642251 (5) [back to overview]	Overall Survival (OS)
NCT01642251 (5) [back to overview]	Neurotoxicity Total Score Change Between Baseline and 3 Months After Treatment Start
NCT01642251 (5) [back to overview]	Overall Response Rate (ORR)
NCT01642251 (5) [back to overview]	Progression Free Survival (Phase II)
NCT01642251 (5) [back to overview]	Recommended Phase II Dose (Phase I)
NCT01670500 (5) [back to overview]	Clinical Response Rate
NCT01670500 (5) [back to overview]	Rate of Pathologic Complete Response (pCR)
NCT01670500 (5) [back to overview]	Rate of Residual Cancer Burden (RCB) 0/1
NCT01670500 (5) [back to overview]	Number of Grade 3 and Grade 4 Adverse Events
NCT01670500 (5) [back to overview]	Rate of Miller Payne 4 and 5
NCT01675765 (2) [back to overview]	Objective Tumor Response
NCT01675765 (2) [back to overview]	Number of Subjects Reporting Adverse Events
NCT01679405 (5) [back to overview]	Number of Adverse Events
NCT01679405 (5) [back to overview]	Objective Response Rate
NCT01679405 (5) [back to overview]	Overall Survival (OS)
NCT01679405 (5) [back to overview]	Time to Progress (TTP)
NCT01679405 (5) [back to overview]	Tumor Control Rate
NCT01687413 (13) [back to overview]	Rate of Distant Metastasis
NCT01687413 (13) [back to overview]	Locoregional Control
NCT01687413 (13) [back to overview]	Disease Specific Survival
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by Scale of Subjective Total Taste Acuity
NCT01687413 (13) [back to overview]	Change in Cognitive Function as Measured by Cognitive Failures Questionnaire
NCT01687413 (13) [back to overview]	Change in Hearing as Measured by Hearing Handicap Inventory - Adult
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by EORTC QLQ-C30
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by Neck Dissection Impairment Index (NDII)
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by Speech Handicap Index
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by the MD Anderson Dysphagia Inventory
NCT01687413 (13) [back to overview]	Change in Quality of Life as Measured by University of Michigan Xerostomia Questionnaire
NCT01687413 (13) [back to overview]	Number of Complications/Acute Toxicity by Organ Class
NCT01687413 (13) [back to overview]	Number of Participants With Disease-free Survival (DFS)
NCT01711541 (2) [back to overview]	Toxicity (Phase I and Phase II)
NCT01711541 (2) [back to overview]	Dose Limiting Toxicity (Phase I)
NCT01726582 (4) [back to overview]	Number of Subjects Completing Therapy Including Surgical Resection.
NCT01726582 (4) [back to overview]	Overall Survival in Months
NCT01726582 (4) [back to overview]	Use of Biomarkers to Determine Course of Treatment
NCT01726582 (4) [back to overview]	Progression-free Survival
NCT01732640 (2) [back to overview]	Number of Participants With Dose Limiting Toxicities
NCT01732640 (2) [back to overview]	Maximum Tolerated Dose (MTD) of Afatinib
NCT01798004 (1) [back to overview]	The Tolerability of BuMel Regimen
NCT01822496 (6) [back to overview]	Progression-free Survival
NCT01822496 (6) [back to overview]	Percentage of Patients With Complete or Partial Response
NCT01822496 (6) [back to overview]	Overall Survival
NCT01822496 (6) [back to overview]	Number of Patients With Grade 3-5 Adverse Events
NCT01822496 (6) [back to overview]	Local-regional Progression-free Survival
NCT01822496 (6) [back to overview]	Distant Progression-free Survival
NCT01893801 (3) [back to overview]	Overall Survival
NCT01893801 (3) [back to overview]	Progression-Free Survival
NCT01893801 (3) [back to overview]	Percentage Change in CA 19-9
NCT01898494 (5) [back to overview]	Swallowing Function Before Surgery Assessed Using MD Anderson Dysphagia Inventory (MDADI)
NCT01898494 (5) [back to overview]	Progression-free Survival Rate at 2 Years
NCT01898494 (5) [back to overview]	Swallowing Function After Surgery Assessed Using MD Anderson Dysphagia Inventory (MDADI)
NCT01898494 (5) [back to overview]	Quality of Life (QOL) at 6 Months After Treatment Assessed by Functional Assessment of Cancer Therapy - Head and Neck Cancer (FACT-HN) Total Score
NCT01898494 (5) [back to overview]	Proportion of Patients With Grade III or IV Oropharyngeal Bleeding or Positive Margins
NCT01907100 (4) [back to overview]	Progression-Free Survival (PFS)
NCT01907100 (4) [back to overview]	Overall Survival (OS)
NCT01907100 (4) [back to overview]	Objective Response According to Modified RECIST- Investigator Assessment
NCT01907100 (4) [back to overview]	Disease Control According to Modified RECIST- Investigator Assessment
NCT01918306 (5) [back to overview]	Maximum Tolerated Dose(MTD) of GDC-0941 and Recommended Phase II Dose of GDC-0941 Given in Combination With Cisplatin. - (Phase Ib)
NCT01918306 (5) [back to overview]	Number of Patients With Dose-limiting Toxicities Per NCI Common Terminology for Adverse Events (CTCAE) - (Phase Ib)
NCT01918306 (5) [back to overview]	Percentage of Patients Achieving Overall Response - (Phase II)
NCT01918306 (5) [back to overview]	Time to Progression - (Phase II)
NCT01918306 (5) [back to overview]	Clinical Benefit Rate - (Phase II)
NCT01938573 (3) [back to overview]	Percent of Patients With Pathologic Complete Response (Phase II)
NCT01938573 (3) [back to overview]	Incidence of Adverse Events Including Any Unfavorable and Unintended Sign, Symptom, Diagnosis, or Disease Temporally Associated With the Use of a Medicinal Product, Whether or Not Related to the Medicinal Product (Phase I and II)
NCT01938573 (3) [back to overview]	Patients With Dose Limiting Toxicity
NCT01982448 (2) [back to overview]	Positive Predictive Value (PPV) of HRD Score
NCT01982448 (2) [back to overview]	Number of Participants With Pathologic Response by HR-deficiency (HRD) Status
NCT01993329 (2) [back to overview]	Provocative Concentration (PC20) After Methacholine Challenge
NCT01993329 (2) [back to overview]	Highest FEV1 After Methacholine Challenge
NCT02000531 (2) [back to overview]	Participants With Adverse Events
NCT02000531 (2) [back to overview]	Progression Free Survival (PFS) Based on Well-documented and Verifiable Progression Events
NCT02052960 (6) [back to overview]	Clinical Benefit Rate
NCT02052960 (6) [back to overview]	Objective Response Rate (ORR)
NCT02052960 (6) [back to overview]	Overall Survival
NCT02052960 (6) [back to overview]	Progression-free Survival (PFS)
NCT02052960 (6) [back to overview]	Time of Global Health Status Deterioration
NCT02052960 (6) [back to overview]	Time to Treatment Failure
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30)
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]	Best Overall Tumor Response as Measured by the RECIST 1.1 Criteria (Response Evaluation Criteria in Solid Tumors)
NCT02082522 (15) [back to overview]	Change From Baseline in Health-related Quality of Life on the 4- and 7-point EORTC QLQ-C30
NCT02082522 (15) [back to overview]	Overall Survival Time
NCT02082522 (15) [back to overview]	Change From Baseline on Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02082522 (15) [back to overview]	Change From Baseline in Performance Status on the Karnofsky Performance Scale (KPS)
NCT02083679 (2) [back to overview]	Number of Subjects With Treatment-emergent Adverse (TEAEs), Serious TEAEs, TEAEs Leading to Discontinuation and TEAEs Leading to Death
NCT02083679 (2) [back to overview]	Number of Subjects With Dose Limiting Toxicities (DLTs)
NCT02092298 (2) [back to overview]	Overall Survival (OS) From the First Laparoscopic HIPEC
NCT02092298 (2) [back to overview]	Overall Survival (OS) After Hyperthermic Intraperitoneal Chemotherapy
NCT02127372 (4) [back to overview]	Phase 1 - Maximum Tolerated Dose (MTD) of Docetaxel and Cisplatin
NCT02127372 (4) [back to overview]	Phase II - Radiographic Response
NCT02127372 (4) [back to overview]	Phase 2: 1 Year Survival
NCT02127372 (4) [back to overview]	Phase 1 - Maximum Tolerated Dose (MTD) of STI571
NCT02128230 (1) [back to overview]	The Remission Rate for Participants With High-risk Myeloma
NCT02196168 (7) [back to overview]	Overall Survival
NCT02196168 (7) [back to overview]	Incidence of Adverse Events Using the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0
NCT02196168 (7) [back to overview]	Levels of Pharmacodynamic Biomarkers
NCT02196168 (7) [back to overview]	Levels of Predictive Biomarkers
NCT02196168 (7) [back to overview]	Overall Response Rate (Complete Plus Partial Response) Using RECIST Criteria v1.1
NCT02196168 (7) [back to overview]	Progression Free Survival
NCT02196168 (7) [back to overview]	Progression Free Survival
NCT02254278 (7) [back to overview]	Percentage of Participants With Grade 3+ Adverse Events
NCT02254278 (7) [back to overview]	Percentage of Participants With Distant Metastasis
NCT02254278 (7) [back to overview]	Percentage of Participants Alive
NCT02254278 (7) [back to overview]	Percentage of Participants With Local-regional Failure
NCT02254278 (7) [back to overview]	Negative Predictive Value (NPV) of Post-treatment FDG-PET/CT Scan [Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET)/Computed Tomography (CT)] for Progression-free Survival and Local-regional Control at Two Years
NCT02254278 (7) [back to overview]	Percentage of Participants Alive Without Progression at Two Years (Progression-free Survival)
NCT02254278 (7) [back to overview]	Mean One-year Total MD Anderson Dysphagia Inventory (MDADI) Score (Patient-reported Swallowing Outcome)
NCT02256982 (1) [back to overview]	Number of Participants Post Operative/Radiation Therapy Complications
NCT02281955 (6) [back to overview]	2 Year Local-regional Control (LRC) Rate After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02281955 (6) [back to overview]	2 Year Overall Survival (OS) Rate After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02281955 (6) [back to overview]	2 Year Regional Control (RC) Rate After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02281955 (6) [back to overview]	2 Year Progression Free Survival After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02281955 (6) [back to overview]	2 Year Distant Metastasis Free Survival (DMFS) Rate After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02281955 (6) [back to overview]	2 Year Local Control (LC) Rate After De-intensified Chemoradiotherapy (CRT) in Human Papilloma Virus (HPV)-Positive and/or p16 Positive Low-risk Oropharyngeal Squamous Cell Carcinoma (OPSCC)
NCT02296684 (6) [back to overview]	Number of Participants in Cohort 1 and 2 Who Experienced Reportable Adverse Events
NCT02296684 (6) [back to overview]	Number of Surgical Complications and/or Delays in Cohorts 1 and 2
NCT02296684 (6) [back to overview]	Locoregional Recurrence Rates in Cohorts 1 and 2
NCT02296684 (6) [back to overview]	Distant Failure Rate in Cohorts 1 and 2
NCT02296684 (6) [back to overview]	Rate of Major Pathologic Treatment Effect in Cohort 1
NCT02296684 (6) [back to overview]	Rate of Major Pathologic Treatment Effect in Cohort 2
NCT02300610 (4) [back to overview]	Overall Response Rate (ORR): Complete Response (CR) + Partial Response (PR)
NCT02300610 (4) [back to overview]	Recommended Dose of Enzalutamide
NCT02300610 (4) [back to overview]	Progression Free Survival (PFS)
NCT02300610 (4) [back to overview]	Overall Survival (OS)
NCT02325401 (5) [back to overview]	Overall Survival
NCT02325401 (5) [back to overview]	Progression Free Survival
NCT02325401 (5) [back to overview]	Number of Participants With Adverse Events
NCT02325401 (5) [back to overview]	Maximum Tolerated Dose (MTD) of Metformin in Combination With Concurrent Cisplatin and Radiation
NCT02325401 (5) [back to overview]	Number of Participants Experiencing No-Reoccurrence at 36 Months
NCT02358863 (1) [back to overview]	The Number of Patients With Tumor Size Reduction (Objective Response Rate)
NCT02392637 (3) [back to overview]	Number of Participants With Treatment Response Rate
NCT02392637 (3) [back to overview]	Median Progression Free Survival (PFS)
NCT02392637 (3) [back to overview]	Median Overall Survival (OS)
NCT02412670 (7) [back to overview]	Proportion of Patients With Renal Insufficiency at Completion of Surgery
NCT02412670 (7) [back to overview]	Proportion of Patients With Renal Insufficiency at Completion of Chemotherapy
NCT02412670 (7) [back to overview]	Event-free Survival
NCT02412670 (7) [back to overview]	Cumulative Incidence of Cancer-specific Death at 24 Months
NCT02412670 (7) [back to overview]	Complete Pathologic Response Rate
NCT02412670 (7) [back to overview]	Recurrence-free Survival
NCT02412670 (7) [back to overview]	Bladder Cancer-free Survival
NCT02445391 (6) [back to overview]	Health-related Quality of Life (HRQL) at 6-month Assessment
NCT02445391 (6) [back to overview]	Proportion of Basal Subtype
NCT02445391 (6) [back to overview]	Health-related Quality of Life (HRQL) at 15-month Assessment
NCT02445391 (6) [back to overview]	3-year Recurrence-Free Survival (RFS) Rate in Basal-Subtype Patients
NCT02445391 (6) [back to overview]	3-year Overall Survival (OS) Rate in Basal-Subtype Patients
NCT02445391 (6) [back to overview]	3-year Invasive Disease-Free Survival (IDFS) Rate in Basal-Subtype Patients
NCT02453282 (29) [back to overview]	Maximum Serum Concentration at Steady State (Cmax_ss) of Durvalumab
NCT02453282 (29) [back to overview]	Duration of Response (DoR); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	DoR; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	DoR; FAS Population
NCT02453282 (29) [back to overview]	Ctrough_ss of Tremelimumab
NCT02453282 (29) [back to overview]	Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT02453282 (29) [back to overview]	Serum Concentrations of Durvalumab
NCT02453282 (29) [back to overview]	Serum Concentrations of Tremelimumab
NCT02453282 (29) [back to overview]	Objective Response Rate (ORR); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	Progression-Free Survival (PFS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs SoC Chemotherapy
NCT02453282 (29) [back to overview]	PFS2; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	Percentage of Participants APF12; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	Percentage of Participants APF12; FAS Population
NCT02453282 (29) [back to overview]	Percentage of Participants Alive and Progression Free at 12 Months (APF12); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	Cmax_ss of Tremelimumab
NCT02453282 (29) [back to overview]	Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy
NCT02453282 (29) [back to overview]	Number of Participants With ADA Response to Tremelimumab
NCT02453282 (29) [back to overview]	Change From Baseline in Disease-Related Symptoms as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaires (EORTC QLQ) at 12 Months
NCT02453282 (29) [back to overview]	Trough Serum Concentration at Steady State (Ctrough_ss) of Durvalumab
NCT02453282 (29) [back to overview]	Time From Randomization to Second Progression (PFS2); PD-L1 (TC >=25%) Analysis Set Population
NCT02453282 (29) [back to overview]	PFS2; FAS Population
NCT02453282 (29) [back to overview]	OS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
NCT02453282 (29) [back to overview]	OS; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	PFS; PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs Durvalumab Monotherapy
NCT02453282 (29) [back to overview]	PFS; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	OS; FAS Population
NCT02453282 (29) [back to overview]	ORR; PD-L1 (TC >=1%) Analysis Set Population
NCT02453282 (29) [back to overview]	ORR; FAS Population
NCT02453282 (29) [back to overview]	PFS; FAS Population
NCT02542293 (20) [back to overview]	DoR; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	APF12; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	Alive and Progression-Free at 12 Months (APF12); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Serum Concentrations of Durvalumab
NCT02542293 (20) [back to overview]	OS; Global and China Cohorts: FAS, PD-L1 Tumor Cell (TC) ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	OS; China Cohort: China Programmed Cell Death Ligand 1 (PD-L1) Negative NSCLC Analysis Set
NCT02542293 (20) [back to overview]	Serum Concentrations of Tremelimumab
NCT02542293 (20) [back to overview]	Time From Randomization to Second Progression or Death (PFS2); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Progression-Free Survival (PFS); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	PFS2; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	PFS; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	OS; Global Cohort: bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, PD-L1-Negative NSCLC, bTMB <20 Mut/Mb, bTMB Non-Evaluable Population, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	OS at Months 12, 18 and 24; Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	OS at Months 12, 18 and 24; Global and China Cohorts: PD-L1-Negative NSCLC and FAS Analysis Sets
NCT02542293 (20) [back to overview]	ORR; Global and China Cohorts: PD-L1-Negative NSCLC, FAS, PD-L1 TC ≥25%, and PD-L1 TC ≥50% Analysis Sets
NCT02542293 (20) [back to overview]	Objective Response Rate (ORR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, bTMB ≥12 Mut/Mb, tTMB ≥14 Mut/Mb, tTMB ≥12 Mut/Mb, tTMB ≥10 Mut/Mb, and tTMB ≥8 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Number of Participants With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT02542293 (20) [back to overview]	Number of Participants With ADA Response to Tremelimumab
NCT02542293 (20) [back to overview]	Duration of Response (DoR); Global Cohort: bTMB ≥20 Mut/Mb, bTMB ≥16 Mut/Mb, and bTMB ≥12 Mut/Mb Analysis Sets
NCT02542293 (20) [back to overview]	Overall Survival (OS); Global Cohort: Blood Tumor Mutational Burden (bTMB) ≥20 Mutations Per Megabase (Mut/Mb) Analysis Set
NCT02567409 (4) [back to overview]	Treatment Limiting Adverse Events
NCT02567409 (4) [back to overview]	Progression-free Survival (PFS)
NCT02567409 (4) [back to overview]	Overall Survival (OS)
NCT02567409 (4) [back to overview]	Confirmed Objective Response Rate
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Primary Tumor Site
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Disease-free Survival (DFS)
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Disease-free Survival (DFS)
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Overall Survival (OS)
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Progression-free Survival (PFS)
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Progression-free Survival (PFS)
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Number of Participants Who Experienced a Grade 3-4 Adverse Event as Measured by NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0
NCT02573493 (19) [back to overview]	Comparison of Median Absolute Weight Loss in Arms 2 and 3 to Arm 1
NCT02573493 (19) [back to overview]	Comparison of Median Percent Weight Loss in Arms 2 and 3 to Arm 1
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Anatomic Tumor Response as Assessed by CT Using RECIST 1.1 Criteria
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Mean Total Score as Measured by FACT-H&N
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Mean Total Score as Measured by the FACT/GOG-NTX-4
NCT02573493 (19) [back to overview]	Arm 1 and Arm 2: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Kaplan-Meier Estimate of Overall Survival (OS)
NCT02573493 (19) [back to overview]	Arm 1 and Arm 3: Comparison of the Rate of Grade 3/4 Adverse Events
NCT02573493 (19) [back to overview]	Arm 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Primary Tumor Site
NCT02573493 (19) [back to overview]	Arm 3: Median Percent Weight Loss
NCT02573493 (19) [back to overview]	Arms 1, 2 and 3: Clinical Complete Response Rate as Measured by Clinical Exam at the Involved Regional Nodes
NCT02573493 (19) [back to overview]	Arms 1, 2, and 3: Clinical Partial Response Rate as Measured by Clinical Exam at the Involved Regional Nodes
NCT02586207 (2) [back to overview]	Evaluation of the Efficacy of Pembrolizumab Given in Combination With Definitive CRT by Determining the Number of Participants With Complete Response at Treatment End (Day 150)
NCT02586207 (2) [back to overview]	Adverse Events Will be Assessed and Graded Using CTCAE 4.0. Occurrences With Max Grade and Percentage/Number of Participants Affected by AEs Will be Provided.
NCT02659059 (17) [back to overview]	Number of Participants With Laboratory Abnormalities in Hepatic Tests - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) - Part 2
NCT02659059 (17) [back to overview]	Overall Survival (OS) - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) - Part 1
NCT02659059 (17) [back to overview]	Number of Participants With Dose Limiting Toxicities (DLTs) - Part 2
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Number of Participants With Laboratory Abnormalities in Thyroid Tests - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) by PD-L1 Expression Levels - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Overall Survival (OS) by PD-L1 Expression Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by Tumor Mutation Burden (TMB) Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by PD-L1 Positive and Negative Levels - Part 1
NCT02659059 (17) [back to overview]	Objective Response Rate (ORR) by PD-L1 Expression Levels-Part 1
NCT02659059 (17) [back to overview]	Number of Participants With Adverse Events (AEs) - Part 2
NCT02659059 (17) [back to overview]	Progression Free Survival (PFS) - Part 2
NCT02709512 (4) [back to overview]	Response Rate
NCT02709512 (4) [back to overview]	Progression Free Survival
NCT02709512 (4) [back to overview]	Overall Survival
NCT02709512 (4) [back to overview]	Overall Survival Phase 3 Interim Analysis
NCT02741570 (8) [back to overview]	Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20 - Extended Collection
NCT02741570 (8) [back to overview]	Objective Response Rate (ORR)
NCT02741570 (8) [back to overview]	Overall Survival (OS) in Randomized Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥ 1
NCT02741570 (8) [back to overview]	Duration of Objective Response (DOR)
NCT02741570 (8) [back to overview]	Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20
NCT02741570 (8) [back to overview]	Progression Free Survival (PFS)
NCT02741570 (8) [back to overview]	Overall Survival (OS) in All Randomized Participants - Extended Collection
NCT02741570 (8) [back to overview]	Overall Survival (OS) in All Randomized Participants
NCT02855944 (12) [back to overview]	Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (ITT Population)
NCT02855944 (12) [back to overview]	Least Squares Mean Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Global Health Status Score for the First 6 Cycles (Efficacy Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (ITT Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Progression-Free Survival (invPFS) by RECIST Version 1.1 for Rucaparib Versus Chemotherapy (Efficacy Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (ITT Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (ITT Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 (Efficacy Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (ITT Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Duration of Response (DOR) by RECIST v1.1 (Efficacy Population)
NCT02855944 (12) [back to overview]	Overall Survival (ITT Population)
NCT02855944 (12) [back to overview]	Overall Survival (Efficacy Population)
NCT02855944 (12) [back to overview]	Investigator Assessed Overall Response Rate (ORR) by RECIST v1.1 and/or CA-125 Response (Efficacy Population)
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab in Part A Cycle 1
NCT02862457 (17) [back to overview]	Number of Participants Who Discontinued Study Treatment Due to An Adverse Event (AE)
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Time to Maximum Concentration (Tmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Time to Maximum Concentration (Tmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Terminal Half-Life (t1/2) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Terminal Half-Life (t1/2) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Number of Participants Experiencing Dose-Limiting Toxicities (DLTs) According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI-CTCAE v.4.0)
NCT02862457 (17) [back to overview]	Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Pembrolizumab in Part B Cycle 1
NCT02862457 (17) [back to overview]	Area Under the Concentration-Time Curve From Zero to the Time of the Last Measurable Concentration (AUC0-t) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Number of Participants Who Experienced At Least One Adverse Event (AE)
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab in Part B Cycles 1, 2, 4, 6, and 8
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Maximum Concentration (Cmax) of Epacadostat in Part A
NCT02862457 (17) [back to overview]	Trough Concentration (Ctrough) of Pembrolizumab in Part A Cycles 1, 2, 4, 6, and 8
NCT02937116 (13) [back to overview]	Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)
NCT02937116 (13) [back to overview]	Number of All Study Participants Who Demonstrate a Tumor Response
NCT02937116 (13) [back to overview]	DOR According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	Number of Participants Experiencing Dose-limiting Toxicities (DLTs)
NCT02937116 (13) [back to overview]	Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator
NCT02937116 (13) [back to overview]	OS for Participants
NCT02937116 (13) [back to overview]	PFS According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	Clearance of IBI308 in Plasma After Single Dose Administration
NCT02937116 (13) [back to overview]	The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration
NCT02937116 (13) [back to overview]	Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants
NCT02937116 (13) [back to overview]	Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants
NCT02937116 (13) [back to overview]	TTR According to RECIST 1.1 as Assessed by Investigator
NCT02937116 (13) [back to overview]	Volume of Distribution of IBI308 in Plasma After Single Dose Administration
NCT02983045 (3) [back to overview]	Part 3 Schedule Finding: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
NCT02983045 (3) [back to overview]	Part 2 and Part 4: Objective Response Rate (ORR) Per RECIST 1.1 at Recommended Phase 2 Dose (RP2D)
NCT02983045 (3) [back to overview]	Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window
NCT02990468 (6) [back to overview]	Incidence of Radiation-induced Xerostomia by Unstimulated Saliva Production
NCT02990468 (6) [back to overview]	Incidence of Radiation-induced Xerostomia by Clinician Scoring
NCT02990468 (6) [back to overview]	Duration of Radiation-induced Mucositis
NCT02990468 (6) [back to overview]	Incidence of Radiation-induced Xerostomia by Stimulated Saliva Production
NCT02990468 (6) [back to overview]	Assess the Safety of the Study Drug by Calculating the Proportion of Patients Who Experience Grade 4 or 5 Study Drug Related Adverse Events, as Assessed by CTCAE v 4.03.
NCT02990468 (6) [back to overview]	Incidence Radiation-induced Mucositis by Clinician Scoring
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	PFS Based on Investigator Assessment According to RECIST 1.1 in LREM Analysis Set
NCT03003962 (44) [back to overview]	Overall Survival (OS)
NCT03003962 (44) [back to overview]	OS in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	OS in Participants With LREM
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	OS at 24 Months in PD-L1 TC > = 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 24 Months
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months in PD-L1 TC > = 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	OS at 18 Months
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	ORR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Objective Response Rate (ORR) as Per RECIST 1.1 Using Investigator Assessment
NCT03003962 (44) [back to overview]	Duration of Response (DoR) as Per RECIST 1.1 Using Investigator Assessment
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% LREM Analysis Set
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=50% Analysis Set
NCT03003962 (44) [back to overview]	DoR as Per RECIST 1.1 Using Investigator Assessment in PD-L1 TC >=25% LREM Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 50% Analysis Set
NCT03003962 (44) [back to overview]	APF12 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Alive and Progression-Free at 12 Months (APF12)
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-LC13
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Time to Deterioration of EORTC QLQ-C30
NCT03003962 (44) [back to overview]	Percentage of Participants With Antidrug Antibody (ADA) Response to Durvalumab
NCT03003962 (44) [back to overview]	Percentage of Participants With ADA Response to Durvalumab in LREM Analysis Set
NCT03003962 (44) [back to overview]	Number of Participants With ECOG Performance Status in PD-L1 TC >=25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Number of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status
NCT03003962 (44) [back to overview]	Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire Version 3 (QLQ-C30)
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC QLQ-LC13 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC QLQ-C30 in PD-L1 TC >= 25% LREM Analysis Set
NCT03003962 (44) [back to overview]	Change From Baseline in EORTC 13-Item Lung Cancer Quality of Life Questionnaire (QLQ-LC13)
NCT03003962 (44) [back to overview]	Time From Randomization to Second Progression (PFS2)
NCT03003962 (44) [back to overview]	Progression Free Survival (PFS) Based on Investigator Assessment According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 50% LREM Analysis Set
NCT03003962 (44) [back to overview]	PFS2 in PD-L1 TC >= 50% Analysis Set
NCT03040999 (7) [back to overview]	Change From Baseline in Global Health Status/Quality of Life (GHS/QoL)
NCT03040999 (7) [back to overview]	Change From Baseline in Physical Functioning
NCT03040999 (7) [back to overview]	Event-free Survival (EFS)
NCT03040999 (7) [back to overview]	Number of Participants Discontinuing Study Drug Due to an AE
NCT03040999 (7) [back to overview]	Change From Baseline in Swallowing, Speech, and Pain Symptoms
NCT03040999 (7) [back to overview]	Overall Survival (OS)
NCT03040999 (7) [back to overview]	Number of Participants With Adverse Events (AEs)
NCT03067610 (7) [back to overview]	Number of Patients With Solitary Elective Volume Recurrence
NCT03067610 (7) [back to overview]	Overall Survival
NCT03067610 (7) [back to overview]	Progression-free Survival
NCT03067610 (7) [back to overview]	Total Number of Participants With Gastrostomy Dependence
NCT03067610 (7) [back to overview]	Probability of Locoregional or Distant Tumor Failure
NCT03067610 (7) [back to overview]	Quality of Life (QOL) Patient Reported Outcomes (PRO)
NCT03067610 (7) [back to overview]	Number of Participants With Definite, Possible, and Probable Protocol-related Toxicities (Grade 3-5)
NCT03164616 (13) [back to overview]	Number of Patients With Anti-Drug Antibody (ADA) Response to Durvalumab
NCT03164616 (13) [back to overview]	PK of Tremelimumab; Peak and Trough Serum Concentrations
NCT03164616 (13) [back to overview]	Time to Deterioration of PRO Symptoms, Assessed Using EORTC QLQ-Lung Cancer Module 13 (QLQ-LC13)
NCT03164616 (13) [back to overview]	Pharmacokinetics (PK) of Durvalumab; Peak and Trough Serum Concentrations
NCT03164616 (13) [back to overview]	Duration of Response (DoR)
NCT03164616 (13) [back to overview]	Number of Patients With ADA Response to Tremelimumab
NCT03164616 (13) [back to overview]	Time to Deterioration of Global Health Status / Health-Related Quality of Life (HRQoL) and Patient Reported Outcome (PRO) Symptoms, Assessed Using European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)
NCT03164616 (13) [back to overview]	Time From Randomization to Second Progression (PFS2)
NCT03164616 (13) [back to overview]	Progression-Free Survival (PFS); D + SoC Compared With SoC Alone
NCT03164616 (13) [back to overview]	PFS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
NCT03164616 (13) [back to overview]	Overall Survival (OS); D + SoC Compared With SoC Alone
NCT03164616 (13) [back to overview]	OS; T + D + SoC Compared With SoC Alone and T + D + SoC Compared With D + SoC
NCT03164616 (13) [back to overview]	Objective Response Rate (ORR)
NCT03317496 (13) [back to overview]	Number of Participants With Treatment Related TEAEs
NCT03317496 (13) [back to overview]	Overall Survival (OS)
NCT03317496 (13) [back to overview]	Phase 1b Lead-in: Number of Participants With Dose-Limiting Toxicities (DLT)
NCT03317496 (13) [back to overview]	Progression Free Survival (PFS) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Time-to-Tumor Response (TTR) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Number of Participants With Grade 3 or Higher Laboratory Abnormalities by CTCAE Grade
NCT03317496 (13) [back to overview]	Number of Participants With Programmed Death-Ligand 1 (PD-L1) Expression
NCT03317496 (13) [back to overview]	Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious TEAEs
NCT03317496 (13) [back to overview]	Serum Concentration of Avelumab
NCT03317496 (13) [back to overview]	Percentage of Participants With Confirmed Objective Response (OR) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Absolute Value of Tumor Mutational Burden (TMB) in Tumor Tissue
NCT03317496 (13) [back to overview]	Duration of Response (DOR) as Per RECIST v 1.1 by Investigator Assessment
NCT03317496 (13) [back to overview]	Number of Participants With Grade 3 or Higher TEAEs Based on National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAE) v 4.03
NCT03345784 (3) [back to overview]	Progression-free Survival
NCT03345784 (3) [back to overview]	Recommended Phase 2 Dose Defined as the Dose Level With < 1/6 Patients With Dose Limiting Toxicities
NCT03345784 (3) [back to overview]	Frequency and Severity of AZD1775 Toxicity Events in Patients With Gynecological Cancer in Combination With Standard RT and Concurrent Cisplatin
NCT03382561 (3) [back to overview]	Response Rate
NCT03382561 (3) [back to overview]	Overall Survival (OS)
NCT03382561 (3) [back to overview]	Progression-free Survival (PFS)
NCT03389477 (1) [back to overview]	Tumor Response Rate of Newly Diagnosed p16INK4a Negative, HPV-unrelated HNSCC to Neoadjuvant Palbociclib Monotherapy
NCT03502148 (7) [back to overview]	Determine a Safe Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Dose-Limiting Toxicities
NCT03502148 (7) [back to overview]	Determine an Efficacious Dose (mg/cm2) of PRV111 (Cisplatin Transmucosal System) Via Number of Tumor Responses
NCT03502148 (7) [back to overview]	Number of Loco-regional Recurrences
NCT03502148 (7) [back to overview]	Systemic Platinum Levels (Cmax)
NCT03502148 (7) [back to overview]	Technical Success - Residual Cisplatin Levels Post-application
NCT03502148 (7) [back to overview]	Tumor Response (Tumor Volume Change From Baseline and Pre-op Visit, Approximately 21 Days Prior to Surgical Excision of the Tumor)
NCT03502148 (7) [back to overview]	Tumor and Lymph Node (if Available) Platinum Levels
NCT03541252 (4) [back to overview]	Imaging-based Tumor Response: Complete Tumor Clearance Determined by Physician Performing Imaging
NCT03541252 (4) [back to overview]	Tumor Response- Clinical Clearance Determined by Clinical Assessment by Physician
NCT03541252 (4) [back to overview]	Change in Occurence of Local Skin Reaction (LSR) Side Effects TOTAL COMPOSITE SCORE
NCT03541252 (4) [back to overview]	Tumor Response- Histological Tumor Clearance Determined by Pathologist
NCT03617913 (2) [back to overview]	Progression-free Survival
NCT03617913 (2) [back to overview]	Proportion of Participants With Complete Response (At 6 Months)
NCT03621696 (4) [back to overview]	Percentage of Participants Taking Narcotics
NCT03621696 (4) [back to overview]	Mean Percent Weight Change
NCT03621696 (4) [back to overview]	Disease Recurrence Rate
NCT03621696 (4) [back to overview]	Change in Serum Creatinine
NCT03690921 (6) [back to overview]	Acute Toxicity
NCT03690921 (6) [back to overview]	Complete Response at 12 Weeks
NCT03690921 (6) [back to overview]	Overall Survival at 24 Months
NCT03690921 (6) [back to overview]	Distant Metastasis-free Survival at 24 Months.
NCT03690921 (6) [back to overview]	Complete Response at 24 Weeks
NCT03690921 (6) [back to overview]	Local Progression Free Survival at 24 Months
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03737994 (12) [back to overview]	Overall Survival (OS)
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Objective Response Rate (ORR), Per Investigator Assessment Using the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Criteria
NCT03737994 (12) [back to overview]	Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03737994 (12) [back to overview]	Duration of Overall Response, Per Investigator Assessment Using RECIST v1.1
NCT03737994 (12) [back to overview]	Number of Participants by Highest Grade Adverse Event Reported
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03737994 (12) [back to overview]	Progression-free Survival (PFS), Per Investigator Assessment Using RECIST v1.1 Criteria
NCT03738228 (8) [back to overview]	Disease-free Survival (DFS) at 2 Years
NCT03738228 (8) [back to overview]	Post-treatment 3-month PET/CT Metabolic Response
NCT03738228 (8) [back to overview]	Immune Response
NCT03738228 (8) [back to overview]	Percentage of Participants With Dose Limiting Toxicities
NCT03738228 (8) [back to overview]	Pre-treatment PD-L1 Expression
NCT03738228 (8) [back to overview]	T Cell Receptor (TCR) Diversity
NCT03738228 (8) [back to overview]	T Cell Receptor (TCR) Simpson Clonality
NCT03738228 (8) [back to overview]	Adverse Events (Grade 3 or Higher) During Treatment Period as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version (v)5
NCT03775486 (11) [back to overview]	Time to Deterioration in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
NCT03775486 (11) [back to overview]	Number of Participants With Treatment-Related Adverse Events
NCT03775486 (11) [back to overview]	Change From Baseline in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
NCT03775486 (11) [back to overview]	Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Lung Cancer (LC)13
NCT03775486 (11) [back to overview]	Concentration of Durvalumab
NCT03775486 (11) [back to overview]	Duration of Response
NCT03775486 (11) [back to overview]	Overall Survival
NCT03775486 (11) [back to overview]	Presence of Anti-drug Antibodies (ADAs) for Durvalumab
NCT03775486 (11) [back to overview]	Progression-free Survival
NCT03775486 (11) [back to overview]	Progression-free Survival in Homologous Recombination Repair Related Gene Mutation (HRRm) Population
NCT03775486 (11) [back to overview]	Time to Deterioration in EORTC Quality of Life Questionnaire (QLQ) QLQ-C30
NCT03786783 (5) [back to overview]	Response Rate
NCT03786783 (5) [back to overview]	Event-free Survival
NCT03786783 (5) [back to overview]	"Percentage of Participants Who Are Feasibility Failure"
NCT03786783 (5) [back to overview]	Percentage of Participants With Unacceptable Toxicity
NCT03786783 (5) [back to overview]	Overall Survival
NCT03790111 (32) [back to overview]	Number of Participants With Progression-free Survival (PFS) as Evaluated by Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate (ORR), Local Reader's Assessment
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate, Local Read
NCT03790111 (32) [back to overview]	Median Progression Free Survival
NCT03790111 (32) [back to overview]	Mean Change From Baseline in Plasma 5-hydroxyindoleacetic Acid (5-HIAA)
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate, Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Mean Change From Baseline in Plasma 5-hydroxyindoleacetic Acid (5-HIAA)
NCT03790111 (32) [back to overview]	Mean Change From Baseline in Plasma 5-hydroxyindoleacetic Acid (5-HIAA)
NCT03790111 (32) [back to overview]	Disease Control Rate End of Study, Local Reviewer
NCT03790111 (32) [back to overview]	Disease Control Rate (DCR), Local Reviewer
NCT03790111 (32) [back to overview]	Disease Control Rate (DCR), Local Reviewer
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate (ORR), Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Disease Control Rate (DCR), Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Disease Control Rate (DCR), Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Change From Baseline in Serum Albumin
NCT03790111 (32) [back to overview]	Change From Baseline in Serum Albumin
NCT03790111 (32) [back to overview]	Change From Baseline in Serum Albumin
NCT03790111 (32) [back to overview]	Change From Baseline in Plasma Carbohydrate Antigen 19-9 (CA 19-9)
NCT03790111 (32) [back to overview]	Change From Baseline in Carbohydrate Antigen 19-9 (CA 19-9)
NCT03790111 (32) [back to overview]	Change From Baseline in Carbohydrate Antigen 19-9 (CA 19-9)
NCT03790111 (32) [back to overview]	Progression Free Survival, Local Radiologist's Assessment
NCT03790111 (32) [back to overview]	Project Overall Survival Rate at Month 12
NCT03790111 (32) [back to overview]	Disease Control Rate (DCR), Central Radiologist's Assessment
NCT03790111 (32) [back to overview]	Project Overall Survival Rate at Month 6
NCT03790111 (32) [back to overview]	Summary of Duration of Progression Free Survival, Local Radiologist's Assessment
NCT03790111 (32) [back to overview]	Weight Change From Baseline
NCT03790111 (32) [back to overview]	Weight Change From Baseline
NCT03790111 (32) [back to overview]	Overall (Objective) Response Rate, Local Reader's Assessment
NCT03790111 (32) [back to overview]	Overall Survival (OS)
NCT03790111 (32) [back to overview]	Progression Free Survival, Local Radiologist's Assessment
NCT03790111 (32) [back to overview]	Weight Change From Baseline
NCT04003636 (6) [back to overview]	Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Response Evaluation Criteria in Solid Tumors Version 1.1 (BICR)
NCT04003636 (6) [back to overview]	Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)
NCT04003636 (6) [back to overview]	Number of Participants Who Experience One or More Adverse Events (AE)
NCT04003636 (6) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
NCT04003636 (6) [back to overview]	Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR
NCT04003636 (6) [back to overview]	Overall Survival (OS)
NCT04012619 (1) [back to overview]	the Maximum Tolerated Dose (MTD)
NCT04372927 (4) [back to overview]	Frequency and Severity of Pneumonitis
NCT04372927 (4) [back to overview]	Frequency of Adverse Events
NCT04372927 (4) [back to overview]	Overall Survival (OS)
NCT04372927 (4) [back to overview]	Response Rate
NCT04924062 (6) [back to overview]	Progression-free Survival (PFS) Per RECIST 1.1 as Assessed by BICR
NCT04924062 (6) [back to overview]	Overall Survival (OS)
NCT04924062 (6) [back to overview]	Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
NCT04924062 (6) [back to overview]	Number of Participants Who Experience One or More Adverse Events (AE)
NCT04924062 (6) [back to overview]	Number of Participants Who Discontinued Study Intervention Due to an Adverse Event (AE)
NCT04924062 (6) [back to overview]	Duration of Response (DOR) Per RECIST 1.1 as Assessed by BICR

Best Confirmed Response to Neoadjuvant Therapy

Response was based on pathology at surgery. A patient achieved complete response if no gross or microscopic tumor were identified with the surgical specimen and nodal tissue. Stable response was defined as a response that did not qualify as complete response or progressive disease (PD), where PD indicated metastatic spread. Best confirmed response rate was defined as the proportion of patients with complete response (CR). A patient was considered unevaluable if the patient did not have surgery, the pathologist did not examine at least 15 lymph nodes, or the pathology report was unavailable. (NCT00003298)
Timeframe: Assessed at surgery time (surgery performed during week 8-10 after registration to the study)

Intervention	percentage of participants (Number)
Experimental Arm	0

Intervention	participants (Number)
	Dose Limiting Toxicity(DLT)/Significant Dose Delay	Complications unrelated to treatment
Arm 1, P I	0	0
Arm 2, P I	0	0
Arm 2, PII	0	1
Arm 3, P I	2	0
Arm 4, P I	2	0

Intervention	Months (Median)
Hepatocellular Carcinoma	2.3
Neuroendocrine Hepatic Metastases	7.2

Intervention	Months (Median)
Hepatocellular Carcinoma	12.0
Neuroendocrine Hepatic Metastases	21.2

Intervention	Proportion of participants (Number)
Hepatocellular Carcinoma	0
Neuroendocrine Hepatic Metastases	0.17

Intervention	Participants (Number)
Peritoneal Mesothelioma	24
Low Grade Mucinous Adenocarcinoma	18
Adenocarcinoma of Gastrointestinal Origin	6

Intervention	Number of participants (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	5
Arm II (RER With CR [ABVE-PC, IFRT])	370
Arm III (RER With CR [ABVE-PC])	380
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	538
Arm V (RER With PD)	29
Arm VI (SER [DECA, ABVE-PC, IFRT])	105
Arm VII (SER [ABVE-PC, IFRT])	100

Intervention	Probability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	0.89
Arm II (RER With CR [ABVE-PC, IFRT])	0.87
Arm III (RER With CR [ABVE-PC])	0.84
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	0.87
Arm V (RER With PD)	0.70
Arm VI (SER [DECA, ABVE-PC, IFRT])	0.79
Arm VII (SER [ABVE-PC, IFRT])	0.74

Intervention	Probability of survival (Number)
Arm I (Patients Off-therapy Before Callback-Induction Only)	0.93
Arm II (RER With CR [ABVE-PC, IFRT])	0.98
Arm III (RER With CR [ABVE-PC])	0.98
Arm IV (RER With Less Than CR [ABVE-PC, IFRT])	0.98
Arm VI (SER [DECA, ABVE-PC, IFRT])	0.96
Arm VII (SER [ABVE-PC, IFRT])	0.93

Intervention	Months (Median)
Cisplatin / Irinotecan / RT (Arm A)	35.0
Paclitaxel / Cisplatin / RT (Arm B)	21.0

Intervention	percentage of participants (Number)
Cisplatin / Irinotecan / RT (Arm A)	15.4
Paclitaxel / Cisplatin / RT (Arm B)	16.7

Intervention	Months (Median)
Cisplatin / Irinotecan / RT (Arm A)	39.8
Paclitaxel / Cisplatin / RT (Arm B)	12.4

Intervention	percentage of participants (Number)
Standard Fractionation RT + Cisplatin	51.4
Accelerated Fractionation RT + Cisplatin	53.4

Intervention	score on a scale * months (Mean)
Standard Fractionation RT + Cisplatin	5.27
Accelerated Fractionation RT + Cisplatin	5.19

Intervention	percentage of participants (Number)
Standard Fractionation RT + Cisplatin	25.6
Accelerated Fractionation RT + Cisplatin	28.2

Intervention	percentage of participants (Number)
Standard Fractionation RT + Cisplatin	25.5
Accelerated Fractionation RT + Cisplatin	28.7

Intervention	percentage of patients (Number)
Standard Fractionation RT + Cisplatin	64.3
Accelerated Fractionation RT + Cisplatin	70.3

Intervention	percentage of participants (Number)
	Acute	Late
Accelerated Fractionation RT + Cisplatin	80.0	25.7
Standard Fractionation RT + Cisplatin	83.7	21.1

Intervention	score on a scale * months (Mean)
Standard Fractionation RT + Cisplatin	90.48
Accelerated Fractionation RT + Cisplatin	91.77

Intervention	score on a scale * months (Mean)
Standard Fractionation RT + Cisplatin	65.81
Accelerated Fractionation RT + Cisplatin	67.10

Intervention	percentage of participants (Number)
Standard Fractionation RT + Cisplatin	55.8
Accelerated Fractionation RT + Cisplatin	57.0

chemdatabank.com

cisplatin

Cross-References

Synonyms (83)

Research Excerpts

Bioavailability

Roles (8)

Drug Classes (1)

Protein Targets (93)

Potency Measurements

Biological Processes (258)

Molecular Functions (62)

Ceullar Components (71)

Bioassays (54)

Research

Studies (16)

Market Indicators

Research Demand Index: 89.41

Study Types

Clinical Trials (1133)

Trial Overview

Trial Outcomes

Best Confirmed Response to Neoadjuvant Therapy

Progression Free Survival

Grade 3 or Higher Toxicity Incidence on Step 1

Overall Survival

Dose Limiting Toxicity(DLT)/Significant Dose Delay of Paclitaxel With Cisplatin as Assessed by CTC 2.0 After 6 Cycles of Treatment

Overall Survival at 2 Years

Disease-free Survival at 2 Years

Time to Progression

Overall Survival

Tumor Response

Number of Participants With Adverse Events

Number of Participants With a Response

Disease Response Assessed by Modified RECIST Criteria

Grade 3 or 4 Non-hematologic Toxicity

Event-free Survival

Overall Survival

Overall Survival Time

Pathologic Complete Response Rate

Recurrence-free Survival Time

Disease-free Survival (Percentage of Participants Alive Without Disease)

Head and Neck Radiotherapy Questionnaire (HNRQ) - AUC at One Year

Local-regional Failure (Alternate Definition) [Percentage of Participants With Local-regional Failure]

Local-regional Failure (Percentage of Participants With Local-regional Failure)

Overall Survival (Percentage of Participants Alive)

Percentage of Participants With Toxicity Grade 3 or Higher

PSS-HN Understandability of Speech Score - AUC at One Year

PSS-HN Public Eating Score - AUC at One Year

Progression-free Survival (Alternate Definition of Disease-free Survival) [Percentage of Participants Alive Without Progression]

Performance Status Scale for Head and Neck Cancer (PSS-HN) Normalcy of Diet Score - Area Under the Curve (AUC) at One Year

Proportion of Patients With Objective Response by Solid Tumor Response Criteria (RECIST)

Duration of Response

Overall Survival

Disease Free Survival (DFS)

Histological Response Determined by FDG Uptake Correlates

Number of Participants With Indicated Severity of CTCAE v2 Graded Neurotoxicity and Infection

Patient Reported Quality of Life as Measured With the Combination of Physical Well-being (PWB) Subscale and Functional Well-being (FWB) Subscale From the FACT-G

Patient-reported Neurotoxicity (Ntx) as Measured by the FACT/GOG-Ntx Subscale (Short)

Pain, Assessed by Brief Pain Inventory

Patient Reported Neurotoxicity Symptoms as Measured With the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity Subscale (Short Version) (FACT/GOG-Ntx Subscale).

Patient-reported Quality of Life as Measured by the Functional Assessment of Cancer Therapy (FACT)-Cervical Trial Outcome of Index (FACT-Cx TOI)

Duration of Overall Survival (OS)

Duration of Progression-free Survival (PFS)

Complete Clinical and Pathologic Response

Treatment-Related Adverse Effects (Grade 3 or Higher) During Study Treatment Period

Median Overall Survival (OS)

Overall Survival

Time to Progression

Proportion of Confirmed Tumor Responses Defined to be Either a Complete Response (CR) or Partial Response (PR)

Overall Survival

Pre-Radiation Therapy Chemotherapeutic Response

Grade 3-4 Hepatic Events

Grade 3-4 Hemorrhage Events

Grade 3-4 Dermatology Events

Grade 3-4 Gastrointestinal Events

Grade 3-4 Constitutional Events

Grade 3-4 Cardiovascular Events

Grade 3-4 Blood/Bone Marrow Events

Grade 3-4 Auditory/Hearing Events

Intervention	score on a scale * months (Mean)
Standard Fractionation RT + Cisplatin	53.36
Accelerated Fractionation RT + Cisplatin	53.63

Intervention	proportion of participants (Number)
PET (Topotecan/Etoposide/Cisplatin/G-CSF)	0.697
PIE (Irinotecan/Cisplatin/Etoposide)	0.576

Intervention	Months (Median)
PET (Topotecan/Etoposide/Cisplatin/G-CSF)	11.9
PIE (Irinotecan/Cisplatin/Etoposide)	11.0

Intervention	Participants (Count of Participants)
	Grade < 2 Sensory neuropathy	Grade 2 or Higher Sensory Neuropathy	Grade <3 infection with Neutrope	Grade 3 or Higher Infection with Neutropenia	Grade <3 infection without Neutropenia	Grade 3 or Higher Infection without Neutropenia
Arm I (Doxorubicin Hydrochloride, Cisplatin, Paclitaxel)	167	473	25	615	22	618
Arm II (Paclitaxel, Carboplatin)	130	534	29	635	13	651

Intervention	units on a scale (Least Squares Mean)
	Baseline	6 weeks	15 weeks	26 weeks
Arm I (Doxorubicin, Cisplatin, Paclitaxel)	39.4	35.5	35.3	39.8
Arm II (Paclitaxel, Carboplatin)	37.9	37.5	36.5	38.5

Intervention	units on a scale (Mean)
	Baseline	Pre-cycle 2	Pre-cycle 5	9 months post cycle 1
Arm I (Paclitaxel, Cisplatin)	4.0	3.5	3.6	2.3
Arm II (Vinorelbine, Cisplatin)	3.9	3.5	4.0	3.2
Arm III (Gemcitabine, Cisplatin)	3.3	3.4	3.5	3.7
Arm IV (Topotecan, Cisplatin)	3.6	3.6	2.5	2.9

Intervention	months (Median)
Arm I (Paclitaxel, Cisplatin)	12.87
Arm II (Vinorelbine, Cisplatin)	9.99
Arm III (Gemcitabine, Cisplatin)	10.28
Arm IV (Topotecan, Cisplatin)	10.25

Intervention	months (Median)
Arm I (Paclitaxel, Cisplatin)	5.82
Arm II (Vinorelbine, Cisplatin)	3.98
Arm III (Gemcitabine, Cisplatin)	4.70
Arm IV (Topotecan, Cisplatin)	4.57

Intervention	Participants (Count of Participants)
	Leukopenia	Anemia	Thrombocytopenia	Neutropenia	Other Hematologic	Constitutional	Cardiovascular	Dermatologic	Gastrointestinal	Genitourinary/Renal	hemorrhage	Infection	Metabolic	Other Neurologic	Pulmonary	Pain	Sexual/reproductive
Cisplatin + Radiation, Then Surgery	18	4	3	11	13	5	4	17	13	3	1	8	10	2	1	10	1

Intervention	Percentage of Participants (Number)
	Complete Response (CR)	Partial Response (PR)
Group 1 (Platin Resistant)	2.5	15
Group 2 (Platin Sensitive)	0	40